// Reference=MNI
// Vogel S E, 2015: Correlation between age and the extent of the ratio 
// dependent neural recovery effect
// Vogel S E, 2015: Parametric regressor of numerical ratio vs. Baseline 
// activation
// Subjects=19
-44.27	-64.24	48.67
41.92	8.21	28.22
35.93	-69.85	51.56
35.25	21.98	0.38
-47.83	11.1	32.35
-41.55	-49.56	-9.47

// Aybek S, 2015: NE > Neutral
// Subjects=12
-4	-28	-20
-2	-22	-2
8	-32	-10
-16	22	60
2	30	52
-5	22	34

// Blasi G, 2015: Subgroup of healthy controls, performing working memory task
// Subjects=322
-48	40	14
-50	46	10
44	14	16
-56	36	14

// Blasi G, 2015: Subgroup of healthy controls, performing attentional control 
// task
// Subjects=265
36	14	30
48	34	12
-44	8	38
-54	-40	36
-52	34	6

// Mazza M, 2015: Healthy Controls (HC)
// Subjects=10
39.39	44.84	-7.17
11.14	-100.74	12.06
-27.62	11.34	19.83
4.62	16.76	45.77
-47.04	17.08	-.5
-24.57	-3.39	-5.73
39.4	35.06	-9.69
-43.83	16.05	-.45
39.39	44.84	-7.17
-47.04	17.08	-.5
-43.84	19.22	-.72
29.73	36.61	-16.4
29.73	37.67	-16.49
61.89	9.31	-14.48
-46.91	10.71	13.42

// Mazza M, 2015: PTSD Sufferers (PTSD)
// Subjects=7
11.12	-54.79	28.28
-53.37	10.16	6.85
-66.02	-7.92	21.89
4.62	16.76	45.77
-47.04	17.08	-.5
-24.57	-3.39	-5.73
39.4	35.06	-9.69
-66.02	-7.92	21.89
46.13	14.15	22.1
-47.04	17.08	-.5
-43.84	19.22	-.72
33.19	-78.31	-30.22
38.58	-64.57	-18.05
61.89	9.31	-14.48
-46.91	10.71	13.42

// Coull J T, 2015: Temporal static - Spatial static
// Coull J T, 2015: Spatial dynamic -Temporal dynamic (Block 2 only)
// Coull J T, 2015: Temporal dynamic - Spatial dynamic (All blocks)
// Coull J T, 2015: Static - Dynamic
// Coull J T, 2015: Spatial static - Temporal static
// Coull J T, 2015: Time x Duration
// Coull J T, 2015: Space x Distance
// Coull J T, 2015: (Time x Duration) - (Space x Distance)
// Coull J T, 2015: (Space x Distance) - (Time x Duration)
// Coull J T, 2015: (Space x Duration) - (Time x Distance)
// Subjects=16
-3	-4	67
-57	2	10
57	5	16
-36	23	1
-54	-46	19
60	-25	-8
18	-4	1
6	-7	73
-3	2	55
-3	2	55
-45	11	-8
-15	-73	46
30	-76	55
-6	56	22
-36	-49	52
36	-55	52
-48	-76	-11
9	-82	7
0	-4	64
30	-97	-5
0	-88	19
-24	-61	-20
15	-67	-11
3	-4	64
9	-88	22
15	-70	-8
-30	-97	-8
30	-97	-5
-30	-97	-8

// Monaco S, 2015: Adaptation effects
// Subjects=11
-23.97	-12.54	68.63
3.68	-8.28	52.34
-12.25	-86.48	33.44
-17.49	-66.74	55.26
-30.39	-27.01	61
-55.08	-39.27	42.24
-44.66	-70.55	-5.44

// Robertson B D, 2015: Main effect of congruency: (incongruent vs. congruent 
// vs. control) and physical size (close vs. far)
// Robertson B D, 2015: Incongruent - Congruent contrast
// Robertson B D, 2015: Control - Congruent contrast
// Robertson B D, 2015: Main effect of physical size difference: (Far - Close)
// Robertson B D, 2015: Close - Far contrast
// Robertson B D, 2015: (Incongruent - Congruent) and (Close - Far)
// Robertson B D, 2015: (Incongruent - Control) and (Close - Far)
// Robertson B D, 2015: (Incongruent - Congruent) masked with (Close - Far), 
// p<0.005
// Robertson B D, 2015: (Incongruent - Congruent) masked with (Close - Far), 
// p<0.05
// Robertson B D, 2015: (Close - Far) masked with (Incongruent - Congruent)
// Robertson B D, 2015: Incongruent - Congruent, Positive Correlation
// Robertson B D, 2015: Incongruent - Congruent, Negative Correlation
// Robertson B D, 2015: Incongruent - Control, Positve Correlation
// Robertson B D, 2015: Incongruent - Control, Negative Correlation
// Robertson B D, 2015: Close - far, Positive Correlation
// Robertson B D, 2015: Close - far, Negative Correlation
// Subjects=16
27	-7	1
66	-7	13
36	-31	40
45	-37	61
57	-19	52
-60	-4	-1
-33	-34	46
-18	-58	-17
-9	-31	-23
60	-58	-11
48	-22	-23
45	-25	-20
48	-55	-20
21	-25	-11
18	32	-17
18	2	-20
-51	-31	7
12	5	46
0	-91	22
-39	2	-17
-33	-25	16
-18	-49	55
-15	-25	34
51	-28	13
24	-67	46
-21	-19	-11
33	14	16
30	29	10
39	44	28
30	38	-17
39	5	-17
15	-31	37
12	-19	4
21	5	25
-57	-4	25
-42	-28	-17
21	5	25
-18	-4	19
-30	-1	10
66	-7	13
27	-7	1
-60	-4	1
-18	-22	19
-33	-34	46
-18	-58	-17
60	-58	-11
48	-22	-23
21	-25	-11
18	32	-17
-12	5	46
0	-91	22
-39	2	-17
-21	-19	-11
39	44	28
30	29	10
12	-19	4
21	-31	7
-42	-28	-17
39	-13	-23
3	-43	4
3	-34	28
-39	38	34
-36	-49	19
-54	-67	-11
48	50	13
24	-61	-14
0	-70	7
30	-82	-20
-36	-76	-23
-18	-31	4
-15	-46	-5
-45	-52	-5
-12	17	-11
24	-61	10
45	32	7
12	-88	-11
-24	-40	-29
21	-25	58
3	-49	61
-6	-85	37
69	-25	31
-63	-7	-2
18	32	-17
18	-19	7
-30	-25	16
-18	-28	-32
-24	8	-23
21	59	-5
27	47	40
33	32	10
-30	44	37
-30	-31	-23
18	-22	-11
-51	14	-20
-3	38	-14
63	-37	-11
48	29	10
-21	-4	-17
-42	-28	40
63	-52	-11
42	50	13
-27	-7	-23
30	38	-17
54	-55	11
-45	-55	-8
45	8	25
-45	2	28
48	38	16
-45	-76	34
-27	-55	49
-3	-73	-23
-6	-37	43
-15	2	43
3	32	-17
21	47	-14
18	-91	4
69	-22	28
57	17	7
9	-55	10
-12	-58	16
-9	-22	-32
-45	35	19
-30	32	16
-6	53	-2
-63	-10	1
54	-55	-11
-45	-55	-8
45	8	25
-45	2	28
-33	-4	43
48	38	16
-27	-55	49
-3	-73	-23
-15	2	43
21	47	-14
36	53	-14
36	62	1
36	44	-17
69	-22	28
-9	-22	-32
-45	35	19
-63	-10	1
-21	-76	7
-45	47	-14
6	-37	61
-39	-49	-26
60	-22	-2
-36	-4	-29
6	-91	25
-12	-19	-29
39	-1	-20
12	-70	-14
27	-58	4
15	2	55
21	8	25
24	-13	10
15	26	7
18	-31	1
-24	-70	28
-27	-73	25
-66	-25	-5
60	-58	-11
36	-31	37
-12	2	43
48	2	25
69	-22	28
-36	-37	43
-51	-31	49
60	17	7
-54	-67	-11
-63	-10	1
48	50	13
24	-49	55
36	-76	-23
42	41	25
54	-58	-11
42	-34	31
45	-49	58
48	-76	-11
-39	-40	46
-51	-31	49
18	-7	16
66	-7	13
27	-7	1
-60	-4	1
-33	-34	46
-18	-58	-17
0	-70	7
-15	-46	-5
21	-25	-11
18	32	-17
30	29	10
0	-91	22
-39	2	-17
-21	-19	-11
-12	-1	43
39	44	28
48	-22	-23
54	-43	-14
12	-19	4
-42	-28	-17
3	-43	4
-39	38	34
48	-43	43
-36	-49	19
24	-61	-14
-18	-31	4
48	41	4
24	-61	10
18	-10	19
-18	-4	19
66	-7	13
27	-7	1
33	-28	40
54	-22	58
-18	-58	-17
-15	-46	-5
-42	-25	40
-36	-28	58
21	-25	-11
18	32	-17
30	38	-17
-57	-1	4
0	-88	25
-39	2	-17
-15	-25	34
-21	-19	-11
48	-22	-23
54	-40	-14
27	47	37
15	-31	37
6	-43	4
3	-34	28
12	-16	4
21	-31	7
-42	-28	-17
-9	-1	40
33	29	10
69	-34	31
-39	38	34
-15	5	49
-36	-49	19
-51	-37	43
-51	-31	34
0	-70	7
-18	-31	4
-18	-22	16
39	-13	-23
12	-79	43
3	-49	61
18	-67	43
-12	17	-11
24	-61	10
6	-73	-8
12	-88	-11
24	-61	-11
21	-25	58
24	-67	-14
-57	-67	-2
51	-58	-14
-45	-55	-8
45	8	25
-45	2	28
48	38	16
-27	-55	49
-3	-73	-23
-15	2	40
21	47	-14
-45	35	19
-45	47	-14
6	-37	61
-57	-28	46
60	-22	-2
15	26	7
36	2	1
-57	-43	49
48	23	4
57	17	10
60	-43	13
39	50	31
-18	-7	22
6	-4	19
-6	-25	19
0	-64	31
-57	-13	-17
27	-13	-11
18	-16	13
39	14	-26
-45	-16	-26
-39	32	-14
39	50	31
-39	-40	58
-27	-58	52
60	23	10
-51	26	-5
-54	-43	49
-42	8	40
27	-85	1
18	-13	25
24	-13	-11
0	-28	13
-12	-43	46
-30	-85	25
-39	-7	34
-60	-13	13
-27	-58	58
-15	47	31

// Yoder K J, 2015: Implicit Moral Evaluation, Nonpsychopaths > Psychopaths
// Yoder K J, 2015: Implicit Moral Evaluation, Psychopaths > Nonpsychopaths
// Yoder K J, 2015: Explicit Moral Evaluation, Nonpsychopaths > Psychopaths
// Yoder K J, 2015: Explicit Moral Evaluation, Psychopaths > Nonpsychopaths
// Subjects=28
4	14	18
34	38	30
-36	-6	36
-34	-70	-6
44	2	-32
-2	26	-6
-38	-16	10
0	-28	-40
28	-2	-32
-6	-40	-30
6	-16	-24
-12	-6	-20
16	-96	-14
-34	-54	34
-60	-14	36
-18	18	38
-22	-42	52
-22	18	-6
16	-28	4
-24	-12	48

// Wen X, 2016: Beauty distance effect: Low Scene vs High Scene & Low Face vs 
// High Face [(BCSL-BCSH) + (BCFL-BCFH)]
// Wen X, 2016: Beauty distance effect: (RT covariate) [(BCSL-BCSH) + 
// (BCFL-BCFH)] , p<0.05
// Wen X, 2016: Beauty distance effect: (RT covariate) [(BCSL-BCSH) + 
// (BCFL-BCFH)] , p>0.05
// Wen X, 2016: Size distance effect: Low Scene vs High Scene & Low Face vs 
// High Face [(SCSL-SCSH) + (SCFL-SCFH)]
// Wen X, 2016: Distance effect in the size comparison (RT covariate) 
// [(SCSL-SCSH) + (SCFL-SCFH)], p<0.05
// Wen X, 2016: Distance effect in the size comparison (RT covariate) 
// [(SCSL-SCSH) + (SCFL-SCFH)], p>0.05
// Wen X, 2016: Distance effect in beauty and size comparison
// Wen X, 2016: Distance effect in beauty and size comparison (RT covariate), 
// p<0.05
// Wen X, 2016: Distance effect in beauty and size comparison (RT covariate), 
// p>0.05
// Wen X, 2016: Beauty comparison interaction effect [(BCSL-BCSH) > 
// (BCFL-BCFH)]
// Wen X, 2016: Beauty comparison interaction effect [(BCSL-BCSH) > 
// (BCFL-BCFH)] (RT covariate)
// Wen X, 2016: Beauty comparison interaction effect [(BCSL-BCSH) < 
// (BCFL-BCFH)]
// Wen X, 2016: Beauty comparison interaction effect [(BCSL-BCSH) < 
// (BCFL-BCFH)] (RT Covariate)
// Wen X, 2016: Distance effect in moral beauty comparison (BCSL-BCSH)
// Wen X, 2016: Distance effect in facial beauty comparison (BCFL-BCFH)
// Wen X, 2016: Conjunction analyses beauty comparison distance effects 
// (BCSL-BCSH) and (BCFL-BCFH), p<0.05
// Wen X, 2016: Conjunction analyses beauty comparison distance effects 
// (BCSL-BCSH) and (BCFL-BCFH), p>0.05
// Subjects=28
-45	-45	48
33	-66	54
-3	21	48
-30	21	3
30	24	-3
0	-33	27
-33	-60	-30
-3	21	51
-30	21	3
30	24	-3
51	-45	57
3	-36	27
-42	-63	-48
-33	-48	51
36	-42	45
9	27	39
-30	21	3
30	21	3
-6	-75	-24
-45	-63	-6
48	-57	-6
15	-12	3
-30	-51	48
24	-66	45
9	27	39
-30	21	3
33	24	3
-6	-72	-21
48	-54	-6
-24	-63	42
33	-63	54
0	21	51
-30	21	3
30	24	-3
-33	-60	-30
-45	9	27
-36	-48	39
39	-54	45
3	18	51
-30	21	3
30	21	3
-30	-54	-30
-51	9	30
-33	12	-18
54	6	-24
-39	-81	33
48	-75	27
-9	-57	15
-3	30	-9
-33	12	-18
51	3	-24
-39	-81	33
48	-75	27
-12	-57	18
12	21	-9
-30	0	0
30	-6	15
-30	-3	18
30	-6	15
0	30	51
-27	24	-3
30	24	-3
-45	54	-3
54	30	18
6	-42	9
36	-81	33
-33	-45	-33
6	21	45
-30	18	3
30	21	3
42	-57	54
-45	6	30
-27	-69	-48
-9	-90	12
6	30	42
27	27	-3
-27	21	-6
51	33	21

// Kleinhans N M, 2016: Healthy Controls
// Subjects=25
32	48	4
20	-78	-26
-6	52	20
-24	36	-18

// Kleinhans N M, 2016: Autism Spectrum Disorder ASD patients
// Subjects=27
40	-50	-24
42	-58	-22
44	-76	-12
42	-62	18
-38	-50	-22
-42	-74	-10
-44	-68	-20
12	-36	6
12	-36	-8
10	-38	-2
-8	-38	4
8	-48	-32
-6	-48	-30
4	-42	-22
12	-52	-42
14	-54	-34
-28	-50	-8
-22	-60	-10
-38	-72	-4
-32	-82	12
-26	-74	-4
-36	-48	-22
32	-50	-10
30	-42	-16
38	-64	-14
22	-44	-8
42	-70	-10
30	-84	24
36	-78	10
30	-74	22
4	-70	44
-6	52	20
-24	36	-18

// Tseng A, 2016: Autistic Participants (ASD)
// Subjects=51
39	-28	67
-6	47	25
-6	-61	-20
-21	20	58
21	41	49
-51	20	13
-3	-52	-38
9	-55	-38
30	-58	4
12	-88	-5
-18	62	10
24	62	10
24	-16	-14
15	53	1
39	-22	-23
-15	-55	10
-9	35	-5
27	-40	1
-39	-31	-14
-3	20	-2
30	44	46
27	32	-11
-54	20	13
-60	-4	19
-54	5	28
-60	-7	13
-33	23	10
24	-70	49
-48	-40	43
63	-13	31
27	5	55
-36	53	13
36	-82	34
12	11	46
45	-40	40
39	5	43
45	14	34
0	29	43
54	-67	-8
63	-55	-2
-9	-88	-8
54	20	1
-48	41	-5
-24	38	46
12	50	49
57	26	16
18	14	13
21	-28	-5
27	-1	-17
12	44	16
12	-46	64
-42	17	49
-15	14	61
-27	-70	52
-45	17	10
-6	-64	52
-9	8	13
27	-55	49
18	23	61
66	-28	-11
-60	-25	-14
33	-40	-23
45	29	22
12	-52	-38
-6	-61	-38
-6	-64	43
51	-25	52
3	-1	37
-6	-22	40
36	-49	58
-3	-70	-8
0	-19	52
-24	-55	67
-6	17	-8
-12	-67	-8
-51	-34	37
6	20	-8
24	-40	-2
9	-79	-2
-30	-94	16
33	44	43
39	23	25
57	20	34
15	47	34
30	-37	-26
-24	-91	-17
-48	-61	7
39	-88	7
-48	-61	-5
0	-88	34
-9	-88	7
-21	-82	-14
21	-58	19
-3	-82	43
-21	53	16
-6	-46	25
36	-82	34
-45	-10	10
42	8	55
15	11	-11
-54	23	13
21	32	58
39	11	34
9	38	46
60	-16	31
48	-67	34

// Tseng A, 2016: Typically Developing Subjects (TD)
// Subjects=84
27	62	19
51	41	16
30	-76	52
39	56	4
57	11	34
-44	-46	48
-42	-55	61
12	-70	64
21	-85	46
48	20	34
-39	-13	10
36	26	-2
15	8	16
-3	-88	-5
-60	-10	-17
18	-34	10
-21	2	7
12	-97	4
21	-100	10
0	56	-8
0	-58	19
-15	-103	1
3	59	10
45	-73	-5
-3	26	-11
-42	-73	-5
-30	-31	-26
18	-76	58
-45	-55	58
0	20	58
9	-61	49
18	8	70
-30	-52	37
39	-19	22
-51	-49	55
-6	-79	43
-9	11	40
51	-10	52
30	-31	67
-6	17	43
-15	-85	-8
63	-55	7
-6	-85	34
-39	5	37
-48	41	1
-36	44	28
54	-40	13
36	35	22
-6	-19	34
-9	26	28
12	-22	34
-48	41	-5
-24	38	46
12	50	49
57	26	16
18	14	13
21	-28	-5
27	-1	-17
12	44	16
12	-46	64
-42	17	49
-15	14	61
-27	-70	52
-45	17	10
-6	-64	52
-9	8	13
27	-55	49
18	23	61
66	-28	-11
-60	-25	-14
33	-40	-23
45	29	22
12	-52	-38
-18	-100	-11
54	35	25
-36	-61	49
-51	26	25
-6	-76	49
30	-61	-32
-6	17	52
27	-97	4
-45	14	19
45	-52	49
36	59	7
-45	5	34
-27	5	64
-24	11	64
12	11	10
-39	-88	19
-12	14	16
-39	-82	-14
54	2	31
-15	-28	-11
12	-88	7
3	-91	22
-39	-28	67
3	-13	61
9	-76	1
-3	-10	55
15	-67	10
36	-46	67
63	-16	25
-63	-34	34
-39	5	4
9	-13	43
-48	11	-32
-3	-28	49
-9	-82	-20
9	-82	-29
-54	20	31
-51	-58	-14
-15	20	67
-45	-1	58
3	-58	-35
6	-13	13
-48	26	37
24	-94	-8
39	2	64
-6	23	46
-12	62	-2
36	-43	-8
-15	-19	16
0	-88	34
-9	-88	7
-21	-82	-14
21	-58	19
-3	-82	43
-21	53	16
-6	-46	25
36	-82	34
-45	-10	10
42	8	55
15	11	-11
-54	23	13
21	32	58
39	11	34
9	38	46
60	-16	31
48	-67	34

// Kana R K, 2015: Theory of Mind ToM > Random, Healthy controls > ASD 
// patients
// Subjects=13
-4	36	34
-24	22	-12
-40	4	34
-42	-56	40
-22	-86	-26
-6	-44	40
2	-8	18

// Moseley R, 2016: Emotion words, Healthy controls > ASD patients
// Moseley R, 2016: Abstract verbs, Healthy controls > ASD patients
// Moseley R, 2016: Animal names, Healthy controls > ASD patients
// Subjects=18
-54	4	24
-58	-18	22
-52	-8	44
-42	-42	-12
-44	-58	-10
56	0	42
50	-14	50
-56	-36	2
-2	4	60
-8	16	18
-4	6	28
10	16	28
30	18	14
-56	6	20
-54	2	40
-42	-8	50
-42	-40	-16
-46	-74	-10
-42	-50	-26
-52	36	2
-14	38	18
-6	0	64
-62	-18	18
-8	-84	20
2	-74	10
-60	-36	2
-52	-28	-2
38	54	18
32	44	20
22	50	16
-42	26	18
-32	18	0
-46	38	0
36	50	18
28	44	18
-42	-48	-16
-38	-44	-24
-38	-34	-20
-60	-38	2
-30	32	-16
-20	30	-16
14	14	2
6	4	-2
-18	10	6
-10	4	6
-18	14	-4

// Chantiluke K, 2015: Controls < Autism Spectrum Disorder (ASD), Placebo
// Chantiluke K, 2015: Controls and Attention Deficit Hyperactivity Disorder 
// (ADHD) < ASD, Placebo
// Chantiluke K, 2015: Controls and ASD > ADHD, Placebo
// Chantiluke K, 2015: Controls > ADHD > ASD, Placebo
// Chantiluke K, 2015: Controls and ASD > ADHD, Fluoxetine
// Chantiluke K, 2015: Controls < ASD and ADHD, Fluoxetine
// Chantiluke K, 2015: ADHD < Controls < ASD, Fluoxetine
// Chantiluke K, 2015: Controls and ASD > ADHD, Fluoxetine
// Chantiluke K, 2015: Controls < ASD < ADHD, Fluoxetine
// Subjects=18
58.94	19.6	22.61
-41.59	34.6	19.16
-30.17	10.39	-33.59
-29.49	-18.85	42.46
-10.17	10.72	65.41
-10.17	10.72	65.41
40.04	-62.65	34.18
-48.68	-63.52	30.81
9.18	-65.95	49.31

// Shafritz K M, 2015: High-Functioning Autistic Participants
// Subjects=15
30	32	20
12	18	46
48	8	28
12	14	52
46	10	16
42	22	-4
34	-58	40
46	-60	-18
-38	-72	-18
38	18	16
38	36	22
34	24	0
-30	24	2
8	22	44
-4	22	44
40	-56	42
38	-50	-16
-42	-52	-16
6	20	46
42	34	30
-42	4	32
32	24	4
-30	20	8
42	-58	44
40	-68	-10
6	18	46
32	26	2
34	-58	48
42	-58	-24
2	40	8
2	48	0
16	-54	14
-14	-64	10
18	-70	-4
-14	-74	-8
-46	6	-18
-36	-74	40
-24	2	-20
-14	-86	-14
34	-58	-20
14	-80	-20
6	-74	6
44	18	-2
-20	18	-14
-24	10	-18
-20	-68	4
14	-70	4
-26	2	-18
2	46	0
-24	14	4
30	-84	-16
4	-84	10

// Shafritz K M, 2015: Healthy Controls
// Subjects=15
32	38	24
8	18	42
32	24	6
-38	10	8
40	6	34
10	14	44
32	2	48
36	34	24
32	26	4
-34	16	10
38	-50	38
2	22	46
44	8	42
42	26	4
-38	18	4
34	-58	44
10	16	42
-10	20	36
42	36	18
32	2	50
38	18	8
-36	16	8
34	-60	40
12	-8	8
4	18	46
38	24	2
-30	42	-8
-42	44	-8
-18	20	-14
-26	4	-14
-34	52	12
-36	-54	-20
36	-56	-22
-22	-76	-18
20	-74	-16
44	18	-2
-20	18	-14
-24	10	-18
-20	-68	4
14	-70	4
-26	2	-18
2	46	0
-24	14	4
30	-84	-16
4	-84	10

// Heim S, 2016: Phonological awareness, Control > Dyslexia
// Heim S, 2016: Magnocellular motion detection, Dyslexia > Controls
// Heim S, 2016: Magnocellular motion detection, Control > Dyslexia
// Heim S, 2016: Attention shifting, Dyslexia > Control
// Heim S, 2016: Auditory discrimination, Dyslexia > Control
// Heim S, 2016: Auditory discrimination, Control > Dyslexia
// Subjects=20
-48	18	21
46	34	17
-32	-78	17
36	-72	13
-40	-72	15
48	-60	15
-32	50	32
42	32	17
48	-26	49
36	-68	29
-22	-68	-27
24	-64	-31
20	28	27
-12	-104	9
62	-24	9

// Brown G G, 2015: Face > Shape matching, GroupxTime Interaction, Alprazolam 
// group decreases
// Brown G G, 2015: Affective Anticipation > Baseline, GroupxTime Interaction, 
// Alprazolam group increases
// Brown G G, 2015: Affective Anticipation > Baseline, GroupxTime Interaction, 
// Alprazolam group decreases
// Subjects=11
2.5	-57.73	18.59
0.37	-57.74	18.61
20.4	26.35	16.91
-36.23	40.35	24.19
49.17	24.6	5.57
34.02	61.01	-4
-37.24	16.83	22.83
7.49	34.13	8.6
-16.05	33.73	5.56
24.59	70.5	23.19
-15.12	87.21	8.87
35.67	25.29	56.97

// Cisler J M, 2016: All Fear > All Neutral, Treatment Prediction
// Cisler J M, 2016: Covert Fear > All Neutral, Treatment Prediction
// Subjects=23
23	2	-3
-22	-1	-7
22	-32	-5
26	3	-9

// Gingnell M, 2016: Escitalopram (ESCIT) + Cognitive Behavioral Therapy 
// (ICBT) > Placebo + ICBT, Faces; Post < Pre
// Gingnell M, 2016: Responders > Non-Responders, Faces; Post < Pre-treatment
// Gingnell M, 2016: Symptom improvement, Faces; Post < Pre-treatment
// Subjects=24
21	-16	55
0	-88	7
-15	-22	61
-21	-73	7
54	-40	37
-60	-43	34
18	47	40
-48	5	1
42	-52	46
45	-37	-11
60	-43	-2
33	2	40
33	2	43

// Strakowski S M, 2016: Emotional distracters > Targets, Nonremitters > 
// Remitters (Baseline)
// Strakowski S M, 2016: Emotional distracters > Targets, Nonremitters > 
// Remitters (Week 1)
// Strakowski S M, 2016: Emotional distracters > Targets, Nonremitters > 
// Remitters (Week 8)
// Subjects=21
42.26	-14.6	63.58
15.04	54.75	26.85
-35.58	51.39	-25.81
26.39	46.13	-30.54
-58.88	7.27	-16.27
-5.92	-59.84	33.36
2.32	-55.21	-3.93
14.84	37.2	-7.36
0.19	-55.22	-3.9
3.23	22.21	6.3
-11.61	2.46	13.7
53.63	-18.47	12.48

// van Rooij S J, 2015: Cued Trial > Go Trial, Group x Time Interaction
// Subjects=17
-48	-24	40

// Culbreth A, 2016: Loseshift-Winstay, Healthy controls > Schizophrenia
// Culbreth A, 2016: Loseshift-Winstay, Healthy controls
// Culbreth A, 2016: Loseshift-Winstay, Schizophrenia
// Culbreth A, 2016: Loseshift, Healthy controls > Schizophrenia
// Culbreth A, 2016: Winstay, Healthy controls > Schizophrenia
// Subjects=36
44.73	48.13	-6.39
5.53	39.26	33.84
-44.96	49.42	4.57
42.92	40.45	32.19
49.21	15.09	6.37
21.76	23.89	53.9
41.98	7.75	36.06
4.62	29.96	51.36
38.99	-49.28	41.99
-40.02	-50.21	50.79
58.32	-46.02	54.88
14.56	-72.09	51.99
33.69	-69.75	39.31
43.44	-59.6	59.54
54.97	-51.9	34.22
4.66	-24.62	33.63
5.71	-44.5	24.13
55.71	-58.66	-12.06
69.53	-27.49	-9.25
56.77	-42.2	-5.64
-1.87	-96.1	-9.37
13.18	-92.96	2.46
10.13	-99.01	20.85
12.99	-16.94	8.36
-15.89	-12.97	7.24
29.97	-5.89	-1.69
33.23	-24.02	-2.44
1.08	-26.29	-15.26
-37.55	-68.82	-52.51
-5.31	-84.26	-34.86
-24.56	-76.89	-34.14
6.56	-84.13	-20.51
44.73	48.13	-6.39
5.53	39.26	33.84
-44.96	49.42	4.57
42.92	40.45	32.19
49.21	15.09	6.37
21.76	23.89	53.9
41.98	7.75	36.06
4.62	29.96	51.36
38.99	-49.28	41.99
-40.02	-50.21	50.79
58.32	-46.02	54.88
14.56	-72.09	51.99
33.69	-69.75	39.31
43.44	-59.6	59.54
54.97	-51.9	34.22
4.66	-24.62	33.63
5.71	-44.5	24.13
55.71	-58.66	-12.06
69.53	-27.49	-9.25
56.77	-42.2	-5.64
-1.87	-96.1	-9.37
13.18	-92.96	2.46
10.13	-99.01	20.85
12.99	-16.94	8.36
-15.89	-12.97	7.24
29.97	-5.89	-1.69
33.23	-24.02	-2.44
1.08	-26.29	-15.26
-37.55	-68.82	-52.51
-5.31	-84.26	-34.86
-24.56	-76.89	-34.14
6.56	-84.13	-20.51
44.73	48.13	-6.39
5.53	39.26	33.84
-44.96	49.42	4.57
42.92	40.45	32.19
49.21	15.09	6.37
21.76	23.89	53.9
41.98	7.75	36.06
4.62	29.96	51.36
38.99	-49.28	41.99
-40.02	-50.21	50.79
58.32	-46.02	54.88
14.56	-72.09	51.99
33.69	-69.75	39.31
43.44	-59.6	59.54
54.97	-51.9	34.22
4.66	-24.62	33.63
5.71	-44.5	24.13
55.71	-58.66	-12.06
69.53	-27.49	-9.25
56.77	-42.2	-5.64
-1.87	-96.1	-9.37
13.18	-92.96	2.46
10.13	-99.01	20.85
12.99	-16.94	8.36
-15.89	-12.97	7.24
29.97	-5.89	-1.69
33.23	-24.02	-2.44
1.08	-26.29	-15.26
-37.55	-68.82	-52.51
-5.31	-84.26	-34.86
-24.56	-76.89	-34.14
6.56	-84.13	-20.51
44.73	48.13	-6.39
5.53	39.26	33.84
-44.96	49.42	4.57
42.92	40.45	32.19
49.21	15.09	6.37
21.76	23.89	53.9
41.98	7.75	36.06
4.62	29.96	51.36
38.99	-49.28	41.99
-40.02	-50.21	50.79
58.32	-46.02	54.88
14.56	-72.09	51.99
33.69	-69.75	39.31
43.44	-59.6	59.54
54.97	-51.9	34.22
4.66	-24.62	33.63
5.71	-44.5	24.13
55.71	-58.66	-12.06
69.53	-27.49	-9.25
56.77	-42.2	-5.64
-1.87	-96.1	-9.37
13.18	-92.96	2.46
10.13	-99.01	20.85
12.99	-16.94	8.36
-15.89	-12.97	7.24
29.97	-5.89	-1.69
33.23	-24.02	-2.44
1.08	-26.29	-15.26
-37.55	-68.82	-52.51
-5.31	-84.26	-34.86
-24.56	-76.89	-34.14
6.56	-84.13	-20.51
44.73	48.13	-6.39
5.53	39.26	33.84
-44.96	49.42	4.57
42.92	40.45	32.19
49.21	15.09	6.37
21.76	23.89	53.9
41.98	7.75	36.06
4.62	29.96	51.36
38.99	-49.28	41.99
-40.02	-50.21	50.79
58.32	-46.02	54.88
14.56	-72.09	51.99
33.69	-69.75	39.31
43.44	-59.6	59.54
54.97	-51.9	34.22
4.66	-24.62	33.63
5.71	-44.5	24.13
55.71	-58.66	-12.06
69.53	-27.49	-9.25
56.77	-42.2	-5.64
-1.87	-96.1	-9.37
13.18	-92.96	2.46
10.13	-99.01	20.85
12.99	-16.94	8.36
-15.89	-12.97	7.24
29.97	-5.89	-1.69
33.23	-24.02	-2.44
1.08	-26.29	-15.26
-37.55	-68.82	-52.51
-5.31	-84.26	-34.86
-24.56	-76.89	-34.14
6.56	-84.13	-20.51

// Wang J, 2015: 2-Negative Feedback (NF) vs 1-Negative Feedback(NF), p < 0.05 
// FDR corrected
// Wang J, 2015: 2-NF vs. 1-NF, p < 0.001 uncorrected
// Wang J, 2015: 2-NF vs 1-NF conjunction 1-NF vs 0-NF, p < 0.05 FDR corrected
// Wang J, 2015: 2-NF vs 1-NF conjunction 1-NF vs 0-NF, p < 0.001 uncorrected
// Subjects=16
48	18	9
-57	12	15
48	15	39
-27	12	45
15	24	45
51	-36	42
-54	-39	45
42	-69	42
36	-60	51
15	-66	45
30	21	-3
-6	18	48
-39	21	12
33	9	54
-45	-39	42
-27	24	6
33	18	0
-21	-12	0

// White D M, 2015: Schizophrenia
// Subjects=22
35	30	24
14	14	-2
18	11	15
6	-23	3
15	-36	-38

// White D M, 2015: Healthy controls
// Subjects=19
35	30	24
14	14	-2
18	11	15
6	-23	3
15	-36	-38
-3	-3	51
-34	12	-3
35	12	-3
50	6	-10
-21	-66	54
-42	-33	45
36	-63	-37
-3	-3	51
-4	-10	-14
8	-21	-1
6	-30	-18
18	27	1.5
-22	-22	24
-21	-93	3

// Wotruba D, 2017: Reward anticipation, At-risk Psychosis > Healthy controls
// Subjects=21
3	-45	27
9	57	30
30	24	48
-24	24	45

// Choi M H, 2017: Driving only - Control
// Choi M H, 2017: Driving with sub-task - Control
// Choi M H, 2017: Sub-task only - Control
// Choi M H, 2017: Driving only - Driving with sub-task
// Choi M H, 2017: Driving only - Driving with sub-task
// Subjects=15
51	-62	-10
37	-4	60
33	-28	65
22	-6	65
8	-57	65
16	-68	55
44	-61	0
50	-34	30
11	10	40
31	-67	5
34	-75	25
51	0	45
-30	-28	60
-28	-48	55
-56	7	25
-51	0	5
-44	-6	15
-31	-89	-10
-23	-4	15
0	-62	-30
41	-62	-20
-12	-46	-45
30	-32	20
9	-4	0
33	5	-10
33	-26	60
45	11	-10
45	-32	60
34	-4	-5
9	-25	20
22	7	30
25	-82	10
50	-40	-10
-28	-31	60
-31	-40	25
-55	3	30
-50	-1	5
-11	-84	-10
-28	19	10
-42	-76	-5
-30	38	30
-20	-81	25
-9	-3	25
-28	53	-5
-25	-6	55
28	-36	-40
0	-59	-35
42	46	-5
36	21	10
58	30	10
16	3	-5
22	-34	30
61	-7	-5
48	-43	60
55	8	5
59	7	-5
17	7	70
-31	41	25
-59	5	20
-30	-37	5
-51	-54	-5
-9	-3	65
0	-61	-30
2	-45	-5
-5	-70	-15
-34	-71	-25
36	-3	60
51	-62	-10
45	-62	0
23	-28	70
28	-87	20
17	-70	55
23	-20	70
34	-75	25
31	-67	5
17	-64	40
9	-3	50
-30	-45	55
-23	-87	15
-50	-65	10
-66	-37	10
-53	-32	45
-5	2	50
-16	-59	-5
-31	-89	-10
8	-67	-30
37	-64	-15
-11	-67	-35
-34	-46	-40
-9	-71	-20
9	-4	0
31	-34	10
45	11	-10
44	-28	-5
19	-39	25
2	-31	0
33	7	-10
-14	-6	10
-9	-3	25
-30	25	15
-55	-1	25
-28	52	-5
-62	-28	5
2	-40	0
-44	-68	-20

// Denkova E, 2015: Brain regions common to Context and Emotion conditions
// Denkova E, 2015: [Context vs Sematic memory (SM)] > [Emotion vs SM] 
// inclusively masked with [Context vs SM]
// Denkova E, 2015: [Emotion vs SM] > [Context vs SM] inclusively masked with 
// [Emotion vs SM]
// Denkova E, 2015: Negative correlation between Context and Emotion ratings
// Denkova E, 2015: Positive correlation between Context and Emotion ratings
// Denkova E, 2015: Positive correlation between Emotion condition and Emotion 
// ratings
// Subjects=17
-45.9	21.06	46.78
60.43	31.01	-1.96
-51.17	35.88	-24.07
-46.86	18.25	-29.13
48.24	31.97	-25.38
43.99	29.18	-20.55
39.56	9.74	-33.12
-6.82	28.07	62.23
-7.42	64.1	22.81
0.78	58.58	-13.76
5.85	45.6	42.35
-62.53	-35.78	2.26
-58.66	-10.71	-28.3
-54.38	-2.19	-29.22
64.52	-5.71	-27.53
22.74	-40.46	-6.57
-50.14	-56.03	37.67
44.93	-55.69	36.02
10.22	-83.1	20.27
10.07	-72.23	10.23
10.35	-42.74	38.69
-7.14	-79.32	15.71
-6.89	-51.2	40.94
1.34	-42.28	9.66
9.27	48.75	-27.5
53.73	-66.53	45.9
-33.44	-40.66	-5.6
-50.18	12.64	48.81
-33.72	20.71	-15.03
44.06	34.06	-14.31
1.61	38.56	47.6
14.57	38.6	47.37
-16.38	64.98	-1.77
-53.94	-27.35	0.16
-41.93	-39.55	6.77
60.65	-39.6	0.54
-20.57	-20.51	-8.93
-20.73	-5.29	-18.28
2.1	-59.52	66.26
-2.95	-93.42	2.47
-19.97	-82.79	25.24
27.48	-65.71	21.62
-3.38	0.72	-12.44
18.46	-48.88	-4.55
-3.63	57.94	-20.34
9.78	50.36	12.68
-53.25	-49.58	49.41
-11.53	-75.5	10.92
-33.76	20.4	-18.36
1.84	23.85	62.5
-11.39	-83.18	20.65
31.62	-81.29	4.04
6.01	-60.39	33.78

// Toyomura A, 2015: Stutterers
// Subjects=10
-54	-26	8
46	-24	-2
-66	-18	-6
58	-16	-18
14	6	0
20	10	-8
18	-40	6
-44	-10	38
54	-4	28
-60	-6	20
-12	-64	-24
14	-66	-22
-22	2	10
22	6	10
-28	-18	-6
16	-4	-6
-36	10	-26
-20	-32	76
-10	16	6
10	-50	-20
-18	-26	64
28	2	-14

// Toyomura A, 2015: Healthy Controls
// Subjects=10
-54	-26	8
46	-24	-2
-66	-18	-6
58	-16	-18
14	6	0
20	10	-8
18	-40	6
-44	-10	38
54	-4	28
-60	-6	20
-12	-64	-24
14	-66	-22
-22	2	10
22	6	10
-28	-18	-6
16	-4	-6
-36	10	-26
-20	-32	76
-10	16	6
10	-50	-20
-18	-26	64
28	2	-14
-32	16	-2
-12	48	22
8	48	18
-10	2	38
10	-14	40
-24	-18	62
-28	-12	8
54	-50	30
-26	-72	6

// Wiener M, 2016: Reproduction > Production, Onset-locked
// Wiener M, 2016: Reproduction > Production, Offset-locked
// Wiener M, 2016: Parametric effect of distance during Reproduction versus 
// Production
// Wiener M, 2016: Regression analysis for Reproduction > Production, 
// Onset-locked
// Wiener M, 2016: Regression analysis for Reproduction > Production, 
// Offset-locked
// Wiener M, 2016: Regression analysis for Production > Reproduction, 
// Onset-locked
// Wiener M, 2016: Production > Reproduction, Onset-locked
// Wiener M, 2016: Production > Reproductioin, Offset-locked
// Subjects=24
-42	15	-12
-39	3	0
-36	0	15
0	9	39
0	-6	42
3	24	30
45	15	-9
57	15	-3
39	3	15
-30	-18	60
-45	-24	45
-36	-42	54
-63	-27	15
60	-15	27
63	-21	21
-27	-63	3
-15	-54	-12
-48	-72	9
15	0	0
6	0	9
-12	-24	39
15	-57	-12
15	-54	-30
24	-42	-3
24	-42	6
36	-57	0
42	-66	6
-36	-60	-45
-3	-21	-6
0	-27	3
-24	-9	-6
-18	-3	-3
54	-30	48
54	-30	39
48	39	-9
33	-18	-9
21	-45	-18
15	-63	-18
-15	-48	-12
-12	-60	-12
-33	-60	-51
6	-57	-6
51	21	24
45	24	12
45	18	6
0	27	45
-21	-54	39
-30	-57	36
-9	-63	24
45	-3	27
54	-3	27
21	-3	-21
33	3	-9
24	0	-6
51	-42	6
60	-45	6
24	33	30
21	21	30
-45	-42	-3
-42	-33	-9
21	12	-9
-15	6	-9
-30	6	-12
-21	6	0
21	-84	-12
12	-81	-3
36	-84	-15
18	-87	-18
39	-69	-12
15	-84	-12
36	-75	-15
30	-75	-21
12	-87	-15
33	-81	-21
24	-84	-15
45	9	33
42	30	21
36	12	60

// Spinelli S, 2017: ADHD
// Subjects=13
-14	-72	-26
-28	-66	-38
-16	-48	-26
20	46	28
20	44	18
-22	6	28
-24	14	18
-26	-4	8
-12	18	10
-12	12	18
-12	0	24
22	48	28
20	44	20
24	50	2
-18	-64	-30
-18	-54	-28
-22	-58	-38
-50	30	-2
-46	36	-14
-54	36	-10

// Spinelli S, 2017: controls
// Subjects=17
42	-82	28
44	-70	34
44	-62	26
20	-6	-28
36	-16	-22
28	-10	-24
22	30	36
22	24	42
14	30	48
-2	-62	22
18	-56	6
22	48	28
20	44	20
24	50	2
-18	-64	-30
-18	-54	-28
-22	-58	-38
-50	30	-2
-46	36	-14
-54	36	-10

// Sharma A, 2016: Healthy Controls
// Subjects=38
16	10	-10
-12	8	-10
24	32	-16
-38	44	-6
10	50	6
44	-44	54
28	-54	44
-20	36	50
2	38	38

// Sharma A, 2016: Unipolar Depression
// Subjects=24
16	10	-10
-12	8	-10
24	32	-16
-38	44	-6
10	50	6
44	-44	54
28	-54	44
-20	36	50
2	38	38
-16	8	-6
16	10	-10
-26	40	-10
0	66	4
28	-54	42
44	-46	34

// Sharma A, 2016: Bipolar Depression
// Subjects=24
16	10	-10
-12	8	-10
24	32	-16
-38	44	-6
10	50	6
44	-44	54
28	-54	44
-20	36	50
2	38	38
-16	8	-6
16	10	-10
-26	40	-10
0	66	4
-34	10	32
-16	8	-12
-40	36	-8
16	10	-10
44	-46	34

// Fuentes-Claramonte P, 2015: Switch > Repeat
// Fuentes-Claramonte P, 2015: Positive correlation between Sensitivity to 
// Reward (SR) Scores and Activation for Switch > Repeat
// Fuentes-Claramonte P, 2015: Negative correlation between SR socres and 
// Activation for Switch > Repeat
// Subjects=28
0	3	9
0	3	9
9	3	6
-9	3	6
-12	9	0
12	9	0
-48	-24	39
-42	-45	33
-48	-33	42
-54	24	21
-51	15	36
-42	-6	54
39	36	21
33	45	24
0	36	18
0	21	24
6	15	36
-3	-69	3
3	-69	3
-3	-60	9
3	-60	9
-9	-33	48
9	-33	48
42	-81	-6
42	-81	6
51	-72	-9
-9	-51	33
-6	-45	15
-3	-54	12
21	-48	66
30	-42	63
18	-42	57
-45	30	12
6	27	39
15	24	36
9	33	27
48	42	9
39	27	15
30	42	24
33	30	33
42	27	33
57	-30	36
48	-15	42
48	-12	57
-36	-33	45
-33	-24	57
-30	-9	51

// Joseph J E, 2015: Face > Texture, Combined Typically Developing Group (TD)
// Subjects=42
-22	-11	-15
25	-10	-16
52	-4	45
-39	-46	-21
2	42	-15
-39	-78	-9
40	-70	-10
38	-59	-17
41	-75	-6

// Kana R K, 2016: Autism Spectrum Disorder Participants (ASD)
// Subjects=17
46	22	22
46	-74	0
-34	-90	16
52	-42	0
-54	38	4
50	-68	8
-42	-70	2
8	-60	66

// Kana R K, 2016: Typically Developing Controls (TD)
// Subjects=15
56	-64	-2
-48	-74	-8
42	4	48
4	-78	-4
-16	-24	0
-48	34	-8
48	-38	4
30	16	28
24	-74	14
-40	-90	0
-16	-64	-8
-20	-28	8
-50	-50	2
-58	18	22
-30	-54	54
4	-68	20
56	-26	-10
-22	16	-6

// Morita T, 2016: Autistic Subjects (ASD)
// Subjects=14
-36	28	0
-42	10	10
-40	2	26
36	-68	-12
18	-70	-4

// Morita T, 2016: Healthy Controls (HC)
// Subjects=18
48	10	28
42	32	10
36	24	0
8	12	60
4	2	34
0	36	6
-32	16	8
40	-66	-12
42	-54	-12
36	-82	6
2	-16	-18
26	-30	-12
8	-18	2
36	-68	-12
18	-70	-4

// Young J S, 2015: Faces > Scenes
// Young J S, 2015: Scenes > Faces
// Subjects=44
48	-76	-16
42	-80	-12
42	-76	-10
40	-70	-18
-40	-82	-16
-40	-72	-22
16	-6	-14
12	-4	-16
18	0	-10
-18	-2	-12
32	-6	-42
-18	-10	-14
0	54	22
-18	58	36
-32	56	26
-10	52	22
-26	-48	-14
26	-40	-14
30	-44	-12
30	-48	-12
-28	-54	-12
22	-36	-18
-22	6	50
-24	4	58
-24	-6	44
-24	18	42
-34	52	2
-42	50	8
20	8	52
22	16	54
22	14	50
20	12	66

// Hodgson T L, 2015: Flip > Hold
// Hodgson T L, 2015: Eye > Hand
// Hodgson T L, 2015: Hand > Eye
// Subjects=15
-30.48	-59.82	53.4
10.55	-75.19	47.5
-30.49	1.4	65.27
-53.06	52.53	85.25
-39.45	66.79	53.35
-36.93	-26.79	62.57
40.42	-36.33	25.21
-3.25	52.03	8.25
-48.56	28.26	9.13
-24.12	2.72	56.07
-19.69	3.57	64.87
-17.68	13.38	54.9
-19.65	-81.47	50.87
-26.4	-92.29	27.41
-13.21	-92.7	45.15
-24.74	-60.94	-4.86
42.68	-83.74	23.14
21.41	-90.04	48.78
34.22	-86.78	37.03
33.58	-60.95	-8.09
14.98	-52.45	60.86
-52.18	-21.19	54.43
-52.27	-13.1	49.15
22.96	-109.91	-3.07
38.09	-103.27	-1.74
31.68	-107.13	3.23
-52.74	-7.91	12.78
-54.84	-16.22	15.88
47.47	-27.69	71.3
58.17	-24.02	64.03
57.45	-20.7	7.69

// Lyu C, 2015: Target-switching > Distractor-switching
// Lyu C, 2015: Target-switching condition > No-switching condition
// Lyu C, 2015: Distractor switching > No-switching condition
// Subjects=19
-18	10	67
30	15	27
-31	-56	58
36	-59	55
6	-72	0
-6	-72	0
-30	10	58
40	10	48
-39	25	-1
54	22	-3
-22	-69	40
39	-57	54
6	-63	-2
-6	-63	-2
-47	-40	9
-8	4	30
-33	24	-3
36	33	-9

// Sekutowicz M, 2016: Task switch > Repetition
// Sekutowicz M, 2016: Correlation of behavioral task switching costs for 
// Switch > Repeat
// Subjects=108
-27	-1	58
-48	14	22
-36	32	16
-51	5	37
-30	20	7
-18	8	1
-3	14	52
12	23	31
-6	20	37
-9	-73	43
-27	-70	43
-27	-67	34
12	-70	49
33	26	7
-15	-16	7
15	-13	10
24	-1	52
24	-7	52
30	-91	7
-21	-34	-2
-3	11	25
21	-34	1
-57	17	31
-51	5	37
-24	-4	58
-18	8	10
-42	20	16
-33	-22	52
-30	26	4
30	26	4
21	17	13
57	17	34
45	29	28
0	14	49
-6	-13	4
-30	-67	46
27	-7	55
6	-31	22
24	-22	16
-9	-70	46
9	-10	7

// Stelzel C, 2017: Abstract rule switching (task switch > task repetition)
// Stelzel C, 2017: Response hand switching (hand switch > hand repetition)
// Stelzel C, 2017: Conjunction (response hand switching and abstract rule 
// switching)
// Subjects=48
-50	12	22
-52	6	38
-26	-4	54
-12	-68	54
-32	-68	48
-52	0	38
-22	-4	50
-44	-26	40
36	-32	40
12	-26	16
12	-58	62
-44	-76	28
16	-22	8
20	2	20
-22	-8	-26
30	-50	-32
2	-54	-10
-26	-30	-28
-52	4	38
-14	-68	56
-26	-4	54

// Vallesi A, 2015: Task switching > Single task (spatial)
// Vallesi A, 2015: Task switching > Single task (verbal)
// Vallesi A, 2015: Task switching > Single task (Conjunction)
// Subjects=31
-38	-48	-4
-48	-46	54
-34	-64	54
-4	12	52
4	18	50
-6	24	40
44	38	26
6	-28	28
-4	-24	26
-44	30	30
-46	30	28
-42	8	26
-34	4	56
-6	12	52
-6	20	46
-48	-46	56
-40	-48	42
-30	-74	50
-4	12	52
4	18	50
-48	-46	54
-40	-48	42
-32	-56	44
-44	30	30

// Ludersdorfer P, 2015: Orthographic > Pitch Evaluation (Auditory words > 
// Auditory tones)
// Ludersdorfer P, 2015: Semantic > Pitch Evaluation (Auditory words > 
// Auditory tones)
// Subjects=24
-48	32	7
-42	5	25
-48	20	22
-60	-28	-5
-45	-64	-11
-27	-67	40
-12	-85	34
60	-22	-5
-60	-34	5
-48	20	19
-33	-67	40
36	26	-11
60	-22	5
9	-76	7

// Armbruster D J N, 2017: Task Switching > Implicit Baseline
// Armbruster D J N, 2017: Distractor Inhibition > Implicit Baseline
// Armbruster D J N, 2017: Task Switching > Distractor Inhibition
// Subjects=20
-46	-2	44
44	4	34
-46	32	36
44	30	30
42	42	12
32	22	-4
0	0	56
-6	16	42
-30	-52	46
54	-36	52
-2	-84	8
-20	0	14
18	2	14
18	-22	4
-2	-60	-12
-48	4	36
44	30	24
40	4	30
46	42	12
34	24	-6
-6	16	46
-42	-36	40
-44	-70	-10
46	-32	44
-44	-2	44
26	-8	52
-58	-28	50
56	-22	44
-54	-2	4
50	0	4
0	10	28
2	32	12
-6	-38	24
12	-8	64
10	-82	0
24	4	14
12	-18	12

// Liu Z, 2015: Rule learning > Rule application
// Liu Z, 2015: Rule Application > Rule Learning
// Liu Z, 2015: Switching > Rule Application
// Liu Z, 2015: Switching > Hypothesis Testing
// Liu Z, 2015: Hypothesis testing > Switching
// Liu Z, 2015: Feature Cued + Externally Cued > Feedback Cued
// Liu Z, 2015: Externally Cued > Feature Cued
// Subjects=12
43	26	36
-32	12	59
-55	11	33
49	13	3
-33	18	-6
-39	59	10
26	56	-17
10	7	5
-16	-2	16
30	-57	44
-38	-57	49
-42	-60	-21
68	-6	2
-6	-53	19
0	50	-16
-49	18	-39
-26	-19	-26
52	40	14
29	-57	7
-19	-59	22
-22	-49	-6
-19	9	-8
-16	9	-9
8	15	52
-8	6	59
60	11	35
-47	2	54
-63	-2	45
70	-13	54
24	-67	30
28	-53	48
-27	-67	34
-50	10	30
33	42	-12
30	36	-34
-32	39	-37
27	35	-14
-41	17	6
43	-46	-23
-47	-58	-10
37	-86	34
27	-62	9
-24	-40	4
20	19	-9
14	20	8
-15	4	-4
-44	53	-18
-14	44	49
30	70	19
-41	41	-10
69	-2	-34
69	20	-30
59	-46	-26
1	-95	-21
-54	-75	-25
-31	-28	-34
-18	3	27
24	-26	19
55	-60	-20
23	-89	-20
36	-66	-19
35	-41	-25
-55	-59	-8
21	18	60
-33	58	4
-34	2	63
-49	40	16
-22	21	57
10	9	-2
-3	7	5
20	-46	-4
0	-59	-6
17	-95	18
-39	-90	5
71	-3	-2
14	-20	61
-9	-49	64

// Manza P, 2016: Stop Signal Task (SST) SST25 > SST75 (Stop Success (SS) > Go 
// Success (GS))
// Manza P, 2016: Brain regions showing a significant correlation between SS > 
// GS and Stop-signal reaction time (SSRT)
// Subjects=16
-33	20	4
-42	14	4
-54	8	13
36	20	-8
48	38	25
9	-16	-11
-54	-37	37
-60	-40	46
-45	-49	55
60	-40	40
63	-34	22
30	-55	40
6	32	34
6	14	46
-6	17	43
-54	-58	-2
-42	-55	-11
-63	-55	13
54	-22	-8
-24	-70	-44
-33	-67	-44
-18	-61	-32
0	-22	-26
51	-49	-11
0	-58	-21
-9	23	46
9	26	37
12	14	58
15	11	34
-6	-19	-2
-9	-22	13
6	-13	1

// Wylie G R, 2017: Color Repeat > Baseline + Motion Repeat > Baseline
// Wylie G R, 2017: Color Switch Cue > Color Repeat Cue
// Wylie G R, 2017: Color Switch Cue > Motion Repeat Cue
// Wylie G R, 2017: Imperative Stimuli vs. Color Repeat Targets
// Wylie G R, 2017: Motion Switch Targets > Motion Repeat Targets
// Subjects=13
-.69	12.67	48.41
-56.34	7.08	36.13
-26.13	-60.07	45.88
-51.73	-46.51	58.42
-13.51	-97.26	4.24
-.9	-59.8	-7.96
7.92	-96.45	12.85
33.25	-64.51	-16.88
28.87	-47.96	-22.68
-39.41	23.07	21.21
-22.59	7.06	-22.24
-52	7.79	44.95
-47.78	-41.11	17.77
-39.44	-60.72	-16.37
20.47	58.98	39.82
25.27	-71.77	55.19
59.02	-62.99	0.54
33.64	-86.81	25.13
46.12	-68.32	-12.25
16.51	-96.05	17.18
-.29	-75.47	64.72
63.25	-59.08	-4.3
-47.69	-.64	45.6
-26.3	21.66	56.87
-26.76	60.87	13.44
-43.63	36.76	33.5
-5.52	59.63	-4.54
-21.71	-62.91	63.91
-60.74	-24.95	7.64
54.81	12.32	38.88
37.36	61.26	12.67
28.64	50.69	-13.11
41.97	25.27	42.4
50.82	-55.04	49.03
59.14	-48.59	21.63
20.44	-51.21	-8.93
-47.67	-79.52	16.53
-.58	-34.54	43.44
-5.33	8.87	-.29
8.26	-40.21	79.5
20.22	16.8	-10.17
-56.1	-29.96	52.62
-35.34	-40.57	-31.48
41.75	49.28	22.55
24.44	-32.1	-37.34

// Xu B, 2015: Stop-inhibit > StGo
// Xu B, 2015: Switch > SwGo
// Xu B, 2015: Stop-inhibit > Switch
// Xu B, 2015: Switch > Stop-inhibit
// Xu B, 2015: Stop-inhibit + Switch
// Subjects=18
64	-44	14
-54	-42	39
54	16	15
-50	12	26
-32	18	6
-12	18	5
-12	12	6
10	-6	5
48	-20	-7
16	13	66
3	49	17
4	28	38
24	52	32
-40	34	36
48	-41	41
-45	-42	48
30	-62	57
-32	-57	60
55	13	12
52	21	0
3	18	48
2	-21	30
30	6	58
-32	7	65
39	31	48
26	49	39
52	21	15
58	-51	32
6	25	57
37	24	5
28	-92	-12
-26	-98	-9
-32	-26	70
-40	-21	51
21	-57	-24
28	-48	-54
64	0	17
-15	-90	24
3	18	48
52	21	0
37	20	0
3	27	36
33	7	57
48	-41	41
-52	-39	39

// Ma J, 2017: ADHD > Control for No-go > Go
// Subjects=15
44	-64	-8
4	-12	-14
34	0	28
32	-60	12
32	-74	-2
-32	-76	12
4	-40	-22
2	-80	-30
-54	-4	16
-48	34	18
32	-28	-8
28	-90	14
-40	-84	-12

// MacDonald A D, 2015: Unprimed > Long-term
// MacDonald A D, 2015: Long-term > Unprimed
// MacDonald A D, 2015: Short-term > Unprimed
// MacDonald A D, 2015: Short-term > Unfacilitated
// Subjects=18
-45	33	15
42	24	21
54	0	21
-48	-51	-15
45	-45	57
0	-66	57
6	-57	48
39	33	39
42	-27	45

// van Rooij D, 2017: Controls = Sibs > ADHD on Successful stop - Go
// van Rooij D, 2017: Controls > Sibs= ADHD on Successful stop - Go
// van Rooij D, 2017: Controls > Sibs > ADHD on Failed stop - Go
// van Rooij D, 2017: Controls > Sibs = ADHD on Failed stop - Go
// van Rooij D, 2017: Controls = Sibs > ADHD on Failed stop - Go
// Subjects=111
-38	20	-18
-2	60	38
-58	-20	34
42	-24	52
48	-42	14
-52	18	-12
-50	-50	-12
48	-44	14
-18	42	30
-2	12	22
-58	-24	26

// Nigri A, 2015: Healthy controls
// Subjects=28
42	32	2
-39	29	3
12	-49	-13

// Nigri A, 2015: Disorder of Consciousness (DOC) patients
// Subjects=42
-30	23	-7

// Richey J A, 2015: Think Positive > Pre-Instruction, Controls > ASD
// Richey J A, 2015: Think Negative > Pre-Instruction, Controls > ASD
// Richey J A, 2015: Think Positive or Negative > Pre-Instruction, Controls > 
// ASD
// Subjects=15
12	7	-9
-23	5	-7
-19	1	-17
25	2	-25
-43	22	30
41	17	33
-23	29	53

// Mutic S, 2017: Aggression > Exercise Chemosignals, All emotional Stroop 
// conditions
// Mutic S, 2017: Aggression Chemosignals > No odor, All emotional Stroop 
// conditions
// Mutic S, 2017: Aggression > Exercise Chemosignals, Threat-related Stroop 
// conditions
// Mutic S, 2017: Aggression Chemosignals > No odor, Threat-related Stroop 
// conditions
// Subjects=18
-6	-1	-7
27	-4	68
48	-25	17
-9	2	-1
15	-28	8
-9	-28	-1
27	-4	68
-12	-1	-7
-3	-10	-10
6	-4	-7
-6	17	32
9	-61	-4
36	-61	20
12	-28	5
18	-22	8
9	-16	2
18	44	29
-24	23	29
-21	-10	-7
-9	-4	-10
60	-4	11

// Segarra N, 2016: Controls
// Subjects=21
14	30	56
8	6	-2
-6	-80	2
-48	40	-22
62	-26	-22
-20	-100	6
0	-24	30
-14	-76	-34
54	-54	40
-40	-62	40
14	30	56
8	6	-2
-6	-80	2
-48	40	-22
62	-26	-22

// Segarra N, 2016: Depression
// Subjects=24
14	30	56
8	6	-2
-6	-80	2
-48	40	-22
62	-26	-22
14	30	56
54	-54	40
-40	-62	40

// Segarra N, 2016: Schizophrenia
// Subjects=21
14	30	56
8	6	-2
-6	-80	2
-48	40	-22
62	-26	-22
-20	-100	6
0	-24	30
-14	-76	-34
54	-54	40
-40	-62	40
14	30	56
54	-54	40
-40	-62	40

// Walter H, 2017: Schizophrenia
// Subjects=16
-15	-9	-9
12	12	6
-6	12	30
-6	42	-6
-12	9	-3
27	-75	-27

// Walter H, 2017: Healthy Controls
// Subjects=16
-12	6	-3
9	6	-3
15	-15	-12
9	-27	-12
-6	-24	-12
-6	12	30
-39	27	-6
-21	-66	21
21	-72	15
-9	-99	6
-6	12	30
-3	51	-6
42	24	-15
9	39	21
42	36	21
39	21	-51

// Yan C, 2016: Gain > Non-gain anticipation, Controls > Negative schizotypy
// Yan C, 2016: Gain > Non-gain outcomes, Controls > Negative schizotypy
// Subjects=15
-30	-48	-42
12	-99	0
0	-90	-3
-63	-36	-6
-15	21	-3
-15	27	-12
66	-21	45
-18	0	-15
-6	-18	-15
-21	-51	-18

// Chou T L, 2015: ADHD patients treated with Atomoxetine
// Subjects=22
30	-15	60
12	-57	60
-18	-51	60
-3	9	42
3	12	42
-39	15	-3
48	-72	12
-24	39	36
30	-27	54
-30	12	15
33	12	0
0	15	39
-21	42	36
18	-48	63
-21	-45	60
-27	-24	63
-3	6	45
-27	39	39
6	33	60
45	42	0
42	12	-27
-45	-9	-15

// Chou T L, 2015: ADHD patients treated with OROS methylphenidate
// Subjects=20
-63	-48	15
36	-39	66
3	30	54
36	-39	66
42	-24	48
-51	15	-6
-39	21	27
36	-69	51
-45	33	24
27	-45	63
-39	-66	57
-42	36	21
18	57	6
42	12	-27
-45	-9	-15

// Chou T L, 2015: Healthy Controls
// Subjects=20
18	-48	63
-21	-45	60
-27	-24	63
-3	6	45
-27	39	39
6	33	60
45	42	0
27	-45	63
-39	-66	57
-42	36	21
18	57	6

// Melchers M, 2017: Vicarious embarrassment films > Control films
// Melchers M, 2017: Control films > Vicarious Embarrassment films
// Subjects=60
-51	-73	-2
48	-58	1
-60	-28	31
63	-21	37
48	35	7
-3	47	-23
-27	-49	-8
27	-46	-8
-36	82	37
42	-76	34

// Takahashi H, 2017: Guilt - Neutral
// Takahashi H, 2017: Embarassment - Neutral
// Takahashi H, 2017: (Guilt > Neutral) + (Embarrassment > Neutral)
// Takahashi H, 2017: Embarrassment - Guilt
// Takahashi H, 2017: Guilt - Embarrassment
// Subjects=19
-6	-95	12
2	-85	6
-16	49	9
4	57	16
-44	-61	20
20	-70	0
-8	50	25
-42	-59	18
-51	-31	-7
-53	1	-24
48	-7	-27
-44	31	-7
-34	-18	-18
-2	-89	4
2	59	17
-12	-77	6
2	-85	6
-10	36	52
4	57	16
-44	-61	20
12	-83	8
38	-68	-5
-10	-62	-2
-8	-80	1
42	-3	-27
32	-18	-13
-20	-14	-9
-16	49	14

// Ely A V, 2015: Non-Dieters
// Subjects=10
-22	16	58
-58	-2	-36
-34	-34	-4
-58	-14	-4
60	-4	6
-26	-6	-6

// Ely A V, 2015: Historical Dieters
// Subjects=10
-22	16	58
-58	-2	-36
62	-42	0
-52	-2	-12
16	-22	-14
8	16	-2
-16	-50	38
-56	-72	-6
50	22	26
-26	14	-14
52	-66	-2
-42	-12	28
-28	-48	-18
-4	56	-14
-2	-14	28
-24	-8	-12
40	24	-12

// Gao X, 2016: Lean Women
// Subjects=13
-1.64	11.66	63
42.75	33.2	7.15
-33.8	3.84	47.3
36.76	-5.25	47.25
-34.03	14.64	21.86
52.6	12.59	28.84
4.08	30.91	-18.97
-15.03	-4.1	-15.82
-17.06	13.46	5.04
36.15	-4.99	-31.94
-18.12	-6.26	-2.22
17.07	-6.82	-12.61
-4.95	-51.97	24.88
-18.01	-28.21	2.97
17.23	-28.26	-.78
-59.9	-7.54	-15.01
-20.72	-65.87	52.99
-33.57	-56.35	53.46
-24.02	-75.64	37.12
17.74	-59.21	53.11
-41.63	-49.27	-19.53
36.32	-35.06	-21.62
-44.47	-47.64	29.43
-45.6	-64.79	14.16
52.19	68.78	-1.51
-40.3	-65.18	8.55
43.04	-64.86	5.34
-40.33	-76.53	-.53
43	-76.2	-3.75
29.97	-75.16	-30.45
1.45	14.88	49.31
5.9	9.05	69.82
0.87	67.07	-5.24
5.1	56.81	-14.47
-52.11	9.93	31.38
57.95	10.59	30.06
43.86	33.72	13.79
-12.08	-49.56	70.49
0.98	10	-13.84
-.67	-46.49	26.6
-.81	25.73	38.39
7.67	11.89	23.84
6	-72.31	49.88
-16.98	9.83	13.15
19.37	4.76	13.15
-9.58	-.75	-.55
-32.25	-3.29	-31.3
30.81	-2.82	-30.95
-10.52	-15.94	9.66
15.12	-15.87	8.24
-1.05	59.51	21.06
6.06	-63.97	61.45
1.47	-59.59	22.1
-15.62	-84.87	13.27
-20.98	-88.33	10.27
-2.11	59.59	22.18
-14.61	-95.32	1.86
14.27	-94.89	4.84
26.87	-83.93	-19.64
3.58	14.9	49.29
-22.06	3.74	44.94
-18.4	31.49	-23.23
1.34	30.23	41.34
3.48	28.13	41.49
-24.62	32.36	2.42
33.09	27.25	-0.04
28.86	14.54	1.07
-33.29	-10.69	-30.67
-35.4	-8.25	-26.39
32.94	-2.9	-32.08
1.3	13.34	29.37
3.48	6.12	32.18
-3.39	38.7	-13.97
19.02	41.83	-16.72
1.39	-62.56	11.2
8.74	-13.36	13.68
-31.1	-10.17	-24.05
-30.94	-33.72	-12.04
-17.96	-40.81	5.14
-22.72	6.83	-38.95
-30.92	-43.41	-13.45
36.34	-34.89	-19.4
-16.36	-52.93	68.59
11.41	-61.65	63.42
-30.5	-37.98	42.96
-9	-57.43	51.04
1.41	-76.65	7.92
3.58	-82.9	9.53
-30.53	-88.85	18.23
-30.71	-90.73	-6.14
-9.56	-63.25	-24.3
1.03	-46.61	-30.28

// Gao X, 2016: Overweight Women
// Subjects=16
-46.06	47.93	-.87
51.26	43.91	7.27
-49.1	27.7	13.13
44.92	24.84	8.95
-30.79	-24.52	10.61
38.31	32.6	-13.93
-49.95	11.35	35.7
53.68	8.37	29.19
-3.88	11.76	50.75
7.98	5.2	61.2
-37.14	15.65	35.19
41.94	5.12	29.59
-37.4	-32.16	-18.78
36.3	-32.06	-24.1
-32.21	-5.14	-27.8
32.96	-2.64	-28.76
-14.83	6.67	13.39
-20.2	-2.33	7.51
-19.13	-1.27	7.41
20.4	-1.12	5.83
-18.02	-30.5	0.93
19.38	-28.07	1.41
-32.48	-53.97	56.59
34.81	-53.82	52.46
-10.02	-71.18	52.2
8.15	-73.27	51.05
-33.56	-55.2	54.48
36.94	-53.98	50.22
-20.95	-91.33	12.75
23.93	-91.06	12.22
-42.49	-58.05	4.63
45.16	-57.27	6.91
-41.63	-48.13	-18.51
38.57	-53.73	-15.62
-33.77	-91.41	12.91
36.79	-87.39	17.34
-32.81	-92.52	-1.51
33.42	-92.38	-5.63
-5.27	-70.71	-24.84
-10.63	60.85	25.52
-49.87	5.52	42.88
50.51	5.43	32.81
-38.4	33.4	16.99
48.14	33.74	13.74
-52.31	22.14	10.29
44.92	26.95	8.77
-41.84	41.98	-9.34
37.27	35.05	-9.67
-50	11.89	28.97
45.03	25.95	23.35
-4.92	16.42	55.95
5.83	5.02	59.01
-37.06	2.16	39.67
50.58	-2.68	37.95
-35.42	-2.96	-26.83
32.98	-2.47	-26.54
-16.93	-26.98	5.08
-32.48	-53.97	56.59
27.4	-53.18	61.41
-24.17	-56.4	24.36
16.71	-58.79	58.66
-33.53	-53.8	58.82
-19.86	-91.15	14.96
21.79	-90.02	12.15
-43.42	-63.2	20.69
50.62	-62.64	19.56
-41.61	-42.5	-14.52
41.72	-38.83	-15.79
-32.78	-91.12	2.83
34.55	-84.03	5.93
-32.81	-92.52	-1.51
33.44	-91.06	-2.39
-7.43	-74.24	-28.98
51.35	39.31	16.58
19.08	10.57	-21.9
40.9	1.06	32.18
-26.06	-62.56	55.01
33.79	-62.2	54.29
36.3	19.61	-2.78
-21.87	-64.53	42.86
28.3	-60.43	36.36
-33.74	-81.21	20.97
31.4	-81.25	14.65
-15.8	-87.81	-11.02
16.33	-86.94	-2.54
-38.43	-65.8	-27.1
-4.39	25.11	-10.58
1	21.26	-5.86
11.14	-79.88	20.35
-2.78	-80.22	17.19
58.05	-51.05	17.39

// Jackson T, 2017: Exercise - Landscape
// Jackson T, 2017: Sedentary - Landscape
// Jackson T, 2017: Exercise - Sedentary
// Jackson T, 2017: (Overweight (OW) > Average weight (AW)) x (Exercise - 
// landscape)
// Jackson T, 2017: (AW > OW) x (Sedentary - landscape)
// Jackson T, 2017: OW > AW
// Subjects=13
-17.6	-7.47	64.79
24.04	-4.3	60.7
-46.71	-63.02	9.56
52.66	-65.86	5.31
-33.61	-40.31	54.34
-1.79	3.52	40.27
29.68	0.97	-36.83
-34.37	-2.07	-29.15
29.82	-.92	-19.95
-24.48	7.42	10.09
23.62	4.53	9.78
17.24	-24.83	2.28
52.31	32.74	0.39
-43.48	-56.14	15.64
52.33	-0.01	-10.24
52.66	-65.86	5.31
-40.55	-42.58	-15.64
-27.89	-1.26	-19.25
29.83	-4.09	-19.68
17.26	-24.57	5.6
-56.18	-23.07	45.35
62.42	-21.48	41.62
0.29	-9.13	27.92
33.55	11.1	52.61
-27.53	-27.24	16.38
-30.68	-36.52	20.54

// Kurosaki M, 2017: Lean Females
// Subjects=11
6	-79	-34
12	-77	-24
31	10	28
-20	-3	-15
-31	12	29
-20	-3	-15
-31	12	29
-31	3	25
-40	26	6
-45	34	-6
-17	-79	-38
-22	-79	-33
-8	-77	-31
-13	20	50
-1	20	39
-8	18	43
-38	16	8
-45	26	8
-36	43	-2

// Kurosaki M, 2017: Lean Males
// Subjects=11
-20	-75	-22
-29	-69	-25
31	-52	31
26	-67	31
17	-67	31
36	-85	4
3	-89	-5
12	-81	-11
-38	-81	-11
-13	-93	-17
-29	-83	-17
3	-93	7
34	-69	-13
36	-50	-15
26	-63	30

// Puzziferri N, 2016: Obese Females
// Subjects=15
42	-20	4
46	-2	12
34	-32	2
-38	-2	-24
-38	18	-26
-36	16	-34
18	8	42
12	14	56
26	-6	48
-4	-30	-36
14	-36	-38
0	-38	-42
48	28	-2
52	16	-4
-18	-36	-28
-16	-38	-16
-14	-44	-26
32	14	-24
34	26	-16
-32	-4	64
-40	-14	48
-36	-10	54
8	-76	-34
14	-76	-44
8	-82	-22
-32	46	8
-20	50	14
-16	62	14
36	-6	38
-28	10	68
-22	18	30
-32	34	44
8	-48	-16
-2	-50	-22
10	32	14
6	44	12
12	28	36
40	-60	-46
30	-52	-48
14	-50	14
8	-54	18
-12	-58	18
26	32	48
26	18	42
6	40	50
-8	34	52
10	40	42
-8	-68	42
-2	-26	-4
6	-24	-2
-6	-36	48
-12	-50	38
-10	-48	30

// Puzziferri N, 2016: Lean Females
// Subjects=15
8	-50	-18
16	-88	-4
10	-12	10
14	-36	3
14	-50	16
-6	-56	16
8	40	46
-26	24	44
-2	66	24
-64	-22	36
-10	-20	36
4	-34	-46
2	-30	-38
8	-76	-34
14	-76	-44
8	-82	-22
-32	46	8
-20	50	14
-16	62	14
36	-6	38
-28	10	68
-22	18	30
-32	34	44
8	-48	-16
-2	-50	-22
10	32	14
6	44	12
12	28	36
40	-60	-46
30	-52	-48
14	-50	14
8	-54	18
-12	-58	18
26	32	48
26	18	42
6	40	50
-8	34	52
10	40	42
-8	-68	42
-2	-26	-4
6	-24	-2
-6	-36	48
-12	-50	38
-10	-48	30

// Tuulari J J, 2015: Entire Cohort: Inhibition > Passive viewing
// Tuulari J J, 2015: Entire Cohort: Inhibition > Imaginary eating
// Tuulari J J, 2015: Entire Cohort: Imaginary eating > Passive viewing
// Tuulari J J, 2015: Entire Cohort: Imaginary eating > Inhibition
// Tuulari J J, 2015: Entire Cohort: Passive viewing > Inhibition
// Tuulari J J, 2015: Entire Cohort: Passive viewing > Imaginary eating
// Tuulari J J, 2015: (Healthy > Obese) x (Inhibition > Passive viewing)
// Tuulari J J, 2015: (Obese > Healthy) x (Inhibition > Passive viewing)
// Tuulari J J, 2015: (Healthy > Obese) x (Imaginary eating > Passive viewing)
// Tuulari J J, 2015: (Healthy > Obese) x (Inhibition > Imaginary eating)
// Subjects=14
-18	52	32
-2	6	60
-8	2	74
50	24	6
-46	-36	18
64	-32	18
8	-74	32
40	-16	-40
48	-62	40
27	-72	-24
-12	4	72
-50	-34	48
-24	-72	42
6	-38	40
44	-74	26
40	8	46
36	14	62
30	20	62
56	-52	24
52	-62	22
6	-76	38
24	16	48
38	52	24
30	20	62
-50	28	8
-66	-28	8
-60	-16	-2
28	32	-6
44	38	-2
44	22	26
6	-38	12
-4	-32	12
38	14	-10
-14	16	30
20	6	22

// Gilead M, 2016: Self-conscious > Basic
// Gilead M, 2016: Basic > Self-conscious
// Gilead M, 2016: Guilt > Other
// Gilead M, 2016: Pride > Other
// Gilead M, 2016: Anger > Other
// Gilead M, 2016: Joy > Other
// Gilead M, 2016: Social > Non-social
// Gilead M, 2016: Negative > Positive
// Subjects=19
-8	46	36
-38	14	46
-28	-38	-24
14	-50	6
-46	-80	32
64	-16	30
-50	-6	-8
8	8	8
58	26	14
-6	16	68
-52	20	8
46	38	-14
-48	-38	-8
-42	-64	42
14	-86	2
-24	-80	-38
22	-80	-24
-2	62	24
-40	-60	26
-52	-6	-28
40	-84	32
-36	-86	36
-8	52	28
-50	26	-10
-38	10	50
-34	52	8
-50	-64	18
-2	-62	38
-22	-80	-44
26	-80	-42
-42	10	52
2	40	52
42	30	-18
-50	-64	20
-52	-8	-28
-20	-86	-32

// Chung Y S, 2016: Healthy Controls
// Subjects=27
46.22	8.58	32.6
41.93	34.7	40.49
52.53	30.57	27.34
-47.83	8.9	31.42
56.85	-41.42	4.33
-10.54	-82.04	-19.37
-25.64	-68.18	-31.51
33.82	-58.6	59.56
-19.68	-62.86	50.5
-11.73	-82.27	-36.07
47.6	-46.43	50.58
-35.73	-53.36	51
17.7	-63.95	46.82
16.09	-80.62	-30.95
-52.85	-42.63	53.64
-35.31	-53.43	-32.64
4.22	-58.83	-37.1
53.79	-47.56	21.61
-42.6	-64.71	-12.65
-42.69	-49.19	-18.41
-30.81	-76.36	-12.92
49.47	-60.16	10.45
44.1	-77	-.35
-27.26	-74.94	32.64
49.3	-56.41	-9.94
38.94	-81.66	22.41
-25.18	-89.79	19.36
31.56	-73.02	38.49
34.35	-69.62	-14.24
-27.69	-57.48	-16.77
35.32	-50.84	-19.17

// Chung Y S, 2016: Schizophrenia
// Subjects=36
35.1	35.84	-13.05
24.5	30.03	-4.64
46.22	8.58	32.6
41.93	34.7	40.49
52.53	30.57	27.34
-47.83	8.9	31.42
56.85	-41.42	4.33
-10.54	-82.04	-19.37
-25.64	-68.18	-31.51
33.82	-58.6	59.56
-19.68	-62.86	50.5
-11.73	-82.27	-36.07
47.6	-46.43	50.58
-35.73	-53.36	51
17.7	-63.95	46.82
16.09	-80.62	-30.95
-52.85	-42.63	53.64
-35.31	-53.43	-32.64
4.22	-58.83	-37.1
53.79	-47.56	21.61
-42.6	-64.71	-12.65
-42.69	-49.19	-18.41
-30.81	-76.36	-12.92
49.47	-60.16	10.45
44.1	-77	-.35
-27.26	-74.94	32.64
49.3	-56.41	-9.94
38.94	-81.66	22.41
-25.18	-89.79	19.36
31.56	-73.02	38.49
34.35	-69.62	-14.24
-27.69	-57.48	-16.77
35.32	-50.84	-19.17

// Nielson M O, 2017: Salience:(Uncertain gain (ug) + Uncertain loss (ul) > 
// Certain neutral (cn) + Uncertain neutral (un))
// Nielson M O, 2017: Behavioral salience: (ug + ul > Certain gain (cg) + 
// Certain loss (cl))
// Nielson M O, 2017: Valence anticipation: (cg + ug > cl + ul)
// Nielson M O, 2017: Winning (Certain win (cw) + Uncertain win (uw) > Zero 
// neutral (zn))
// Nielson M O, 2017: Losing outcome (Certain lose (ocl) + Uncertain lose 
// (oul) > zn)
// Subjects=31
51.82	-48.06	42.86
48.13	6.19	1.55
12.82	5.47	-4.67
38.68	37.51	35.83
35.62	-69.76	11.41
32.07	28.82	6.53
29.04	-25.39	7.76
19.84	-34.28	58.8
19.26	45.37	15.33
0.75	-39.45	76.18
-31.98	-17.01	-2.27
-31.85	30.49	33.89
24.57	-51.59	-27.9
23.95	-95.29	12.57
13	-5.85	14.12
2.59	-4.14	50.89
1.44	-87.4	6.59
-29.91	3.18	-2.88
-29.33	-11.68	66.39
-34.21	-55.28	-29.15
-43.32	-13.85	53.35
-45.43	-28.92	51.29
-49.82	-26.89	36.68
11.67	9.01	-13.88
-1.92	-17.57	15.27
-11.78	9.47	-5.84
70.61	-39.37	-11.61
45.46	-60.79	44
48.26	33.88	29.34
48.39	12.19	37.85
47.99	57.46	3.94
38.73	-87.14	-7.24
26.11	-91.77	16.71
6.72	-86.82	-.21
6.5	42.64	22.39
-0.02	-54.02	-29.65
-16	-73.41	-31.18
-32.11	-71.1	-41.23
10.95	-78.51	-3.19
-1.3	50.25	-16.07

// Sabharwak A, 2016: Psychosis group
// Subjects=46
-48	36	-4
-64	-48	14
-32	-4	-12
50	-10	44
-10	38	30
-42	22	38
-64	-44	-8
-36	-64	26
-26	28	10
-12	18	38
32	-68	-42
-8	2	2
10	48	6
-36	52	12
10	48	4
-60	-18	-22

// Simon J J, 2015: Expectation of reward: Large reward > No reward, All 
// subjects
// Simon J J, 2015: Expectation of reward: Small reward > No reward, All 
// subjects
// Subjects=23
-9	-87	-4
-12	0	-4
9	6	-8
-39	18	0
36	27	0
-6	27	20
-12	12	8
9	-9	12
-42	0	32
-39	33	28
42	45	24
38	-30	-54
29	3	-63
54	3	-30
12	-30	-81
9	-45	3
55	-9	-75
51	-6	12
-9	6	0
12	6	-4
-39	18	4
36	21	-4
0	12	28
24	-54	-20

// Arrondo G, 2015: Healthy Controls
// Subjects=21
-2	-56	-18
10	10	56
-14	-8	12
10	16	-4
32	32	-6
-26	24	-4
-30	-22	-4
-38	42	-4
24	-68	-26
-12	-18	-14
46	0	44
26	-70	-56
36	0	48
50	-42	16
24	52	0
-32	-40	34
-34	-8	42
34	58	-10
-40	-58	-20
8	-74	-36
-4	14	20
20	-12	-10
50	18	-8
-32	58	-10
-40	-4	54
26	-58	-22
34	34	20
-28	-4	42
2	36	30

// Paulus F M, 2015: Vicarious embarrassment ((Embarrassment WITH > Neutral) 
// AND (Embarrassment FOR > Neutral))
// Paulus F M, 2015: Vicarious Embarrassment (Parametric modulations)
// Paulus F M, 2015: Embarrassment WITH > Embarrassment FOR
// Paulus F M, 2015: Embarrassment FOR > Embarrassment WITH
// Subjects=32
-3	14	55
-6	-10	7
-36	26	-2
-6	56	22
45	17	-29
33	-61	-26
-3	-22	-17
-48	14	22
12	11	10
-39	-55	-26
-30	-16	-8
51	2	46
-30	23	7
69	-37	22
3	-1	61
-54	-37	28
51	-37	4
33	26	7
-9	23	28
-51	-31	25
-54	-58	16
51	-49	7
-15	-88	7
66	-43	13
-21	-7	-14

// Gunther V, 2017: Happy > Neutral
// Gunther V, 2017: Neutral > No-face
// Gunther V, 2017: Sad > Neutral, High > Low Social Anhedonia
// Subjects=18
54	-46	37
48	20	31
-51	-49	31
66	-37	-2
57	-52	1
-60	-37	34
15	8	52
48	-4	37
-33	32	31
18	-46	-44
-6	-28	1
-39	41	31

// Kirschner M, 2016: Reward anticipation > No reward anticipation
// Subjects=25
10	15	-3
12	6	3
-14	20	-14
4	-6	3
9	24	-5
-6	20	-5
-36	-30	52
12	-91	4
9	-87	4
-48	-30	45
-9	8	1
-42	-19	52
-46	-24	49
-38	-28	57
-42	-25	46
4	8	49
-33	36	30
30	28	21
34	34	31
33	31	43
36	-15	-13
-34	-6	-6
34	1	-6
42	-61	3
46	46	4
64	-21	15
-42	-51	-12
-63	-21	12

// Makowski C S, 2016: Schizophrenia
// Subjects=15
14	-90	-38
36	-86	-36
64	-20	40
4	32	-10
-4	36	-10
-4	22	-12
-28	56	24
-20	50	24
-48	28	-16
10	-44	38
18	-44	40
46	-58	40
36	-54	56
40	-40	54
-14	-44	58
30	12	-18
34	18	-22
24	2	-12
10	34	38
22	20	50
30	24	52
-24	-48	24
-30	-54	26
-8	-8	34
42	22	-18
-40	4	36
-54	20	20
56	14	10
56	-20	36
12	-54	14
-6	-56	8
-8	-54	10
-38	-64	32
32	-68	-10
48	-20	38
60	-12	40
-46	30	-16
-46	18	-12
-40	-66	34
-44	0	36
-40	12	34

// Makowski C S, 2016: Healthy Controls
// Subjects=15
-34	-92	8
-30	16	-22
-10	-8	-8
-12	-10	-14
-14	14	2
10	8	0
36	20	-24
28	16	-22
24	34	-16
44	-86	6
10	-48	40
-14	-46	42
-2	-42	38
34	-66	-12
26	-84	-2
40	-84	-14
-14	56	0
8	34	36
6	24	18
-42	-60	-8
-48	-60	-16
52	38	2
10	-44	38
18	-44	40
46	-58	40
36	-54	56
40	-40	54
-14	-44	58
30	12	-18
34	18	-22
24	2	-12
10	34	38
22	20	50
30	24	52
-24	-48	24
-30	-54	26
-40	30	0
-30	22	-14
-14	-4	-14
20	-24	-16
32	-24	-20
-6	-54	14
-26	14	-22
-34	20	-18
-24	22	-10
42	-82	24
26	-72	42
32	20	-30
30	34	-14
30	22	-18
30	34	-14
-44	-60	-10
-48	-54	-22
-32	-88	4
-24	-92	-10
0	36	-4
8	46	18
6	36	40
2	4	30
0	-12	36

// Richter A, 2015: Schizophrenia
// Subjects=16
-12	6	9
12	0	3
-9	-18	-15
6	-24	-18
-30	42	12
36	42	12
-36	51	21
-33	39	21
39	33	33
-42	3	33
51	6	30
-36	-15	63
27	-6	51
-30	21	0
33	21	0
-27	-57	42
33	-54	42
-36	-45	45
-15	24	-9
-33	36	30
36	42	33
-33	15	33
42	-6	48
-36	-18	63
27	-3	51
-30	24	-12
-33	-57	27
33	-72	36
-36	-42	51
36	63	9
-39	54	18

// Richter A, 2015: Healthy Controls
// Subjects=16
-15	6	6
12	6	3
-6	-18	-18
6	-24	-18
-36	42	12
27	45	0
-36	51	21
-33	39	21
36	30	30
-42	3	33
42	3	42
-36	-15	63
24	-9	48
-30	18	3
33	21	3
-30	-51	45
33	-54	45
-39	-48	63
-15	24	-9
-33	36	30
36	42	33
-33	15	33
42	-6	48
-36	-18	63
27	-3	51
-30	24	-12
-33	-57	27
33	-72	36
-36	-42	51
36	63	9
-39	54	18

// Schmidt A, 2018: Healthy Controls
// Subjects=13
12	-74	14
-2	-84	20
22	-70	6
-6	-24	-10
6	-22	-10
-48	-54	-4
-46	12	-16
-14	-74	24
-26	-76	20
-8	-78	6
-14	-70	44
52	10	2
44	8	6
18	-96	8
24	-86	6
54	-36	34
6	6	44
-30	-44	36
-50	2	36
12	0	8
12	-14	8
-36	-4	12
-20	-34	54
-14	-26	54
-14	8	-8
-4	-20	12
12	-74	14
-4	-36	-46
22	-18	12
14	0	8
-40	-16	-22
26	-68	-4
-18	34	14
-14	-2	6
46	6	14
2	-60	-6
40	-40	16
-20	-50	2
28	34	8
-6	10	-2
-14	-36	-8
2	-58	-10
-8	-30	-8
-46	-64	0
-46	14	-14
-48	-6	40
44	6	-2
-16	6	-8
-6	-12	40
46	-8	44
4	6	46
10	10	40
54	-2	36
26	-10	8
-40	0	10
-12	-80	6
-6	-74	4
-30	-10	-8
-16	32	16
-32	20	18
-47	-52	-40
10	18	-2
-18	-40	34
-4	-12	12
-4	-14	0
-26	-26	30
38	-48	-38
20	-94	10
-20	-86	14
30	-24	28

// Schmidt A, 2018: Ultra-high-risk for Psychosis (UHR)
// Subjects=23
12	-74	14
-2	-84	20
22	-70	6
-6	-24	-10
6	-22	-10
-48	-54	-4
-46	12	-16
-14	-74	24
-26	-76	20
-8	-78	6
-14	-70	44
52	10	2
44	8	6
18	-96	8
24	-86	6
54	-36	34
6	6	44
-30	-44	36
-50	2	36
12	0	8
12	-14	8
-36	-4	12
-20	-34	54
-14	-26	54
-14	8	-8
-4	-20	12
12	-74	14
-4	-36	-46
22	-18	12
14	0	8
-40	-16	-22
26	-68	-4
-18	34	14
-14	-2	6
46	6	14
2	-60	-6
40	-40	16
-20	-50	2
28	34	8
-6	10	-2
-14	-36	-8
2	-58	-10
-8	-30	-8
-46	-64	0
-46	14	-14
-48	-6	40
44	6	-2
-16	6	-8
-6	-12	40
46	-8	44
4	6	46
10	10	40
54	-2	36
26	-10	8
-40	0	10
-12	-80	6
-6	-74	4
-30	-10	-8
-16	32	16
-32	20	18
-47	-52	-40
10	18	-2
-18	-40	34
-4	-12	12
-4	-14	0
-26	-26	30
38	-48	-38
20	-94	10
-20	-86	14
30	-24	28
20	-20	64
0	-16	58
-10	-4	70
4	-6	64
18	6	-6

// Smieskova R, 2015: Healthy Controls
// Subjects=19
56	-32	44
36	-40	38
56	-40	38
-8	-14	42
-22	-10	56
-14	-24	50
48	6	20
54	6	10
32	16	8
38	24	-4
48	6	20
36	18	8
18	38	22
6	22	32
0	32	26
-62	-24	26
-64	-38	36
-60	-34	42
-66	-40	30
-62	-38	44
-64	-22	26
24	-82	22
34	-78	14
18	-88	34
-46	6	6
-10	4	-6
10	2	-6
24	-98	-6
54	-32	42
58	-24	36
42	-40	42
4	28	28
4	26	26
-28	-56	-30
-42	-62	-30
-26	-64	-26
-52	-28	22
-62	-24	38
-52	-56	-8
-48	-58	2
-44	-46	-14
-28	-12	72
-20	-8	60
-38	-10	58
-6	-4	56
4	-2	42
-8	-8	42
-26	-96	-6
8	-24	-10
8	-20	-20
12	-14	-14
-38	-38	14
54	-36	18
46	-42	18
36	-42	-36
30	-72	8
-46	-38	48
-46	-36	62
-58	-34	52
2	-56	-34

// Smieskova R, 2015: Clinical At-risk Mental State (ARMS)
// Subjects=34
56	-32	44
36	-40	38
56	-40	38
8	40	24
-2	32	26
4	50	4
-62	-24	26
-64	-38	36
-60	-34	42
64	-36	12
64	-24	4
58	-18	0
-40	-32	14
-64	-44	18
-62	-44	18
-24	-100	-8
-40	26	2
-2	42	10
4	54	-2
-6	30	-6
50	14	22
64	8	20
24	-98	-6
-6	6	-6

// Smieskova R, 2015: First-episode Psychosis (FEP)
// Subjects=29
48	6	20
54	6	10
32	16	8
-66	-40	30
-62	-38	44
-64	-22	26
-60	-32	6
-52	-24	4
-46	-32	10
58	-26	6
-52	8	16
-34	20	-2
46	6	34
-12	2	-4
-50	-4	-8
-28	-96	-10
-18	-100	-2
-22	-104	-2
60	12	6

// Smieskova R, 2015: Subgroup of FEP, Medicated (FEP-M)
// Subjects=12
38	24	-4
48	6	20
36	18	8
18	38	22
6	22	32
0	32	26
8	40	24
-2	32	26
4	50	4
66	-24	38
-52	-50	-12
-58	-34	-6
-64	-32	4
-34	-48	-50

// Smieskova R, 2015: Subgroup of FEP, Unmedicated (FEP-UM)
// Subjects=17
-8	-14	42
-22	-10	56
-14	-24	50
24	-82	22
34	-78	14
18	-88	34
40	30	-2
-52	10	18
-14	0	-2
-18	-6	-6
-58	-30	6
-32	22	0
-26	16	-2
60	12	6
52	16	4
-44	40	22
-38	30	18
-46	30	12
60	-30	10
-34	94	-6
44	50	10

// Stip E, 2016: Subgroup of Schizophrenia, Ziprasidone
// Subjects=13
1.28	15.37	28.08
-30.14	26.05	-23.75
10.96	-59.76	5.28
-5.02	-65.94	9.33
36.25	22.36	-8.59
-34.29	25.11	-8.01
55.9	-62.15	11.65
33	25.25	-12.14
17.41	-62.64	8.79
8.12	-95.53	38.42
7.73	22.35	35.23
1.66	6.11	73.47
-37.46	15.57	-7.17
-40.61	-33.32	-19.77
-43.73	-65.32	-20.39
-53.11	-72.83	7.11
-53.48	-7.5	-15.09

// Stip E, 2016: Healthy Controls
// Subjects=15
68.66	-52.81	7.38
39.43	-40.47	-36.81
45.83	45.13	-3.92
36.25	22.36	-8.59
23.56	13.79	5.66
20.3	-62.53	-31.4
-8.19	-13.95	35.11
-8.38	51.06	36.35
-40.67	15.55	-7.14
-56.29	-72.6	10.47
-56.55	-24.73	-3.57
10.96	-79.57	-3.1
-14.48	-100.64	15.69
36.25	22.36	-8.59
-34.29	25.11	-8.01
55.9	-62.15	11.65
33	25.25	-12.14
17.41	-62.64	8.79
8.12	-95.53	38.42
7.73	22.35	35.23
1.66	6.11	73.47
-37.46	15.57	-7.17
-40.61	-33.32	-19.77
-43.73	-65.32	-20.39
-53.11	-72.83	7.11
-53.48	-7.5	-15.09

// Subramaniam K, 2015: Reward anticipation > Baseline, Healthy Controls + 
// Schizophrenia, p< .05
// Subramaniam K, 2015: Reward outcome > Neutral outcome, Healthy Controls + 
// Schizophrenia, p< .05
// Subramaniam K, 2015: Punishment anticipation > Baseline, Healthy Controls + 
// Schizophrenia, p< .05
// Subramaniam K, 2015: Reward anticipation > Baseline, Healthy Controls > 
// Schizophrenia, p< .001
// Subramaniam K, 2015: Loss outcome > Neutral outcome, Healthy Controls > 
// Schizophrenia p< .001
// Subjects=20
12	-88	2
12	-92	-4
12	-94	-22
10	8	-4
-42	-36	42
-50	2	40
40	-6	50
-8	-28	-14
-2	-34	-12
-20	10	-8
20	12	-6
-8	36	-8
-6	38	10
-36	-40	38
46	-32	40
-20	-82	-10
-20	-96	0
54	10	42
-24	56	20
-14	54	6
24	22	62

// Winton-Brown T, 2017: Healthy Controls
// Subjects=32
-21	-13	-8
18	-7	-5
-15	-16	-11
-21	-31	-5
-39	-85	-8
-30	-88	13
-39	-64	-8
36	-85	10
42	-79	-5
42	-64	-5
6	-28	-17
-30	20	-8
-33	32	-5
-24	29	-14
-24	-70	34
45	29	-2
51	29	10
36	29	-2
24	-40	-14
24	-28	-17
42	-64	-5
-24	-40	-14
-27	-70	-8
-18	-25	-20
39	-85	10
33	-88	19
27	11	-26
27	2	-23
36	2	-20
21	-7	-14
18	-7	-5
12	-7	-5
45	-76	-5
-39	-46	-20
42	-52	-17
-39	29	-14
-48	20	19
-48	26	7
39	11	25
51	29	13
51	17	28
-6	50	28
-9	29	46
-51	-7	-17
-3	41	-17
-3	50	-14

// Winton-Brown T, 2017: Ultra High Risk for Psychosis (UHR)
// Subjects=29
-21	-13	-8
18	-7	-5
-15	-16	-11
-21	-31	-5
42	-70	-11
36	-82	-11
30	-82	10
-36	-79	-17
-27	-61	-8
-27	-85	4
48	38	7
0	-34	34
-3	-46	19
-12	-52	16
-12	-13	-11
-18	-28	-5
6	-22	-17
9	-31	-11
-45	38	7
-3	26	-8
18	-10	-8
6	-7	-11
27	-31	-2
-39	23	-2
30	2	-23
-27	-58	-14
-39	-67	-8
48	-67	-5
42	-52	-8
36	-70	-8
33	-79	13
-15	-34	22
-42	8	31
-39	-55	-17
-39	-67	-14
-42	-64	16
42	-76	-2
39	-49	-17
42	-61	-11
0	50	-17
39	8	31
39	35	-14
48	32	10
0	56	22
-15	38	37
15	-31	1
-3	-55	19
-39	17	-35
-45	8	-35
57	-4	-17
48	-13	-14
42	17	-32
24	-52	43
-54	-7	-17
39	-13	-29

// Lu J, 2017: Familiar > Baseline
// Lu J, 2017: Unfamiliar > Baseline
// Lu J, 2017: Unfamiliar > Familiar
// Subjects=29
-3	3	69
1	3	69
-48	-3	51
54	0	48
-60	0	16
-39	-45	42
48	-39	48
-15	-75	51
21	-70	51
-54	9	18
63	13	30
-21	3	65
24	0	54
-27	5	57
32	1	58
-27	-66	39
30	-63	36
-23	-74	39
26	-68	39
-52	12	-3
60	-33	12
-3	3	69
2	3	69
-48	0	54
57	6	45
-56	-1	41
-39	-45	42
46	-49	42
-21	-72	48
22	-68	55
-51	9	18
50	12	18
-24	-2	65
22	6	55
-30	4	55
33	3	58
-30	-71	40
33	-73	40
-18	-76	41
26	-73	41
-53	13	-8
-54	10	36
-42	-39	45
32	-52	44
-23	-62	44
26	-65	51
-57	12	27
-23	-3	53
-33	-84	-4
32	-86	-3
-35	-87	-3
31	-86	4
-14	-92	3
27	-67	42
57	-29	17

// McPherson M J, 2016: NegImprov > NegChrom
// McPherson M J, 2016: NegChrom > NegImprov
// McPherson M J, 2016: AmbImprov > AmbChrom
// McPherson M J, 2016: AmbChrom > AmbImprov
// McPherson M J, 2016: PosImprov > PosChrom
// McPherson M J, 2016: PosChrom > PosImprov
// Subjects=12
-4	0	66
-52	12	32
-54	10	16
-54	10	20
4	14	64
-30	-36	-8
-34	58	2
-30	30	38
-44	18	40
-6	36	48
-4	50	24
-2	-42	36
-54	-58	38
-52	-60	24
-8	-64	38
32	-16	-14
40	50	4
4	-42	32
48	-64	46
48	-66	42
6	-64	38
-2	12	60
-2	-8	62
-54	8	12
-50	18	16
52	16	12
54	18	15
54	-26	0
-28	54	18
-36	22	40
-38	34	42
-14	40	20
2	-38	36
-54	-56	42
-52	-66	32
-4	-60	42
28	-16	-20
10	64	15
46	24	40
24	22	42
-2	-38	36
8	38	28
50	-54	48
46	-70	34
8	-62	44
-56	10	34
-52	10	22
-26	-36	-2
-25	60	2
-30	32	42
-2	30	54
-6	46	20
-2	-44	34
-8	42	16
-56	-58	30
-58	-88	28
-2	-64	36
32	56	2
38	24	40
32	26	46
2	30	52
6	46	38
4	-38	34
6	42	16
60	-48	40
58	-58	24
10	-64	32

// Derbyshire S W G, 2017: Patients
// Subjects=13
-4	-26	-16
-18	-26	0
14	-16	0
-22	-20	14
-54	0	-2
48	14	-4
-56	22	32
48	24	20
-46	-34	52
54	-34	44
-56	-4	18
52	-62	0
-46	-36	52
8	-8	-12
6	-4	-2
8	6	14
-22	2	0
-22	-2	-14
-30	14	-8
10	18	32
10	0	0
16	-6	20
-38	-2	-8
16	20	30
-52	20	18
46	52	-2
62	-12	38
66	-8	8
6	-6	0
10	16	2
12	32	-4
14	-4	16
12	12	4
4	32	14

// Derbyshire S W G, 2017: Healthy Controls
// Subjects=15
8	-18	-14
8	-6	2
14	8	18
-6	-80	48
4	-78	44
0	-28	26
-20	30	40
30	44	30
0	8	68
-8	20	32
2	16	46
10	12	34
6	20	36
6	46	22
-10	46	2
6	30	48
50	42	22
-48	-56	44
38	-46	44

// Bianchi F, 2018: High Frequency (HF), Musicians > Non-musicians
// Bianchi F, 2018: HF and Low Frequency (LF), Musicians > Non-musicians
// Bianchi F, 2018: HF and LF, Non-musicians > Musicians
// Subjects=15
-3	-37	-11
48	2	13
39	-1	13
51	8	22
-27	-82	34
54	23	16
6	-13	25
-63	-19	7
51	-22	1
51	-22	1
51	8	22
39	-1	13
-3	-34	-11
-63	-19	7
-48	-49	-14
-54	-37	-5
39	44	7
24	56	10
-48	5	19
60	-43	-5
-3	-10	25
51	-64	-5
33	-73	40
3	-37	34
-36	44	1
33	-34	-2
-30	-40	1

// Bogert B, 2016: Main Effect of Emotion
// Bogert B, 2016: Implicit > Explicit
// Bogert B, 2016: Explicit > Implicit
// Subjects=56
56	-2	-4
-50	-10	-2
-18	-8	-19
2	48	-14
-6	24	36
-6	16	54
-32	48	8
30	-64	-32
-44	8	30
48	-42	54
48	38	20
10	10	2
-26	4	63
36	-76	42
-58	-54	-18
30	10	58
-2	20	44
-50	-34	38
52	10	36
-40	-80	-12
44	-78	-8
-6	62	36
12	62	36

// Karmonik C, 2016: Bach > Baseline
// Karmonik C, 2016: Gagaku > Baseline
// Karmonik C, 2016: Bach Visual > Baseline
// Karmonik C, 2016: Self > Baseline
// Karmonik C, 2016: Cronkite > Baseline
// Karmonik C, 2016: Click > Baseline
// Karmonik C, 2016: Chaplin > Baseline
// Subjects=12
-1.58	77.03	-0.03
59.31	19.9	1.61
-60.48	18.27	2.34
43.39	-45.47	4.15
-.98	33.38	46.56
-49.83	-44.59	0.47
-61.35	21.39	1.42
55.04	17.7	1.06
-1.54	99.05	-27.75
-57.29	76.32	9.48
3.22	63.81	48.76
19.92	79	45.51
17.62	-23.2	-16.6
43.01	31.87	13.4
-49.85	28.84	12.82
-11.71	10.1	3.7
13.93	-2.08	11.89
-31.63	92.68	-23.52
-5.47	55.28	-27.82
30.03	40.27	51.65
-28.18	21.38	6.62
17.5	77.61	-19.14
47.88	12.55	-.21
-55.33	10.75	2.25
-.77	-24.52	50.63
20.82	58.48	-41.11
-36.44	58.24	-37.64
-53.25	9.88	50.14
-3.75	56.77	-40.35
2.26	26.17	34.19
-55.52	2.62	1.81
59.66	12.16	1.92
37.46	64.83	41.03
19.98	58.82	-38
-9.32	-48.08	41.22
-20.62	75.37	-44.61
24.78	-15.03	0.36
4.73	-37.27	24.21
42.13	-31.12	-15.32
-18.4	-1.96	19.06
-57.33	11.57	6.21
60.89	19.12	-1.69
53.36	-9.52	36.04
51.59	-36.34	3.07
59.87	15.56	3.31
-59.73	13.74	1.38
40.17	-17.73	27.29
-7.14	7.05	68.58
-52.19	-31.93	4.67
27.95	-42.87	25.41
-57.03	-14.59	21.56
16.8	-11.53	-34.97

// Sikka R, 2015: Main effect of Melody Recognition
// Subjects=20
-47	6	4
-41	22	4
-54	9	14
-41	6	24
39	29	1
49	9	1
45	19	24
-24	26	-9
55	13	-13
55	-7	-6
9	-7	4
-21	6	4
-21	0	-13
-31	-14	-3
22	9	4
29	-17	-3
-11	-17	-9
-4	-24	1
9	-24	-3
-50	-40	24
-1	-1	63
-4	13	53
6	13	40
-8	13	37
65	-34	14
-50	-7	47
-44	-4	57
52	3	50

// Mueller K, 2015: Forward Consonant (FC) > Backward Dissonant (BD)
// Mueller K, 2015: Correlation between BOLD and Pleasantness rating
// Subjects=23
52	-17	0
52	0	-8
50	3	-15
-56	-17	0
-53	0	-8
-50	-10	-5
0	-10	0
-6	-30	-8
12	-27	-10
2	-24	0
-23	-10	-12
-13	-14	-20
-18	-2	-10
22	10	0
54	-14	0
54	-2	-5
62	-27	5
-53	-14	0
-53	-2	-8
-53	-22	-5
-18	-2	-12
14	-27	-10
-13	-14	-18
-6	-30	-8
-16	-27	-12
-3	-10	-10
7	-10	-5
0	-7	2
14	0	-12
17	3	2

// Feldker K, 2017: Panic-related scenes > Neutral scenes: Patients > Controls
// Subjects=26
2.28	-40.24	-2.95
19.48	-43.51	8.28
-9.55	-31.22	-9.15
27.02	-54.92	11.38
-49.2	9.07	-7.61
-39.58	-.73	-11.36
-64.02	7.18	10.56
-36.4	-8.63	-17.42
-50.09	5.49	15.01

// Feldker K, 2016: Disorder-related scenes > Neutral scenes: Patients > 
// Controls
// Subjects=11
32.47	4.41	48.72
55.95	-2.31	42.32
23.95	9.1	55.11
40.95	16.98	45.34
38.68	15.59	27.64
55.82	9.52	30.18
-33.67	-76.12	31.7
-42.26	-76.52	27.37
-27.2	-73.28	40.31
-44.54	16.46	46.36
-29.64	33.47	44.76
-23.25	39.86	44.16
-27.54	26.46	36.41
-23.07	8.82	55.68
-42.45	26.88	43.23
-3.86	26.2	58.46
-38.02	6.61	56.04
2.41	13.78	34.9
4.35	24.93	13.86
-2.06	33.7	17.66
-4.03	24.48	36.3
11.12	30.86	62.36
-8.48	62.18	28.73
0.52	7.53	64.44
-4.11	52.15	36.21
-1.85	40.33	48.33
-8.63	47.44	3.21
-30.11	52.8	-8.15
-2.2	65.25	12.79
-13	55.18	-6.32
-4.44	37.8	-11.65
-2	-31.63	-1.39
-8.63	-29.5	-28.26
-6.25	-2.79	14.08
-23.52	1.91	-6.19
-17.05	17.95	8.01
-34.27	9.96	-11.2
-36.34	6.23	-4.17
17.19	5.46	8.66
2.1	-33.32	-23.6
-8.53	4.45	-2.11
-14.89	-32.39	-10.1
-32.2	29.01	-12.82
-23.67	9.17	-22.41
6.57	-7.12	12.07
-8.56	-11.21	-11.95

// Fitzgerald J M, 2017: Main Effect of Group
// Fitzgerald J M, 2017: Main effect of Condition
// Fitzgerald J M, 2017: Group x Condition Interaction
// Subjects=30
-50	6	54
-2	16	62
38	-64	-32
52	24	18
-36	26	-6
42	30	-14
50	-60	16
52	2	-30
-40	-62	20
-20	-78	-30
42	30	-14
14	-76	-26
56	-6	2
-50	-4	6
-10	0	44
-58	-40	0
0	-56	-38
20	-46	-10
-26	-4	-20
-22	-86	-2
-20	34	-16
-40	14	12
-42	-20	18

// Moon C M, 2015: Healthy Controls (HC) > General Anxiety Disorder (GAD), 
// Neutral distractors
// Moon C M, 2015: GAD > HC, Anxiety distractors
// Moon C M, 2015: HC > GAD, Anxiety distractors
// Subjects=18
-12	-66	4
12	-66	12
18	-34	-20
20	-32	-18
20	-33	-13
-16	-57	15
-12	-80	48
22	-92	24
-7	-79	19
-30	-40	2
16	-74	54
-8	-72	62
-20	-95	24
-36	44	34
-36	-56	-22
42	-60	-16

// Reinecke A, 2015: Main effect of task across groups: Reappraise > Maintain
// Reinecke A, 2015: Main effect of task across groups: Maintain > Reappraise
// Reinecke A, 2015: Main effect of group: Patients > Controls
// Reinecke A, 2015: Group x Task Interaction: Maintain vs. Reappraise
// Subjects=18
-4	20	50
-36	-64	-28
36	-60	-52
16	22	-16
26	-32	22
-20	-42	24
-8	28	38
-46	30	28
-56	-28	-12
-32	-68	40
20	36	54
48	56	-2
14	-42	4

// Aue T, 2015: Phobics > Controls: Snakes > Spiders
// Subjects=17
6	-61	55
12	-61	67
21	-70	55
-21	-76	40
-24	-61	55
-24	-76	31
9	-70	25
0	-82	25
-9	-64	61
-3	-55	61
33	41	22
-48	35	16
-39	23	19
42	-79	10
33	-67	25
30	-79	10
18	26	37
18	17	64
9	17	58
-15	17	67
-21	8	70

// Binelli C, 2016: Social Anxiety Disorder (SAD) Patients
// Subjects=20
18	-98	2
-14	-98	2
46	-78	-2
38	-54	-24
-40	-54	-18
44	18	26
66	-16	10
44	-24	12
-58	-32	12
0	30	32
-8	18	56
-42	24	24
30	-74	-16
-28	-74	-10
-4	-68	42
68	-28	-10
-62	-44	-14
12	-56	-46
48	-68	2
-4	50	16
-24	30	40
-52	-42	-14
64	-20	-18
-58	-46	-12

// Binelli C, 2016: Williams-Beuren Syndrome (WBS) Patients
// Subjects=20
36	-96	-8
-36	-94	-8
40	-48	-20
64	-18	-16
-20	-8	-10
44	22	34
-40	24	24
12	18	42
18	-98	6
-16	-98	-2
42	-62	8
64	-18	-16
12	-18	68
48	-68	2
-4	50	16
-24	30	40
-52	-42	-14
64	-20	-18
-58	-46	-12

// Binelli C, 2016: Healthy Controls (HC)
// Subjects=20
30	-94	-6
-26	-96	-6
44	-82	-6
40	-50	-24
-38	-54	-20
16	-6	-20
-16	-4	-22
48	18	28
-54	20	32
-54	-28	10
4	-26	54
-8	18	56
-42	24	24
30	-74	-16
-28	-74	-10
-4	-68	42
68	-28	-10
-62	-44	-14
12	-56	-46
18	-98	6
-16	-98	-2
42	-62	8
64	-18	-16
12	-18	68

// Heitmann C Y, 2018: Disorder-related scenes > Neutral scenes, Social 
// Anxiety Disorder (SAD) > Healthy Controls (HC)
// Subjects=30
-45.45	-76.36	29.62
-10.62	-44.43	-14.72
-5.22	46.25	28.91
-26.9	59.42	-5.4
-57.56	-40.59	-2.23
-1.68	-39.21	38.27
-10.26	-53.86	28.45
-41.39	8.14	34.76
-10.06	-52.95	54.02
-22.41	0.14	-1.59
17.8	-49.81	64.59
-4.23	-11.64	-4.16

// Yin D, 2017: Generalized anxiety disorder (GAD) Patients
// Subjects=20
24	-4.8	-15
-21	-9	-18
34	-18	15
9	45	-18
-3	54	24
9	-51	12
3	0	42
12	-18	6
54	-63	3
-48	-75	12
-42	-45	-18
42	-39	-21
39	-18	57
48	18	15

// Yin D, 2017: Healthy Controls
// Subjects=14
57	27	18
36	-12	15
48	-60	9
-39	-45	-15
-48	-78	3
42	-30	60
48	18	15

// Fonzo G A, 2015: Positive relationship between [Trait Anxiety and (Fear > 
// Happy)], All Participants
// Fonzo G A, 2015: Positive relationship between [Trait Anxiety and (Angry > 
// Happy)], All Participants
// Fonzo G A, 2015: Faces > Shapes: Patients > Healthy Controls (HC)
// Fonzo G A, 2015: Faces > Shapes: Panic Disorder (PD) > HC, Generalized 
// Anxiety (GAD), and Social Anxiety (SAD)
// Fonzo G A, 2015: Faces > Shapes: GAD,  HC, and SAD > PD
// Fonzo G A, 2015: Faces > Shapes: PD and GAD > HC and SAD
// Fonzo G A, 2015: Fear > Happy: GAD, SAD, and PD > HC
// Fonzo G A, 2015: Angry > Happy: PD and SAD > GAD and HC
// Fonzo G A, 2015: Angry > Happy: PD > GAD, HC, and SAD
// Subjects=14
33.26	20.25	19.5
39.57	-23.61	-11.46
-20.03	20.24	37.96
-9.28	9.99	42.04
-30.55	-23.18	41.72
-50.82	-40.47	40.06
40.14	-48.5	51.95
-18.7	-8.87	60.46
-36.35	-72.9	-36.57
-38.43	28.74	11.81
-34.68	-62.33	45.05
-1.11	-67.49	-38.54
-36.87	-28.79	52.3
-19.73	-10.74	63.97

// Heitmann C Y, 2017: Disorder-related scenes > Neutral scenes: Social 
// Anxiety Disorder (SAD) > Healthy Controls (HC)
// Subjects=24
-38.38	14.91	11.85
-63.8	-46.58	17.3
5.96	-50.74	53.65
44.9	-21.55	-12.81
26.82	-28.46	-4.22
39.48	27.03	-3.44
48.01	23.66	-6.6
9.89	25.97	40.48
6.66	43.21	43.53
43.11	11.7	45.75

// Aviram-Friedman R, 2018: [Obese Binge Eating Disorder (BED) > Obese], 
// Visual cues of food > Nonfood
// Aviram-Friedman R, 2018: [Obese BED > Obese], High energy processed food 
// (HEPF) > Low energy processed food (LEUF)
// Subjects=14
34	-4	12
8	8	44
-38	-64	18
24	-60	8
-38	-64	18
-38	-64	18
16	-84	26
24	-60	8
-66	-22	22
16	-84	26
54	-38	24
8	8	44
-16	-8	50
-16	-8	50
-16	-8	50

// Demos K E, 2017: Short sleep > Long Sleep, Food > Nonfood
// Subjects=30
24	22	-19
3	54	-30

// Janssen L K, 2017: Main effect: Food > Neutral
// Janssen L K, 2017: Interaction effect: [Food > Neutral] > [Emotion > 
// Neutral]
// Subjects=69
-36	-62	38
-44	-60	34
-58	-52	30
-56	-38	-8
-48	-42	-6
-48	-52	-14
-30	32	-10
-34	10	44
-22	34	-14
38	-58	34
38	-52	40
46	-48	30
60	-42	-2
54	-34	-8
52	34	24
44	30	24
34	26	18
-4	-34	36
-6	-64	40
-4	-42	32
14	-84	-34
30	30	-20
-34	-62	38

// Lee J E, 2017: Bulimia Nervosa
// Subjects=12
-18	44	48
-24	20	-8
-42	8	54
18	16	-4
6	6	2
60	0	26
16	-92	-4
20	44	48
-16	34	58
8	14	8
-42	8	54
-48	-44	-4
26	-70	2
-34	-72	34
20	44	48
-16	34	58
6	14	10
-40	8	52
-48	-44	-4
26	-70	2
-34	-72	34
60	0	28
-28	-86	0

// Lee J E, 2017: Binge Eating Disorder
// Subjects=13
-18	44	48
-24	20	-8
-42	8	54
18	16	-4
6	6	2
60	0	26
16	-92	-4
6	6	2
60	0	28
20	44	48
-16	34	58
6	14	10
-40	8	52
-48	-44	-4
26	-70	2
-34	-72	34
60	0	28
-28	-86	0

// Lee J E, 2017: Healthy Controls
// Subjects=14
-18	44	48
-24	20	-8
-42	8	54
18	16	-4
6	6	2
60	0	26
16	-92	-4
20	44	48
-16	34	58
8	14	8
-42	8	54
-48	-44	-4
26	-70	2
-34	-72	34
6	6	2
60	0	28

// Opel N, 2015: Obese > Controls; Reward > Control
// Opel N, 2015: Group x Condition [Obese vs. Controls x Reward/Loss vs. 
// Control]
// Subjects=28
36	18	-14
-28	24	-8
50	-70	28
12	-80	24
34	-72	-32
-36	32	24
-28	60	6
6	42	6
-38	-56	34
-26	22	-10
-26	40	16

// Reiter A M F, 2017: Exploitation > Exploration, All Participants
// Reiter A M F, 2017: Conjuction Single- Update and Double- Update RPE, All 
// Participants
// Reiter A M F, 2017: Double- Update RPE, All Participants
// Reiter A M F, 2017: Single-Update RPE, All Participants
// Subjects=22
-28	26	-2
32	24	-8
-4	16	46
44	22	-10
-32	20	-8
-6	52	-12
32	36	-12
-4	18	-8
-40	-68	30
2	50	-12
-8	54	-2
8	12	-10
14	6	-14
28	-4	4
30	-12	4
30	6	4
-12	6	-14
-18	-6	-18
-26	-4	-18
28	-18	-18
26	-6	-20
18	-8	-18
-34	36	-16
30	36	-14
26	30	-18
-14	60	-2
-14	66	-6
-6	60	-8
-6	50	-14
6	-48	30
-4	-36	38
-60	-40	-12
-62	-32	-14
-56	-58	-8
-40	-70	-42
-40	-78	-30
-28	-86	-28
44	-74	-32
44	-68	-42

// Stice E, 2018: Intervention > Control: High-Calorie > Low-Calorie; Baseline 
// > Follow-up
// Subjects=20
48	-24	24
36	-12	9
-48	-12	-6
-45	0	12
-46	0	-12
-57	-39	27
33	0	-6
42	6	0
51	0	6

// Verdejo-Romn J, 2017: Willingness to pay task: Highly palatable foods > 
// Plain foods; All Participants
// Verdejo-Romn J, 2017: Activations during Monetary Incentive delay task 
// anticipation: All Participants
// Verdejo-Romn J, 2017: Deactivations during Monetary Incentive delay task 
// anticipation, All Participants
// Verdejo-Romn J, 2017: Activations during Monetary Incentive delay task 
// feedback, All Participants
// Verdejo-Romn J, 2017: Deactivations during Monetary Incentive delay task 
// feedback, All Participants
// Subjects=37
16	-80	0
-10	-68	22
-2	28	40
-6	26	34
2	-10	-8
-10	16	-4
-6	4	0
62	-44	28
-8	50	0
-30	58	6
0	60	0
-36	14	-14
-14	18	-4
-26	32	-10
-36	14	34
-32	26	24
32	20	-6
40	16	-8
30	30	-10
10	-68	22
2	28	40
6	26	34
-2	-10	-8
8	50	0
-12	90	0
8	-12	-8
-6	-16	-10
-4	0	42
0	-8	56
8	-26	0
-22	-26	10
-16	-88	-20
22	-72	-20
-14	-36	-10
-38	-22	-16
38	-20	-16
12	12	-4
-12	8	-2
-32	30	-6
34	26	-8
-26	24	6
34	26	-2
40	-8	38
-40	-16	50
-20	-2	12
20	4	16
16	-68	42
-10	-76	40
-36	-36	48
54	12	-6
20	6	-12
-20	2	-10
-32	38	28
36	32	24
12	90	0
4	0	42
56	-58	28
-46	-62	28
2	-62	30
-2	-62	30
-30	-86	-2
30	-84	8
-28	-64	38
32	-66	32
-4	-38	30
-34	-60	-16
34	-48	-20
-6	-58	12
-18	-36	-8
20	-34	-4
-16	14	-12
18	18	-8
-26	-12	0
28	-18	-2
-44	-44	38
40	-36	26
20	12	6
-18	14	0
-42	2	24
48	36	18
-44	48	-4
-20	20	56
4	-38	30
6	-58	12
46	18	0
-32	22	-10

// Kleint N I, 2015: Heartbeats > Tones
// Kleint N I, 2015: 100 bpm > 50 bpm
// Kleint N I, 2015: 50 bpm > 100 bpm
// Kleint N I, 2015: Heartbeat: 50 bpm > 100 bpm
// Kleint N I, 2015: Heartbeat: 100 bpm > 50 bpm
// Kleint N I, 2015: Tones: 100 bpm > 50 bpm
// Subjects=36
42	39	3
36	0	27
-42	24	6
9	48	39
39	-57	57
15	-3	24
-33	39	9
45	3	54
-30	-78	-42
-39	-72	-30
21	-60	-21
-51	-6	48
-3	3	60
-48	6	3
-6	-27	63
-9	-21	66
21	-60	-24
-30	-27	24
33	-75	0
-51	-6	48
-54	0	33

// Minkova L, 2017: Harsh > Neutral distractors, Entire Cohort
// Subjects=15
42	-52	-20
40	-42	-22
42	-26	-20
-50	20	10
-42	28	4
-36	26	-14
-6	14	58
20	-10	-12
-40	-58	26
54	-38	8
52	-34	0
44	-42	16
-10	54	34
-42	4	44
-34	8	40
-20	-12	-10
-42	-36	-16
54	32	2
4	48	-18

// Kraus J, 2018: Social Anxiety Disorder (SAD) > Healthy Controls (HC), 
// Aversive/fearful > Neutral stimuli
// Kraus J, 2018: SAD < HC, Aversive/fearful > Neutral stimuli
// Subjects=12
30	0	-16
32	-2	-14

// Misra G, 2015: Force Only > Baseline
// Misra G, 2015: Pain Only > Baseline
// Misra G, 2015: Conjunction Analysis: Force Only and Pain Only
// Misra G, 2015: Force Pain > Force Only
// Misra G, 2015: Force Pain > Pain Only
// Misra G, 2015: Force Pain > Force Warm
// Subjects=15
5	13	45
0	-3	60
1	6	48
-43	2	6
-27	-4	2
-14	-19	9
-38	-15	56
-28	-92	-3
-42	-72	-1
-30	-51	57
-18	-75	-47
39	11	6
28	3	5
12	-19	7
38	-6	56
30	-96	-3
35	-85	4
45	-39	49
33	-46	52
16	-74	-45
23	-56	-21
58	9	28
47	-62	-1
62	-22	38
63	-32	22
0	26	31
-1	0	61
0	12	57
-47	-13	13
-26	-5	8
-22	8	-6
-16	17	6
-60	-33	24
-39	-40	47
-28	-52	51
-21	-74	-50
-30	-91	-1
-45	-70	3
39	16	3
24	10	-5
11	8	8
13	17	0
62	-28	20
50	-35	46
33	-60	-23
31	-87	-2
43	-76	-10
28	-68	35
40	5	-13
55	5	31
0	9	48
1	0	62
2	7	57
-44	1	8
-24	9	1
-26	-5	5
-44	-71	4
-28	-92	-2
-15	-76	-45
38	18	4
39	2	12
47	-63	5
34	-87	-2
57	7	29
62	-21	37
63	-32	22
43	-41	49
-1	13	39
-7	11	56
-1	33	27
-55	-20	14
-19	-71	43
-27	-58	-24
-5	-59	-7
-3	-5	57
-44	-20	52
-13	-19	7
-15	-69	-48
39	-8	55
62	-17	36
37	-43	54
37	-85	4
0	15	39
15	-80	-12

// Sevel L S, 2015: Pain > Rest
// Subjects=24
-6	8	41
6	5	56
0	-4	62
-6	23	26
15	-13	5
-21	14	-1
48	-34	23
21	17	2
60	-16	23
6	29	23
9	-25	-16
54	-46	29
54	-27	24
15	-49	71
-9	-19	2
33	44	29
33	-22	17
54	11	-7
54	-37	44
6	-25	23
-57	-22	14
-48	-37	50
33	2	5
18	11	11
-9	-79	5
0	-58	-7
12	-13	-13
33	23	2

// Matsuo Y, 2017: Healthy Controls
// Subjects=13
35.36	13.23	11.14
0.29	28.28	43.74
0.38	6.07	45.6
38.69	27.74	33.31
-2.83	-69.73	15.2
-28.41	-72.54	22.42
16.43	-56.16	23.87
-6.01	-13.51	40.63
-25.38	21.27	37.93

// Matsuo Y, 2017: Patients
// Subjects=11
-38.09	-56.74	21.2
26.08	-29.44	38.25
-18.83	19.42	54.74
-6.01	-13.51	40.63
-25.38	21.27	37.93

// Perlaki G, 2015: VAS 7 > VAS 1 (Activation)
// Perlaki G, 2015: VAS 7 < VAS 1 (Deactivation)
// Subjects=18
-32	-20	18
36	8	6
-4	0	44
4	-12	-2
54	-2	6
38	-16	8
-36	4	10
-56	-2	8
-4	8	-10
10	34	-14

// Petschow C, 2016: Healthy Controls
// Subjects=13
-63	-31	19
-48	-31	19
-51	-19	22
45	-28	22
54	-37	19
63	-19	25
-21	-10	61
-12	-16	70
-33	-19	19
-57	-22	31
-54	-28	19
57	-19	16
45	-31	22
57	-43	19
15	-7	67
0	-13	67
-15	-7	67
51	2	7
51	17	1
36	11	7
-39	2	-14
-39	-1	-5
-33	8	7
0	5	40
-6	2	46
12	-52	46
9	-70	37
3	-49	61
-6	-55	43
-15	-46	46
6	-31	22
6	-46	13
27	41	28
-15	-25	4
-9	-25	13
21	-28	7

// Petschow C, 2016: Parkinson's Disease Patients
// Subjects=13
6	17	46
6	8	37
6	8	55
-33	-22	16
-51	-1	4
-39	5	7
51	-1	7
51	11	13
36	-1	10
-30	26	4
45	-19	22
63	-19	16
51	-28	25
-63	-22	19
-60	-28	28
-54	-34	13
-33	-19	16
12	-25	4
-45	-19	10
42	-1	-17
57	-16	19
39	-13	10
-6	8	40
3	8	43
-3	17	31
-6	-49	61
9	-52	64
-18	-43	64
6	-31	25
12	-52	46
9	-70	37
3	-49	61
-6	-55	43
-15	-46	46
6	-31	22
6	-46	13
27	41	28
-15	-25	4
-9	-25	13
21	-28	7

// Asghar M S, 2016: Placebo: Pain > Baseline (Activation)
// Asghar M S, 2016: Placebo: Pain > Baseline (Deactivation)
// Asghar M S, 2016: CGRP: Pain > Baseline (Activation)
// Asghar M S, 2016: CGRP: Pain > Baseline (Deactivation)
// Asghar M S, 2016: Sumatriptan + CGRP: Pain > Baseline (Activation)
// Asghar M S, 2016: Sumatriptan + CGRP: Pain > Baseline (Deactivation)
// Subjects=27
-34	10	42
-12	8	50
66	-18	24
-56	-22	26
46	-32	38
50	-44	52
-50	2	6
40	-18	22
60	-30	-4
-36	-74	-18
38	-10	22
-44	-10	4
6	-18	-20
-2	-58	-18
40	-68	-30
44	-78	-34
26	-80	-24
30	-78	-20
36	-80	-42
28	-12	66
40	-14	62
28	-20	66
22	-32	70
-2	-40	64
-40	-42	-24
-12	-46	2
-40	-50	10
-6	-40	42
-24	4	-32
-10	20	4
10	18	0
-6	16	6
10	14	0
-6	6	-6
6	6	-8
-26	-36	-26
24	-62	-56
-40	12	12
-30	32	4
40	22	-2
32	22	-2
-32	0	16
14	-20	-24
-14	-22	-24
6	18	64
-8	-38	62
-30	-8	62
32	-32	54
-52	0	46
-30	0	50
-24	12	44
-36	16	42
-24	36	40
-40	24	34
-28	34	32
-48	24	22
-46	32	8
48	6	18
-36	24	-16
34	-46	60
30	-50	52
-46	-36	50
-40	-36	40
42	-36	56
38	-34	50
-34	-34	62
-42	-42	58
-24	-46	56
-54	-12	50
-34	-24	48
-58	-14	16
-60	-24	16
-4	-46	38
-6	-54	18
-52	-52	34
-6	-54	18
-4	-66	26
10	-70	18
10	-60	18
12	-66	10
-12	-62	14
0	-40	50
-2	-40	42
0	-26	40
0	28	34
0	-48	24
-14	14	6
-14	-26	6
-24	10	-8
28	2	-12
32	-6	20
30	-80	-44
-14	-82	-24
10	-66	-46
-4	6	44
-38	34	44
-22	26	48
-52	22	24
-52	22	10
-50	-18	36
-54	-26	54
-42	-58	24
-38	18	-6
-6	-14	14
42	-74	-40

// Bagdanov V B, 2015: Early Cold > Baseline
// Bagdanov V B, 2015: Sustained Cold > Baseline (Activation)
// Bagdanov V B, 2015: Sustained Cold > Baseline (Deactivation)
// Bagdanov V B, 2015: Laser > Baseline
// Subjects=24
-3	-73	49
-57	-70	-75
45	5	58
27	-4	-8
6	-40	46
3	-43	16
12	47	-11
-9	29	-17
48	23	28
-21	-25	25
18	-16	28
-18	-1	25
-18	-13	28
12	-37	13
-33	-22	19
-21	-25	25
-12	-19	19
-12	29	-17
3	35	-17
36	17	-2
-30	20	-5
45	-16	16
-39	-7	-2
-30	14	7
42	-7	10
48	11	19
18	-4	-14
-21	-4	-14
-15	8	-11
9	2	4
3	-22	31
-60	-28	22
63	-22	22
0	20	25
-60	-49	43
33	-49	43
60	-40	37
48	38	7
-15	-34	-8
-18	-7	-14
6	-28	4
12	-10	10
54	-10	16
27	29	-17
12	-64	31
-48	38	19
36	53	31
6	11	61
0	-31	-5
-60	-60	7
-18	-73	-32
12	-91	-26
-9	8	4
9	5	7

// Sinke C, 2017: Pain > Control
// Sinke C, 2017: Control > Pain
// Sinke C, 2017: Postive Expectancy > Negative Expectancy
// Sinke C, 2017: Stimulation X Expectancy (Positive Expectancy 
// [Pain>Control]) > (Negative Expectancy [Pain>Control])
// Subjects=21
-36	8	6
-4	14	50
0	24	30
38	-18	18
54	-2	8
34	8	14
54	-22	24
14	-10	8
8	-16	28
6	14	36
2	8	40
2	24	28
20	-44	68
-20	-10	-24
28	-28	-24
32	-14	-22
-24	-74	-8
-2	38	8
-4	22	-8
-6	46	2
-30	-36	-2
58	-54	40
8	44	22
32	-38	2

// Aue T, 2018: Spider Phobic Patients
// Subjects=20
45	44	-14
6	41	43
-30	23	-8
-39	26	34
-27	-67	46
48	-52	43
12	-85	7
-9	-76	-29
27	-61	-32
-27	-67	-32
0	-55	-35
-6	-55	46
-18	-61	13
-15	-91	-11
18	-97	-2
48	11	-26
-9	-4	31
-27	47	40
42	-1	34
-60	-37	16
9	-82	34
12	-97	7
-24	-55	46
-12	-1	16
-21	-76	-41
18	-97	-2
45	-13	-26
6	-43	55
51	2	43
36	47	37
-39	41	34
9	17	64
-36	14	-8
0	32	13
-18	56	31
-6	-49	31
-48	-70	34
0	35	13
-42	29	1
39	32	4
-36	20	-20
-51	-61	10
57	-55	13
-27	47	25
-12	-34	40
18	-43	55
66	-31	31
-57	-43	28
-24	-73	-41
0	32	13
-21	56	31
-24	44	46
48	35	-11
-36	20	-20
36	11	-17
-3	-13	34
-6	-49	28
66	-31	31
-60	-40	28
-51	-58	10
-24	-76	-38
30	23	-5
39	29	22
-6	-79	-5
45	-79	-2
42	-46	43
-27	-64	40
-6	-79	-5
36	-85	-8
15	-97	25
3	-91	22
30	-79	-17
-12	-49	-5
51	32	34
-45	20	40
-39	53	-2
-21	14	-17
42	14	-47
9	-16	-26
9	11	10
-54	-64	31
45	-46	52
3	-91	19
66	-46	25
30	62	16
42	23	-17
-21	14	-17
9	29	55
60	-58	10
45	8	-47
9	-1	13
3	-94	19
-45	-64	-38
21	-40	-50
21	-103	13
-30	-76	-17
18	-82	-14

// Aue T, 2018: Healthy Controls
// Subjects=19
45	44	-14
6	41	43
-30	23	-8
-39	26	34
-27	-67	46
48	-52	43
12	-85	7
-9	-76	-29
27	-61	-32
-27	-67	-32
0	-55	-35
-6	-55	46
-18	-61	13
-15	-91	-11
18	-97	-2
48	11	-26
-9	-4	31
-27	47	40
42	-1	34
-60	-37	16
9	-82	34
12	-97	7
-24	-55	46
-12	-1	16
-21	-76	-41
-15	-91	-8
42	29	13
0	32	13
-18	56	31
-6	-49	31
-48	-70	34
0	35	13
-42	29	1
39	32	4
-36	20	-20
-51	-61	10
57	-55	13
-27	47	25
-12	-34	40
18	-43	55
66	-31	31
-57	-43	28
-24	-73	-41
30	23	-5
39	29	22
-6	-79	-5
45	-79	-2
42	-46	43
-27	-64	40
27	26	-5
42	8	28
48	-76	1
-24	-79	28
24	-58	52
-39	-43	-20
39	-46	-32
-3	-61	-38
15	-97	25
3	-91	22
30	-79	-17
-12	-49	-5
51	32	34
-45	20	40
-39	53	-2
-21	14	-17
42	14	-47
9	-16	-26
9	11	10
-54	-64	31
45	-46	52
3	-91	19
66	-46	25
51	32	34
-42	20	40
9	53	34
-51	-49	49
24	-97	22
3	-91	16
21	-103	13
-30	-76	-17
18	-82	-14

// Br?scher A K, 2016: Uncontrollable Pain > Uncontrollable Warm
// Br?scher A K, 2016: Controllable Pain > Controllable Warm
// Br?scher A K, 2016: Positive Correlation between Pain Rating and Activation 
// during Uncontrollable Pain
// Br?scher A K, 2016: (Uncontrollable Pain > Uncontrollable Warm) > 
// (Controllable Pain > Controllable Warm)
// Subjects=23
-28	-66	-28
-28	-66	-28
24	-58	-28
38	8	8
14	-20	10
-18	-20	14
6	20	30
36	14	6
-32	16	4
56	-20	22
-36	-10	64
-36	-10	64
22	-2	54
-42	-36	54
-36	-26	56
16	-64	42
16	-64	42
10	-62	60
-16	-62	58
42	-12	14
42	-12	14
38	-14	16
-38	12	-4
56	0	4
4	12	44
12	-6	6
-14	-18	16
6	18	60
-26	-62	-22
10	28	50
10	28	50
10	22	32
2	38	16
46	20	-10
46	20	-10
50	20	-4
44	20	0
54	8	0
44	10	-2
8	-84	-10
8	-84	-10
-44	16	-2
-44	16	-2
-32	20	-14
-38	10	0
4	-2	6
4	-2	6
14	0	2
-34	-26	54
-34	-26	54
-38	-30	52

// Jensen K B, 2015: High Pain > Low Pain
// Jensen K B, 2015: Placebo Main Effect: Low Pain > Control Pain
// Jensen K B, 2015: Placebo: Nonconscious > Conscious
// Jensen K B, 2015: Placebo: Conscious > Nonconscious
// Jensen K B, 2015: Nocebo Main Effect: High Pain > Control Pain
// Jensen K B, 2015: Nocebo: Nonconscious > Conscious
// Subjects=24
36	5	7
-33	-16	16
0	17	34
0	-16	7
9	26	-8
36	29	-2
-3	-91	28
0	-13	31
-42	-4	4
42	2	-14
39	-1	-2
-6	-19	-5
9	-16	-5
6	-1	10
30	-4	-14
33	-10	-14

// Chevrier A, 2015: Stop > Rest
// Chevrier A, 2015: Respond > Rest
// Subjects=14
-5.96	-74.53	22.32
-29.29	-52.98	55.36
29.21	-89.52	4.22
-38.3	-64.43	-9.38
21.96	-21.23	62.14
18.86	-37.74	69.14
51.59	-25.2	21.99
53.63	-16.27	13.41
-4.93	-57.34	24.22
-5.94	-52.26	34.95
-9.23	-44.42	26.53
11.05	-57.76	17.38
46.55	-41.86	54.67
-5.94	14.72	61.68
-1.74	6.23	47.84
-9.27	-11.84	34.95
8.63	37.11	19.49
22.45	56.22	17.72
32.95	51.06	-8.73
-25.27	-89.67	7.09
46.85	-14.7	-34.6
17.43	-93.1	0.19
-22.38	12.54	7.4
-14.95	-7.73	-7.71
22.43	6.58	-4.88
17.28	-7.94	14.24
-30.95	-72.27	-28.88
-5.86	-64.61	40.45
1.59	-79.17	30.43
-48.06	-22.02	-10.59
48.07	-8.67	-11.7
3.08	12.93	-17.45
-25.82	22.19	-19.01
-7.69	63.68	-7.09
-0.05	4.96	-10.06

// Schreiber K L, 2017: Cuff Stimulation: Patients > Healthy Controls
// Schreiber K L, 2017: Postoffset: Patients > Healthy Controls
// Schreiber K L, 2017: Positive Correlation: PAS Pain Rating and Postoffset 
// brain responses
// Subjects=15
20	2	-24
20	-2	-22
38	18	-42
20	-2	-34
26	-10	-22
40	0	-42
54	-56	-20
-16	62	20
48	-74	-32
8	36	-8
-2	2	72
-22	40	50
20	64	24
-4	-6	42
-28	-8	66
-52	-6	50
-36	-22	-22
-46	-72	-24
-28	12	-16
-6	44	8
16	44	50
-32	-20	42
20	-14	-26
-10	28	28
22	-20	-16
-14	-8	-20
30	-24	-24
-16	-12	-18
8	8	-10
-6	14	-4
-18	-6	-32
16	-6	-20
0	-60	62
8	-66	66
-24	16	-8
-56	36	0
-20	-4	-16
-12	20	2
-42	-6	-12
-22	-16	-20
-36	-10	6
14	-98	14
-8	-94	4
-4	52	24
0	48	14

// Shinozaki T, 2016: Healthy Controls
// Subjects=15
-34	-22	4
42	-44	18
-32	16	4
-26	-10	64
8	-16	58
12	20	54
-20	-58	-24
4	20	28
12	-64	-28
-52	-24	28
46	2	40
12	-76	12
-28	2	2
50	44	16
-26	-60	-28
48	-52	42
18	-80	-28
-58	-12	40
-6	-40	32
-12	-34	-26
36	4	-26

// Shinozaki T, 2016: Patients
// Subjects=16
34	-12	16
-36	8	-10
26	2	50
32	-38	38
-40	14	38
-66	-16	-12
46	-70	-14
46	-44	-4
56	-64	6
16	-76	24
0	-26	32
18	8	46
16	-20	44
16	-68	34
-8	-8	30
-12	-48	34
42	-52	28
-8	-70	-30
-48	-58	-16
16	-20	44
-18	-20	-24
0	-2	54

// Hu J, 2016: Go > 0, Correlation with stop signal anticipation
// Hu J, 2016: Go < 0, Correlation with stop signal anticipation
// Subjects=78
-15	-16	10
-42	-25	52
-48	-43	55
-48	-37	49
24	59	25
36	59	1
39	47	25
12	-13	7
3	32	58
6	20	49
12	8	55
45	-49	55
57	-43	49
36	-46	37
-33	-70	-26
-27	-70	-21
-12	-79	-26
6	41	-14
-3	50	-5
-21	29	43
-39	11	55
-9	-58	19
-9	-52	10
9	-58	22
-27	-34	-14
-21	-22	-17
-42	-76	34
-24	-85	34
21	32	40
30	32	52
51	-70	4
33	-85	7
27	-22	-17
30	-31	-17

// Hu S, 2015: Alcohol Dependent (AD)
// Subjects=24
6	26	61
48	29	-14
57	-46	25
63	-22	-11
42	17	31
-51	-46	28
-42	26	-8
-6	-16	1
-18	-43	1
-3	14	-8
-18	-46	25
30	-37	-11
57	-55	22
18	38	37
-6	-1	-2
3	50	22
-42	-76	22
54	5	-17
-18	-13	-17
-12	-22	61
-21	38	43

// Hu S, 2015: Healthy Controls (HC)
// Subjects=70
60	-46	43
36	59	-2
-57	-46	40
3	-22	28
-12	-82	-26
6	23	61
-30	-37	-11
-21	-13	-17
48	-70	1
-21	14	49
54	-1	-8
24	23	46
57	-55	22
18	38	37
-6	-1	-2
3	50	22
-42	-76	22
54	5	-17
-18	-13	-17
-12	-22	61
-21	38	43

// Hu S, 2015: Regional activations to Stop Signal Anticipation
// Hu S, 2015: Regional activations to Prediction Error
// Hu S, 2015: Regional activations to Reaction Time
// Subjects=114
57	-43	49
33	56	-5
-57	-46	40
-24	-70	49
9	-70	49
3	-25	28
3	35	52
51	17	1
54	-40	43
39	17	-2
39	50	4
48	11	40
15	-13	10
24	-1	-2
-57	-40	49
51	-25	-8
-36	17	-2
-18	-19	7
-51	8	10
-36	17	-2
-18	-19	7
-51	8	10
-36	41	19
-39	-55	-26
48	-31	-8
6	29	31
33	23	4
-33	20	7
12	5	61

// Veverka T, 2016: W4 > W0: Passive flexion-extension movement of the 
// affected wrist > Rest
// Veverka T, 2016: W4 > W11: Passive flexion-extension movement of the 
// affected wrist > Rest
// Veverka T, 2016: W0 > W11: Passive flexion-extension movement of the 
// affected wrist > Rest
// Subjects=7
10	-102	6
40	-72	-12
-30	-76	-32
32	-76	-24
-14	-38	-22
-6	10	56
-12	-38	50
0	-10	60
-28	-46	72
-2	-14	64

// Boraxbekk C J, 2016: Training related improvements across all groups
// Boraxbekk C J, 2016: Untrained sequence conjunction
// Boraxbekk C J, 2016: Motor training > Imagery training
// Boraxbekk C J, 2016: Imagery training > Motor training
// Subjects=18
36	-20	52
36	-22	62
-4	-64	-28
-6	-56	-16
-16	-54	-22
8	-10	64
-2	-6	66
40	-30	50
28	-8	60
32	-16	54
36	-20	64
-24	-54	-24
12	-4	60
-40	-14	58
-8	-6	62
24	-54	-26
56	8	24
30	-98	-10

// Walz A D, 2015: Conjunction over task and time: Fist clenching
// Walz A D, 2015: Conjunction over task and time: Finger sequence
// Walz A D, 2015: Conjunction over task and time: Writing
// Subjects=15
-51	-24	42
-36	-12	54
-3	-6	60
9	-2	60
-57	6	27
-36	-45	57
-33	-42	54
-51	-31	44
-42	-69	3
45	-66	0
27	-65	-19
-45	-27	42
45	-30	45
-42	-36	45
42	36	45
-27	-6	51
27	-6	51
-6	-3	60
0	3	57
-57	3	39
54	3	39
-12	-96	-3
15	-96	3
-33	-12	48
-27	-51	57
33	-48	54
-36	-9	54
27	-6	54
-3	-6	60
-57	6	27
57	9	21
-35	-45	57
30	-54	54
-51	-27	39
-42	-72	0

// Alonso-Lana S, 2016: Healthy Controls
// Subjects=28
-50	8	28
36	22	4
44	-44	52
6	-76	40
2	66	-8
60	-10	-16
-52	10	24
-2	40	-8
2	-50	26
28	-46	76
-34	-62	-32
-32	16	-30
26	12	-26
40	-22	70

// Alonso-Lana S, 2016: Bipolar Disorder, Cognitively Preserved
// Subjects=27
-32	-48	42
2	4	58
-42	-66	-8
30	-52	42
46	-68	-10
8	-52	-16
-24	-6	4
10	-56	22
4	64	0
-20	26	44
60	-64	18
-42	-44	42
-4	-56	22
-2	54	-10
-32	8	-24
30	10	-20
-52	-68	28
26	-40	76
46	-10	0
-26	-58	50
-32	16	-30
26	12	-26
40	-22	70

// Alonso-Lana S, 2016: Bipolar Disorder, Cognitively Impaired
// Subjects=23
-30	-54	44
10	16	40
32	-48	48
8	-52	32
60	-60	20
10	-80	-28
-4	-54	26
50	-6	-36
28	-38	74
-42	-58	-24
30	-4	52
-14	72	4
-6	32	-2
32	0	-42

// Brooks J O, 2015: Memory Load: Bipolar II Depressed < Healthy Controls
// Subjects=19
-33.99	53.21	-22.52
-30.84	65.47	-12.28
-38.69	-56.44	48.28
-49.23	-76.65	29.75
-45	-74.11	36.21
-28.09	-65.87	47.75
-17.51	-67.68	51.14
16.22	-49.95	43.07

// Cerullo M A, 2016: Bipolar I Disorder (BP-I)
// Subjects=25
27.99	104.9	-7.05
-3.43	71.78	63
-51.67	69.95	43.63
24.61	103.08	-30.28
-20.09	108.04	-3.42
-38.73	-1.3	29.38
57.48	42.57	51.37
-13.56	30.15	-20.38
15.24	29.81	-27.37
44.53	64.18	43.01
9.48	20.07	53.8
63.76	24.69	26.03
70.06	13.67	6.81
-23	51.69	11.38
-7.29	38.67	-34.55
-54.98	22.69	10.83
6.01	76.64	42.41
-32.09	-54.94	37.15
-45.56	40.5	-7.5
2.59	100.71	23.7
21.65	23.24	-30.24
41.3	1.32	14.86
-26.07	-6.2	6.23
-39.39	57.77	-32.44
18.36	108.01	-7.2
-38.7	-4.22	32.97
-55.13	-5.25	-20.28
-16.7	-2.11	-24.33
32.07	8.55	67.89
-13.65	25.95	-33.41
2.8	37.01	25.69

// Cerullo M A, 2016: Major Depressive Disorder (MDD)
// Subjects=25
27.99	104.9	-7.05
-3.43	71.78	63
-51.67	69.95	43.63
24.61	103.08	-30.28
-20.09	108.04	-3.42
-38.73	-1.3	29.38
57.48	42.57	51.37
-13.56	30.15	-20.38
15.24	29.81	-27.37
44.53	64.18	43.01
9.48	20.07	53.8
63.76	24.69	26.03
63.58	9.69	-2.82
-38.95	-13.39	-3.06
-.44	26.71	16.56
24.61	103.08	-30.28
18.43	19.79	-33.26
-45.56	89.88	11.78
3.13	-2.43	52.42
-26.57	51.25	-35.38
-42.62	64.1	-32.93
-64.71	-1.63	-13.78
-26.17	-33.63	-18.23
41.18	-13.17	-7.34
35.14	43.46	64.93
-29.08	-60.14	10.79
-58.51	-.47	-40.72

// Cerullo M A, 2016: Healthy Controls
// Subjects=25
70.06	13.67	6.81
-23	51.69	11.38
-7.29	38.67	-34.55
-54.98	22.69	10.83
6.01	76.64	42.41
-32.09	-54.94	37.15
-45.56	40.5	-7.5
2.59	100.71	23.7
21.65	23.24	-30.24
41.3	1.32	14.86
-26.07	-6.2	6.23
-39.39	57.77	-32.44
18.36	108.01	-7.2
-38.7	-4.22	32.97
-55.13	-5.25	-20.28
-16.7	-2.11	-24.33
63.58	9.69	-2.82
-38.95	-13.39	-3.06
-.44	26.71	16.56
24.61	103.08	-30.28
18.43	19.79	-33.26
-45.56	89.88	11.78
3.13	-2.43	52.42
-26.57	51.25	-35.38
-42.62	64.1	-32.93
-64.71	-1.63	-13.78
-26.17	-33.63	-18.23
32.07	8.55	67.89
-13.65	25.95	-33.41
2.8	37.01	25.69
41.18	-13.17	-7.34
35.14	43.46	64.93
-29.08	-60.14	10.79
-58.51	-.47	-40.72

// Pomarol-Clotet E, 2015: Subgroup of Bipolar Disorder, Mania
// Subjects=38
-30	-2	62
24	6	58
18	8	16
-18	-10	18
30	-44	-32
-44	-70	-10
-2	46	-28
-46	-42	56
26	-50	56

// Pomarol-Clotet E, 2015: Subgroup of Bipolar Disorder, Depression
// Subjects=38
-32	-2	50
8	-64	62
-32	-54	-30
0	46	-20
40	-44	56

// Pomarol-Clotet E, 2015: Subgroup of Bipolar Disorder, Euthymia
// Subjects=38
-6	16	-10
-46	-42	56
26	-50	56
40	-44	56

// Pomarol-Clotet E, 2015: Healthy Controls
// Subjects=38
-30	-2	62
24	6	58
18	8	16
-18	-10	18
30	-44	-32
-44	-70	-10
-2	46	-28
-32	-2	50
8	-64	62
-32	-54	-30
0	46	-20
-6	16	-10

// Sepede G, 2015: Healthy Controls
// Subjects=24
48.36	5.25	30.62
-49.94	3.69	33
48.24	21.65	22.56
41.06	-3.83	51.54
0.4	7.39	48.84
41.94	-77.26	-3.65
-40.35	-79.96	-3.59
-14.88	-27.82	-6.02
-13.73	-18.24	7.66
-24.52	-.67	1.85
18.22	-53.23	-21
-28.82	-47.08	-19.86
4.37	-64.94	-19.86
50.67	-58.87	27.05
-47.62	-63.6	29.69
-0.08	49.69	4.03
-.62	-55.83	29.62
48.36	5.25	30.62
-49.94	3.69	33
-43.31	-18.17	52.6
0.4	7.39	48.84
33.47	-85.26	3.81
-26.35	-89.76	5.99
13.14	-90.04	-1.13
-8.27	-91.65	-6.32
28.36	-68.63	40.39
-26.13	-62.27	44.95
-14.88	-27.82	-6.02
-24.52	-.67	1.85
19.28	-52.16	-21.1
4.36	-65.03	-20.97
50.67	-58.87	27.05
-47.62	-63.6	29.69
-0.08	49.69	4.03
-.62	-55.83	29.62
45.21	-67.76	8.9
-46.7	-70.6	7.97
40.68	-53.98	-18.97
-34.09	0.84	8.52
35.34	-26.55	-7.82
-55.57	-2.6	-6.56
-10.57	-24.19	-.8
49.55	-54.99	22.28
-29.82	-48.6	-11.92
-6.9	-85.22	35.5
-.79	-72.95	0.94
-3.17	-61.19	-25.66
41.91	28.99	35.4
0.99	38.69	-.63
40.86	25.89	36.78
18.11	62.11	11.7
-9.06	-65.69	40.58
48.49	-38.45	29.83
-48.11	3.87	-6.07
23.73	38.65	38.14
5.68	28.74	49.22
24.9	-66.82	9.06

// Sepede G, 2015: Euthymic Borderline Personality Disorder Patients
// Subjects=23
48.36	5.25	30.62
-49.94	3.69	33
48.24	21.65	22.56
41.06	-3.83	51.54
0.4	7.39	48.84
41.94	-77.26	-3.65
-40.35	-79.96	-3.59
-14.88	-27.82	-6.02
-13.73	-18.24	7.66
-24.52	-.67	1.85
18.22	-53.23	-21
-28.82	-47.08	-19.86
4.37	-64.94	-19.86
50.67	-58.87	27.05
-47.62	-63.6	29.69
-0.08	49.69	4.03
-.62	-55.83	29.62
48.36	5.25	30.62
-49.94	3.69	33
-43.31	-18.17	52.6
0.4	7.39	48.84
33.47	-85.26	3.81
-26.35	-89.76	5.99
13.14	-90.04	-1.13
-8.27	-91.65	-6.32
28.36	-68.63	40.39
-26.13	-62.27	44.95
-14.88	-27.82	-6.02
-24.52	-.67	1.85
19.28	-52.16	-21.1
4.36	-65.03	-20.97
50.67	-58.87	27.05
-47.62	-63.6	29.69
-0.08	49.69	4.03
-.62	-55.83	29.62
45.21	-67.76	8.9
-46.7	-70.6	7.97
40.68	-53.98	-18.97
-34.09	0.84	8.52
35.34	-26.55	-7.82
-55.57	-2.6	-6.56
-10.57	-24.19	-.8
49.55	-54.99	22.28
-29.82	-48.6	-11.92
-6.9	-85.22	35.5
-.79	-72.95	0.94
-3.17	-61.19	-25.66
41.91	28.99	35.4
0.99	38.69	-.63
-9.06	-65.69	40.58
48.49	-38.45	29.83
-48.11	3.87	-6.07
23.73	38.65	38.14
5.68	28.74	49.22
24.9	-66.82	9.06

// Sepede G, 2015: Relatives of Borderline Personality Disorder Patients
// Subjects=22
48.36	5.25	30.62
-49.94	3.69	33
48.24	21.65	22.56
41.06	-3.83	51.54
0.4	7.39	48.84
41.94	-77.26	-3.65
-40.35	-79.96	-3.59
-14.88	-27.82	-6.02
-13.73	-18.24	7.66
-24.52	-.67	1.85
18.22	-53.23	-21
-28.82	-47.08	-19.86
4.37	-64.94	-19.86
50.67	-58.87	27.05
-47.62	-63.6	29.69
-0.08	49.69	4.03
-.62	-55.83	29.62
48.36	5.25	30.62
-49.94	3.69	33
-43.31	-18.17	52.6
0.4	7.39	48.84
33.47	-85.26	3.81
-26.35	-89.76	5.99
13.14	-90.04	-1.13
-8.27	-91.65	-6.32
28.36	-68.63	40.39
-26.13	-62.27	44.95
-14.88	-27.82	-6.02
-24.52	-.67	1.85
19.28	-52.16	-21.1
4.36	-65.03	-20.97
50.67	-58.87	27.05
-47.62	-63.6	29.69
-0.08	49.69	4.03
-.62	-55.83	29.62
45.21	-67.76	8.9
-46.7	-70.6	7.97
40.68	-53.98	-18.97
-34.09	0.84	8.52
35.34	-26.55	-7.82
-55.57	-2.6	-6.56
-10.57	-24.19	-.8
49.55	-54.99	22.28
-29.82	-48.6	-11.92
-6.9	-85.22	35.5
-.79	-72.95	0.94
-3.17	-61.19	-25.66
41.91	28.99	35.4
0.99	38.69	-.63
40.86	25.89	36.78
18.11	62.11	11.7
48.49	-38.45	29.83
-48.11	3.87	-6.07
23.73	38.65	38.14
5.68	28.74	49.22
24.9	-66.82	9.06

// Young K D, 2016: Healthy Controls
// Subjects=16
-25.31	18.69	45.95
28.09	27.47	44.6
0.39	-39.96	28.27
-17.14	-13.71	-16.1
53.31	45.18	-4.01
36.41	16.33	9.76
-20.37	-5.27	-16.77
0.39	-39.96	28.27
36.41	16.33	9.76
-31.58	-63.42	30.61
60.16	-66.7	7.53
-17.14	-13.71	-16.1
4.68	15.16	52.6
2.29	19.09	21.07
-17.21	-3.48	-21.42
-18.8	-61.57	25.85
-19.12	55.94	31.61
2.29	19.09	21.07
-18.8	-61.57	25.85

// Young K D, 2016: Major Depressive Patients
// Subjects=16
-25.31	18.69	45.95
28.09	27.47	44.6
0.39	-39.96	28.27
-17.14	-13.71	-16.1
-25.31	18.69	45.95
28.09	27.47	44.6
53.31	45.18	-4.01
36.41	16.33	9.76
-20.37	-5.27	-16.77
53.31	45.18	-4.01
0.39	-39.96	28.27
36.41	16.33	9.76
-31.58	-63.42	30.61
60.16	-66.7	7.53
-20.37	-5.27	-16.77
4.68	15.16	52.6
-19.12	55.94	31.61
-17.21	-3.48	-21.42
2.29	19.09	21.07
-18.8	-61.57	25.85
2.29	19.09	21.07
-18.8	-61.57	25.85

// Young K D, 2016: Bipolar Patients
// Subjects=16
-25.31	18.69	45.95
28.09	27.47	44.6
53.31	45.18	-4.01
0.39	-39.96	28.27
36.41	16.33	9.76
-31.58	-63.42	30.61
60.16	-66.7	7.53
-20.37	-5.27	-16.77
0.39	-39.96	28.27
36.41	16.33	9.76
-31.58	-63.42	30.61
60.16	-66.7	7.53
-17.14	-13.71	-16.1
2.29	19.09	21.07
-17.21	-3.48	-21.42
-18.8	-61.57	25.85
-19.12	55.94	31.61
-19.12	55.94	31.61
-17.21	-3.48	-21.42
2.29	19.09	21.07
-18.8	-61.57	25.85

// Alonso-Lana S, 2019: Bipolar Patients
// Subjects=26
-54	6	22
-6	2	56
-28	-54	42
38	-4	52
2	-66	30
0	64	10
50	-72	28
-38	-52	54
38	-58	-32
44	-42	42
8	-60	18
-50	-66	24
-8	68	16
-7	-36	-13
-2	-16	70
34	44	30
-44	-28	40
-62	-18	48
12	46	-24
-24	-58	2
-4	54	26
-40	-36	24
-14	-42	26
-32	-4	58
-24	-60	14
-44	-4	59
-9	-70	52
-7	-36	-13
-4	34	-16
-7	-36	-13
24	28	-16
-44	-4	59
-9	-70	52
-32	-6	54
10	-70	52
-44	-18	60
10	-68	50
-6	-78	52

// Alonso-Lana S, 2019: Healthy Controls
// Subjects=26
0	4	52
34	20	4
36	-48	42
-46	-82	-10
2	-52	32
-4	60	-8
54	0	-26
-58	-6	-24
34	22	4
38	-48	48
46	-74	-6
16	-60	24
0	64	8
-40	-84	34
52	-70	20
64	-10	-16
-8	68	16
-7	-36	-13
-44	-28	40
-62	-18	48
12	46	-24
-24	-58	2
-14	-42	26
-32	-4	58
-24	-60	14
-44	-4	59
-9	-70	52
-7	-36	-13
-4	34	-16
-7	-36	-13
24	28	-16
-44	-4	59
-9	-70	52
-32	-6	54
10	-70	52
-44	-18	60
10	-68	50
-6	-78	52

// Goikolea J M, 2019: First Episode Mania Patients
// Subjects=31
-43.67	6.28	49.32
51.14	12.3	28.06
-50.56	37.15	23.97
-44.5	53.72	-5.78
55.82	-33.13	47.05
-28.29	-57.37	56.48
42.05	23.19	-4.23
-48.43	-64.87	0.42
-31.46	-66.03	-24.41
3.82	-40.94	35.26
-9.89	45.34	-5.54
-3.57	54	-16.59

// Goikolea J M, 2019: Healthy Controls
// Subjects=31
-30.67	3.35	51.63
40.52	3.83	41.41
55.28	33.92	18.01
40.01	48.13	10.14
51.51	-37.4	47.54
-28.35	-55.66	51.83
-37.82	21.3	2.92
35.56	26.35	-4.44
-39.77	-62.5	2.28
-3.26	-56.38	-14.64
31.24	-67.73	-23.07
-1.4	51.88	-16.42
3.19	44.09	3.32
-5.54	41.2	-4.09
-9.14	-54.06	33.42
3.8	-43.28	33.25
16.74	-56.52	28.74
-47.89	-69.53	42.33
32.99	13.45	-38.98
-31.84	8.76	-39.65
-9.89	45.34	-5.54
-3.57	54	-16.59

// Han X, 2018: Healthy Controls
// Subjects=10
-30	-75	-6
-12	-96	6
-18	-87	-9
24	-78	-6
15	-99	6
-6	-96	6
39	-57	-12
6	-87	-3
27	-9	-12
27	-4	-12
57	21	30
-48	9	-21
-39	24	-6
-45	6	12
-12	0	15
45	-3	-6
57	-12	24
15	18	57
15	3	66
63	-36	21
69	-27	21
54	-33	39
-57	-33	27
-27	-42	48
-48	-54	27
-6	-18	42
-36	-3	12
-33	-51	-24
-60	9	15
-60	15	24
3	-84	-3
24	-72	-9
21	-90	-6
3	-87	-3
-21	-90	12
6	-78	3

// Han X, 2018: Bipolar Disorder
// Subjects=10
18	-93	3
21	-96	12
-21	-99	9
-9	-90	0
36	-90	0
15	-90	15
27	-9	-12
27	-4	-12
57	21	30
-48	9	-21
57	-51	30
-2	23	47
5	22	41
-34	25	-4
-36	-3	12
-33	-51	-24
-60	9	15
-60	15	24
54	-66	0
-36	-78	12
-36	-81	-21
27	-78	15
42	-84	0
48	6	42
-42	0	57
-45	3	45
-51	18	36

// Kryza-Lacombe M, 2019: Age Group x Diagnosis
// Kryza-Lacombe M, 2019: HC Youths < HC Adults, Time Course
// Kryza-Lacombe M, 2019: BD Youths > BD Adults, Time Course
// Kryza-Lacombe M, 2019: Diagnosis, Time Averaged
// Kryza-Lacombe M, 2019: Age Group, Time Averaged
// Kryza-Lacombe M, 2019: Age Group x Diagnosis, Time Averaged
// Kryza-Lacombe M, 2019: BD Youths < BD Adults, Time Averaged
// Kryza-Lacombe M, 2019: BD Youths < HC Youths, Time Averaged
// Kryza-Lacombe M, 2019: HC Adults < BD Adults, Time Averaged
// Kryza-Lacombe M, 2019: HC Adults < HC Youths, Time Averaged
// Kryza-Lacombe M, 2019: Face Emotion, Time Averaged
// Kryza-Lacombe M, 2019: Diagnosis x Face Emotion, Time Averaged
// Kryza-Lacombe M, 2019: Age Group x Diagnosis x Face Emotion, Time Averaged
// Kryza-Lacombe M, 2019: Negative Valence, HC Youths > HC Adults, Time 
// Averaged
// Kryza-Lacombe M, 2019: Neutral Valence, BD Youths > BD Adults, Time 
// Averaged
// Kryza-Lacombe M, 2019: Age Group x Diagnosis x Face Emotion, Time Averaged, 
// Sphericity-corrected
// Kryza-Lacombe M, 2019: Diagnosis, Time Averaged, Emotion Intensity Included
// Kryza-Lacombe M, 2019: Age Group, Time Averaged, Emotion Intensity Included
// Kryza-Lacombe M, 2019: Face Emotion, Time Averaged, Emotion Intensity 
// Included
// Kryza-Lacombe M, 2019: Intensity (Linearly), Time Averaged, Emotion 
// Intensity Included
// Kryza-Lacombe M, 2019: Intensity (Quadratically), Time Averaged, Emotion 
// Intensity Included
// Kryza-Lacombe M, 2019: Intensity (Cubically), Time Averaged, Emotion 
// Intensity Included
// Kryza-Lacombe M, 2019: Age Group x Diagnosis, Time Averaged, Emotion 
// Intensity Included
// Kryza-Lacombe M, 2019: Diagnosis x Face Emotion, Time Averaged, Emotion 
// Intensity Included
// Kryza-Lacombe M, 2019: Face Emotion x Intensity (Modeled Linearly), Time 
// Averaged, Emotion Intensity Included
// Kryza-Lacombe M, 2019: Diagnosis x Intensity (Modeled Quadratically), Time 
// Averaged, Emotion Intensity Included
// Kryza-Lacombe M, 2019: Age Group x Diagnosis x Face Emotion, Time Averaged, 
// Emotion Intensity Included
// Kryza-Lacombe M, 2019: Age Group x Diagnosis x Intensity (Linearly), Time 
// Averaged, Emotion Intensity Included
// Kryza-Lacombe M, 2019: Diagnosis x Face Emotion x Intensity (Linearly), 
// Time Averaged, Emotion Intensity Included
// Kryza-Lacombe M, 2019: Age Group x Face Emotion x Intensity 
// (Quadratically), Time Averaged, Emotion Intensity Included
// Kryza-Lacombe M, 2019: Diagnosis x Face Emotion x Intensity (Cubically), 
// Time Averaged, Emotion Intensity Included
// Kryza-Lacombe M, 2019: Age Group x Diagnosis x Face Emotion x Intensity 
// (Linearly),  Time Averaged, Em Int Included
// Kryza-Lacombe M, 2019: Age Group x Diagnosis x Face Emotion x Intensity 
// (Quadratically), Time Averaged, Em Int Included
// Subjects=22
0.16	42.31	32.53
2.41	-82.87	-3.84
28.77	-55.68	-39.88
0.16	42.31	32.53
2.41	-82.87	-3.84
0.16	42.31	32.53
2.41	-82.87	-3.84
-13.29	-68.54	45.33
-64.02	-43.35	-9.73
-8.68	36.98	-8.18
-40.6	-41.95	-21.27
66.56	-18.42	25.71
61.01	-20.59	-1.93
-7.28	40.41	36.12
-32.18	55.67	1.67
-7.28	40.41	36.12
-32.18	55.58	0.56
-7.28	40.41	36.12
-32.18	55.58	0.56
-7.28	40.41	36.12
-32.18	55.58	0.56
-32.18	55.58	0.56
-10.41	-82.95	-3.68
50.39	20.61	22.62
53.92	-38.53	42.04
2.03	53.76	1.44
-8.19	-54.62	18.45
14.85	-61.48	-44.81
-24.33	32.02	39.25
-29.84	-8.19	1.42
-58.8	-14.94	-14.41
-15.97	-37.94	-12.97
-5	-27.31	27.28
-15.93	-21.05	-1
10.98	-66.11	5.81
-15.77	-79.81	-3.88
29.33	-75.11	25.31
-53.03	-65.46	19.87
-15.77	-79.81	-3.88
-53.03	-65.46	19.87
-53.03	-65.46	19.87
-15.77	-79.81	-3.88
-53.01	-65.2	23.2
-64.02	-43.35	-9.73
-13.29	-68.54	45.33
-26.39	-51.73	16.19
37.61	-50.34	0.84
-8.68	36.98	-8.18
-40.6	-41.95	-21.27
66.56	-18.42	25.71
61.01	-20.59	-1.93
-18.97	-79.83	-3.85
-29.96	23.53	-1.24
50.39	20.61	22.62
-47.64	-15.45	46.84
-2.87	19.89	45.6
-5.45	64.72	6.18
56.1	-32.63	49.32
32.35	27.33	42.34
-21.08	27.01	42.98
-8.17	-54.36	21.77
24.01	-63.89	33.36
-24.05	-3.45	62.29
-58.79	-17.05	-14.23
12.65	-51.17	-48.99
-47.82	-47	10.46
-2.71	-38.87	42.72
-5	-27.31	27.28
-36.86	-36.36	50.7
-26.79	56.13	7.15
-10.43	-79.78	-3.95
-29.35	-19.6	60.36
44.76	45.13	-3.91
50.42	-33.98	4.89
23.53	-49.14	-23.64
21.63	-79.59	-4.33
16.67	-62.48	52.28
16.38	-56.76	16.12
37.93	-71.21	33.81
-50.82	-11.87	52.16
-29.84	-8.19	1.42
32.18	-42.51	-7.56
50.73	-14.26	53.42
18.05	-64.89	-47.9
28.77	-9.55	-21.44
-13.79	-21.04	-1.03
-40.1	-36.81	45.2
18.39	-69.03	-5.18
-32.11	26.69	-1.48
39.5	23.95	-2.07
-4.92	-20.91	41.23
53.92	-66.08	29.85
-50.78	-49.99	40.86
-36.83	-25.1	58.68
-2.87	19.89	45.6
22.04	-62.19	55.54
-34.78	-42.49	40.04
-8.75	43.95	-14.34
-29.68	31.99	39.31
-58.78	-14.76	-12.19
-26.68	-3.14	-2.38
34.5	-87.8	-1.56
23.38	-61.68	-48.23
-21.04	-95.53	-.28
-61.77	-42.22	4.64
-8.11	-23.04	41.45
-63.76	-24.23	31.04
48.56	-55.28	32.35
5.23	53.78	1.4
-21.14	29.75	37.17
34.47	30.51	42.05
48.3	13.45	26.59
16.1	-46.47	-15.97
-13.54	-82.11	7.43
10.96	-77.36	-2.17
42.71	27.31	-.16
-40.39	12.92	27.65
-8.35	40.4	36.13
-32.18	55.67	1.67
-45.42	-22.24	55.19
50.69	-25.69	43.23
-42.64	22.8	17.93
-15.79	-80.07	-7.21
45.09	13.43	26.63
18.56	-87.04	9.71
45.06	-58.3	-6.39
-3.28	59.61	8.81
-50.83	-15.3	49.1
-40.51	-46.55	-11.97
-3.37	38.87	-11.75
61.26	-10.36	34.01
16	-71.61	-38.39
-24.35	-78	-7.28
29.28	-77.83	17.74
29.04	-67.11	-8.81
-29.52	-81.78	13.17
-53	-67.32	23.38
-15.78	-77.7	-4.06
5.63	-71.68	2.99
55.86	-18.65	23.62
-56.4	-23.18	16.37
7.83	3.66	41.26
-8.71	38.83	-11.69
2.46	-73.56	6.53
-50.82	-66.88	28.89

// Moser D A, 2018: Healthy Volunteers
// Subjects=48
-44	-36	40
-6	14	56
-40	20	-4
60	-52	-10
-8	-14	8
-2	-26	-12
-32	-60	-28
-4	-44	-18
6	-72	-42
28	-56	-34
-44	-36	40
-6	14	56
-40	20	-4
60	-52	-10
-32	-60	-28
28	-56	-34
-44	-36	40
-6	14	56
28	-56	-34
-30	-84	-2
44	-38	42
-42	-48	44
28	8	58
-28	4	60
2	22	44
-2	24	44
4	12	26
-12	-94	0
16	-90	-8
-28	-86	-16
-50	-38	-6
50	-42	-2
40	-50	-22
32	-96	-2
-26	-96	-6
-38	-56	-20
18	-4	-12
-16	-4	-12
46	12	30
-44	20	24
8	-84	2
-6	-84	0
48	-40	12
-42	28	-14
32	36	-10
2	-64	34

// Moser D A, 2018: Bipolar Disorder
// Subjects=37
-44	-36	40
-6	14	56
-40	20	-4
60	-52	-10
-8	-14	8
-2	-26	-12
-32	-60	-28
-4	-44	-18
6	-72	-42
28	-56	-34
-44	-36	40
-6	14	56
28	-56	-34
-30	-84	-2
44	-38	42
-42	-48	44
28	8	58
-28	4	60
2	22	44
-2	24	44
4	12	26
-12	-94	0
16	-90	-8
-28	-86	-16
-50	-38	-6
50	-42	-2
40	-50	-22
32	-96	-2
-26	-96	-6
-38	-56	-20
18	-4	-12
-16	-4	-12
46	12	30
-44	20	24
8	-84	2
-6	-84	0
48	-40	12
-42	28	-14
32	36	-10
2	-64	34

// Moser D A, 2018: Schizophrenia
// Subjects=92
-44	-36	40
-6	14	56
-40	20	-4
60	-52	-10
-8	-14	8
-2	-26	-12
-32	-60	-28
-4	-44	-18
6	-72	-42
28	-56	-34
-44	-36	40
-6	14	56
-40	20	-4
60	-52	-10
-32	-60	-28
28	-56	-34
-30	-84	-2
44	-38	42
-42	-48	44
28	8	58
-28	4	60
2	22	44
-2	24	44
4	12	26
-12	-94	0
16	-90	-8
-28	-86	-16
-50	-38	-6
50	-42	-2
40	-50	-22
32	-96	-2
-26	-96	-6
-38	-56	-20
18	-4	-12
-16	-4	-12
46	12	30
-44	20	24
8	-84	2
-6	-84	0
48	-40	12
-42	28	-14
32	36	-10
2	-64	34

// Rodriguez-Cano E, 2017: Major Depressive Disorder
// Subjects=26
0	6	56
-32	-58	54
-50	-74	-10
36	-58	50
4	-78	50
-8	64	32
-44	-70	30
44	-80	28
4	18	48
-30	-48	42
46	-50	48
6	-56	18
-2	52	-10
0	48	-18
-16	-86	8
-2	50	-16

// Rodriguez-Cano E, 2017: Bipolar Depressive Disorder
// Subjects=26
-42	-44	44
38	34	24
34	-58	54
6	-66	60
-40	-46	42
34	-50	42
6	-50	30
4	68	32
-4	-68	20
-2	50	-16
22	-66	-38
-40	12	18
-2	50	-16

// Rodriguez-Cano E, 2017: Healthy Controls
// Subjects=26
-54	-2	48
-38	-44	44
36	-2	50
-42	-72	-12
34	-50	42
4	-78	50
-4	68	26
-42	-76	36
-62	-12	-18
2	16	48
-2	50	-14
6	-52	18
18	-92	36
0	48	-18
-16	-86	8
4	68	32
-4	-68	20
-2	50	-16
22	-66	-38
-40	12	18
-2	50	-16

// Zhang L, 2019: Healthy Controls
// Subjects=15
-44	28	-8
-28	58	22
0	26	40
-50	10	-20
50	20	-14
-56	-32	-2
-54	-60	20
-2	4	66
-48	34	2
28	-92	-2
2	14	50
58	6	-22
-30	16	35
36	-90	-4
-52	28	14
40	34	16
-42	16	38
-52	24	0
-42	28	-10
54	26	-4
44	4	-32
50	18	-14
-4	2	64
-2	14	60
10	10	62
-22	48	22
-60	-32	2
-54	-58	16
-56	-48	-2
12	-10	0
-8	-14	2
0	-18	-4
-44	28	-8
-28	58	22
0	26	40
50	20	-14
-56	-32	-2
-54	-60	20
-2	4	66
-48	34	2
28	-92	-2
2	14	50
58	6	-22
-30	16	35
36	-90	-4
-52	28	14
40	34	16
-46	30	-6
2	14	50

// Zhang L, 2019: Schizophrenia
// Subjects=16
-44	28	-8
-28	58	22
0	26	40
-50	10	-20
50	20	-14
-56	-32	-2
-54	-60	20
-2	4	66
-48	34	2
28	-92	-2
2	14	50
36	-90	-4
-52	28	14
40	34	16
-42	16	38
-52	24	0
-42	28	-10
54	26	-4
44	4	-32
50	18	-14
-4	2	64
-2	14	60
10	10	62
-22	48	22
-60	-32	2
-54	-58	16
-56	-48	-2
12	-10	0
-8	-14	2
0	-18	-4
-44	28	-8
-28	58	22
0	26	40
50	20	-14
-56	-32	-2
-54	-60	20
-2	4	66
-48	34	2
28	-92	-2
2	14	50
26	54	18
36	-90	-4
-52	28	14
40	34	16
-48	34	2
2	14	50
-46	30	-6
2	14	50
-48	30	-4
2	14	50

// Zhang L, 2019: Bipolar Disorder
// Subjects=15
-44	28	-8
-28	58	22
0	26	40
-50	10	-20
50	20	-14
-56	-32	-2
-54	-60	20
-2	4	66
-48	34	2
28	-92	-2
2	14	50
58	6	-22
-30	16	35
-42	16	38
-52	24	0
-42	28	-10
54	26	-4
44	4	-32
50	18	-14
-4	2	64
-2	14	60
10	10	62
-22	48	22
-60	-32	2
-54	-58	16
-56	-48	-2
12	-10	0
-8	-14	2
0	-18	-4
-44	28	-8
-28	58	22
0	26	40
50	20	-14
-56	-32	-2
-54	-60	20
-2	4	66
-48	34	2
28	-92	-2
2	14	50
26	54	18
58	6	-22
-30	16	35
-48	34	2
2	14	50
-46	30	-6
2	14	50
-48	30	-4
2	14	50

// Kirschner M, 2019: High Reward > No Reward, All Subjects
// Kirschner M, 2019: High Reward > No Reward, Healthy Controls > Bipolar 
// Disorder
// Subjects=25
-40	-19	51
-45	-30	46
-39	-22	61
-8	24	-12
-10	21	0
-30	-88	-14
-18	-81	-18
-12	-88	-12
14	-93	4
15	-90	-9
12	-88	12
40	24	-2
32	34	0
34	28	-8
8	27	-9
10	18	-5
10	6	9
-30	30	-5
2	17	43
-2	3	57
3	11	52
26	-3	54
32	-3	46
36	0	55
33	33	28
-12	-67	46
-4	-72	49
-6	-66	57
38	-51	-33
-34	-51	54
-27	-49	51
-21	-55	57
12	-67	48
15	-60	48
-36	-81	24
-27	-81	31
-26	-69	31
8	-75	-23
15	-82	-21
15	-3	15
46	-46	-11
-22	-61	-5
-6	-57	-2
-10	-49	-2
42	-12	36
32	-9	37
45	-6	31
-9	-49	34
-16	-45	33
-24	-82	4
-33	-73	9
-16	-87	1
-27	-78	40
-33	-70	33

// Manelis A, 2018: Healthy Controls (HC) < Bipolar Disorder, Loss 
// Anticipation, Longitudinal
// Subjects=17
48	-72	-8

// D'Cruz A M, 2016: Healthy Controls
// Subjects=23
16	14	-6
-14	14	-6
10	-18	4
-10	-20	4
-10	8	6
-28	58	-12
34	26	-6
-30	22	-6
2	16	40
-2	16	42
-8	22	24
10	38	20
-8	32	20
40	26	26
-46	30	30
52	8	26
-56	2	30
8	0	56
-10	2	54
46	-30	42
-46	-36	46
18	-74	8
-10	-90	0
28	-66	44
-16	68	54
10	-70	46
-10	-68	52
12	-76	-6
-14	-70	-6
10	8	-2
12	-18	6
-6	-8	4
2	16	40
-10	12	40
2	34	30
-2	36	30
2	36	20
-2	40	20
-46	30	30
40	-8	34
-28	10	42
2	20	56
-2	20	56
42	-38	46
-42	-54	46
32	86	14
4	-74	46
-4	-74	46

// D'Cruz A M, 2016: Autism Spectrum Disorder (ASD)
// Subjects=17
26	0	50
-24	-6	50
-6	6	44
-58	6	28
44	-30	44
-40	-32	44
10	8	-2
12	-18	6
-6	-8	4
2	16	40
-10	12	40
2	34	30
-2	36	30
2	36	20
-2	40	20
-46	30	30
40	-8	34
-28	10	42
2	20	56
-2	20	56
42	-38	46
-42	-54	46
32	86	14
4	-74	46
-4	-74	46

// Sullivan D R, 2018: Mild Traumatic Brain Injury (mTBI)
// Subjects=17
-8	8	48
22	-60	60
-26	-58	56
32	-36	38
42	22	-6
-8	-86	8
-32	20	4
52	-40	50
32	38	24
-36	-50	38
-4	-30	36
-36	-70	40
-28	26	50
-4	60	28
-54	22	18
40	-76	-50
-54	22	18
-4	-92	12

// Sullivan D R, 2018: Controls, non-mTBI
// Subjects=16
52	-26	50
4	24	42
42	24	-8
-54	16	-8
-46	6	42
-8	-75	50
-34	54	6
-4	-30	36
-36	-70	40
-28	26	50
-4	60	28
-54	22	18
40	-76	-50
-54	22	18
-4	-92	12

// Velasquez F, 2017: Autism Spectrum Disorder (ASD)
// Subjects=19
4	38	12
18	-40	46
44	-76	22
-50	-50	18
-16	-72	-34
40	-64	20
10	-22	-4
20	44	26
-24	-88	8
56	-54	48
-20	-98	24
12	-50	42
-10	48	-4
-46	-62	20
-62	-6	26
-38	-22	18
22	66	-8
18	-20	78
70	-24	22
40	-88	-6
-26	58	-14
46	-82	14
38	50	-12
-58	-12	44
42	-12	36
24	30	42

// Velasquez F, 2017: Healthy Controls (HC)
// Subjects=22
4	38	12
18	-40	46
44	-76	22
-50	-50	18
-16	-72	-34
40	-64	20
10	-22	-4
20	44	26
-24	-88	8

// Cortese B M, 2018: Combat Veterans with PTSD (CV+PTSD)
// Subjects=21
40	-30	22
54	-18	26
50	-28	22
44	-14	18
36	-30	48
44	-32	50
-28	-70	26
-36	-72	26
-22	-62	28
-38	-78	32
-40	-74	18
-18	-68	28
-48	-36	54
-42	-26	30
-46	-24	20
-58	-28	22
-52	-30	52
-58	-26	30
0	-46	56
12	-36	56
6	-46	58
10	-46	56
10	-50	62
-14	-60	56
-38	-52	22
-18	-54	22
-38	-64	28
-34	-60	24
-56	-70	26
14	-52	36
60	-30	28
60	-30	18
36	-42	32
42	-44	22
52	-40	28
32	-42	34
-28	-54	62
-56	-26	30
-36	-50	60
-42	-30	34
-48	-40	50
-44	-44	56

// Cortese B M, 2018: Combat Veterans without PTSD (CV-PTSD)
// Subjects=27
40	-30	22
54	-18	26
50	-28	22
44	-14	18
36	-30	48
44	-32	50
-28	-70	26
-36	-72	26
-22	-62	28
-38	-78	32
-40	-74	18
-18	-68	28
-48	-36	54
-42	-26	30
-46	-24	20
-58	-28	22
-52	-30	52
-58	-26	30
0	-46	56
12	-36	56
6	-46	58
10	-46	56
10	-50	62
-14	-60	56
-38	-52	22
-18	-54	22
-38	-64	28
-34	-60	24
-56	-70	26
14	-52	36
60	-30	28
60	-30	18
36	-42	32
42	-44	22
52	-40	28
32	-42	34
-50	-24	36
-46	-26	42
-46	-18	54
-52	-16	26
-40	-28	32
-52	-22	18

// Dretsch M N, 2016: Unpredictable > Predictable, Deployment-Exposed Controls 
// (DEC) > PTSD
// Subjects=33
63.28	-33.47	10.28
-59.7	-19.75	6.08
46.37	-55.81	25.73
-51.14	-31.75	1.41
43.79	-8.78	-12.76
37.34	-13.65	-20.08
-22.54	-2.29	-19.23

// Fonzo G A, 2016: Incongruent > Congruent, All Groups
// Fonzo G A, 2016: Post-Congruent Incongruent (cI) > Post-Incongruent 
// Incongruent (iI), All Groups
// Fonzo G A, 2016: Happy > Fearful words, All Groups
// Fonzo G A, 2016: Face Valence > Word Valence, All Groups
// Subjects=20
-40	10	23
-40	-54	29
39	17	7
54	-42	22
34	-45	43
0	-23	27
0	-23	27
20	5	12
-20	-5	48
27	-59	51
2	-79	6
-37	-69	-15
32	54	5
-14	-78	-37
-32	-94	10
13	-84	-2
-13	-81	-6
4	-81	-5
-4	-81	-5

// Moser D A, 2015: Interpersonal Violence-Related PTSD (IPV-PTSD)
// Subjects=17
-6	29	10
54	-22	-20
42	2	28
-27	5	58

// Moser D A, 2015: Healthy Controls
// Subjects=21
-9	-1	28
-48	17	1
-15	-7	52
-6	29	10
54	-22	-20
-45	8	25
-39	-10	43
18	-70	52

// Moser D A, 2015: Emotional > Neutral: IPV-PTSD > Controls
// Moser D A, 2015: Emotional > Neutral: Controls > IPV-PTSD
// Moser D A, 2015: Group x Film Condition
// Moser D A, 2015: Menacing > Prosocial, Entire Cohort
// Moser D A, 2015: Prosocial > Menacing, Entire Cohort
// Subjects=16
30	-10	-17
-15	41	-14
-33	-34	58
42	-49	46
-60	-16	40
30	37	29
36	50	16
36	26	43
-18	26	55
39	-31	19
-54	11	34
48	-58	52
3	-58	-5
-9	50	28
27	8	55
3	17	22
-51	35	-2
42	-76	19
-21	8	64
-36	-22	19
39	-19	19
9	-7	28
-6	22	64
51	-28	1
-45	-70	46
45	-64	49
60	-1	7

// Nguyen-Louie T T, 2018: Positive Correlation between age of weekly drinking 
// and (6 dot > 2 dot) at Follow-up
// Subjects=133
-7.6	68.93	5.85
-44.94	29.87	-.48
0.51	-37.54	45.91
11.68	62.96	9.48
13.29	-24.77	44.7

// Wesley M J, 2017: Healthy Controls
// Subjects=11
-23.92	-62.47	59.15
49.45	-29.03	56.83
-52.49	4.9	35.04
-7.01	-41.19	33.23
-3.42	-46.24	59.44
44.51	38.55	22.22
-2.99	58.36	30.03
21.22	25.63	57.51
29.96	-57.9	47.7
-32.66	-79.7	47.56
-53.15	-42.26	58.77
-12.19	43.23	-16.5
11.6	27.05	-18.67
-56.17	43.23	8.9
24.61	67.9	-7.24
-12.03	43.31	-4.18
-67.03	20.88	0.09
9.62	21.8	-5.79
3.19	44.09	3.32
-29.49	36.47	-18.9
-44.27	28.07	6.84
9.56	21.38	-10.23
-10.1	31.77	-24.37

// Wesley M J, 2017: Heavy Drinkers who were Alcohol Non-Dependent (A-ND)
// Subjects=11
-39.26	10.22	56.7
42.86	-37.54	46.58
-2.8	26.97	38.74
38.57	13.03	59.58
-32.68	-60.14	50.11
-48.31	11.53	25.35
-11.26	-42.81	39.06
-7.49	65.71	17.05
-48.06	-61	30.28
3.69	43.47	42.6
-44.37	50.3	3.52
-39.06	-57.2	58.89
37.69	19.56	-8.28
47.24	-44.76	49.46
-42.35	23.02	-12.87
1.96	-68.21	53.68
37.67	54.43	-2.77
27.8	15.43	62.89
55.3	30.83	19.44
-36.93	-76	52.87
3.19	44.09	3.32
-29.49	36.47	-18.9
-44.27	28.07	6.84
9.56	21.38	-10.23
-10.1	31.77	-24.37

// Wesley M J, 2017: Heavy Drinkers who were Alcohol Dependent (A-D)
// Subjects=13
34.37	-55.03	55.18
-36.99	-44.75	54.26
-41.63	14.18	41.78
40.57	15.09	47.02
-39.95	39.03	9.04
55.36	-14.67	14.97
-4.91	-63.49	24.19
-3.35	45.78	-1.21
31.18	-21.16	-18.71
-52.61	-26.64	19.12
-55.62	-63.15	30.62
-7.34	-34.86	9.07
44.7	25.76	34.69
-37.53	-49.86	11.07
47.08	-40.48	37.84
-3.01	45.08	25.74
-36.93	-76	52.87
11.6	27.05	-18.67
-56.17	43.23	8.9
24.61	67.9	-7.24
-12.03	43.31	-4.18
-67.03	20.88	0.09
9.62	21.8	-5.79

// Reckless G E, 2015: Motivation > Neutral
// Subjects=18
-27	23	-23
6	14	61
-9	-16	-14
30	29	-26
27	-88	-20

// Jurick S M, 2018: Mild Cognitive Impairment (MCI)
// Subjects=20
28.98	43.2	27.66
3.38	3.95	17.87
16.01	41.58	7.87
24.62	2.71	-.12
3.18	19.5	-1.28
3.36	16.98	21.23
11.93	4	17.76
3.34	3.61	13.43
28.97	10.11	12.6

// Jurick S M, 2018: Healthy Controls
// Subjects=29
28.98	43.2	27.66
3.38	3.95	17.87
16.01	41.58	7.87
24.62	2.71	-.12
3.18	19.5	-1.28
3.36	16.98	21.23
11.93	4	17.76
3.34	3.61	13.43

// Jurick S M, 2018: Subgroup of MCI, Amnestic Mild Cognitive Impairment 
// (aMCI)
// Subjects=12
28.97	10.11	12.6

// Rajmohan R, 2017: Healthy Controls > Alzheimer's Disease Patients
// Subjects=4
-1	33	47
0	-48	11

// Ammons C J, 2018: Autism Spectrum Disorder (ASD)
// Subjects=14
20	-64	-10
-24	8	0
-28	-22	-8
-54	18	2
62	-46	8
-20	-62	-8
-44	-76	4
30	4	-6
4	58	24
-40	-52	-20
44	-52	38
-6	82	8
10	-78	-2
44	-52	50
0	22	48
-44	-52	46
-16	-20	56
16	-52	48
-16	-60	14
54	-14	-12
-52	-4	-14
52	-34	6
20	-90	-8
-10	50	12
-44	-74	22
6	60	8
62	-16	8
-6	30	52
-10	-40	40
-16	20	42
24	26	42
-2	-66	34
32	-10	2
-2	-44	62
467	-60	26
-26	50	30
6	-10	38
-8	0	36
8	24	-4
26	-36	62
-38	-74	30
44	-70	34

// Ammons C J, 2018: Healthy Controls
// Subjects=14
14	-88	16
60	-40	12
-38	14	52
26	-30	-2
-36	-58	8
56	26	22
-56	-42	12
-2	38	46
-26	-34	-2
12	-90	16
-20	-32	2
6	58	34
44	-76	0
-46	-66	-20
-56	-42	18
-46	12	46
-52	-22	0
-6	82	8
12	-72	-6
-40	-68	20
-30	-48	-12
52	-52	6
24	-90	-6
4	-8	40
6	60	20
56	-24	2
-10	46	16
8	8	68
-6	30	52
-10	-40	40
-16	20	42
24	26	42
-2	-66	34
32	-10	2
-2	-44	62
467	-60	26
-26	50	30
6	-10	38
-8	0	36
8	24	-4
26	-36	62
-38	-74	30
44	-70	34

// Chouinard B, 2017: Autism Spectrum Disorder (ASD)
// Subjects=12
-54	18	18
52	30	-8
-48	6	38
-6	12	58
6	20	58
-52	4	38
-38	-24	66
-24	-6	36
10	30	32
-42	-62	54
-62	-24	-2
64	-36	2
-60	-16	-2
70	-16	-2
-46	-58	42
-18	-4	6
-14	-2	6
-32	-80	-28
28	-74	-30
-26	-84	18
16	-90	20
-12	-16	6
14	-18	6
60	-52	-10
-10	-74	-26
-14	18	56
52	30	-8
4	-18	14
44	-54	56

// Chouinard B, 2017: Healthy Controls
// Subjects=12
-44	26	-18
-46	12	38
-10	48	28
-24	-14	68
-42	-22	48
32	18	18
-54	-22	-4
58	36	0
-44	-40	-2
32	-34	-2
-16	-18	22
24	-2	24
-2	-26	10
6	-82	-18
-26	-84	18
16	-90	20
-12	-16	6
14	-18	6
60	-52	-10
-10	-74	-26
-12	28	30
12	-12	32

// Cooper R A, 2017: Encoding - Baseline, All Subjects
// Cooper R A, 2017: Encoding - Baseline, Healthy Controls > ASD
// Cooper R A, 2017: Positive Correlation between Encoding and Subsequent 
// Memory Success, All Subjects
// Cooper R A, 2017: Positive Correlation between Encoding and Subsequent 
// Memory Success, Healthy Controls > ASD
// Cooper R A, 2017: Retrieval - Baseline, All Subjects
// Cooper R A, 2017: Retrieval - Baseline, Healthy Controls > ASD
// Cooper R A, 2017: Successful > Unsuccessful Retrieval, All Subjects
// Cooper R A, 2017: Positive Correlation between Retrieval and Precision, All 
// Subjects
// Subjects=20
42	-72	-12
-45	3	33
-6	9	57
54	33	27
51	9	30
30	0	51
60	-21	42
45	-72	-12
-48	-69	-9
-6	6	60
-51	3	48
-51	33	6
-24	-3	60
-57	-39	-18
33	-87	12
-51	6	33
54	12	33
30	18	6
48	30	24
9	-78	24
-6	6	-6
60	9	6
63	-18	21
-66	-24	-15
-24	-24	57
6	-6	51
-9	-81	24
54	-24	-21
51	-51	51
-66	-30	-15
-57	-48	48

// Cygan H B, 2019: All Conditions > Fixation, All Subjects
// Cygan H B, 2019: All Conditions > Fixation, ASD > Healthy Controls
// Cygan H B, 2019: Past-Self - Fixation, ASD > Healthy Controls
// Subjects=15
14.75	-35.61	45.75
32.93	36.44	46.16
6.27	46.15	-9.26
-40	-18.25	-6.58
39.75	-4.11	-20.54
44.29	44.54	5.94
55.34	-19.23	12.06
59.46	-20.67	-3.55
59.68	-49.72	7.16
-12.62	-72.31	10.63
-62.7	-14.07	-6.61
-62.36	-46.55	13.41
36.97	-19.3	12.38

// Ewbank M P, 2017: Different-Identity > Same-Identity, Healthy Controls > 
// Autism Spectrum Conditions (ASC)
// Ewbank M P, 2017: Different-Identity > Same-Identity, Positive correlation 
// with Cambridge Face Memory Test (CFMT)
// Subjects=15
38	-54	-6
-30	-64	34
-24	26	-14
-46	42	18
-54	34	6
2	26	-22
42	-20	-22
-10	62	26
24	-6	-22

// Hsu C, 2018: Mimicking > Anti-Mimicking, All Subjects
// Hsu C, 2018: Mimicking > Anti-Mimicking, Healthy Controls > ASD
// Hsu C, 2018: Mimicking > Anti-Mimicking, Positive correlation with Empathy 
// Quotient (EQ)
// Subjects=26
-42	-62	-9
-51	-59	-12
-35	-55	-12
32	-17	59
32	-78	46

// Kestemont J, 2016: Autism Spectrum Disorder (ASD)
// Subjects=12
-36	18	46
8	4	64
8	0	64
8	4	64
-50	0	28
8	2	64
8	4	64
8	4	64
8	4	64
24	-54	54
-24	-84	6
8	4	64
24	-54	54
-28	-82	6
22	-90	-6
26	-96	-4
10	2	62
28	-78	0
8	4	64
8	2	62
-38	-54	32
26	-96	-4

// Kestemont J, 2016: Subclinical Autism
// Subjects=18
-10	56	32
-20	48	34
-50	32	2
-40	16	52
-8	14	66
40	-20	24
-4	-20	32
6	-22	32
-6	-44	24
24	-74	-30
-26	-82	-34
8	0	64
-50	0	30
8	2	62
-30	-94	-8
-50	0	28
8	2	64
8	4	64
8	2	62
26	-94	-2
8	4	64
24	-54	54
-28	-82	6
22	-90	-6
24	-92	-6
26	-96	-4
8	2	62
10	2	62
28	-78	0
6	4	62
24	-90	-6
8	2	62
-38	-54	32
26	-96	-4

// Kestemont J, 2016: Healthy Controls
// Subjects=20
8	4	64
8	0	64
-50	0	30
8	2	62
-30	-94	-8
8	4	64
-50	0	28
8	2	64
8	4	64
8	4	64
8	2	62
26	-94	-2
8	4	64
24	-54	54
-24	-84	6
8	4	64
24	-54	54
-28	-82	6
22	-90	-6
24	-92	-6
8	2	62
10	2	62
6	4	62
24	-90	-6
8	4	64
8	2	62

// Lassalle A, 2017: Autism Spectrum Disorder (ASD)
// Subjects=27
-38	18	20
-50	24	26
-34	42	-14
48	-70	-8
40	-66	-12
62	-40	6
42	-38	-24
40	-52	-16
66	-42	6
52	-38	8
4	-40	34
-2	-34	32
6	-56	28
-2	-56	28
30	-94	6
56	-8	-14
44	-56	30
48	-40	-22
32	-94	14
-40	-76	-12
-42	-44	-14
-22	-12	-20
-38	-46	-16
-30	-6	-26
-48	-56	-14
-18	-96	-18
-20	-8	-34
28	6	12
4	52	20
0	54	30
2	66	10
-2	68	22
-46	32	-6
-48	24	-2
-42	42	2
-44	32	0
-16	10	20
4	-26	38
-6	-30	34
-24	-4	-32
-12	14	4
-50	-2	-32
-54	-42	-16
-34	-24	-16
-38	-12	-34
-6	-18	48
2	-10	2
-8	-10	0
-24	-14	-4
-30	-4	-22
-30	-12	-36
-14	14	12
4	-14	-20
-32	-14	-8
-34	-20	10
14	-50	20
-8	-52	14
8	40	32
-2	40	32
42	16	38
2	36	42
0	46	44
10	40	36
46	-48	22
2	42	6
-4	38	20
58	-60	32
50	-48	14
54	-42	14
48	20	26
-38	-54	38
-12	-68	34
-48	-46	42
-34	-58	52
-36	-64	52
42	-58	-16
64	-44	2
66	-38	6
46	-66	-12
66	-38	-2
46	-76	-16
36	-66	-16
54	-50	16
40	-62	14
-20	-12	-12
-40	-44	-18
-40	-56	-18
-26	-10	6
6	-12	4
-10	-22	-4
-24	-4	0
-34	-26	-12
-10	-28	-6
-48	-56	-16
62	-62	4
60	-58	8
42	-54	-10
38	-56	-18
38	-90	6
42	-58	-6
46	-70	-8
28	-78	-16
22	-90	30
46	-50	-4
34	-58	-14
20	-74	30
-22	18	52
-36	40	18
-30	12	50
-10	30	16
-4	28	42
-50	36	20
-48	32	20
-50	38	16
-46	4	6
-36	0	-2
-24	2	-20
-28	0	-8
36	16	50
34	-14	40
44	-46	20
22	-18	54
-20	18	8
-26	32	28
-22	38	30
-12	30	34
-4	-30	60
-14	-36	60
6	-30	38
-14	-26	36
-20	-10	6
-24	-10	12
8	40	32
0	40	24
10	30	24
-4	38	20
16	40	44
10	10	18
68	-12	-10
66	-8	-6
0	-22	-40
-60	-8	34
-52	-8	48
24	-8	-30
36	-12	-38
-40	-34	6
-22	-4	-32
-24	-10	-22
-20	-10	-16
4	-10	2
-8	-8	2
-14	-68	36
32	-28	-26
30	-26	-18
-34	24	-24
-52	10	6
-48	36	20
-48	52	-6
-52	10	30
-36	4	-14
-30	0	-12
-22	0	-4
-46	12	-10
-36	16	8
24	-94	20
28	-60	-6
22	-74	-4
20	-72	6
30	-54	-16
42	-64	0
46	-60	2
16	-30	-18
-16	-30	-16
0	-22	-20
18	-32	-6
-18	-34	-2
16	12	-12
30	-4	-16
18	10	-24
26	-16	-4
12	-46	-10
20	-32	-2
-50	-52	-8
-40	-68	-6
-26	-82	-6
-50	-56	10
-54	-56	18
-32	-54	-8
48	8	4
40	4	24
44	-8	6
48	12	2
58	12	8
56	18	22
42	-4	44
44	-90	4
-22	-98	14
12	-28	78
20	-32	78
-2	-58	8
-6	-62	6
54	20	-24
64	2	-12
-24	-76	46
-20	-30	66
-18	-24	74
-20	-58	-2
-6	0	54
8	14	50
8	12	54
-4	18	62
44	32	2

// Lassalle A, 2017: Healthy Controls
// Subjects=21
18	0	20
18	12	2
40	10	24
24	20	-12
-50	18	30
-40	2	38
-42	12	26
16	-98	12
38	-88	26
48	-78	-10
50	-44	-14
44	-54	-12
14	-98	0
-18	-100	10
32	-86	26
-30	-84	6
22	-80	-12
-24	-92	8
8	-94	6
-12	-86	-6
6	-86	2
-44	-70	-8
-38	-32	-20
-52	-48	-6
-44	-32	-18
-16	-26	-16
-10	-28	-14
-14	-34	-12
-16	-42	-12
-26	-32	-10
-28	28	-18
-34	38	-6
-50	32	12
-8	42	-16
-48	8	16
-44	52	-10
-38	4	40
-48	10	38
-32	26	-6
-50	34	14
-50	18	30
-50	40	12
-36	0	32
-32	30	-8
58	-58	8
60	-40	12
62	-46	10
42	-78	-8
32	-68	-20
-32	-78	-22
-48	-80	-2
-30	-102	4
-40	-60	-18
-38	-54	-20
-6	-14	-8
-10	-12	18
12	14	4
-16	-4	20
18	-4	2
-12	-10	-16
-50	6	18
-46	26	16
-46	10	34
-44	0	40
-40	8	24
-46	30	22
-44	38	16
52	36	14
48	2	40
62	22	6
50	12	36
52	-44	-12
64	-48	6
44	-80	-2
46	-54	-18
70	-42	10
30	-80	-20
-38	-56	44
-40	-48	40
-28	-66	44
-28	-56	44
46	-70	-8
28	-78	-16
22	-90	30
46	-50	-4
34	-58	-14
20	-74	30
-22	18	52
-36	40	18
-30	12	50
-10	30	16
-4	28	42
-50	36	20
-48	32	20
-50	38	16
-46	4	6
-36	0	-2
-24	2	-20
-28	0	-8
36	16	50
34	-14	40
44	-46	20
22	-18	54
-20	18	8
-26	32	28
-22	38	30
-12	30	34
-4	-30	60
-14	-36	60
6	-30	38
-14	-26	36
-20	-10	6
-24	-10	12
8	40	32
0	40	24
10	30	24
-4	38	20
16	40	44
10	10	18
68	-12	-10
66	-8	-6
0	-22	-40
-60	-8	34
-52	-8	48
24	-8	-30
36	-12	-38
-40	-34	6
-22	-4	-32
-24	-10	-22
-20	-10	-16
4	-10	2
-8	-8	2
-14	-68	36
32	-28	-26
30	-26	-18
-34	24	-24
-52	10	6
-48	36	20
-48	52	-6
-52	10	30
-36	4	-14
-30	0	-12
-22	0	-4
-46	12	-10
-36	16	8
24	-94	20
28	-60	-6
22	-74	-4
20	-72	6
30	-54	-16
42	-64	0
46	-60	2
16	-30	-18
-16	-30	-16
0	-22	-20
18	-32	-6
-18	-34	-2
16	12	-12
30	-4	-16
18	10	-24
26	-16	-4
12	-46	-10
20	-32	-2
-50	-52	-8
-40	-68	-6
-26	-82	-6
-50	-56	10
-54	-56	18
-32	-54	-8
48	8	4
40	4	24
44	-8	6
48	12	2
58	12	8
56	18	22
42	-4	44
44	-90	4
-22	-98	14
12	-28	78
20	-32	78
-2	-58	8
-6	-62	6
54	20	-24
64	2	-12
-24	-76	46
-20	-30	66
-18	-24	74
-20	-58	-2
-6	0	54
8	14	50
8	12	54
-4	18	62
44	32	2

// Nijhof A D, 2018: False Belief (FB) > True Belief (TB), Healthy Controls > 
// ASD
// Nijhof A D, 2018: FB > TB, All Subjects
// Nijhof A D, 2018: (FB > TB Explicit) > (FB > TB Spontaneous), All Subjects
// Nijhof A D, 2018: Agent False Belief of Present Ball (P-A+) > Agent False 
// Belief of Absent Ball (P+A-), All Subjects
// Subjects=21
57	-1	-20
57	-52	34
12	-70	1
45	32	37
-21	50	31
48	-46	31
48	32	31

// Tietze F A, 2019: Incongruent > Congruent
// Tietze F A, 2019: Healthy Controls > Asperger's Sydrome
// Subjects=16
53.32	25.55	-10.17
52.56	-24.02	9.61
0.09	-19.99	-2.39
0.23	33.14	37.76
-45.73	-26.64	12.07
-55.63	23.12	-4.25
-43.6	-24.51	11.87

// Lelieveld G, 2016: Justifiable Lies > Unjustifiable Lies
// Lelieveld G, 2016: Justifiable Lies > Honest Reports
// Lelieveld G, 2016: Unjustifiable Lies > Honest Reports
// Lelieveld G, 2016: (Justifiable Lies > Unjustifiable Lies) large deviance > 
// (JL > UL) small deviance
// Lelieveld G, 2016: Justifiable Lies > Unjustifiable Lies for large deviance
// Subjects=44
3	26	19
9	41	-5
21	17	-2
-3	23	22
3	32	13
-24	23	7
0	17	46
-15	8	-2
-24	26	4
12	-70	52
45	-34	43
42	-37	40
-3	14	49
12	20	1
-39	5	28
-15	-70	55
-21	-70	49
45	-37	40
30	53	28
27	56	25
-3	26	25
27	44	34
6	32	22
-9	32	22
30	50	28

// Ofen N, 2017: Conjunction Analysis: Lie > True, Episodic and Belief
// Ofen N, 2017: Deception Main Effects: Belief-lie > Belief-true & 
// Episodic-lie > Episodic-true
// Ofen N, 2017: Preparation-lie > Preparation-true
// Ofen N, 2017: Negative Correlation between Preparation-lie > 
// Preparation-true and Deception Index
// Subjects=18
-62	-52	28
-54	-54	30
-58	-62	26
56	-48	30
56	-42	44
14	12	58
-10	14	58
46	-10	42
54	4	-40
26	-18	2
30	-2	-14
6	-78	40
46	12	-30
-26	-56	36
-30	-70	50
36	-84	-4
-44	-92	-8
34	-56	50
26	-70	32
28	-64	38
-22	-24	24
-32	-4	50
34	4	44
22	10	26
-18	60	8
-46	-82	-2
4	-50	14
-56	-44	8
-52	-56	-2
-50	30	26
70	-38	4
-18	-22	-4
-16	-94	8
58	32	8
-16	-96	-14
-44	32	0
-8	62	16

// Peth J, 2015: Guilty Action
// Subjects=20
-52	32	-4
-36	24	-2
-44	18	24
34	26	-4
42	8	34
4	24	52
-62	-50	32
66	-40	34
48	18	28
52	-46	32

// Peth J, 2015: Guilty Intention
// Subjects=20
52	22	-6

// Peth J, 2015: Innocent
// Subjects=20
-8	16	52
-48	20	10
40	22	-6

// Pornpattananangkul N, 2018: Opportunity (O) > No-Opportunity (N-O) 
// (covariate: Overall Dishonesty)
// Pornpattananangkul N, 2018: N-O > O (covariate: Overall Dishonesty)
// Pornpattananangkul N, 2018: Opportunity-Self (O-S) > No-Opportunity-Self 
// (N-O-S) (covariate: O-S Dishonesty)
// Pornpattananangkul N, 2018: N-O-S > O-S (covariate: O-S Dishonesty)
// Pornpattananangkul N, 2018: Opportunity-Donation (O-D) > 
// No-Opportunity-Donation (N-O-D) (covariate: O-D Dishonesty)
// Pornpattananangkul N, 2018: O-S > O-D (covariate: Self Serving Dishonesty)
// Pornpattananangkul N, 2018: Self > Donation (covariate: Self Serving 
// Dishonesty)
// Pornpattananangkul N, 2018: O > N-O
// Pornpattananangkul N, 2018: N-O > O
// Pornpattananangkul N, 2018: O-S > O-D
// Pornpattananangkul N, 2018: O-D > O-S
// Pornpattananangkul N, 2018: S > D
// Pornpattananangkul N, 2018: D > S
// Pornpattananangkul N, 2018: N-O-S > N-O-D
// Pornpattananangkul N, 2018: N-O-D > N-O-S
// Subjects=31
-66	-18	6
36	-30	69
-60	-6	36
60	-21	15
3	57	-6
27	-78	-21
9	27	27
39	-81	36
36	-24	72
-9	39	-15
-12	-27	57
6	-87	-9
27	-51	54
0	45	-9
-60	-6	36
-24	-24	63
-18	-72	-3
-42	-78	15
-15	-48	12
9	12	12
18	15	-12
-15	27	12
-21	24	-3
9	9	15
18	12	-15
57	-63	39
-60	-60	30
-6	51	21
-6	39	57
-39	18	51
12	39	54
-63	-15	-18
9	-60	-12
3	42	42
45	-48	36
9	-84	-6
-60	3	12
66	3	15
9	6	42
9	12	3
-3	39	24
42	24	0
51	-48	39
-9	-84	-9
0	33	-21
51	-33	63
-51	-15	57
9	12	3
3	33	33
-9	-84	-9
-6	-54	21
-39	-63	30
-36	-42	-27
-9	42	-12
15	-105	9

// Shao R, 2017: Dishonest (D) > Truthful (T); Cue Phase
// Shao R, 2017: Low (L) > High Psycopathic Personality Inventory (H), D > T; 
// Cue Phase
// Shao R, 2017: Initial Session (T1) > Testing Session (T2), D > T; Cue Phase
// Shao R, 2017: (L(T2(D>T)>T1(D>T)) > H(T2(D>T)>T1(D>T)); Cue Phase
// Shao R, 2017: D > T; Face-responding Phase
// Shao R, 2017: T1(D>T) > T2(D>T)); Face-responding Phase
// Shao R, 2017: L(T2(D>T) > T1(D>T)) > H(T2(D>T) > T1(D>T))); Face-responding 
// Phase
// Shao R, 2017: T1 > T2; Control Visuo-spatial Control Task
// Shao R, 2017: H(T2-T1) > L(T2-T1); Control Visuo-spatial Control Task
// Shao R, 2017: L-H; Control Visuo-spatial Control Task
// Shao R, 2017: T1 > T2; Control Visuo-spatial Control Task
// Shao R, 2017: T2 > T1; Control Visuo-spatial Control Task
// Shao R, 2017: Familiar (F) > Unfamiliar (UF)
// Shao R, 2017: UF > F
// Shao R, 2017: L(F>UF) > H(F>UF)
// Subjects=23
39	-69	9
12	-51	54
33	-33	42
-39	-78	18
-42	-3	51
-30	6	0
-45	6	24
33	-72	42
-48	-69	3
-48	33	12
24	-39	63
51	15	27
18	-42	-6
-15	-45	66
-21	-57	12
48	-12	-18
-54	6	-18
9	12	66
33	51	24
-42	24	-9
-3	-57	54
24	24	42
-6	12	57
-57	-48	30
-33	-60	-30
-6	-18	-18
51	-45	42
-27	9	63
-57	-45	3
60	21	9
-48	-60	39
-6	-51	-6
-12	24	27
12	-60	-30
-24	0	-12
-27	-45	-18
24	15	-3
27	-42	-18
-6	-27	51
-24	-9	60
-39	9	18
3	9	36
-21	-75	42
21	-21	69
-9	-90	24
-9	-63	6
-27	-57	-6
27	-57	48
27	-6	63
-21	9	-3
9	-51	27
57	-3	-18
-6	57	-6
3	-54	27
-54	-9	-18
-54	-60	12
24	-84	0
9	15	6
-57	-39	21

// Suchotzki K, 2015: Main effect of Proportion (1:1 > 1:4)
// Subjects=32
-44	-34	52
-36	-6	62

// Sun D, 2015: Main effect of Face (Unfamiliar (U) > Familiar (F))
// Sun D, 2015: Main effect of face (F>U)
// Sun D, 2015: Main effect of Response Type (Lie (L) > (Truth) (T))
// Sun D, 2015: Interaction effect between Response Type and Face (F(L-T) > 
// U(L-T))
// Subjects=17
46	14	2
-8	-56	20
-2	60	-4
54	-6	-24
-44	-68	20
50	-58	12
-48	18	0
-48	-54	52
-42	10	50
8	16	62
50	16	0
-46	18	0

// Sun P, 2017: Main effects of decision (lying > honest)
// Sun P, 2017: Interaction between financial position & decision 
// (lying-honest)non-deprived>(lying-honest)deprived
// Subjects=21
8	-38	32
-6	-36	30
-10	-54	22
8	-48	38
50	24	28

// Sun D, 2015: Dishonest > Honest (positive effect)
// Sun D, 2015: Dishonest > Honest (negative effect)
// Sun D, 2015: Main effect of Detection (Not Detected > Detected)
// Subjects=25
39	23	7
9	35	19
-33	23	-5
45	-1	46
9	-28	43
45	-55	31
63	-4	22
15	2	-8
-12	5	-8
0	-22	25
-3	53	1

// Yin L, 2016: S_Lie_InC, S_Truth_InC, S_Truth_C > Fixation
// Subjects=44
3	42	26
9	24	63
-5	30	-3
5	28	-3
40	21	-10
45	55	-4
-39	18	-10
45	-42	48
-60	-48	36
44	20	42
-24	49	21
48	30	26
42	48	17

// Yin L, 2017: Self-benefit lie > Charity-benefit lie
// Yin L, 2017: Self-benefit lie > Charity-benefit lie
// Yin L, 2017: Charity-harm truth > Self-harm truth
// Subjects=47
36	24	-4
34	24	-6
-2	42	-18

// Yin L, 2016: Main effect of means (Lies>Truth)
// Yin L, 2016: Main effect of means (Truth>Lies)
// Yin L, 2016: Main effect of ends (Beneficial>Harmful outcome)
// Subjects=38
58	-48	12
-3	22	60
-36	22	9
40	16	24
12	-65	-3
-12	4	-10
12	12	-6
-10	7	-7

// Gu X, 2015: Empathetic Pain (Painful > Non-Painful), Both Groups
// Gu X, 2015: Empathetic Pain (Painful > Non-Painful), ASD > Healthy Controls
// Gu X, 2015: Empathetic Pain (Painful > Non-Painful), ASD < Healthy Controls
// Gu X, 2015: All Images (Painful & Non-Painful), ASD > Healthy Controls
// Gu X, 2015: All Images (Painful & Non-Painful), ASD < Healthy Controls
// Gu X, 2015: Correlation with Skin Conductance Responses, ASD > Healthy 
// Controls
// Gu X, 2015: Correlation with Skin Conductance Responses, ASD < Healthy 
// Controls
// Subjects=17
-32	-90	6
-46	-46	-14
-62	-28	38
-34	-42	48
-38	-46	58
52	-62	-8
30	-88	2
36	-86	10
-38	-4	14
-50	6	22
-38	0	2
-38	20	2
62	-24	40
54	-32	48
40	-34	42
54	36	0
54	10	40
20	-84	12
-24	-26	-4
-6	-28	-20
10	-26	-18
14	-54	10
12	-42	18
-6	-50	6
-12	-78	10
-24	-92	12
32	-36	-4
30	-22	-10
34	-36	-12
42	28	8
34	28	14
30	26	-2
-34	22	-14
-38	12	-12
-42	-54	2
-48	-50	6
-46	-66	12
-16	-58	-40
-26	-48	-34
52	-30	8
40	-38	8
60	20	14
54	18	30
-20	-6	58
-20	-18	52
-28	6	48
14	-62	46
-8	-38	24
-14	-44	36
-42	-74	36
-32	-64	24
58	-8	-6
24	-90	2
30	-68	24
24	-82	12
-8	-24	-38
22	-34	-36
-12	-34	-40
-16	-70	-22
-24	-68	-22
-34	-66	-18
-38	-84	8
-22	-94	4
-30	-82	14
54	-36	34
40	6	-8
38	22	-12
-8	16	42
-16	10	42
-6	-30	56
-10	-40	68
-10	-48	64
-26	10	16
-12	-46	12
24	28	2
22	24	14
14	22	12
26	-56	-44
32	-60	-40
14	-64	-40
-54	-16	-26
-52	12	-24
-44	2	-30
34	-4	-30
40	14	-26
34	-6	-22
-54	-64	14
-52	-68	28
-44	-78	14
-4	-46	-50
0	-50	-44
-42	-50	-16
-52	-62	-16
-42	-70	-16

// Okamoto Y, 2018: Autism Spectrum Disorder (ASD)
// Subjects=18
-16	50	14
6	36	10
-30	-88	-10
-36	-60	-10
28	-76	2
34	-54	-16
8	-78	-4
-6	-80	-8
-18	-76	-10
-10	-100	6
16	-98	10
18	-84	-26
12	-58	-42
-6	-54	-46
36	-76	46
-36	-64	46

// Okamoto Y, 2018: Healthy Controls
// Subjects=18
-16	50	14
6	36	10
-30	-88	-10
-36	-60	-10
28	-76	2
34	-54	-16
8	-78	-4
-6	-80	-8
-18	-76	-10
-10	-100	6
16	-98	10

// Pantelis P C, 2015: Awkward > Baseline, All Participants
// Pantelis P C, 2015: Awkward > Baseline, Healthy Controls > ASD
// Subjects=17
28	22	-16
48	26	-12
48	6	-40
48	8	-22
4	40	28
28	48	26
54	-44	20
64	-48	18
56	-54	38
48	-26	-12
8	-90	10
6	-86	4
4	-88	-10
20	-78	-18
-28	-76	-14
-34	16	-26
-34	18	-12
4	-52	48
18	-72	26
-26	46	20
-34	48	14
2	-24	40
4	-18	26
-8	-50	-12
2	-62	-18
40	-2	52
52	-36	2
56	-44	18
56	-42	20

// Rosenblau G, 2017: Emotional > Neutral, Healthy Controls
// Rosenblau G, 2017: Emotional > Neutral, ASD
// Rosenblau G, 2017: Explicit > Implicit Emotional, Healthy Controls
// Rosenblau G, 2017: Explicit > Implicit Emotional, ASD
// Rosenblau G, 2017: Implicit > Explicit Emotional, Healthy Controls
// Rosenblau G, 2017: Implicit > Explicit Emotional, ASD
// Rosenblau G, 2017: Basic > Complex Emotional, ASD
// Rosenblau G, 2017: Emotional > Neutral, All Participants
// Rosenblau G, 2017: Complex > Basic Emotional, Healthy Controls > ASD
// Rosenblau G, 2017: Complex > Basic Emotional, Female ASD > Male ASD
// Rosenblau G, 2017: Implicit > Explicit Emotional, Healthy Controls > ASD
// Rosenblau G, 2017: Emotional > Neutral, Correlation with task performance, 
// ASD > Healthy Controls
// Subjects=6
48	-18	0
52	-26	4
56	-18	0
48	-22	0
66	-30	6
58	-24	-2
56	24	0
-42	-26	2
-48	-14	-2
-46	-18	0
-46	-24	-4
-48	-12	-6
-64	-28	6
46	30	2
58	34	8
52	32	4
50	4	-22
58	20	20
52	4	-18
-66	-34	6
-68	-26	4
-60	-22	4
-54	-18	-14
-38	4	-32
-46	-4	-6
16	-72	6
0	-88	2
16	-72	14
-10	-76	20
-18	-60	-2
14	-86	16
56	-14	-8
58	-8	-4
54	-32	0
60	-16	-2
54	28	-4
56	28	0
-52	2	-20
-52	-2	-20
-50	-10	-2
-48	-38	6
-60	-26	8
-64	-26	6
54	-16	-8
52	-20	-2
52	-16	-4
50	-10	-4
42	-20	-4
-2	-48	38
-44	-70	40
-22	36	36
14	50	-4
24	32	36
2	46	-8
-50	-26	24
-48	-26	20
-4	-46	38
-4	-48	42
-2	-30	48
10	-4	48
12	62	0
6	42	-8
10	48	-4
-26	-26	-18
-26	-26	-22
40	-14	12
40	-16	16
36	-10	2
36	-20	2
38	-14	2
46	-12	10
-64	-6	-2
-60	-10	-6
-64	-8	-8
-56	-22	0
42	-28	8
42	-32	12
38	-32	8
38	-28	8
62	-12	-2
64	-28	6
20	-56	-4
-64	-22	12
-62	-22	6
-20	-58	-6
-64	-26	16
-38	-48	20
10	-2	40
-10	-10	36
-12	-26	44
-12	-30	44
-10	4	40
-8	-36	50
38	-34	10
42	-30	10
52	-18	6
44	-34	24
46	2	-14
44	-12	-4
56	-38	10
26	-4	-22
-44	-22	2
-64	-8	-6
-64	-6	0
-50	-22	2
-58	-8	8
-56	-4	6
-38	-4	10
58	-18	6
46	-26	36
64	-30	4
66	-32	8
38	-34	14
52	-30	10
-44	-68	44
-46	-68	40
-60	-56	26
-48	-68	44
-56	-62	34
-58	-64	24
-16	58	4
-24	48	-10
-26	48	-4
-22	68	-8
-6	46	22
6	42	20
-24	36	52
-20	28	30
-20	30	26
-20	28	22
-18	36	54
-14	34	56
52	-18	-10
52	16	12
58	8	-22
56	-44	20

// Sato W, 2017: Supraliminal Averted > Supraliminal Straight, All 
// Participants
// Sato W, 2017: Supraliminal Averted > Supraliminal Straight, Healthy 
// Controls > ASD
// Sato W, 2017: Subliminal Averted > Subliminal Straight, Healthy Controls > 
// ASD
// Subjects=16
-52	-58	40
50	-48	46
56	-52	26
34	46	-6
-14	50	-2
-40	6	-28
-32	-6	-24
-8	-64	22

// Schelinski S, 2016: Autism Spectrum Disorder (ASD)
// Subjects=16
39	-25	10
-36	-34	10
0	-37	-2
-6	-37	-41
-15	-76	-47
-42	-64	-29
15	-79	-41
24	-61	-23
-39	26	4
21	-7	-14
54	-1	46
15	-13	7
6	5	64
21	-49	-44
-60	-34	4
63	-16	-2
54	5	43
-48	-10	40
-39	23	4
-36	8	10
27	-61	-23
18	-76	-41
6	2	67
-18	-7	-14
-36	2	-17
51	-22	7
-36	-34	13
3	-40	-11
12	-37	-44
-6	-37	-41
-21	-82	-41
15	-79	-44
24	32	-17
-39	29	-14
-48	-64	-23
-27	-40	-20
27	-37	-17
45	2	7
-60	-31	10
9	-40	55
-57	-22	7
66	-25	10
-15	-76	-44
27	-58	-26
-27	23	4
30	23	4
-6	5	58
-51	-7	43
54	2	43
-21	-1	10
-51	-31	55
-48	20	25
39	-52	43
3	-61	28
-24	-76	-32
27	-85	-41
54	-31	-11
-6	65	16
42	32	31
39	-52	43
3	-73	43
18	-52	-41
-6	-55	-41
-39	-64	-26
51	-19	-2
66	-34	7
6	29	37
6	-94	4
30	14	46
-24	11	52
-57	-22	7
66	-25	10
24	-61	-23
18	-64	-44
-15	-76	-44
-30	-58	-29
54	2	43
33	23	7
-27	23	1
21	2	10
33	-76	-41
-45	-61	-8
24	-1	-5
18	-52	-41
33	-46	-29
-18	-58	-23
-9	-91	-5
60	2	28
-51	-4	34
-12	-22	46
-9	-19	4
51	-19	10
6	-34	40
6	-1	37
-6	59	22
3	-61	1
12	-82	-5
36	8	10
30	-58	13

// Schelinski S, 2016: Healthy Controls
// Subjects=16
51	-13	4
-63	-19	1
0	-34	-2
-15	-79	-44
21	-79	-38
21	-49	-44
-63	-22	-2
60	-4	-8
-18	-76	-35
48	-13	7
-42	-28	13
0	-40	-5
-15	-88	-35
-15	-79	-44
-9	-91	-29
21	-85	34
-39	-76	22
-30	-34	-26
24	-28	-17
27	50	31
36	41	19
-9	-52	4
-3	-40	52
54	-37	37
45	2	7
-60	-31	10
9	-40	55
-63	-19	4
54	-16	1
-12	-79	-32
27	-58	-29
24	-64	-44
-30	26	7
-9	-1	58
42	32	28
-48	41	-2
-51	-4	49
39	-52	40
12	-10	10
9	-19	-11
-36	-52	43
3	-61	28
-24	-76	-32
27	-85	-41
54	-31	-11
-6	65	16
9	-67	46
30	14	49
-51	26	31
-27	8	52
-39	-67	-29
-9	-55	-44
-33	17	-5
-30	47	13
-39	-55	43
54	-46	19
3	-73	43
18	-52	-41
-6	-55	-41
-39	-64	-26
51	-19	-2
66	-34	7
6	29	37
6	-94	4
30	14	46
-24	11	52
45	-34	7
6	-58	37
48	-28	-5
-9	-1	58
-63	-19	4
54	-16	4
21	-58	-23
-12	-79	-32
-30	-58	-29
39	23	13
-48	-37	40
-24	-7	52
42	26	28
33	-76	-41
-48	-49	-5
54	-61	-2
-24	-4	-5
18	-61	-20
33	-22	-14
27	-1	-14
63	5	19
-33	-16	67
-51	-7	-14
42	-19	37
12	-7	40
-6	8	37
-48	-7	-29
-3	-13	55
21	-61	-5
51	-25	22
-6	-52	13

// Schipul S E, 2016: Autism Spectrum Disorder (ASD)
// Subjects=16
10	-90	-8
26	0	60
-24	-4	64
54	12	14
-24	-36	-42
40	38	18
-56	6	36
10	24	44
22	-30	-6
-24	26	0
-2	-48	-26
64	-6	22
6	2	26
-62	-8	32
-8	-30	72
-46	50	0
-24	-36	10
36	18	-2
32	2	34
-8	12	52
16	-26	14
-58	-14	44
8	-80	-2
68	-6	24
-10	-48	-24
42	-6	60
-22	-84	-12
18	-26	-32
-40	-4	62
-62	-8	30
-6	0	72
-52	-78	4
-10	-28	72
-26	28	2
-40	-70	-26
-12	-92	36
10	8	56
-28	-76	52
34	40	12
44	50	0
-52	-6	8
-28	-34	4
34	-66	-30
-2	32	-2
38	-20	34
52	-42	32
-54	-32	0
-12	8	-12
50	-28	-12
42	12	34
44	16	-24
14	-10	40
6	-36	44
48	24	-6
-26	56	-8
-22	50	24
-4	-38	22
32	32	-8
-24	-10	14
62	-36	-2
2	20	52
10	-64	38
48	-34	16
38	-20	40
8	32	20
-64	-28	2
-32	-46	68
-2	-16	60
-12	6	-14
-20	52	24
-14	-50	72
34	34	-10
50	-36	16
12	-54	64
56	-6	-6
62	-38	-4
-30	56	-6
34	16	34
10	46	-6
36	6	42
-2	16	54
-34	-36	48
0	28	0
-18	-46	0
38	-56	18
10	-32	-38
32	-12	28
22	-46	-2
24	-74	14
-32	56	28
-36	14	-14
6	-22	26
-8	-4	-2
-24	-52	-40
-46	-2	-28
10	0	-8
6	-42	40
4	-76	-18
10	-6	4
-30	-20	14
-14	-58	-12
6	-70	-38
52	-10	-2
-6	-70	-2
44	-50	10
-26	-22	20
4	-20	10
-44	-66	32
-44	10	52
-6	42	56
-20	-16	-14
32	34	-22
-62	-46	16
44	-30	30
-62	-18	-18
-2	8	72
-52	24	32
60	10	0
18	-32	-36
-62	-6	6
-8	-18	-6
60	-58	-4
-18	-30	-8
-56	24	0
-10	40	38
34	24	10
38	-44	-36
64	-50	20
-32	-20	38
-6	-8	42
-8	-56	-30
-34	-32	6
4	-56	66
58	6	-20
-38	-28	-10
30	-40	-46
-12	-30	-14
-46	-52	-34
-26	-56	18
12	-58	-40
-26	12	-24
16	-36	-48
-16	-32	-34
-6	-86	-34
-44	-66	28
-62	-14	-26
8	-52	74
-8	-98	28
24	-2	-40
-14	64	30
-24	-48	30
-22	-66	-36
46	-60	-40
-16	24	12
-20	-52	-42
40	-44	-30
34	-62	16
36	-36	10
12	-14	-10
24	-48	-30
-36	8	-14
40	-48	-8

// Schipul S E, 2016: Healthy Controls
// Subjects=16
18	-88	-6
48	6	22
32	10	58
-22	-2	56
40	60	-8
50	46	20
28	42	-16
44	56	12
-48	2	36
-58	-14	44
8	-80	-2
68	-6	24
-10	-48	-24
42	-6	60
-22	-84	-12
18	-26	-32
-40	-4	62
-62	-8	30
-6	0	72
-52	-78	4
-10	-28	72
-26	28	2
-40	-70	-26
-12	-92	36
10	8	56
-28	-76	52
34	40	12
44	50	0
-52	-6	8
12	-30	8
36	-22	24
-40	-34	46
-22	-6	56
54	-60	-22
40	-76	-2
-42	-22	30
30	-30	0
-56	10	40
-44	-72	0
34	42	-16
24	-100	12
28	-70	30
-8	-22	76
-42	-78	30
-14	-62	22
-38	8	62
-6	-42	44
0	-54	4
-12	16	4
38	-20	40
8	32	20
-64	-28	2
-32	-46	68
-2	-16	60
-12	6	-14
-20	52	24
-14	-50	72
34	34	-10
50	-36	16
12	-54	64
56	-6	-6
62	-38	-4
-30	56	-6
34	16	34
10	46	-6
36	6	42
-2	16	54
-34	-36	48
-6	-70	-2
44	-50	10
-26	-22	20
4	-20	10
-44	-66	32
-44	10	52
-6	42	56
-20	-16	-14
32	34	-22
-62	-46	16
44	-30	30
-62	-18	-18
-2	8	72
-52	24	32
60	10	0
18	-32	-36
-62	-6	6
-8	-18	-6
60	-58	-4
-18	-30	-8
-56	24	0
-10	40	38
34	24	10
38	-44	-36
64	-50	20
-32	-20	38
-6	-8	42
-8	-56	-30
-34	-32	6
4	-56	66
58	6	-20
62	12	2
-54	-38	12
6	-62	16
-62	-4	6
50	-48	6
-44	10	50
-28	20	4
26	-36	-36
-26	-24	12
-2	-42	42
-36	-62	36
32	32	-22
30	-4	-12
-40	-14	8
36	4	28
44	-30	30
6	-22	10
64	-6	-28
4	-74	-26
-36	-10	36
-40	-72	46
-6	2	6
60	-58	28
-60	42	52
-8	-74	34
26	-72	-24
-10	-4	72
36	-20	6
6	-82	48
44	32	-16
12	-84	-12
22	-86	-8
60	-60	-2
8	-90	4
18	-36	28
20	-50	16
42	-34	-8
36	-56	-4
-26	-46	-4
54	-36	10
-18	-34	20

// Stanfield A C, 2017: Social > Gender, All Participants
// Stanfield A C, 2017: Social > Gender, Healthy Controls
// Stanfield A C, 2017: Social > Gender, ASD
// Stanfield A C, 2017: Social > Gender, Schizotypal Personality Disorder 
// (SPD)
// Stanfield A C, 2017: Social > Gender, ASD < Healthy Controls
// Stanfield A C, 2017: Social > Gender, ASD < SPD
// Stanfield A C, 2017: Social > Gender, ASD < SPD (voxel-based inference P < 
// .05 FWE corrected)
// Stanfield A C, 2017: Social > Gender, ASD < Comorbid (CM)
// Stanfield A C, 2017: Social > Gender, ASD < SPD (only antipsychotic naive 
// participants)
// Stanfield A C, 2017: Social > Gender, Negative Correlation with Positive 
// Symptoms (PANSS), ASD
// Stanfield A C, 2017: Social > Gender, Positive Correlation with Negative 
// Symptoms, CM
// Stanfield A C, 2017: Gender > Baseline, ASD > SPD and Healthy Controls
// Stanfield A C, 2017: Gender > Baseline, ASD > CM and Healthy Controls
// Subjects=9
-54	32	-2
51	29	-5
-9	-32	58
-48	2	-35
-57	-43	1
-9	-85	1
-39	-67	-44
9	32	58
12	56	34
12	-82	1
-36	-70	-44
30	-82	-44
-9	-85	4
-12	32	58
-6	56	34
-54	17	4
51	35	25
-48	-1	-38
-63	-40	1
-9	-85	1
-15	5	-5
-3	-25	-26
30	-58	-44
-45	-55	-41
-24	-52	31
-15	-40	-38
33	-64	-44
33	-64	-44
51	35	25
-18	-19	49
24	-55	-41
18	35	-17
33	-64	-44
-18	-10	-14
-18	-19	49
-18	-10	-14
-18	-19	49

// Ciaramidaro A, 2018: Autism Spectrum Disorder (ASD)
// Subjects=33
44	-46	-22
-40	-46	-22
42	36	-12
-48	26	-10
56	-62	8
-56	-54	6
-48	-76	32
2	46	-20
4	56	32
8	50	46
48	22	22
-50	22	16
22	-4	-20
-20	-6	-18
52	-20	-10
-54	-22	-12
4	-54	24
-2	72	-2
42	-46	-22
-40	-48	-20
28	32	-14
-36	30	-20
56	-64	8
56	-54	32
-46	-70	28
2	56	-12
2	54	36
2	54	36
48	22	22
24	-2	-24
-20	-6	-18
4	-56	26
4	-78	0
42	-46	-22
-40	-46	-22
28	32	-14
-32	32	-16
58	-60	16
-48	-74	32
2	46	-18
8	56	32
52	28	16
22	-4	-20
-22	-6	-20
58	-4	-22
6	-56	26
-4	-72	0
54	-46	-18
-36	-56	-14
26	30	-18
-38	28	-14
66	-46	-2
-58	-48	-2
-60	-56	18
-10	38	-14
-4	52	0
-8	44	50
42	16	30
-50	20	24
20	-8	-22
-18	-12	-22
-58	-14	-28
0	-88	12

// Ciaramidaro A, 2018: Paranoid Schizophrenia (SCZ)
// Subjects=20
44	-46	-22
-42	-48	-22
-38	30	-16
58	-54	6
-58	-58	6
48	-64	16
-56	-70	10
0	50	-18
6	58	36
58	28	20
-40	14	22
20	-4	-24
-16	-10	-22
56	-4	-24
-50	-16	-18
2	-50	26
0	-82	2
42	-46	-22
-42	-48	-22
36	38	-16
50	-50	6
54	-60	22
-54	-68	34
-2	54	-16
10	62	18
6	60	34
44	22	24
20	-6	-22
-22	-6	-24
50	-14	-16
-56	-8	-18
0	-60	38
-6	-84	-8
-40	-46	-22
38	40	-14
-38	32	-16
60	-46	2
-56	-70	10
0	40	-24
6	58	34
40	22	24
18	-12	-22
-30	-16	-20
52	-2	-28
0	-58	36
-2	-90	4
-34	-56	-14
-12	-4	-16

// Ciaramidaro A, 2018: Healthy Controls
// Subjects=25
42	-42	-22
-40	-46	-22
54	32	-4
-48	34	-4
60	-58	6
-58	-46	4
-56	-70	12
0	40	-26
-2	50	-15
-4	38	46
52	26	18
-48	24	16
22	-6	-18
-20	-8	-20
50	-12	-16
2	-62	34
4	-80	2
42	-40	-24
-40	-48	-22
26	32	-16
-36	30	-18
52	-48	4
-66	-44	4
58	-64	22
-42	-68	24
0	48	-16
12	64	16
-14	62	22
-6	26	48
44	18	28
-46	26	16
22	-6	-20
-22	-6	-20
48	-16	-14
-50	-18	-14
2	-62	34
6	-80	0
42	-40	-24
-40	-48	-22
26	32	-16
-34	34	-14
62	-60	4
-64	-46	4
60	-62	26
-44	-64	22
0	48	-16
12	64	12
14	36	48
44	18	30
-44	20	38
22	-6	-18
-18	-10	-20
56	-4	-24
2	-62	34
6	-74	2
-34	-56	-14
-12	-4	-16
54	-46	-18
-36	-56	-14
26	30	-18
-38	28	-14
66	-46	-2
-58	-48	-2
-60	-56	18
-10	38	-14
-4	52	0
-8	44	50
42	16	30
-50	20	24
20	-8	-22
-18	-12	-22
-58	-14	-28
0	-88	12

// Sun D, 2016: Dishonest > Honest
// Sun D, 2016: Human > Computer
// Sun D, 2016: Computer (Dishonest-Honest) > Human (Dishonest-Honest)
// Subjects=25
-3	-13	7
12	5	-2
-12	8	-3
-27	29	-2
42	23	4
9	8	58
45	-49	-17
-42	-64	-17
9	44	-14
6	-88	-5
-9	50	37
0	-55	31
-39	2	-5

// Yin L, 2019: Lying  > Truth-telling
// Yin L, 2019: Truth-telling > Lying
// Yin L, 2019: Negative Correlation between Lying and Lying Percentages
// Yin L, 2019: Negative Correlation between Lying > Truth-telling and Lying 
// Percentages
// Subjects=37
-24	-4	56
-12	-64	54
28	2	62
-10	-90	-8
-14	-94	24
-12	42	12
-36	54	14
2	16	60
44	36	0
-28	12	38
-12	-48	16
38	54	6
-2	-4	-2
50	-48	50
-12	12	-2
-50	20	6
8	-34	40
34	28	-6
6	28	32
-64	-46	28
8	-12	-2
2	-32	-18
44	2	54

// Barbeau E B, 2015: Autism Spectrum (AS)
// Subjects=22
34	-24	70
-38	-28	64
50	-66	2
42	-66	12
18	-76	12
-42	-74	10
-38	-22	64
10	18	64
52	20	-2
-18	-44	70
40	-26	62
-12	-92	30
-12	-78	14
16	-76	12
14	-66	14
-6	-80	26
6	-74	24
8	-60	-2

// Barbeau E B, 2015: Healthy Controls
// Subjects=24
40	-24	64
-36	-22	66
26	-70	-12
-46	-74	8
-20	-76	-8
-26	-80	20
-20	-58	50
-38	-22	64
10	18	64
52	20	-2
-18	-44	70
40	-26	62
-12	-92	30
-12	-78	14
16	-76	12
14	-66	14
-6	-80	26
6	-74	24
8	-60	-2

// Hames E C, 2016: Session 1 VV2 - VA2, ASD > Healthy Controls
// Hames E C, 2016: Session 1 AA2 - VV2, Healthy Controls > ASD
// Hames E C, 2016: Session 2 AA_MM2 - AA2, Healthy Controls > ASD
// Subjects=10
36	-65	-2
25	-91	3
-56	-30	9
46	-50	-9

// Lassalle A, 2019: Autism Spectrum Disorders (ASD)
// Subjects=19
-8	-88	-6
-6	-98	-4
-22	-84	-10
2	-20	36
4	4	46
4	2	34
0	-2	32
16	-94	-8
-24	-94	6
24	-78	-2
-22	-90	-14
50	-76	-2
40	-56	-14
-2	-70	18
18	-84	10
-2	-72	14
-8	-86	14
32	-38	-26
16	-56	14
-12	-72	30
-48	38	6
-42	14	22
-50	8	20
-46	34	-8
-40	16	28
-42	18	2
-48	26	28
-46	10	28
-42	8	26
4	-22	4
-12	-10	0
2	-26	-4
6	-34	26

// Lassalle A, 2019: Healthy Controls
// Subjects=20
-6	-90	-4
16	-64	-4
-8	-86	-6
-26	-70	-6
-22	-88	24
-4	-32	-4
8	-84	14
12	-84	32
-18	-28	0
-2	-56	6
-30	-54	-8
16	-40	2
-2	-42	30
18	-28	-8
-12	-40	-6
-8	2	10
4	48	32
0	50	34
8	66	14
-4	62	16
2	54	16
0	52	12
-6	34	22
4	46	-16
4	20	-22
-4	20	-24
-54	24	10
-46	22	-12
-42	8	32
-50	38	6
-28	26	-2
-52	18	-16
-40	-52	16
-56	-48	32
-44	-54	26
-44	-54	6
12	-86	-4
0	-74	-4
14	-86	4
-12	-80	6
24	-64	-8
-34	-70	-14
14	-90	2
-18	-96	-4
2	-28	-4
34	-88	-12
16	-78	-8
30	-58	-6
22	-30	0
-2	-26	0
22	-66	20
-4	-88	12
6	-78	34
0	-76	24
-50	-48	32
20	-64	28
-4	-68	26
10	-48	4
-16	-48	4
-14	-40	-6
-54	-40	8
-38	-38	-18
22	-36	2
-32	-76	-6
-50	-66	40
-36	-56	36
2	52	12
-4	54	16
-28	28	-4
-52	24	12
-28	28	0
-4	54	22
0	62	12
-4	58	40
-42	18	0
-36	12	34
-36	4	32
6	30	28
-4	34	22
0	22	-4
-4	26	-4
-48	18	-14
-10	22	0
-10	8	56
-4	50	-12
36	28	4
44	28	-8
36	12	-8
-48	38	6
-42	14	22
-50	8	20
-46	34	-8
-40	16	28
-42	18	2
-48	26	28
-46	10	28
-42	8	26
4	-22	4
-12	-10	0
2	-26	-4
6	-34	26

// Murphy C M, 2017: Delayed Reward > Immediate Reward, Healthy Controls > ASD
// Subjects=38
35.12	-.17	-24.53
11.7	65.33	12.62
47.37	-7.1	36.13
39.77	-85.28	-10.76

// Perkins T J, 2015: Action Observation > Baseline, High-Functioning Autism 
// (HFA)/Asperger's (AS) > Controls, p<0.05
// Perkins T J, 2015: Action Observation > Baseline, HFA/Asperger's > 
// Controls, p<0.001
// Perkins T J, 2015: Action Observation > Baseline, Healthy Controls > HFA/AS
// Subjects=12
34	-10	56
12	38	-12
12	26	-4
24	-58	10
18	-74	12
34	-60	10

// Simard I, 2015: Autistic (AUT)
// Subjects=15
-44	28	28
-42	4	34
-26	0	56
-24	-64	50
-28	-90	-6
-26	-72	34
-28	22	-4
-4	-24	-10
-6	-74	-26
50	10	30
40	32	24
30	0	56
36	-76	-14
28	-94	-4
34	-86	12
30	24	0
10	-74	-26
34	-66	-50
2	-54	-38
-16	-82	26
-22	-90	20
-42	20	34
-2	-58	38
2	-56	54

// Simard I, 2015: Healthy Controls
// Subjects=18
-48	24	34
-48	26	24
-44	16	30
-32	-88	-10
-28	26	-2
-10	8	12
-16	-2	0
-4	-22	-10
36	60	8
30	8	56
50	28	34
46	8	28
30	26	-2
18	-66	58
28	-94	-4
16	-2	0
6	-22	-8
-16	-82	26
-22	-90	20
-42	20	34
-2	-58	38
2	-56	54

// Solomon M, 2015: Early Stimulus, Healthy Controls > Autism Spectrum 
// Disorders
// Solomon M, 2015: Stimulus, Healthy Controls > Autism Spectrum Disorders
// Solomon M, 2015: Feedback, Autism Spectrum Disorders > Healthy Controls
// Subjects=22
14	52.95	5.62
0.97	52.38	0.3
40.38	32.34	36.35
33.46	62.9	7.67
-5.59	28.78	-10.7
0.8	37.96	-16.2
-9.04	22.85	-27.98

// Sommer M, 2018: Autism Spectrum Disorders (ASD)
// Subjects=15
-8	6	66
-50	-10	42
-42	18	24
42	-66	-6
-6	6	66
-46	-4	44
50	-2	34
-60	-26	0
52	-38	16
-40	-68	8
46	-60	-8
-8	-28	-2
-4	6	64
32	28	10
-6	54	-10
-12	80	18
14	-56	-2
-22	52	0
38	48	-12
-42	4	60
-40	-30	8
-58	-46	36
6	-4	8

// Sommer M, 2018: Healthy Controls
// Subjects=15
8	8	66
-40	0	42
-64	-32	2
50	-40	14
48	-58	-8
-8	-28	-2
-6	6	66
-46	-4	44
50	-2	34
-60	-26	0
52	-38	16
-40	-68	8
46	-60	-8
-8	-28	-2
42	20	-6
42	-44	2
14	40	-14
26	24	54
-20	26	54
68	-24	26
12	-56	26
-12	80	18
14	-56	-2
-22	52	0
38	48	-12
-42	4	60
-40	-30	8
-58	-46	36

// Travers B G, 2015: Autism Spectrum Disorder (ASD)
// Subjects=15
30	-4	64
18	68	6
4	10	54
-22	-96	-2
24	-78	-22
22	-46	62

// Travers B G, 2015: Healthy Controls
// Subjects=15
-22	-6	56
32	-8	62
16	-6	54
-52	0	42
-30	-12	60
-16	-62	62
20	-62	60
-46	-30	50
30	-46	54
52	-72	-6
50	-68	4
24	-86	-18
28	-62	-22
-24	-6	62
-6	4	52
-50	2	40
-58	6	20
-42	0	34
22	-60	58
-44	-30	48
44	-26	60
28	-38	48
-28	-54	54
38	-32	40
34	-88	16
46	-76	-6
32	-90	-10
10	-100	-8
-14	-104	-10
14	-78	-20
30	-58	-24
22	-46	62

// Jia B, 2015: Mild Cognitive Impairment (MCI) < Healthy Controls (HC), KI3 + 
// Baseline
// Jia B, 2015: MCI > HC, KI3 + Baseline
// Jia B, 2015: MCI < HC, Sham + Baseline
// Jia B, 2015: MCI > HC, KI3 > Baseline
// Jia B, 2015: MCI > HC, Sham > Baseline
// Jia B, 2015: MCI < HC, Sham > Baseline
// Jia B, 2015: MCI > HC, KI3 > Sham
// Jia B, 2015: MCI < HC, KI3 > Sham
// Subjects=8
10.5	-40.5	-12.5
10.5	37.5	-12.5
19.5	-34.5	-27.5
-13.5	-73.5	8.5
-4.5	-22.5	77.5
-4.5	-25.5	74.5
1.5	-4.5	68.5
-13.5	-13.5	-9.5
28.5	7.5	32.5
-25.5	1.5	29.5
-25.5	-10.5	38.5
10.5	-16.5	-3.5
-46.5	-7.5	32.5
13.5	34.5	35.5
-10.5	-19.5	53.5
49.5	-31.5	11.5
55.5	-28.5	5.5
7.5	-43.5	38.5
-43.5	19.5	20.5

// Doll A, 2016: [Attention to breath(ATB)-Passive viewing(PV)]picture - 
// [ATB-PV]no-picture
// Doll A, 2016: ATB - PV
// Doll A, 2016: [PV-ATB]picture - [PV-ATB]no-picture
// Doll A, 2016: PV - ATB
// Doll A, 2016: [PV-ATB]picture
// Doll A, 2016: [ATB-PV]picture
// Subjects=26
-60	-40	25
-60	-40	16
-57	-55	7
0	-46	52
66	-34	28
60	-46	13
63	-40	46
6	23	40
-6	32	25
-36	-49	16
-48	-28	-2
-63	-46	22
-9	50	37
-15	26	52
-6	23	37
-12	35	28
-36	23	46
24	-7	-14
30	-7	-14
30	-4	-17
-45	-31	-2
-45	-49	22
-60	-37	37
-57	-46	16
-9	-49	43
0	-70	28
9	-34	43
0	-46	55
-24	14	55
-15	8	64
12	-7	67
18	2	67
0	-1	40
3	2	49
-6	23	37
-6	32	25
-51	5	10
-48	11	-5
51	-40	22
69	-28	31

// Abe N, 2018: Negative Correlation between PCL-R and Op-Win > No-Op Win
// Subjects=67
-2	28	20
-14	60	14
-12	-8	4

// Anderson N E, 2018: Standard stimuli > Baseline, Negative Correlation with 
// PCL-R scores
// Subjects=222
-9	3	63
15	9	54
-27	57	-3
39	18	-12
-30	18	-12
48	-18	39
-24	-24	66
-15	-21	69
-42	-27	36
-54	-18	39
51	-21	9
45	0	-18
51	6	-9
42	-57	0
-6	3	42
-36	-9	-3
-27	6	-21
33	-54	-9
24	-63	0
-6	-93	-3
-33	-78	6
-39	-66	3
-36	-18	9
-6	15	0
3	-30	-15
-12	-48	-24
6	-27	-24
-3	-60	-12
9	-48	-21
3	-30	-33

// Godinez D A, 2015: Attention Deficit/Hyperactivity Disorder(ADHD)
// Subjects=20
-64	-32	30
36	6	-14
30	34	-10
-28	40	-12
32	-70	52
-8	-78	-6
28	-40	60
-10	-30	40
14	-88	26
38	-52	28
-44	50	12
-22	-46	-10
-68	-30	40
-20	10	52
6	-94	-8
48	-8	42
14	-42	56
-66	-28	30
-48	-8	26
-36	6	-10
38	-14	38
30	34	-12
14	-20	40
-28	36	-14
54	-6	12
34	6	-14
-52	-64	0
6	18	22
-36	-66	-4
-64	-30	30
50	-8	44
26	-78	44
-8	-78	-6
-28	38	-8
14	-18	36
42	46	-4
-8	14	28
-38	-38	62
50	-38	52
-20	-46	-12
68	2	12
40	-70	-16
6	28	32
-14	-30	40
-50	-46	40
36	6	-14
-6	12	26
30	34	-10
-38	-2	-8
-28	42	-2
14	-56	58
-50	-62	-6
28	-78	44
-10	-78	-4
38	-50	34
-42	48	12
-44	-52	-24
48	-10	38
-68	-30	36
-44	48	10
-8	-78	-6
22	-78	-4
-68	-38	40
48	-6	14
-46	52	6

// Godinez D A, 2015: Control Co-twins of ADHD
// Subjects=20
40	10	-14
-28	20	-18
-2	-4	34
16	-2	-14
-44	-16	48
-68	-30	40
-20	10	52
6	-94	-8
48	-8	42
14	-42	56
-28	-74	-18
48	-10	38
42	10	-10
-38	10	-14
-10	14	66
0	-2	36
24	2	-14
-44	-10	48
-34	8	-16
-32	54	-12
-68	-30	36
-44	48	10
-8	-78	-6
22	-78	-4
-68	-38	40
48	-6	14
-46	52	6

// Godinez D A, 2015: Healthy Controls
// Subjects=20
-64	-32	30
36	6	-14
30	34	-10
-28	40	-12
32	-70	52
-8	-78	-6
28	-40	60
-10	-30	40
14	-88	26
38	-52	28
-44	50	12
-22	-46	-10
40	10	-14
-28	20	-18
-2	-4	34
16	-2	-14
-44	-16	48
-28	-74	-18
-66	-28	30
-48	-8	26
-36	6	-10
38	-14	38
30	34	-12
14	-20	40
-28	36	-14
54	-6	12
34	6	-14
-52	-64	0
6	18	22
-36	-66	-4
-64	-30	30
50	-8	44
26	-78	44
-8	-78	-6
-28	38	-8
14	-18	36
42	46	-4
-8	14	28
-38	-38	62
50	-38	52
-20	-46	-12
68	2	12
40	-70	-16
6	28	32
-14	-30	40
-50	-46	40
36	6	-14
-6	12	26
30	34	-10
-38	-2	-8
-28	42	-2
14	-56	58
-50	-62	-6
28	-78	44
-10	-78	-4
38	-50	34
-42	48	12
-44	-52	-24
42	10	-10
-38	10	-14
-10	14	66
0	-2	36
24	2	-14
-44	-10	48
-34	8	-16
-32	54	-12

// Ko C H, 2018: Attention Deficit Hyperactivity Disorder (ADHD)
// Subjects=29
32	-54	46
-30	-56	38
-36	-48	42
-42	8	36
-42	0	30
48	4	24
40	30	28
36	30	30
-6	8	54
8	12	52
-28	26	2
-44	-56	-12
-54	6	18
54	8	12
-42	-50	34
34	-48	-20
-56	-26	24
58	-24	28
-2	-44	34
-36	-52	-20
-26	-60	0
-44	32	18
-20	-62	2
-36	14	22

// Ko C H, 2018: Healthy Controls
// Subjects=21
-54	6	18
54	8	12
-42	-50	34
-20	-62	2
-36	14	22

// Lindholm P, 2019: Fearful > Baseline, ADHD > Healthy Controls
// Subjects=23
-28	-74	50

// Materna L, 2019: Negative View > Neutral View, ADHD > Healthy Controls
// Materna L, 2019: Negative View > Neutral View
// Materna L, 2019: Negative Reappraise > Negative View
// Subjects=30
14	44	22
10	44	-4
-16	34	20
-50	-62	6
50	-64	2
-26	-4	58
-32	28	-2
-42	6	50
-52	-34	-2
52	32	-4
-50	-54	22
40	12	48
58	-52	36
48	-36	0
-16	6	12
20	52	34
-26	50	26

// Salmi J, 2018: Visual Bimodal > Unimodal Focused Attention, ADHD > Healthy 
// Controls
// Salmi J, 2018: Auditory Focused Attention > Control Task, ADHD > Healthy 
// Controls
// Salmi J, 2018: Divided Attention > Control Task, ADHD > Healthy Controls
// Salmi J, 2018: Visual Distractors, ADHD > Healthy Controls
// Salmi J, 2018: Auditory Distractors, ADHD > Healthy Controls
// Subjects=16
42	68	66
66	25	28
50	23	41
33	21	31
42	87	58
50	36	39
45	33	20
35	34	70
24	36	37
42	49	56

// Schulz K P, 2017: Stimulus Conflict > Fixation, ADHD
// Schulz K P, 2017: Stimulus Conflict > Fixation, Healthy Controls
// Schulz K P, 2017: Response Conflict > Fixation, Healthy Controls
// Schulz K P, 2017: Combined Conflicts > Fixation, ADHD
// Schulz K P, 2017: Combined Conflicts > Fixation, Healthy Controls
// Schulz K P, 2017: Combined Conflicts > Fixation, ADHD < Healthy Controls
// Schulz K P, 2017: Combined Conflicts > Fixation, Persistent ADHD < Remitted 
// ADHD
// Subjects=11
-6	-82	42
-10	-76	48
10	-78	50
-54	26	22
-42	10	30
-26	14	54
-28	64	-16
44	14	26
34	14	58
50	30	20
12	-78	50
-4	-68	54
-22	-74	50
-44	10	28
-52	22	26
-42	10	52
26	56	-10
38	62	0
50	34	28
36	12	56
48	32	36
-54	-46	54
-28	-64	62
30	-62	40
-16	-66	54
-28	-64	52
-22	-70	46
36	-60	50
14	-78	52
8	-74	50
30	-86	32
-6	-82	44
-24	12	48
-50	12	28
-40	4	36
-18	-38	-20
-46	8	-22
8	-46	-38
20	-78	0
42	16	-20
54	6	-20
16	50	-12
32	-86	30
10	-72	40
54	-62	20
44	-80	20
-30	-50	50
-2	-32	50
-14	30	22
-32	38	0
-52	28	20
24	34	-12
46	2	-14
32	12	44
38	46	-16
42	-68	22
42	-40	42
26	-46	50
-30	-56	-2
-30	-34	-30

// Tajima-Pozo K, 2018: Unpleasant > Neutral, Healthy Controls > ADHD
// Subjects=9
-36	44	18

// Tanaka S C, 2018: Loss > Gain, ADHD < Healthy Controls
// Tanaka S C, 2018: Group x Condition Interaction
// Subjects=14
38	-56	-22
20	-72	54
38	12	-36
-40	16	-30

// Wilbertz G, 2017: Loss > Gain Anticipation, ADHD > Healthy Controls
// Subjects=28
-36	11	-26

// Anderson N E, 2017: Emotion implicit > Neutral implicit
// Anderson N E, 2017: Emotion explicit > Neutral explicit
// Anderson N E, 2017: Emotion explicit > Emotion implicit
// Anderson N E, 2017: Neutral explicit > neutral implicit
// Subjects=120
48	-75	-6
-45	-72	-3
51	-63	6
-45	24	12
51	36	9
18	-57	0
-15	-66	3
-24	0	-25
24	0	-15
-9	54	18
-6	54	24
-48	24	-6
-9	24	63
-54	-63	21
-3	27	36
42	-63	-6
39	21	-12
-12	33	57
15	24	66
-51	24	-9
27	54	24
0	45	36
-60	-54	36
45	24	-15
-18	51	33
33	18	-24
3	-15	42
0	48	9
54	-57	45
0	-51	30
21	-105	0
-30	-102	0
60	-9	3
27	-51	-15
-6	-36	54
-60	-9	3
15	-81	36
-21	-93	33
-24	-69	-15
-18	-72	0
3	-3	51
15	51	3
9	39	48
6	42	-12
-24	9	-21
24	6	-33

// Deming P, 2018: Self > Case
// Deming P, 2018: Self < Case
// Deming P, 2018: Other > Case
// Deming P, 2018: Other < Case
// Deming P, 2018: Self > Other
// Deming P, 2018: Self < Other
// Deming P, 2018: Positive Correlation between Other > Case with PCL-R Facet 
// 3 Scores
// Deming P, 2018: Negative Correlation between Self > Other with PCL-R Factor 
// 2 Scores
// Subjects=57
-5.2	-60.5	45
-5.2	3.05	31
-29.8	20	-11
33.2	20	-14.5
-47.2	-60.5	27.5
-22.8	-11.5	-11
-5.2	-50	24
-1.8	-11.5	34.5
-8.8	-95.5	17
8.8	-85	31
19.2	-74.5	-35.5
-19.2	-74.5	-35.5
5.2	-46.5	-35.5
43.8	34	20.5
-36.8	27	27.5
-29.8	-4.5	52
26.2	-1	48.5
47.2	2.5	24
-43.8	2.5	24
-19.2	41	-4
50.8	-43	-11
-57.9	-50	-7.5
33.2	-60.5	45
5.2	-39.5	41.5
-12.2	58.5	27.5
-47.2	20	6.5
36.8	27	-11
-47.2	-57	20.5
-22.8	-11.5	-11
-5.2	-50	27.5
8.8	-81.5	-7.5
-8.8	-95.5	13.5
19.2	-74.5	-35.5
-26.2	-67.5	-32
-8.8	-50	-35.5
43.8	30.5	20.5
29.8	-4.5	45
-36.8	27	27.5
-29.8	-4.5	52
-43.8	2.5	24
47.2	2.5	27.5
-54.2	-50	-7.5
43.8	-46.5	45
-26.2	-67.5	31
8.8	-36	38
-33.2	-64	-4
8.8	51.5	24
-5.2	37.5	-11
-57.8	-4.5	-11
19.2	-81.5	-7.5
1.8	-57	27.5
12.2	48	6.5
36.8	-57	13.5
12.2	-53.5	24
-1.8	-50	24
36.8	-74.5	20.5

// Volman I, 2016: Healthy Male Controls (HCs)
// Subjects=19
-16	-96	24
-30	-76	34
-52	22	-10
18	-98	16
30	58	12
54	-42	54
10	10	2
-34	6	-10
18	-76	-38

// Volman I, 2016: Psychopathic Patients (PPs)
// Subjects=15
-16	-96	24
-30	-76	34
-52	22	-10
18	-98	16
8	-82	38
-30	-72	34
-32	-32	6
28	-74	46
-24	-66	-38
30	58	12
54	-42	54
10	10	2
-34	6	-10
18	-76	-38
52	-40	54
6	22	66
6	6	4

// De Martino M, 2019: Conjugation effect in regular verbs (2nd and 3rd 
// conjugations > 1st conjugation)
// De Martino M, 2019: Main effect of regularity (irregular > regular)
// De Martino M, 2019: Conjugation effect independent of regularity (2nd 
// conjugation > 3rd conjugation)
// De Martino M, 2019: Regularity x Conjugation
// Subjects=23
-46.64	-3.01	42.44
-1.74	10.63	49.71
-50	1.95	24.22
-47.02	32.66	8.23
-5.44	31.88	-5.56
-43.43	-12.85	38.77
49.46	-6.46	30.48

// Nevat M, 2017: Inflection > Repetition
// Subjects=17
29	-82	0
-11	12	-2
-5	14	52
12	14	-2
-42	6	32
-20	-67	28

// Prehn K, 2017: L1 (Native) German Speakers
// Subjects=20
-6	38	46
30	17	55
12	32	55
-21	23	52
-15	29	43
-9	53	25
-9	-55	22
12	-52	19
9	-61	28

// Prehn K, 2017: L2 (Non-Native) German Speakers
// Subjects=20
-6	38	46
30	17	55
12	32	55
45	-43	55
-27	-4	46
39	-55	58
51	-34	49
-27	2	64
-6	26	49

// Schultz D H, 2016: Image with 500 ms shock (CS+) > Image without shock 
// (CS-)
// Schultz D H, 2016: Psycopathy > Controls
// Schultz D H, 2016: High Anxiety > Low Anxiety
// Schultz D H, 2016: Low Anxiety > High Anxiety
// Schultz D H, 2016: Positive Correlation between Anxiety (WAS) and (CS+ > 
// CS-), Psychopathy
// Schultz D H, 2016: Negative Correlation between Anxiety (WAS) and (CS+ > 
// CS-), Psychopathy
// Schultz D H, 2016: Positive Correlation between Anxiety (WAS) and (CS+ > 
// CS-), Controls
// Schultz D H, 2016: Negative Correlation between Anxiety (WAS) and (CS+ > 
// CS-), Controls
// Schultz D H, 2016: Psychopathy (Low Anxiety > High Anxiety), Controls (High 
// Anxiety > Low Anxiety)
// Schultz D H, 2016: Psychopathy (High Anxiety > Low Anxiety), Controls (Low 
// Anxiety > High Anxiety)
// Subjects=9
-13.04	70.64	-19.77
-5.96	-6.4	50.07
31.67	64.23	-31.01
-56.75	65.47	6.71
1.11	4.77	1.1
44.48	46.62	-39.71
2.58	16.63	58.07
20.51	63.72	46.11
19.09	9.59	-20.7
-4.02	-12.75	22.7
-12.87	63.07	13.09
51.64	0.58	38.78
8.39	43.42	-8.92
-5.6	89.49	-3.7
-.33	36.12	-33.86
14.58	62.01	-30.62
57.62	48.89	2.32
-18.26	25.2	-8.2
-.77	-47.51	13.31
13.84	80.75	19.11
40.53	-22.6	-26.06
28.67	-13.84	-35.58
51.32	-14.82	-8.99
10.99	55.89	55.8
-7.59	38.3	-4.96
38.82	-50.02	18.64
-41.73	-16.23	-18.95
-27.43	12.25	45.4
45.5	65.83	-39.11
-6.47	48.76	6.41
23.37	6.36	-21.6
-31.29	61.45	-20.01
29.58	54.87	-27.97
13.75	46.88	-5.93
27.42	71.06	-24.84
-35.1	58.56	39.38
-5.27	-10.24	0.2
-21.98	-5.26	52.39
16.22	62.47	44.04
-12.85	79.79	22.84
-44.48	-.54	46.67
31.98	69.6	10.92
-22.44	-8.92	-8.64
54.57	12.03	7.68
23.87	41.17	56.89
-46.23	0.09	-41.46
16.64	57.91	-42.57
34.44	-54.42	3.45
45.75	60.82	-7.46
35.64	-50.84	22.09
6.54	25.46	20.49
-7.44	-35.86	-14.36
2.37	-55.84	1.7
-18.15	14.26	1.64
12.61	2.18	-33.39
-36.43	34.95	-4.35
-43.73	64.26	31.19
-9.23	22.65	54.36
-36.43	34.95	-4.35
-43.73	64.26	31.19
-9.23	22.65	54.36
35.64	-50.84	22.09
6.54	25.46	20.49
-7.44	-35.86	-14.36
2.37	-55.84	1.7
-18.15	14.26	1.64
12.61	2.18	-33.39
32.44	-58.52	19.43
-34.87	-63.15	20.59
-29.12	102.47	1.06
20.09	105.57	9.15
-44.99	88.6	15.78
-7.09	-65.19	19.32
5.55	-13.21	15.93
4.82	-51.51	43.69
-18.15	14.26	1.64
3.35	-28.17	1.6
-42.68	65.15	28.88
52	67.95	-25.98
0.62	-23.22	65.9
-14.85	69.09	36.03

// Sethi A, 2018: Primary
// Subjects=50
-14	-68	24
-20	-58	18
-6	-42	44
16	-54	22
8	-64	20
10	-46	6
-38	2	-12
-56	-18	18
-38	-16	2
38	-16	0
46	0	4
58	4	6
-30	20	36
8	32	10
-4	32	28
48	0	-12
46	0	4
46	-8	-8
-40	0	-16
-50	4	-16
-38	-16	2
-26	26	24
8	32	20
-14	30	28

// Sethi A, 2018: Secondary
// Subjects=100
48	0	-12
46	0	4
46	-8	-8
-40	0	-16
-50	4	-16
-38	-16	2
-12	52	-8
-4	36	8
-6	32	-4
36	-20	2
20	-8	2
-6	-16	-10
-46	-28	10
-30	-34	14
-42	-36	24
-2	-42	42
-8	-48	20
8	-44	24
-26	26	24
8	32	20
-14	30	28

// Sethi A, 2018: Comparison
// Subjects=82
-14	-68	24
-20	-58	18
-6	-42	44
16	-54	22
8	-64	20
10	-46	6
-38	2	-12
-56	-18	18
-38	-16	2
38	-16	0
46	0	4
58	4	6
-30	20	36
8	32	10
-4	32	28
-12	52	-8
-4	36	8
-6	32	-4
36	-20	2
20	-8	2
-6	-16	-10
-46	-28	10
-30	-34	14
-42	-36	24
-2	-42	42
-8	-48	20
8	-44	24
-26	26	24
8	32	20
-14	30	28

// Whitehead J C, 2018: Instrumental music > Speech (Continuous multiband 
// sequence)
// Whitehead J C, 2018: Singing > Speech (Continuous multiband sequence)
// Whitehead J C, 2018: [Instrumental music and singing] > Speech (Continuous 
// multiband sequence)
// Whitehead J C, 2018: Speech > Instrumental music (Continuous multiband 
// sequence)
// Whitehead J C, 2018: Singing > Instrumental music (Continuous multiband 
// sequence)
// Whitehead J C, 2018: [Speech and singing] > Instrumental music (Continuous 
// multiband sequence)
// Whitehead J C, 2018: Speech > Singing (Continuous multiband sequence)
// Whitehead J C, 2018: Instrumental music > Speech (Interleaved silent steady 
// state)
// Whitehead J C, 2018: Speech > Instrumental music (Interleaved silent steady 
// state)
// Subjects=24
66	-28	12
46	-6	-6
-48	-6	-4
50	4	-8
66	-26	10
-48	0	-6
66	-26	10
48	4	-8
-48	-6	-4
64	-8	-4
-62	-12	0
62	-20	-2
-60	-12	2
62	-20	-2
-60	-12	1
64	-8	-4
-60	-22	-2
48	-32	24
42	-12	-10
-48	-6	0
56	-28	-2
-64	-28	4

// Dhakal K, 2019: Improvised > Prelearned
// Dhakal K, 2019: Improvised > Rest
// Dhakal K, 2019: Prelearned > Rest
// Dhakal K, 2019: Vocalized improvised > Vocalized prelearned
// Dhakal K, 2019: Imagine improvised > Imagine prelearned
// Dhakal K, 2019: Vocalize > Rest
// Dhakal K, 2019: Imagine > Rest
// Subjects=24
-9	5	68
-57	11	17
-54	11	29
-24	-10	53
30	-67	-22
63	-4	14
63	-10	2
51	-34	11
-3	2	71
-57	-4	-4
-57	-13	2
-9	-40	-40
54	-13	-1
63	-4	14
-54	-16	2
-63	-25	5
-60	11	23
-57	11	17
-45	2	41
-45	-1	29
12	2	59
-3	5	62
-12	5	50
-24	-10	59
63	-4	14
45	-22	8
54	-13	2
-42	-16	35
3	-1	68
-3	-7	71

// Heath S, 2015: Aphasia Patient 1 (P01)
// Subjects=1
-12	-51	81
3	-7	-9
51	-54	-12
60	-3	30
-9	-48	81
54	-54	-15
-3	48	0
6	-75	-9

// Heath S, 2015: Aphasia Patient 2 (P02)
// Subjects=1
-9	-69	39
-3	-66	36
-39	-54	42
63	-27	-15
54	-54	21
3	54	-3
-21	-78	-36
-27	-60	24
-9	-63	57
-24	-63	21
-39	33	9
-3	-33	-21
36	51	-9
-9	-81	-30
66	-33	-3
45	-54	48
-24	-63	21

// Karcher N R, 2019: Unexpected reward and Unexpected punishment > Fixation
// Karcher N R, 2019: Unexpected reward and Unexpected punishment > Fixation, 
// Psychosis > Healthy Controls
// Karcher N R, 2019: Unexpected reward > Fixation
// Karcher N R, 2019: Unexpected reward > Fixation, Psychosis > Healthy 
// Controls
// Karcher N R, 2019: Unexpected punishment > Fixation
// Karcher N R, 2019: Unexpected reward > Unexpected punishment
// Karcher N R, 2019: Unexpected reward > Unexpected punishment, Psychosis > 
// Healthy Controls
// Subjects=20
18	14	-6
14	2	4
14	12	4
14	8	2
-12	12	2
-22	10	0
14	10	8
14	4	4
14	4	4
12	10	6

// Knolle F, 2018: Psychosis
// Subjects=13
-24	-90	-20
4	-94	-4
-26	-96	-4
46	-50	-38
-50	-68	-32
52	-60	-28
-8	-96	-6
-48	-82	4
6	-86	-2
-10	2	-20
44	-72	10
-26	-2	-12
-46	-76	-26
16	-40	-46
-12	-16	-6
-40	16	4
2	16	18
-14	-14	-24
-8	6	36

// Knolle F, 2018: Healthy Controls
// Subjects=34
-24	-90	-20
4	-94	-4
-26	-96	-4
46	-50	-38
-50	-68	-32
52	-60	-28
-8	-96	-6
-48	-82	4
6	-86	-2
-10	2	-20
44	-72	10
-26	-2	-12
-46	-76	-26
16	-40	-46
-12	-16	-6
-40	16	4
2	16	18
-14	-14	-24
-8	6	36
44	22	-12
42	-70	12
0	-76	14
2	-84	0
8	-72	16
36	-74	28
-38	-20	-2

// Martinsen S, 2018: Fibromyalgia (FM)
// Subjects=19
-40	-60	-34
-22	6	2
-24	-56	-50
22	-18	24
42	-2	-16
20	-68	-18
-64	-36	20
-46	-2	-20
-6	-84	-16
42	-12	0
-14	6	22
48	-58	0
-44	-32	2
-22	4	-14
26	0	-14
62	-32	14

// Martinsen S, 2018: Healthy Controls (HC)
// Subjects=20
-40	-60	-34
-22	6	2
-24	-56	-50
22	-18	24
42	-2	-16
20	-68	-18
-64	-36	20
-46	-2	-20
-6	-84	-16
42	-12	0
-14	6	22
48	-58	0
-44	-32	2

// Schwarzmeier H, 2019: Full Acquisition: ACS+ > ACS-
// Schwarzmeier H, 2019: Early Acquisition: A1CS+ > A1CS-
// Schwarzmeier H, 2019: Late Acquisition: A2CS+ > A2CS-
// Schwarzmeier H, 2019: Full Extinction Training: ETCS+ > ETCS-
// Schwarzmeier H, 2019: Early Extinction Training: ET1CS+ > ET1CS-
// Schwarzmeier H, 2019: Late Extinction Training: ET3CS+ > ET3CS-
// Schwarzmeier H, 2019: Early Extinction Recall: ER1CS+ > ER1CS-
// Schwarzmeier H, 2019: Panic Disorder (PD) > Healthy Controls (HC), ACS+ > 
// ACS-
// Schwarzmeier H, 2019: PD > HC, A1CS+ > A1CS-
// Schwarzmeier H, 2019: PD > HC, ER2CS+ > ER2CS-
// Schwarzmeier H, 2019: PD > HC, ER3CS+ > ER3CS-
// Schwarzmeier H, 2019: HC > PD, A1CS+ > A1CS-
// Schwarzmeier H, 2019: HC > PD, A2CS+ > A2CS-
// Schwarzmeier H, 2019: HC > PD, ETCS+ > ETCS-
// Schwarzmeier H, 2019: HC > PD, ET1CS+ > ET1CS-
// Schwarzmeier H, 2019: HC > PD, ER1CS+ > ER1CS-
// Subjects=10
15	2	70
-33	-28	16
48	-19	7
-45	-4	40
-6	-46	52
45	-1	46
-9	5	49
48	-4	49
6	-13	-20
12	-1	73
-45	-34	10
39	-31	16
6	-52	52
-12	2	-2
9	-22	1
18	11	1
15	-13	1
27	44	13
-36	20	7
45	20	1
45	2	55
0	11	55
51	2	34
33	26	4
-42	14	10
0	11	55
-27	20	4
51	2	37
30	59	13
-3	-22	-5
30	-46	40
-54	-28	34
21	-70	43
-48	37	46
33	-4	-17
45	-4	-11
-36	-25	-20
33	-4	-14
-30	-13	19
-3	-55	-26
-12	-64	-14
42	5	-5
-42	14	19
-30	41	-2
24	29	37
42	-25	22
-42	-19	43
-60	-19	22
-54	-4	13
-57	-37	46
39	-4	40
-54	-34	-14
-3	29	61
-6	-52	34
-15	2	34
0	20	64
6	-73	43
45	-43	25
54	-43	31
39	11	37

// Balodis I M, 2018: Pos. Correlation between Iowa Gambling Task Scores (IGT) 
// & Win Prospect (A1W) > Neutral, All
// Balodis I M, 2018: Pos. Correlation between IGT Scores and A1W > Neutral, 
// Gambling Disorder (GD)
// Balodis I M, 2018: Neg. Correlation between IGT Scores & Loss Anticipation 
// (A2L) > Neutral, GD
// Balodis I M, 2018: Neg. Correlation between IGT Scores & Loss Prospect 
// (A1L) > Neutral, All Non-smokers
// Subjects=14
-12	36	6
-6	-54	3
-18	-44	30
-9	6	-6
0	30	6
-9	-99	21
12	-40	60
59	-5	42
-33	0	-33
18	-27	45
-18	51	-7.5
12	-15.5	33
-60.5	-57	24

// Brevers D, 2015: Pathological Gamblers (PG)
// Subjects=10
24.66	-8.92	0.86
24.66	-8.92	0.86
23.59	-2.33	3.66

// Brevers D, 2015: Healthy Controls (HC)
// Subjects=10
23.69	51.43	38.19
-11.75	66.93	21.68
48.09	49.69	13.52
-67.12	-21.39	12.99
28.93	-6.78	0.63
-51.31	14.86	-1.38
-37.89	-22.82	60.73
-67.11	-22.36	14.19
-39.31	-22.11	14.97
-67.09	-40.85	9.05
32.95	58.72	-6.02
2.43	41.5	49.3
-41.49	6.05	21.55
32.98	63.46	0.27
-45.89	-29.32	-8.89
18.28	-9.76	4.35
45.98	18.15	5.03
-44.32	-26.29	57.75
40.09	-22.61	56.47
-14.77	-2.59	17.51
40.83	-20.57	13.92
-60.57	-58.36	16.02
-22.37	8.23	6.65
31.12	-14.97	4.64
-18.12	-57.85	-22.43
24.66	-8.92	0.86
24.66	-8.92	0.86
23.59	-2.33	3.66

// Kaldewaij R, 2019: Main Effect of Group (Panic Disorder (PD) > Healthy 
// Controls (HC))
// Kaldewaij R, 2019: Happy > Neutral, PD > HC
// Kaldewaij R, 2019: Fearful > Neutral, PD > HC
// Subjects=17
6	54	6
6	62	14
38	-86	14
-40	-86	-20
-6	-56	18

// Kober H, 2016: Initial Video Viewing: Females > Males
// Kober H, 2016: Initial Video Viewing: Cocaine videos > Sad and Gambling 
// videos
// Kober H, 2016: Initial Video Viewing, Cocaine-dependent Group: Cocaine 
// videos > Sad and Gambling videos
// Kober H, 2016: Final Video Viewing: Females > Males
// Kober H, 2016: Final Video Viewing: Gambling videos > Sad and Cocaine 
// videos
// Kober H, 2016: Final Video Viewing, Pathological Gamblers (PG): Gambling 
// videos > Cocaine and Sad videos
// Kober H, 2016: Final Video Viewing, Female PG > Male PG: Gambling videos
// Kober H, 2016: Final Video Viewing, Male PG > Female PG: Sad videos > 
// Cocaine videos
// Subjects=8
32	-42	7
43	-68	4
17	-36	1
43	30	3
-49	25	16
-49	-3	32
37	-3	24
-3	38	8
38	-48	2
48	-25	4
46	8	25
-6	37	41
3	10	59
-20	28	17
-34	-19	3
-9	54	21

// Massau C, 2017: Moral > Control, All Participants
// Massau C, 2017: General Offenses (GO), All Participants
// Massau C, 2017: Sexual offenses against adults (SOA) > Control, All 
// Participants
// Massau C, 2017: Child sexual abuse (SOC) > Control, All Participants
// Subjects=15
18.64	-94.62	-0.02
-2.69	-48.83	31.67
-61.76	-6.39	-16.35
-3.73	44.04	-31.29
-11.65	-92.81	-1.93
24.65	-84.95	-34.7
63.48	0.02	-23.6
-7.35	62.39	27.47
-42.5	33.89	-22.9
-50.06	4.76	56.31
-25.03	-87.25	-33.63
53.06	-32.19	-0.06
52.46	18.08	-36.4
-45.64	-73.26	48.26
25.19	-39.34	16.81
18.64	-94.62	-0.02
-61.76	-6.39	-16.35
-2.69	-48.83	31.67
-1.57	44.04	-31.33
-9.49	-92.8	-1.97
24.65	-84.95	-34.7
-48.07	-62.17	29.28
61.35	-1.91	-21.13
-7.35	62.39	27.47
-42.5	33.89	-22.9
-53.09	31.05	-6.75
-50.06	4.76	56.31
18.64	-94.62	-0.02
-61.79	-6.6	-18.57
-.56	-46.9	29.2
-1.57	44.04	-31.33
-11.65	-92.81	-1.93
61.32	0.01	-23.56
24.66	-87.07	-34.49
-7.35	62.39	27.47
-40.35	36.02	-23.15
-50.06	4.76	56.31
53.06	-32.19	-0.06
52.47	15.96	-36.19
-25.03	-89.38	-33.42
48.11	17.86	-38.55
20.78	-46.57	8.63
18.64	-94.62	-0.02
-2.69	-48.83	31.67
-61.79	-6.6	-18.57
-3.71	46.37	-29.28
-11.68	-93.01	-4.15
24.65	-84.95	-34.7
61.32	0.01	-23.56
-40.35	36.02	-23.15
-50.06	4.76	56.31
-25.03	-87.25	-33.63
37.93	-38.83	-1.39
53.06	-32.19	-0.06
52.46	18.08	-36.4
25.19	-39.34	16.81
40.04	-34.77	-4.07

// Ponseti J, 2016: Pedophiles > Healthy Controls, Girls > Women
// Ponseti J, 2016: Pedophiles > Healthy Controls, Boys > Men
// Subjects=24
-14	-4	-16
34	-70	-12
-38	-46	-20
-34	-66	-12
14	-38	-4
30	-50	-22
20	-28	0
32	-84	-8
-8	-82	-8
-34	-70	16
-16	-12	14
-12	50	22
10	36	22
-4	30	24
14	52	24
-10	14	62
-26	-62	54
-42	-68	-14
-30	-46	-22
-42	-72	-4
-38	-60	0
-26	-48	50
-36	-2	54
42	-68	-8
40	-58	-18
46	-56	-16
-12	14	-8

// Powers S J, 2016: Family History of Developmental Dyslexia (FHD+)
// Subjects=29
-36	-60	-20
36	-70	-10
-42	38	-12
32	4	-28
54	-6	32
-42	34	-8
-42	30	24
30	-68	-10
58	-4	30

// Powers S J, 2016: Healthy Controls
// Subjects=21
-36	-60	-20
36	-70	-10
-42	38	-12
32	4	-28
-38	24	-12
30	-70	-10
32	10	-28
-42	34	-8
-42	30	24
30	-68	-10
58	-4	30

// Ristow I, 2019: Main effect of stimulus age, Child > Adult
// Ristow I, 2019: Main effect of condition, Expectancy > Picture-viewing
// Ristow I, 2019: Main effect of group, Pedophilic Sex Offenders (PSO) > 
// Healthy Controls (HC)
// Ristow I, 2019: PSO > HC, Child > Adult
// Ristow I, 2019: PSO > HC, Expectancy > Picture-viewing
// Ristow I, 2019: Expectancy-adults > Picture-viewing adult, Expectancy-child 
// > Picture-viewing child
// Ristow I, 2019: PSO > HC: Expectancy-adults > Picture-viewing adult, 
// Expectancy-child > Picture-viewing child
// Ristow I, 2019: HC > PSO: Expectancy-adults > Expectancy-child
// Ristow I, 2019: HC > PSO: Picture-viewing adult > Picture-viewing child
// Subjects=13
20	-84	-8
-14	-94	2
-38	-48	58
8	-50	30
66	-20	34
-8	-82	8
-36	-4	50
-32	22	0
-8	6	58
4	-20	-2
6	-16	30
42	-62	4
58	-26	-10
-32	-52	38
20	4	4
-42	-70	30
10	-68	44
-32	52	16
-50	-20	-20
30	58	-8
44	-60	26
44	44	-18
-62	-24	-22
-26	-64	54
-28	24	4
26	-64	40
-44	-76	-8
2	-84	8
62	-42	28
-36	16	-4
2	24	38
-5	12	35
-10	-70	25
26	48	30
0	24	38
40	-2	52
-28	26	4
28	-66	52
-28	54	20
-30	-80	26
34	28	-4
-42	-46	50
-48	-62	-12
24	-84	-20
-30	-88	22
32	-82	16
40	-74	0
-18	-32	-4
48	-70	-10

// Worhunsky P D, 2017: Regional integration of loss-chase-related functional 
// brain networks
// Subjects=18
-6	41	10
24	2	-2
-21	2	-11
57	-55	40
36	17	52
-30	-76	25
30	-85	25
-57	-13	4
57	-10	1
-33	-85	31
36	-79	43
27	47	13
-21	50	10
15	-55	-2

// Bauer C, 2015: Early Blind
// Subjects=8
46	10	50
-24	-64	64
36	-72	-18
-56	-30	44
-42	-66	-4
-36	-64	-6
42	-76	-16
-16	-92	14
40	-78	20
-22	-66	-12
-22	-60	-2
-18	-86	22
8	-70	3
40	-80	4
12	-70	3
4	-42	3
-12	-68	3
-24	-62	64
38	-50	52
48	12	50
28	-58	58
0	28	50
40	-80	4
8	-52	4
4	-56	3

// Bauer C, 2015: Sighted Controls
// Subjects=7
2	-80	-12
-28	28	4
-30	26	-8
30	-6	42
-12	-80	50
54	-18	28
-6	16	50
8	-48	74
24	-34	-18
-36	-72	30
30	-30	-18
-26	6	-24
-56	-44	-8
-40	12	44
22	-86	28
42	-76	-16
-16	-92	14
40	-78	20
-22	-66	-12
-22	-60	-2
-18	-86	22
8	-70	3
40	-80	4
12	-70	3
4	-42	3
-12	-68	3
-24	-62	64
38	-50	52
48	12	50
28	-58	58
0	28	50
40	-80	4
8	-52	4
4	-56	3

// Begue I, 2018: All Subjects: Movement > Rest
// Subjects=10
48	-61	1
-48	-73	1
-36	-10	52
9	-16	4
-3	-25	-8
18	14	-5
51	11	19
-6	-16	52
36	-43	49
30	-7	52
-9	-19	4
-6	-1	55
33	23	1
-30	-94	1

// Chechko N, 2018: Healthy Controls
// Subjects=27
34	-34	-2
-36	34	40
-2	26	48
6	22	36
6	38	16
-44	32	20
-38	34	38
-48	20	-14
-50	22	-10
-34	20	-4
48	28	-6
-38	42	-2
-48	44	-10
46	18	34
-46	16	40
-36	12	28
50	-50	44
-24	16	66
-12	14	64
12	-82	-32
-42	0	42
-52	-46	52
36	62	2
50	32	22
24	54	26
-20	34	50

// Chechko N, 2018: Dissociative Amnesia
// Subjects=1
34	-34	-2
-36	34	40
54	-46	1
62	-10	-26
-58	-30	-16
56	-52	-20
-32	-36	-20
-28	-34	78
64	2	14
60	-2	34
-30	-34	76
-2	26	48
6	22	36
6	38	16
-44	32	20
-38	34	38
-48	20	-14
-50	22	-10
-34	20	-4
48	28	-6
-38	42	-2
-48	44	-10
46	18	34
-46	16	40
-36	12	28
50	-50	44
-24	16	66
-12	14	64
12	-82	-32
-42	0	42
-52	-46	52
36	62	2
50	32	22
24	54	26
-20	34	50
-50	-68	30
-42	-78	36
-58	-64	14
-4	-56	38
0	-72	30
-4	-70	14
-4	-70	14
44	-80	26
50	-72	20
40	-68	20
54	-46	10
-2	54	4
6	66	10
-10	-56	8
-14	-42	0
-32	-80	-38
-26	36	42
-64	-10	-24
22	-12	-18
18	-28	-10
-12	60	-20
-2	54	-20
-32	-36	-20
50	18	-20
62	-10	-26
40	30	0
56	-56	-32
-24	-18	-16
-36	8	30
-32	36	-20
-58	-30	-16
56	-52	-20
-24	60	4
-48	22	-16

// Gagnon L, 2015: Tastes > Saliva, All Subjects
// Gagnon L, 2015: Tastes > Saliva, Sighted Controls > Congenitally Blind
// Subjects=9
-40	8	-8
-40	-36	54
-36	-44	52
32	-8	24
44	-16	22
18	-10	38
-22	-18	38
-46	-44	30
2	-2	-6

// Kargel C, 2017: Nogo > Go, All Subjects
// Kargel C, 2017: Group by condition interaction
// Kargel C, 2017: P-CSO (child sexual abuse) > P+CSO (no child sexual abuse), 
// Nogo > Go
// Subjects=37
-50	-57	49
-57	-29	-11
51	-52	52
62	-32	-2
32	19	-14
-41	26	43
46	24	46
30	51	34
5	10	61
-25	54	34
-32	17	-20
5	-22	34
3	37	22
-43	-71	-8
-37	-55	-14
35	-78	-5
8	-20	24
-7	-45	25
-7	-61	28
-20	24	43

// Sojka P, 2019: Functional Movement Disorder (FMD) > Healthy Controls (HC): 
// Negative Look > Neutral Look
// Sojka P, 2019: FMD > HC: Negative Regulate > Negative Look
// Subjects=15
-22	-32	76
28	-42	64
-12	-34	44
-40	-8	20
42	-14	-8
20	-58	-50
16	-70	64
-22	-32	76

// Dogonowski A, 2019: Finger Tapping: Baseline < Recovery
// Dogonowski A, 2019: Finger Tapping: Baseline > Recovery
// Subjects=1
14	-4	74
-20	-8	72
6	60	32

// Gibbels C, 2019: All Participants: No-go > Baseline
// Subjects=31
-22	24	8
-4	34	22
46	-42	-8
-54	-22	-14
2	24	46

// Horndasch S, 2018: Adults with Anorexia > Adult Controls, High-calorie
// Horndasch S, 2018: Adolescents with Anorexia > Adolescent Controls, 
// High-calorie
// Horndasch S, 2018: Adults with Anorexia > Adult Controls, Low-calorie
// Horndasch S, 2018: Adolescents with Anorexia > Adolescent Controls, 
// Low-calorie
// Horndasch S, 2018: Adults with Anorexia > Adult Controls, Negative
// Horndasch S, 2018: Adolescents with Anorexia > Adolescent Controls, 
// Negative
// Horndasch S, 2018: Adults with Anorexia > Adult Controls, Neutral
// Horndasch S, 2018: Adolescents with Anorexia > Adolescent Controls, Neutral
// Horndasch S, 2018: Adults with Anorexia > Adult Controls, Positive
// Horndasch S, 2018: Adolescents with Anorexia > Adolescent Controls, 
// Positive
// Subjects=15
-27.4	13.65	49.75
35.62	19.23	47.44
-44.56	1.95	37.54
-19.66	-83.56	44.43
-2.79	-85.85	13.2
21.71	-89.82	0.99
-24.24	-90.09	1.54
52.28	3.88	-15.03
7.33	1.78	-24.37
31.08	-74.73	-24.92
-18.08	-75.02	-24.33
-3.81	4.7	55.8
34.23	-45.64	-20.71
-37.37	-51.53	-21.62
-44.56	1.95	37.54
-19.66	-83.56	44.43
-2.79	-85.85	13.2
21.71	-89.82	0.99
-24.24	-90.09	1.54
52.28	3.88	-15.03
7.33	1.78	-24.37
31.08	-74.73	-24.92
-18.08	-75.02	-24.33
-3.81	4.7	55.8
34.23	-45.64	-20.71
-42.64	-72.8	-20.89
-33.61	-7.31	68.3
30.39	9.4	58.36
-43.55	4.61	30.62
-45.78	25.66	27.76
-24.5	36.91	19.88
-.9	10.53	20.71
4.44	12.67	20.47
33.63	-85.75	25.04
-14.4	-85.52	32.27
6.66	-66.65	-.79
24.46	30.75	-9.16
25.39	66.7	-12.18
-43.64	-47.91	-1.78
-19.36	30.4	-9.74
26.45	41.36	-23.45
21.2	3.81	-26.93
-27.75	29.77	10.48
51.49	16.64	26.29
-60.71	9.37	24.84
-46.68	-37.42	24.14
10.68	36.18	7.27
-3.83	-86.66	16.63
-43.41	-88.38	11.65
-22.61	56.27	-5.18
22.79	-88.5	4.21
18.09	2.61	-14.53
34.23	-45.64	-20.71
31.08	-74.73	-24.92
-42.64	-72.8	-20.89
27.97	-31.99	4.99
-8.96	-32.79	66.81
-32.96	44.31	33.86
58.19	-40.79	39.95
-57.21	-42.45	42.53
-1.73	-35.32	33.49
-11.79	62.19	15.39
-10.64	39.91	16.13
-51.19	19.4	16.08
12.24	-81.73	23.83
-16.56	-83.51	31.01
34.67	-84.94	21.62
16.33	-48.47	13.19
-12.51	-49.61	14.73
13.93	33.37	11.93
-13.87	40.77	13.86
-51.21	18.09	12.85
42.81	22.88	11.37
-5.23	-5.5	6.49
19.46	-33.82	9.7
16.32	-47.5	12
-13.59	-50.76	13.73
6.66	-66.65	-.79
8.87	-82.32	2.73
6.66	-66.65	-.79
8.87	-82.32	2.73
21.73	-93.96	2.45
-18.86	-95.18	4.13
26.45	41.36	-23.45
-24.41	-79.75	-16.06
17.22	-90.93	-26.75
47.51	-25.37	47.7
21.84	-35.72	39.94
19.51	-4.78	27.34
-17.85	-15.58	28.67
-61.77	9.45	25.96
65.4	5.89	23.68
50.27	50.13	19.03
-49.1	45.31	20.58
-43.45	-38.28	26.41
19.56	-29.53	23.83
-10.39	-29.97	20.87
42.75	42	10.88
31.09	16.55	13.15
49.18	22.49	5.75
-27.5	-49.96	11.59
-8.22	-80.14	4.98
51.58	-71.41	2.44
-41.28	-87.4	10.43
22.75	-67.01	6.87
-29.95	7.16	-6.55
10.95	-76.31	-2.25
-27.59	-88.31	-16.42
-12.73	-74.9	-23.29
17.29	-89.1	-16.87
7.76	21.55	38.64
-10.58	3.18	9.17
-13.36	-84.63	29.95
13.33	-81.47	27.15
-8.47	5.14	6.75
7.53	8.24	4.08
-17.78	-96.14	5.31
19.58	-94.06	1.37
8.82	-69.63	1.67
44.7	35.73	-15.38
50.64	9	51.47
5.21	55.72	-.99
29.69	66.99	-8.91
-32.3	63.19	-11.23
58.71	15	-9.35
8.79	-68.92	-2.85
49.35	18.74	26.13
-9.29	80.23	69.6
18.62	-69.89	25
42.67	54.34	5.38
-4.92	-85.78	14.33
-43.42	-87.41	10.45
20.63	-87.71	0.82
-32.03	-20.78	-9.76
36.37	-43.34	-18.69
25.73	-72.64	-25.04
-27.59	-88.31	-16.42
-12.73	-74.9	-23.29
48.33	19.25	32.79
7.59	37.36	22.82
40.57	44.9	7.31
-40.63	53.3	13.12
29.3	-81.97	19.2
-17.65	-82.71	27.61
10.04	-85.69	14.16
44.01	-64.73	-6.95
-31.27	52.9	-20.41
33.91	52.15	-22.21
-2.24	-6.65	-22.44
25.37	43.38	-24.73
8.79	-68.92	-2.85
28.06	46.94	48.55
-3.8	2.68	57.09
24.2	-59.72	59.77
-48.81	15.3	45.39
-61.63	-9.96	36.51
-31	57.93	17.08
-3.87	-82.69	12.95
33.56	-74.46	19.63
20.6	-85.77	-1.57
47.28	-73.97	-2.87
17.29	-89.1	-16.87
-27.59	-88.31	-16.42
-12.73	-74.9	-23.29
25.73	-72.64	-25.04
-58.77	1.87	-3.55
9.4	24.17	-24.05
9.49	-6.84	-25.91
44.67	5.72	-31.83
39.56	-43.5	-20.95
1.22	54.29	35.97
5.58	28.77	35.83
-19.71	-64.26	46.16
26.19	-59.05	40.73
-10.81	73.31	7.75
-0.06	44.4	4.48
7.53	8.24	4.08
-10.58	3.18	9.17
27.81	7.04	0.6
5.81	-86.34	19.83
1.27	-9.98	16.83
-24.49	-4.73	4.42
29.75	58.78	-4.88
4.1	62.95	-3.82
-24.78	54.86	-9.5
36.13	55.22	-10.23
44.7	35.73	-15.38
-42.92	35.2	-14.33
25.73	-72.64	-25.04
8.79	-68.92	-2.85
-23.25	-76.6	-2.95
66.3	-26.62	-11.52
-65.13	-31.72	-10.7
25.37	43.38	-24.73
29.87	-18.01	-20.74
-37.51	-18.92	-26.58
58.71	15	-9.35
-59.99	-11.83	-29.15

// Fonville L, 2015: Anorexia Nervosa
// Subjects=32
-2.6	-61.88	47.99
-44.97	48.19	2.44
47.12	35.39	21.42
-29.5	12.92	54.29
-34.16	-60.31	-25.38
1.34	28.03	40.4
40.04	-46.19	40.61
39.88	21.37	47.21
-5.76	-61.38	54.68
-29.51	-47.55	29.25

// Fonville L, 2015: Healthy Controls
// Subjects=32
1.72	-73.48	48.91
51.3	-63.4	-31.68
5.62	24.88	40.62
-49.25	23.96	-7.74
55.77	20.01	28.18
1.54	-26.96	45.01
16.04	9	-.55
40.1	-25.78	56.74
-5.76	-61.38	54.68
-29.51	-47.55	29.25

// Phillipou A, 2016: Anorexia Nervosa (AN)
// Subjects=24
14	-84	8
24	-8	54
-24	-10	58
-10	-86	12
-8	8	54
-25	-2	52
-8	8	54
28	-98	-4

// Phillipou A, 2016: Healthy Controls (HC)
// Subjects=25
16	-76	6
-24	-10	56
-26	-10	56
24	-6	60
30	-54	52
-8	-80	8
-10	4	54
28	-10	32
30	-10	34

// Emmorey K, 2016: Subgroup of Deaf, Skilled readers
// Subjects=14
-.71	26.76	51.69
6.71	26.2	43.84
-48.93	14.1	29.88
-27.02	19.67	-37.75
-60.74	-52.42	-3.44
3.44	4.64	26.73
-45.84	39.24	24.39
-.75	22.99	44.2
6.71	26.2	43.84
51.53	10.47	29.03
-41.13	-45.19	47.03
33.68	-55.66	42.59
-38.55	-24.22	-26.13

// Emmorey K, 2016: Subgroup of Deaf, Less-skilled readers
// Subjects=14
3.54	26.53	48.31
-34.3	37.17	-3.44
-49.04	28.3	20.89
58.93	25.06	24.38
-30.99	19.55	2.46
33.11	23.11	1.42
-56.49	-44.99	-4.11
3.54	18.78	44.5
47.97	57.29	1.73
48.29	29.83	31.91
-45.76	32.43	32.77
28.67	44.35	-12.58
-48.87	7.04	34.94
-30.92	9.23	6.67
36.29	22.78	-3.05
-41.15	-40.96	46.68
50.77	-36.89	49.74
-26.85	-17	-30.21

// Kaneko H, 2017: Subgroup of CLBP, His Group
// Subjects=10
64.44	-28.12	24.32
49.46	-24.07	23.03
40.59	23.15	1.33
-36.3	14.32	4.07
42.27	-57.38	47.1
34.22	58.66	20.73
5.86	11.96	66.23
5.62	24.88	40.62
46.29	16.92	44.17
51.42	35.68	24.69
45.23	23.6	48.08
4.56	27.16	42.67
42.69	21.68	-4.15
18.8	-29.63	64
46.51	-55.49	43.54
54.57	-24.23	-7.12
50.49	-22.29	18.41
47.18	33.79	28.24
31.13	53.24	33.49
-45.75	29.18	31.93
42.72	24.14	0.11
24.18	-65.43	54.67
1.3	38.6	39.52
24	18.33	64.38
7.07	-26.1	69.41
2.53	-35.47	31.22
-8.7	49.92	-5.92
-28.98	62.2	3.32
-11.76	21.78	2.05
-50.19	5.52	1.62

// Kaneko H, 2017: Subgroup of CLBP, Non-His Group
// Subjects=11
66.53	-49.48	9.35
51.62	9.13	39.18
53.97	-49.02	44.03
45.48	-64.93	45.46
14.5	-32.11	59.79
1.39	24.14	45.19
0.92	25.86	-15.17
-50.25	38.98	7.74
-47.05	19.11	-1.78
-56.55	11.45	10.12
55.89	-29.31	23.4
48.14	-15.64	-5.54
66.32	-26.45	-9.3
47.6	-54.17	46.77
-42.15	-64.4	46.43
54.57	9.83	6.75
-45.92	5.46	0.46
35.22	23.92	-2.02
16.64	-26.55	62.65
18.13	9.56	-7.31
13.89	22.02	2.85
-4.06	34	35.51
-2.23	49.5	1.84
-.71	12.5	46.19
-5.27	58.94	27.85
-25.72	25.41	-4.79
-29.94	60.05	16.89
-38.16	47.94	53.69
51.38	-31.74	-7.57
-59.7	-40.69	-3.31
-62.95	-25.74	-2.3
67.58	-46.39	7.97
46.14	24.18	27.95
20.37	55.67	24.49
-5.32	65.03	24
46.25	-27.43	21.12
49.47	11.23	39.03
-2.61	-9.24	68.11
-39.12	11.72	53.39
-53.14	3.75	34.14
-10.74	22.42	-3.59
36.81	-79.47	23.36
22.03	-37.01	64.58
16.64	-72.68	44.21
8.18	-65.27	58.19
3.48	30.33	42.42
-51.08	22.71	31.42
0.4	-90.32	10.19
-40.03	-62.44	44.01
-47.76	-29.94	24.64

// Le H, 2018: Deaf Signers
// Subjects=12
-32.98	-45.91	-4.3
-28.49	-19.53	33.58
-7.1	-25.75	33.86
16.37	-53.5	16.96
-20.22	-33.4	-8.84
-3.74	-21.99	54.69
-13.93	88.5	25.47
19.2	82.1	22.28
-16.22	73.65	-1.14
15.92	68.1	6.77
-10.46	-28.54	11.83
-45.72	-12.2	19.78
18.51	-56.74	16.09
-7.19	-26.78	20.56
18.35	-27.65	6.96
12.73	61.74	7.34
-52.39	51.03	12.33
60.69	38.74	-19.17
-7.58	38.38	-3.85
25.49	44.58	-9.21
12.73	61.74	7.34
-7.22	-24.83	18.17
-52.36	52.35	15.56
-23.02	-16.02	51.07
-45.71	-12.12	20.89
-3.97	-44.1	16.4
-4.09	-32.19	5.37
15.76	69.82	-12.33
-4.21	82.98	35.86

// Le H, 2018: Hearing Nonsigners
// Subjects=12
-32.98	-45.91	-4.3
-28.49	-19.53	33.58
-7.1	-25.75	33.86
16.37	-53.5	16.96
-20.22	-33.4	-8.84
-3.74	-21.99	54.69
-13.93	88.5	25.47
19.2	82.1	22.28
-16.22	73.65	-1.14
15.92	68.1	6.77
-10.46	-28.54	11.83
-45.72	-12.2	19.78
18.51	-56.74	16.09
-7.19	-26.78	20.56
18.35	-27.65	6.96
12.73	61.74	7.34
-52.39	51.03	12.33
60.69	38.74	-19.17
-7.58	38.38	-3.85
25.49	44.58	-9.21
12.73	61.74	7.34
-7.22	-24.83	18.17
-52.36	52.35	15.56
-23.02	-16.02	51.07
-45.71	-12.12	20.89
-3.97	-44.1	16.4
-4.09	-32.19	5.37
15.76	69.82	-12.33
-4.21	82.98	35.86
-26.48	-41.67	8.65
21.78	-47.32	27.53
-14.65	-57.29	12.06
19.53	-47.39	13.06
-29.65	-47.94	10.33
-10.46	-28.54	11.83
6.62	-27.46	10.43
15.93	64.93	7.03
-6.47	81.68	19.27
19.2	82.1	22.28
-52.39	52.09	12.24

// Aguirre N, 2019: 2-back: Trained groups < Untrained groups (S2 > S1)
// Aguirre N, 2019: 3-back: Trained groups < Untrained groups (S2 > S1)
// Aguirre N, 2019: 2-back: Trained groups < Untrained groups (S3 > S1)
// Subjects=14
36	-61	44
48	-37	41
48	-43	56
39	53	8
-54	-55	41
-45	-37	62
6	35	41
42	8	59
24	23	53
-15	29	53
9	20	62
0	17	62
-51	17	29
-48	11	47
-42	8	56
-45	14	14
39	-52	38
60	-43	35
54	-40	47
45	8	41
39	17	29
33	53	23
3	32	32
9	23	44

// Akbar N, 2016: Pediatric-onset Multiple Sclerosis
// Subjects=20
28	2	44
-26	-96	-14
28	2	44
38	-86	-14
-4	6	32
12	-56	74
16	16	8
-10	-86	46
-48	-76	24

// Akbar N, 2016: Healthy Controls
// Subjects=16
-20	-96	-12
42	30	28
-48	-76	24

// Bartholdy S, 2019: Healthy Controls (HC)
// Subjects=43
20	42	10
18	39	10
12	33	15
8	44	12

// Bartholdy S, 2019: Developers
// Subjects=43
20	42	10
18	39	10
12	33	15
8	44	12
9	3	15
0	-2	15
16	-4	14
48	-46	32
58	-57	22
54	-64	26
30	20	38
24	15	50
24	26	57

// Bartholdy S, 2019: Recoverers
// Subjects=43
20	42	10
9	3	15
0	-2	15
16	-4	14
48	-46	32
58	-57	22
54	-64	26
30	20	38
24	15	50
24	26	57

// Bartholdy S, 2019: Maintainers
// Subjects=43
20	42	10

// Oliva R, 2019: No-Go: Binge Eaters (BE) > Healthy Controls (HC)
// Oliva R, 2019: No-Go: HC > BE
// Oliva R, 2019: Go: BE > HC
// Oliva R, 2019: Go: HC > BE
// Oliva R, 2019: No-Go food: BE > HC
// Oliva R, 2019: No-Go food: HC > BE
// Oliva R, 2019: No-Go neutral: BE > HC
// Oliva R, 2019: No-Go neutral: HC > BE
// Oliva R, 2019: Stop: BE > HC
// Oliva R, 2019: Stop: HC > BE
// Oliva R, 2019: Go (SST): BE > HC
// Oliva R, 2019: Go (SST): HC > BE
// Oliva R, 2019: Stop food: BE > HC
// Oliva R, 2019: Stop neutral: BE > HC
// Oliva R, 2019: Stop neutral: HC > BE
// Subjects=21
36	-88	-6
19	-91	30
-45	-67	-22
-27	-84	-26
1	-70	50
1	-63	42
43	53	-2
12	7	-2
26	14	-2
36	-88	-6
-45	-67	-22
-34	-84	-38
36	-74	46
29	-67	58
1	-63	42
5	-70	50
43	53	-2
33	56	2
-13	-70	-46
-13	-53	-46
36	-88	-6
-45	-67	-22
-24	-81	-26
5	-70	50
5	-63	42
-13	-70	-46
-13	-39	-38
26	14	-2
12	7	-2
-38	-21	58
36	-88	-6
-34	-84	-38
-45	-67	-22
43	53	2
33	56	2
1	-63	42
5	-67	54
-20	-70	-22
-31	49	26
-48	-39	18
-34	42	22
36	-28	46
29	-25	42
-17	-74	-18
36	-28	46
19	-25	46
36	-11	46
-20	-21	70
-10	-18	54
-31	49	26
-45	42	42
-17	-74	-22
36	-28	46
15	-25	46
22	-25	42

// Skunde M, 2016: Healthy Controls > Bulimia Nervosa: No-go > Go
// Subjects=28
33	-25	38
15	-28	70
33	-28	66
18	11	18
27	17	10

// Cyr M, 2016: Bulimia Nervosa (BN)
// Subjects=27
33	-16	-29
0	-16	-2
-30	-1	-8
-15	26	64
30	32	55
-48	26	10
51	14	34
0	-16	-2
57	20	37
36	-19	-20
-15	26	64
36	-19	-20
0	-13	1
-21	32	55
-54	17	-2
0	-13	1
0	-13	1
-21	32	55
-54	17	-2
0	-13	1

// Cyr M, 2016: Healthy Controls (HC)
// Subjects=27
33	-16	-29
0	-16	-2
-30	-1	-8
-15	26	64
30	32	55
-48	26	10
51	14	34
0	-16	-2
57	20	37
36	-19	-20
-15	26	64
0	-13	1
-21	32	55
-54	17	-2
0	-13	1

// Guleria A, 2017: Diarrhea-predominant irritable bowel syndrome (IBS-D)
// Subjects=10
-60	-46	28
-42	14	1
6	5	64
-33	32	-8
57	-37	1
-54	-25	-2
-24	-61	-23
-24	-88	-23
-39	-52	-23
36	-82	-17
-42	14	4
-57	-27	-8
-24	-61	23
-33	32	-5
6	-52	61
-18	-61	58
-15	-58	7
-39	-49	-23
60	-16	-11
12	-16	52
6	-28	52

// Guleria A, 2017: Constipation-predominant irritable bowel syndrome (IBS-C)
// Subjects=10
-63	-43	31
-42	14	4
6	-13	49
6	-1	64
-60	-28	-11
-42	14	4
-57	-27	-8
-24	-61	23
-33	32	-5
6	-52	61
-18	-61	58
-15	-58	7
-39	-49	-23
60	-16	-11
12	-16	52
6	-28	52

// Guleria A, 2017: Healthy Controls (HC)
// Subjects=10
-60	-34	25
6	4	64
-12	-85	-23
6	-52	61
-18	-61	58
-42	14	4
-57	-27	-8
-24	-61	23
-33	32	-5
6	-52	61
-18	-61	58

// Miyake Y, 2016: Bulimia Nervosa (BN)
// Subjects=15
-10	54	12
-2	50	14
14	48	20
14	42	18
10	44	28
-12	22	18
-14	60	42
-36	32	-14
10	42	54
40	-10	14
-42	-40	16
-64	-42	28
-58	-62	20
16	38	-10
-2	-18	30
-18	-60	52
-22	30	48
32	44	30

// Miyake Y, 2016: Healthy Controls (HC)
// Subjects=20
14	42	18
10	44	28
-12	22	18
-14	60	42

// Ip K I, 2017: Bilingual
// Subjects=14
-32	16	-4
-52	16	30
0	38	38
-8	38	52
-40	-38	8
-36	10	20
-50	12	40
-12	30	44
-54	-44	-8
-12	-8	32

// Ip K I, 2017: Monolingual
// Subjects=11
-42	30	30
54	18	-6
-44	12	40
-54	26	24
38	-4	66
-4	2	68
-52	-28	52
36	-18	70
-54	-40	-14
54	-66	-66
-50	-36	32
-18	-68	-8
22	-54	0
16	-46	-46
-50	-62	-12
-44	-42	16
-14	-66	-66
44	-72	-34
-4	-26	2

// Meng X, 2016: Typical readers
// Subjects=13
-60	-14	2
-48	24	18
64	-12	2
-44	-48	-14
10	-78	-20
-4	26	42
-10	2	16
-44	2	58
56	0	50
56	34	20
-28	-62	-24
36	16	-4
34	-10	-26
-14	-84	10
-26	-66	-50
-24	-64	36
-48	-62	-16
12	-78	-18
-40	0	58
-42	8	34
58	-44	-8
34	-64	58
-26	-72	56
-30	-78	-20

// Meng X, 2016: Impaired readers
// Subjects=12
-56	-10	0
-18	-26	-22
-36	22	-4
-10	-68	-18
-4	22	38
64	-12	2
-20	-80	-2
-34	-60	-46
38	20	10
20	-90	6
-42	-24	-22
52	4	52
42	-22	-24
-12	6	18
-48	-62	-16
12	-78	-18
-40	0	58
-42	8	34
58	-44	-8
34	-64	58
-26	-72	56
-30	-78	-20

// Pierce L J, 2015: International Adoptees
// Subjects=21
-38	28	6
-30	22	-10
-54	8	-14
-44	-50	26
-60	-18	-16
-40	-44	52
-18	-54	26
40	-8	48
56	6	-2
52	-36	-2
34	-46	48
12	-66	36
-4	16	50
-38	-46	46
-8	-54	22
-6	-54	16
34	20	0
4	18	-8
28	4	56
-48	46	-4
-38	28	6
-40	-44	52
52	-36	-4
62	-38	-4
34	-46	48
-62	-16	-16
-44	-50	32
-18	-56	26
-8	-84	-2
40	-10	42
56	6	-2
12	-68	34
46	-62	52
-4	16	50
-38	-46	46
32	20	6
28	4	56
34	20	0
28	4	56
4	18	-8
-6	14	-10
-8	-54	22
-2	14	50
-34	20	2
-46	14	-8
-60	-18	8
-50	-54	52
36	58	16
66	-20	8
50	-50	50
-32	22	4
-60	-16	8
-34	-50	40
4	20	50
46	30	34
32	22	6
46	6	-8
66	-22	10
62	-34	-14
40	-50	46
-32	54	16
-32	22	2
-40	26	30
-30	2	56
-2	14	22
-58	-22	2
-62	-30	-16
-34	-50	40
-28	-60	-32
30	10	58
32	22	6
4	16	22
4	-6	18
64	-22	8
42	-50	44
28	-62	-28
-34	-50	42
38	32	36
36	30	30
16	4	0
18	-4	22
40	-46	48
-2	22	50
-18	0	22
-32	-48	36
-44	-56	54
-40	-60	60
-54	-60	-28
32	0	70
34	28	28
36	28	0
36	58	16
60	-20	-10
44	-52	48
38	30	34
36	6	38
12	-4	16
44	-46	50

// Pierce L J, 2015: Bilinguals
// Subjects=12
-38	28	6
-30	22	-10
-54	8	-14
-44	-50	26
-60	-18	-16
-40	-44	52
-18	-54	26
40	-8	48
56	6	-2
52	-36	-2
34	-46	48
12	-66	36
-4	16	50
-38	-46	46
-8	-54	22
-6	-54	16
34	20	0
4	18	-8
28	4	56
-38	28	6
-30	22	-10
40	22	14
50	22	30
52	-36	-2
46	-42	14
-44	-50	26
-18	-54	26
56	8	-2
48	-6	2
12	-66	36
46	-62	52
-4	16	50
-38	-46	46
32	20	6
28	4	56
34	20	0
28	4	56
4	18	-8
-6	14	-10
-8	-54	22
-62	-28	10
62	-12	2
24	-40	20
-62	-26	10
8	20	50
34	22	8
62	-12	4
-2	16	54
-32	22	4
-28	4	58
-12	18	38
-64	-28	8
-34	-48	40
-26	-64	-30
34	58	12
48	32	34
28	14	60
34	22	6
62	-24	4
56	-30	-10
38	-50	46
28	16	48
30	8	56
38	-42	48
-2	22	50
-18	0	22
-32	-48	36
-44	-56	54
-40	-60	60
-54	-60	-28
32	0	70
34	28	28
36	28	0
36	58	16
60	-20	-10
44	-52	48
38	30	34
36	6	38
12	-4	16
44	-46	50

// Pierce L J, 2015: Monolinguals
// Subjects=10
-38	28	6
-30	22	-10
-54	8	-14
-44	-50	26
-60	-18	-16
-40	-44	52
-18	-54	26
40	-8	48
56	6	-2
52	-36	-2
34	-46	48
12	-66	36
-4	16	50
-38	-46	46
-8	-54	22
-6	-54	16
34	20	0
4	18	-8
28	4	56
-38	28	6
-30	22	-10
40	22	14
50	22	30
52	-36	-2
46	-42	14
-48	46	-4
-38	28	6
-40	-44	52
52	-36	-4
62	-38	-4
34	-46	48
-44	-50	26
-18	-54	26
56	8	-2
48	-6	2
12	-66	36
-62	-16	-16
-44	-50	32
-18	-56	26
-8	-84	-2
40	-10	42
56	6	-2
12	-68	34
-4	16	50
-38	-46	46
32	20	6
28	4	56
34	20	0
28	4	56
4	18	-8
-6	14	-10
-8	-54	22
-6	10	60
-36	28	6
-42	22	30
-54	16	24
-44	6	-16
-60	-30	10
0	18	52
4	38	36
50	22	30
34	22	4
56	-16	4
42	-50	52
-32	22	2
-60	-30	10
2	18	52
32	24	-2
60	-12	2
48	-40	12
52	-36	-2
42	-50	52
-2	18	50
-32	22	2
-42	22	30
-44	6	-14
-62	-30	10
-40	-44	50
48	32	36
32	22	0
54	-36	-2
38	-50	46

// Dong D, 2017: Conduct Disorder (CD)
// Subjects=30
-9	0	42
-40	-30	18
-27	-21	51
-57	-6	0

// Dong D, 2017: Healthy Controls (HC)
// Subjects=36
12	-39	30
36	-33	18
6	-60	42
42	-63	39
-33	-60	39
39	-54	27
30	15	54
27	30	51
-24	54	9
60	-3	30
54	-30	-24
60	-45	-9
42	-45	18

// Fehlbaum L V, 2018: Main Effect of Group, Healthy Controls (HC) > Conduct 
// Disorder (CD)
// Fehlbaum L V, 2018: Main Effect of Group, CD > HC
// Fehlbaum L V, 2018: Main Effect of Task, Incongruent (IC) > Congruent (C)
// Fehlbaum L V, 2018: Main Effect of Task, IC > Blank screen (B)
// Fehlbaum L V, 2018: Main Effect of Task, B > IC
// Fehlbaum L V, 2018: Main Effect of Task, C > B
// Fehlbaum L V, 2018: Main Effect of Task, B > C
// Subjects=39
40	-10	20
-62	-2	26
50	-18	-4
16	-16	-2
-30	-82	26
-30	12	22
-32	-44	-26
48	34	28
32	-54	8
4	26	44
4	-2	32
-28	-24	30
54	-34	18
-46	-82	-8
42	-52	-14
-18	14	62
4	-82	0
34	-86	0
-46	-36	58
42	-40	52
-24	0	-8
-54	8	38
26	6	-8
-2	-34	44
-40	-84	28
36	-16	44
42	-80	30
-28	-36	-18
-44	-38	-38
32	-88	-88
-38	-90	-90
44	-40	-40
-18	0	0
6	-38	50
36	-20	56
-44	-82	22
64	-52	6
28	-44	-12
36	-12	6

// Klapwijk E T, 2016: Autism Spectrum Disorders (ASD)
// Subjects=23
22	-10	-26
34	-22	62
-6	-14	44
-14	-72	12
48	-10	-10
10	44	-2
28	-24	-18
-24	-18	-22
-20	-4	-18
28	-30	58
30	-92	12
-18	-88	0
-16	2	22
58	-8	-18
32	-16	-22
48	-68	20
-4	64	10
2	-46	24
22	-10	-26
38	-22	52
-4	-12	44
-12	-86	44
4	32	20
46	-22	-14
66	-42	28
12	44	-2
-22	-46	0
-20	-4	-18
26	-34	-8
-48	-52	54
56	-8	-18
-4	64	10
52	-54	14

// Klapwijk E T, 2016: Conduct Disorder & Callous-Unemotional traits (CD/CU+)
// Subjects=23
4	-74	-8
14	-24	10
-14	-72	12
48	-10	-10
10	44	-2
28	-92	12
-30	-92	4
-36	22	4
-4	-24	-14
-20	-8	-14
-2	16	44
-48	-52	54
30	-92	12
-18	-88	0
-16	2	22
58	-8	-18
32	-16	-22
48	-68	20
-4	64	10
2	-46	24
-14	-74	10
46	-22	-14
66	-42	28
12	44	-2
40	-80	0
-30	-92	4
-42	14	24
-48	-52	54
-48	-52	54
56	-8	-18
-4	64	10
52	-54	14

// Klapwijk E T, 2016: Healthy Controls (HC)
// Subjects=33
22	-10	-26
34	-22	62
-6	-14	44
4	-74	-8
14	-24	10
28	-24	-18
-24	-18	-22
-20	-4	-18
28	-30	58
28	-92	12
-30	-92	4
-36	22	4
-4	-24	-14
-20	-8	-14
-2	16	44
-48	-52	54
22	-10	-26
38	-22	52
-4	-12	44
-12	-86	44
4	32	20
-14	-74	10
-22	-46	0
-20	-4	-18
26	-34	-8
40	-80	0
-30	-92	4
-42	14	24
-48	-52	54

// Klapwijk E T, 2016: Happiness > Anger & Disappointment, Healthy Controls 
// (HC) > Conduct Disorder (CD)
// Klapwijk E T, 2016: Happiness > Anger, HC > CD
// Klapwijk E T, 2016: Happiness > Disappointment, HC > CD
// Subjects=32
58	-38	50
-2	-32	66
-40	-56	60
-40	-56	60
38	22	52
38	-38	52
56	-36	48

// Michalska K J, 2016: Harm > No Harm (Inverse Quadratic relationship with 
// Conduct Disorder (CD) Symptoms)
// Michalska K J, 2016: Harm > No Harm (Inverse Quadratic relationship with 
// Callousness)
// Michalska K J, 2016: Intentional > Unintentional Harm (Inverse Linear 
// relationship with CD Symptoms)
// Michalska K J, 2016: Intentional > Unintentional Harm (Inverse Quadratic 
// relationship with CD Symptoms)
// Michalska K J, 2016: Pain > No Pain
// Michalska K J, 2016: Intentional Pain > Unintentional Pain, p<0.05 
// corrected
// Michalska K J, 2016: Intentional Pain > Unintentional Pain, p<0.001 
// uncorrected
// Michalska K J, 2016: Pain > No Pain (Inverse Linear relationship with CD 
// Symptoms)
// Michalska K J, 2016: Pain > No Pain (Inverse Quadratic relationship with CD 
// Symptoms)
// Michalska K J, 2016: Pain > No Pain (Inverse Quadratic relationship with 
// Callousness)
// Michalska K J, 2016: Intentional Pain > Unintentional Pain (Inverse 
// Quadratic relationship with CD Symptoms)
// Michalska K J, 2016: Intentional Pain > Unintentional Pain (Inverse Linear 
// relationship with Callousness)
// Michalska K J, 2016: Pain > No Pain (Positive Linear relationship with 
// Reactive Aggression)
// Michalska K J, 2016: Intentional Pain > Unintentional Pain (Negative Linear 
// relationship with Reactive Aggression)
// Subjects=107
26	-20	16
28	-10	10
34	-18	10
28	-22	14
38	26	-8
-26	16	-18
-34	20	8
-8	48	8
-8	20	30
-6	-30	-10
22	-6	-16
-20	-8	-16
54	-40	22
-54	-32	26
12	4	12
38	6	12
-36	-4	18
22	-6	-10
-22	-8	-16
34	6	-20
2	24	24
-2	40	4
-56	-18	18
2	56	32
6	18	6
-12	22	10
-12	18	14
-26	-16	18
30	-36	-4
-10	54	-8
-6	40	46
36	-14	8
36	-6	11
-28	-32	20
-12	52	-14
10	0	58
-6	-12	48
4	-30	-14
-2	-30	-16
-36	0	10
36	-16	10
0	-28	-22

// Kreczmanski P, 2019: Migraine with Aura
// Subjects=8
-20	-62	-2
20	-62	-2
-24	-26	-4
-26	-30	-2
-24	-46	-18
-22	-40	-18
-4	-84	-46
-54	-22	-24
10	-20	-6
-2	-62	-46
38	-44	2
-8	-92	0
8	-92	0
-26	-28	-4
-26	-28	-22
24	-26	-2
-2	-36	-28
2	-36	-28
10	-52	-30
-32	58	-2

// Kreczmanski P, 2019: Migraine without Aura
// Subjects=8
-12	-92	-6
12	-92	-6
14	-86	-16
26	-72	-14
-18	-48	-48
10	-20	-6
-2	-62	-46
38	-44	2
-30	-62	-18
8	-96	-4
4	-36	-30
-4	-36	-30
34	-80	-26
40	-68	-8
-2	-36	-28
2	-36	-28
10	-52	-30
-32	58	-2

// Russo A, 2017: Migraine without aura with cutaneous allodynia (MwoA CA+)
// Subjects=20
-5.37	44.71	8.97
-41.77	53.67	4.18
-54.14	-26.29	31.1

// Russo A, 2017: Migraine without aura with cutaneous allodynia (MwoA CA-)
// Subjects=20
42.09	-29.51	35.84

// Russo A, 2017: Healthy Controls (HC)
// Subjects=20
-5.37	44.71	8.97
-41.77	53.67	4.18
-54.14	-26.29	31.1
42.09	-29.51	35.84

// Russo A, 2019: Migraine with Aura (MwA) > Migraine without Aura (MwoA), 51 
// C
// Russo A, 2019: MwA > Healthy Controls, 51 C
// Subjects=17
-8.98	53.61	-40.8
1.45	-94.97	5
-46.44	-53.59	48.91
-37.19	11.8	26.6
-5.18	44.48	33.52

// Schwenck C, 2017: Conduct Problems
// Subjects=19
-4	34	-14
-20	-82	-4
8	12	-6
-8	12	-6
10	52	-2
-22	-16	-20
-26	26	-10
48	-72	24
0	10	-8
54	34	8
54	-42	24

// Schwenck C, 2017: Healthy Controls
// Subjects=24
8	12	-4
-12	10	-8
20	56	24
64	-44	20
-22	-12	-18
10	52	-2
-22	-16	-20
-26	26	-10
48	-72	24
54	-46	22
44	16	26
-36	46	14
-8	12	48
-10	26	30
54	34	8
54	-42	24

// Szab E, 2019: Migraine
// Subjects=41
39	32	32
27	59	2
48	35	26
45	47	11
39	50	-4
51	-16	32
57	-16	41
57	-13	29
51	-1	23
48	-4	29
57	-10	21
60	-13	17
45	-25	53
42	-37	50
12	11	-1
12	20	-4
9	14	8
24	5	5
30	11	-1
42	-58	32
45	-28	50
54	-16	44
-36	-79	13
-24	-85	-13
39	-85	-1
-39	-61	-16
-33	-88	2
-27	-91	5
45	-61	-16
-27	-91	-4
-33	-88	8
-42	-79	-1
-30	-85	20
-30	-64	-13
30	-76	-16
21	-82	-13
36	-85	14
24	-94	8
21	-4	-13
30	17	-22
45	23	23
48	8	32
51	35	11
42	32	-10
51	-1	20
42	2	56
-21	-4	-16
-33	-19	-10
-21	-25	-7
30	-88	8
27	-91	11
42	-70	-10
36	-49	-16
45	-55	-13
39	-37	-19
27	-64	35
30	-67	29
-30	-82	8
-27	-88	5
-39	-85	-1
-42	-67	-10
-33	-55	-13
-33	-61	-10
-39	-61	-10
-42	-55	-16
-21	-85	-10
-24	-67	32
-21	-64	38
27	-4	-16
33	-16	-13
-33	-88	8
-27	-88	17
-33	-85	14
-24	-70	-10
-18	-79	-13
-12	-94	17
-42	-79	-4
3	-85	-1
36	-79	11
21	-73	-13
30	-82	17
9	-85	-10
12	-91	17
45	-55	-16
39	-64	-13
45	-67	-10
51	32	8
39	32	-1
48	11	29
45	29	2
54	29	2
54	8	44
45	2	47
42	5	56
51	11	-25
24	-1	-19
24	-16	-13
42	-10	-25
51	-13	-13
51	-4	-19
39	32	32
30	59	2
48	32	29
45	47	11
39	50	-4
51	-16	32
57	-16	29
57	-16	41
51	-1	23
57	-10	20
60	-13	17
12	11	-1
12	20	-4
9	14	8
24	5	5
30	11	-1
21	11	-1
42	-58	32

// Szab E, 2019: Healthy Controls
// Subjects=49
39	32	32
27	59	2
48	35	26
45	47	11
39	50	-4
-36	-79	13
-24	-85	-13
39	-85	-1
-39	-61	-16
-33	-88	2
-27	-91	5
45	-61	-16
-27	-91	-4
-33	-88	8
-42	-79	-1
-30	-85	20
-30	-64	-13
30	-76	-16
21	-82	-13
36	-85	14
24	-94	8
21	-4	-13
30	17	-22
45	23	23
48	8	32
51	35	11
42	32	-10
51	-1	20
42	2	56
-21	-4	-16
-33	-19	-10
-21	-25	-7
-33	-88	8
-27	-88	17
-33	-85	14
-24	-70	-10
-18	-79	-13
-12	-94	17
-42	-79	-4
3	-85	-1
36	-79	11
21	-73	-13
30	-82	17
9	-85	-10
12	-91	17
45	-55	-16
39	-64	-13
45	-67	-10
51	32	8
39	32	-1
48	11	29
45	29	2
54	29	2
54	8	44
45	2	47
42	5	56
51	11	-25
24	-1	-19
24	-16	-13
42	-10	-25
51	-13	-13
51	-4	-19
39	32	32
30	59	2
48	32	29
45	47	11
39	50	-4

// Ware A L, 2015: Go: Healthy Controls (HC) > Fetal Alcohol Syndrome (FAS) & 
// ADHD
// Ware A L, 2015: Go > Stop: FAS & ADHD > HC
// Ware A L, 2015: Medium: FAS & ADHD > HC
// Ware A L, 2015: Hard: FAS & ADHD > HC
// Ware A L, 2015: Hard > Easy: FAS & ADHD > HC
// Ware A L, 2015: Go > Control: HC
// Ware A L, 2015: Go < Control: HC
// Ware A L, 2015: Go > Stop: HC
// Ware A L, 2015: Go < Stop: HC
// Ware A L, 2015: Easy > Control: HC
// Ware A L, 2015: Easy < Control: HC
// Ware A L, 2015: Medium < Control: HC
// Ware A L, 2015: Hard > Control: HC
// Ware A L, 2015: Hard < Control: HC
// Ware A L, 2015: Hard < Easy: HC
// Ware A L, 2015: Go < Control: FAS & ADHD
// Ware A L, 2015: Go > Stop: FAS & ADHD
// Ware A L, 2015: Medium: FAS & ADHD
// Ware A L, 2015: Hard: FAS & ADHD
// Ware A L, 2015: Hard > Easy: FAS & ADHD
// Subjects=7
53.61	1.24	30.68
-46.81	-8.01	32.83
-48.81	-9.9	36.13
53.44	-2.82	34.59
-28.72	-6.6	-4.19
-6.21	4.81	50.47
14.28	-10.15	39.67
-36.92	-1.9	-12.96
54.31	2.38	-30.43
-43.26	-15.77	46.37
58.02	-12.64	29.67
-7.41	2.86	45.96
-25.91	-1.2	29.56
-13.4	-7.18	13.08
1.78	1.72	31.79
12.15	26.12	56.05
-.72	12.33	43.98
7.91	-83.42	16.22
-44.76	-13.99	46.13
-.19	4.76	54.86
-57.56	-13.96	7.8
-25.42	-5.27	8.49
63.56	-32.51	18.56
55.45	-11.89	0.98
53.42	0.06	33.23
-2.65	-90.42	2.21
38.08	-53.91	46.85
55.38	-35.59	-4.06
49.98	-11.99	40.19
52.39	-6.01	36.09
-32.12	-17.29	7.79
-22.5	-86.52	21.51
-45.69	-8.72	11.13
41.37	-46.96	45.68
4.56	31.41	30.16
52.7	-33.43	-3.43
2.36	-22.07	28.31
42.48	8.38	31.77
34.25	52.34	7.77
41.78	40.32	23.63
-28.54	-81.57	-39.28
-30.42	-54.59	47.03
-50.09	-10.79	35.66
-7.1	-56.8	20.4
51.57	-6.8	41.08
16.75	-52.89	10.99
-2.21	30.06	38.05
-10.73	-19.8	64.4
-22.79	-15.84	-15.53
-49.96	-9.84	39.71
-54.91	-7.37	7.44
49.65	-5.38	41.76
-.6	0.68	55.77
-26.96	-9.38	0.93
57.51	-7.74	6.29
41.08	-61.56	44
-44.32	-12.82	48.93
-20.14	-86.41	22.7
-2.35	-69.83	22.11
21.89	-63.07	22.05
4.5	27.67	34.04
42.76	22.48	4.82
33.2	52.52	10.22
1.75	0.11	-28.97
5.14	-27.7	39.24
18.06	33.05	35
16.12	-3.34	4.95
50.51	26.64	0.14
54.65	-40.9	10
19.94	-8.55	12.93
61.24	-26.69	25.24
1.96	-25.33	57.7
-14.26	-37.92	69.76
-49.36	-18.12	44.08

// Zhang J, 2015: Healthy Controls > Conduct Disorder, Stop > Rest
// Subjects=29
50	18	-14
62	-18	-12
18	8	6
40	48	2
54	-72	2
58	-36	20
36	-64	-30
6	34	18
6	-18	12
-62	-42	30
-38	-4	54
-46	22	8
-22	-72	-24
-66	-24	-12
-20	2	14
-52	-52	-18
-2	6	62
-30	-94	16

// Lemire-Rodger S, 2019: Working memory > Control
// Lemire-Rodger S, 2019: Inhibtion > Control
// Lemire-Rodger S, 2019: Task switching > Control
// Lemire-Rodger S, 2019: Working memory + Inhibition + Task switching > 
// Control, Univariate Contrast
// Lemire-Rodger S, 2019: Working memory + Inhibition + Task switching > 
// Control, Conjunction Analysis
// Lemire-Rodger S, 2019: Task switching > Control + Inhibition + Working 
// Memory
// Lemire-Rodger S, 2019: Task switching < Control + Inhibition + Working 
// Memory
// Lemire-Rodger S, 2019: Inhibition > Control + Task switching + Working 
// Memory
// Lemire-Rodger S, 2019: Inhibition < Control + Task switching + Working 
// Memory
// Subjects=22
33	3	54
33	3	54
-48	3	45
18	3	21
36	36	30
30	45	9
-30	21	3
-36	57	15
-12	0	3
51	-39	45
51	-39	45
-42	-48	51
57	-54	9
-33	-66	-27
39	-60	-30
51	12	24
33	0	42
9	24	45
-24	-63	48
57	-42	27
30	-57	33
45	-54	-9
-42	-69	-12
9	-87	3
21	-75	-6
36	51	0
-3	-33	45
-3	-33	45
3	18	48
-33	0	45
-42	30	33
-30	0	60
-41	44	17
28	9	51
-48	15	0
9	-66	45
9	-66	45
36	-69	45
-45	-42	48
9	-12	15
-51	-39	-9
-51	-39	-9
63	-42	-3
33	6	51
33	6	51
42	27	33
33	57	6
-36	57	12
-39	27	36
6	24	45
21	18	0
21	18	0
-30	24	3
9	-69	51
9	-69	51
39	-48	45
-36	-60	45
60	-48	-6
-27	-72	-24
6	-48	-18
39	-57	-26
40	23	3
47	12	24
34	52	10
37	-57	49
58	-48	-9
-36	-72	45
-3	-69	42
0	-30	36
3	6	54
-24	0	63
36	-72	42
9	-87	6
9	-78	15
21	-24	-12
-42	42	18
66	-42	-3
48	30	3
-3	51	12
-39	33	-3
18	24	45
42	42	-6
-39	24	-9
-6	42	51
51	21	12
-30	-9	57
-3	0	51
-57	6	27
-15	-27	6
24	-51	-18
18	6	0
-18	-75	-12
30	-6	54
-15	-57	15
12	-93	15
9	36	0
30	-51	6
42	-33	18
-33	-15	-3
18	-12	12
51	-33	51
36	-42	36

// Dominguez J F, 2017: Healthy Controls (HC): Alternate > Baseline, Avg 
// across all time points
// Dominguez J F, 2017: Pre-Huntington's Disease (Pre-HD): Alternate > 
// Baseline, Avg across all time points
// Dominguez J F, 2017: Symptomatic Huntington's Disease (Symp-HD): Alternate 
// > Baseline, Avg across all time points
// Dominguez J F, 2017: HC: Alternate < Baseline, Avg across all time points
// Dominguez J F, 2017: Pre-HD: Alternate < Baseline, Avg across all time 
// points
// Dominguez J F, 2017: Symp-HD: Alternate < Baseline, Avg across all time 
// points
// Dominguez J F, 2017: HC > Symp-HD: Alternate > Baseline (longitudinal)
// Subjects=16
-30	24	8
32	26	2
-24	-2	62
26	8	54
-46	14	36
40	36	34
-42	28	20
48	20	4
-44	6	26
54	14	6
-42	2	36
36	-2	62
-60	-40	14
48	-26	-2
46	-30	-4
-48	-60	-2
58	-50	-4
-46	-38	-18
-44	-60	-6
52	-58	-14
-46	-34	46
48	-32	52
-38	-42	44
44	-40	56
-46	-38	40
50	-34	52
-36	-44	38
52	-42	44
-40	-52	48
50	-50	50
-24	-68	54
18	-68	52
-42	-76	-14
42	-74	14
-4	6	60
4	8	60
-10	14	50
4	16	52
-6	18	30
10	14	32
-8	-68	56
10	-66	52
-18	-76	32
-28	30	0
32	28	0
-4	-76	-14
10	-64	-10
-40	-36	-22
-34	-62	-18
32	-60	-18
-32	-66	-16
32	-64	-18
-30	20	10
38	22	6
-46	8	4
46	10	0
-60	-38	24
62	-34	28
-56	-38	14
56	-36	22
-32	-90	20
-14	-24	16
14	-14	0
-18	2	22
18	-4	22
-24	-10	6
22	-2	6
-18	-6	2
14	2	0
-30	24	6
32	26	2
-4	12	54
28	4	58
-46	14	36
34	42	32
-38	30	18
48	20	4
-44	6	26
48	12	16
-42	8	30
36	-2	62
-54	-42	8
46	-34	6
-52	-58	-6
58	-50	-4
-48	-62	-12
48	-50	-8
-46	-38	50
48	-32	52
-40	-44	46
34	-44	46
-42	-40	40
46	-34	46
-40	-42	42
44	-38	48
-40	-52	48
40	-52	52
-24	-68	54
30	-70	44
-42	-68	-14
40	-78	8
-12	-76	14
12	-70	10
-4	8	58
8	8	54
-4	12	54
2	14	54
-8	18	28
8	28	24
-8	-68	48
10	-66	52
-30	26	-2
32	28	0
-6	-72	-12
10	-68	-12
-38	-44	-26
-38	-58	-22
32	-62	-18
-34	-64	-18
34	-68	-20
-36	16	10
32	20	12
-48	6	6
46	10	0
-48	-40	24
62	-34	24
-50	-40	20
0	-76	12
4	-78	12
-14	-94	-4
34	-90	2
-16	-16	14
14	-6	12
-18	4	18
18	0	22
-24	6	10
24	-4	10
-20	-8	4
16	-2	4
-30	24	8
32	26	2
-4	12	54
28	4	60
-46	14	36
44	32	36
48	20	4
-56	10	14
50	18	0
-44	4	34
50	6	22
-52	-58	-4
58	-52	-6
-42	-60	-6
44	-54	-6
-34	-38	40
52	-28	50
-40	-44	46
28	-54	48
-42	-40	40
52	-34	50
-38	-48	44
52	-42	44
-46	-52	48
36	-54	50
-32	-66	52
12	-70	56
-40	-82	2
48	-70	-6
-10	-64	6
12	-72	10
-4	8	58
6	8	54
-4	8	56
6	12	52
-4	8	28
8	22	28
-6	-68	56
10	-68	56
-30	28	2
34	28	0
-10	-62	4
10	-68	-12
-36	-58	-22
34	-58	-20
-24	-88	-8
38	-62	-18
-32	24	8
46	20	0
-38	8	12
46	10	0
0	-84	10
4	-72	16
-22	-94	-10
-10	-16	10
10	-18	10
-20	2	6
24	12	8
-18	2	6
18	-2	4
-36	-16	18
36	-18	18
-14	38	48
6	56	20
-16	40	48
24	36	48
-48	32	-2
0	-30	68
2	-32	66
-48	8	-28
44	12	-26
-54	-6	-8
58	-4	-14
-58	-8	-10
56	-12	-10
-60	-6	-18
58	-4	-16
-60	-10	-20
56	-12	-12
44	-16	-28
0	-34	66
2	-34	66
22	-42	68
-48	-54	24
58	-54	22
-44	-66	34
52	-66	32
-12	-62	10
-8	-8	48
10	-10	46
-8	30	-8
2	30	-4
-4	58	0
8	38	-6
-2	40	-2
6	34	-4
-6	-52	18
8	-52	30
-6	-52	16
8	-54	18
-2	-88	32
4	-88	34
-36	32	-14
14	24	-14
-20	-18	-22
20	-16	-22
-30	-36	-12
26	-32	-14
-16	-42	-6
12	-88	-6
-30	-36	-16
40	-14	-24
-26	-46	-10
22	-78	-8
-36	-14	22
36	-16	20
-34	-26	22
36	-20	20
-50	-4	-8
48	0	-6
-52	-16	2
36	-26	16
-40	-32	6
40	-30	16
-20	-62	18
-10	-92	32
14	-98	18
-12	-34	6
22	-34	2
-14	20	-6
10	18	2
-14	6	-8
14	10	-6
-16	4	-6
24	-2	-4
-30	-34	-10
30	-18	-12
-24	-8	-18
28	-10	-14
-12	16	-8
12	10	-6
-34	-16	16
36	-16	18
-4	56	18
6	56	20
-16	52	38
-4	-24	66
2	-32	66
-50	8	-24
52	8	-28
-56	-8	-10
58	-4	-14
-58	-8	-10
56	-8	-12
-62	-6	-18
58	-6	-16
-60	-10	-20
58	-8	-14
44	-16	-28
0	-34	66
16	-38	68
-24	-42	66
20	-44	70
-38	-58	28
52	-58	30
-50	-66	38
52	-66	32
56	-66	14
-8	-10	50
10	-10	46
-8	30	-8
4	26	-6
-4	58	0
8	38	-6
-4	38	-2
2	34	-2
-4	-52	28
8	-52	24
-4	-56	30
2	-54	28
0	-86	36
4	-86	36
-36	32	-14
18	26	-16
-18	-16	-22
22	-22	-20
-30	-30	-16
24	-30	-16
-30	-42	-8
26	-38	-10
-30	-32	-20
40	-12	-28
-30	-44	-10
28	-44	-12
-36	-16	20
36	-14	20
-34	-24	20
38	-20	22
-56	-6	2
60	2	4
-36	-24	10
50	-20	12
-60	-14	4
52	-22	12
-12	-102	12
8	-88	34
-12	-34	6
22	-34	2
-10	20	-2
12	22	-4
-14	12	-8
14	10	-8
-24	-8	-6
-24	-18	-16
28	-20	-12
-24	-10	-16
16	-4	-16
-12	16	-8
12	8	-8
-34	-16	18
36	-16	18
-10	38	54
4	56	24
-18	60	22
-8	-28	48
-54	4	-24
48	6	-26
-60	-8	-6
58	-4	-14
-60	-10	-6
56	-10	-12
-62	-6	-18
58	-6	-16
-60	-10	-20
56	-8	-16
44	-20	-22
-48	-60	30
-50	-66	38
22	-84	44
-6	28	-8
4	26	-6
-4	58	0
2	46	-8
-2	38	-4
2	34	-2
-4	-50	34
8	-48	36
-8	-54	16
8	-48	38
0	-88	34
8	-86	38
-20	10	-16
20	14	-16
-20	-20	-22
20	-20	-20
-30	-36	-14
28	-32	-18
-28	-42	-8
-30	-36	-16
42	-20	-22
-30	-44	-10
-44	-20	22
38	-18	20
-48	-26	18
38	-34	22
-58	-6	2
-54	-16	8
-60	-12	2
-10	-92	32
10	-90	32
-12	-34	6
10	-30	6
-14	20	-6
-18	16	-10
14	8	-8
-18	-4	-8
-28	-36	-8
28	-16	-12
-18	-4	-12
30	-6	-22
-12	16	-8
12	10	-6
-48	-70	-10
-6	-68	16
10	-64	14
-8	54	4
12	54	10
-2	30	18
12	34	18
-8	-40	46
10	-66	40
-32	-40	-10
-22	-46	-6
-32	-54	-16
50	-10	10
52	-14	8
-10	-30	12
8	14	8
10	6	16
24	6	8
30	-2	10
-24	-28	-12

// Kano M, 2017: Healthy Controls (HC)
// Subjects=29
15	-39	-14
6	-32	48
14	-42	42
3	5	27
11	-32	3
-6	-41	30
9	-44	6
-9	11	32
-18	-18	18
-29	-29	-17
-3	-3	-8
12	12	9
-9	-9	17
33	-53	-33
-12	-51	41
-6	-42	32
17	-42	41
-41	-66	-44
5	-45	32
17	-59	26
-6	-54	32
-8	-60	44
-45	12	-12
-33	18	6
-50	9	12
-44	3	-9
-15	2	0
45	15	-11
35	38	27
51	26	24
39	2	-17
5	-20	30

// Kano M, 2017: Irritable Bowel Syndrome (IBS)
// Subjects=26
15	-39	-14
6	-32	48
14	-42	42
3	5	27
11	-32	3
-6	-41	30
9	-44	6
-9	11	32
-18	-18	18
-29	-29	-17
-3	-3	-8
12	12	9
-9	-9	17
-56	5	-3
-44	-17	18
-32	-15	15
-56	-3	13
-56	-17	0
-20	-24	14
-18	-86	18
-32	-77	-8
9	-72	1
-23	-54	-2
-24	-68	-17
-9	-86	27
6	-21	74
-44	-47	59
-35	-56	59
-36	-66	44
5	-45	32
17	-59	26
-6	-54	32
-8	-60	44
15	54	4
-27	42	42
-27	20	60
17	41	36
-41	-36	62
-42	-57	56
-59	20	23
-44	-12	59
62	-11	-3
56	-53	12
62	3	-9
48	-56	30
39	-81	-2
6	-42	32
20	-56	26
-2	-74	41
-8	-17	56
-12	-74	35
-6	-20	33

// Labuschagne I, 2018: Huntington's Disease (HD)
// Subjects=9
-38	10	48
-18	58	4
-10	28	40
-22	-20	6
-28	-2	8
-50	48	-2
-36	60	0

// Miro-Padilla A, 2019: Trained Group (S1>S2) >Control Group (S1>S2), 2-back
// Miro-Padilla A, 2019: Trained Group (S1>S3) > Control Group (S1>S3), 2-back
// Miro-Padilla A, 2019: Trained Group (S1>S2) > Control Group (S1>S2), 3-back
// Miro-Padilla A, 2019: Trained Group (S1>S3) > Control Group (S1>S3), 3-back
// Subjects=25
-24	-1	59
42	53	8
51	-49	47
0	14	53
-42	26	29
3	44	44
54	-40	44
24	26	59
-54	2	38
36	-70	50
6	29	41
-36	53	11
30	2	53
-39	-55	47
48	-43	44
-66	-43	2
6	29	38
-33	17	-7
36	11	-1
48	5	29
-39	8	29
36	-52	47
-33	1	53

// Schmid J, 2015: IBS
// Subjects=17
22	20	2
22	-66	-24
-40	6	-10
68	-12	20
4	-44	10
46	-54	60
-34	-76	50
46	-54	60
-36	-16	-12
-10	-48	32
5	-50	32
4	-48	10
66	-12	18
-38	-16	-4
-42	-10	4
-46	-64	38
-42	-60	48
4	-46	10
26	-30	-12
4	-44	10
34	12	-24
-8	34	58
22	-66	-24

// Schmid J, 2015: IBS Control
// Subjects=17
8	-72	-34
-8	-74	-32
0	-40	-40
-16	-40	-42
30	-8	-26
36	-20	-10
24	-24	-12
12	-58	-32
-20	-62	-30
-38	-18	12
-34	-16	10
-40	14	-8
-62	-46	22
26	2	-14
8	-50	32
-18	0	10
6	-10	18
14	-30	10
-14	-6	6
-38	-16	10
-64	-38	22
8	-8	16
2	-48	10
44	-22	42
4	-48	2
4	-46	10
44	-22	42
52	-8	28
-42	-34	64
-50	-12	24
46	-54	60
-34	-76	50
46	-54	60
-36	-16	-12
-10	-48	32
5	-50	32
4	-48	10
66	-12	18

// Schmid J, 2015: Ulcerative Colitis (UC)
// Subjects=15
-18	38	54
14	36	60
-52	24	14
56	26	18
-18	38	54
-52	24	14
-44	0	46
32	-28	48
-62	-18	40
-62	-18	40
-58	4	14
4	-46	10
26	-30	-12
4	-44	10
34	12	-24
-8	34	58
22	-66	-24

// Schmid J, 2015: UC Control
// Subjects=15
-62	-18	40
-62	-18	40
-58	4	14

// Siemann J, 2018: INC > CON (Valid, Invalid, Neutral)
// Siemann J, 2018: INC > CON (Valid, Invalid)
// Siemann J, 2018: INC > CON, spatial cueing
// Siemann J, 2018: INC > CON, feature-based cueing
// Siemann J, 2018: INC > CON, subset of valid cued trials, spatial cueing
// Siemann J, 2018: INC > CON, subset of valid cues, feature-based cueing
// Siemann J, 2018: Conjunction Analysis: INC > CON, spatial and feature-based 
// cuing
// Subjects=21
-43.76	-74.27	25.92
-41.82	-83.57	6.64
-30.74	-83.69	27.75
-30.57	-.29	58.71
-21.81	-4.85	66.86
-49.98	-15.45	58.31
-2.69	3.68	42.16
-11.47	4.84	32.11
-9.05	-18.37	47.81
-55.78	8.94	32.46
-27.17	-56.44	-25.43
0.97	52.38	0.3
-17.34	-53	68.19
31.17	60.89	-2.18
29.03	-51.68	-23.5
29.13	-60.83	-18.11
21.32	11.05	62.31
-43.76	-74.27	25.92
-.47	-7.91	44.39
-23.98	-53.1	55.99
-26.45	-2.89	42.09
-17.34	-53	68.19
-30.57	-.29	58.71
-23.92	-54.82	60.64
-24.28	1.58	43.86
-13.12	-60.3	58.75
-26.43	3.8	44.79
-24.06	-5.58	59.13

// Veroude K, 2016: Main effect of Reward Anticipation, All Subjects
// Veroude K, 2016: Main effect of Reward Reciept, All Subjects
// Subjects=40
2	-4	58
-4	-92	18
4	44	-4
44	-56	-14
0	-36	38
-50	-52	-12
-50	14	34
-20	26	52

// Gonzalvez G G, 2016: Healthy Controls (HC)
// Subjects=23
-54	14	-14
-22	-18	-20
-32	-24	-22
-56	-64	12
36	-8	-26
-52	0	-18
24	-4	-28
-28	-8	-22
-46	-20	-2
-26	-2	28
32	-10	-18
-46	-4	-2
44	-16	0
68	-38	2
26	-54	-14

// Gonzalvez G G, 2016: Left Temporal Lobe Epilepsy (LTLE)
// Subjects=20
52	10	-22
-58	-38	-2
20	-20	-22
-58	-4	-18
-22	-20	-20
34	-28	-12
-48	24	-6
50	14	-20
-58	-30	0
-32	-48	-16
32	-56	-14
-28	-16	-24
-32	-24	-22
-56	-64	12
36	-8	-26
-52	0	-18
24	-4	-28
-28	-8	-22
-46	-20	-2
-26	-2	28
32	-10	-18
-46	-4	-2
44	-16	0
68	-38	2
26	-54	-14

// Gonzalvez G G, 2016: Right Temporal Lobe Epilepsy (RTLE)
// Subjects=13
-56	16	-8
-58	10	-8
-48	-32	-2
-34	-8	-44
-54	-16	-16
-26	-16	-20
40	-54	-22

// Hennion S, 2016: Subgroup of Mesial Temporal Lobe Epilepsy, Left MTLE
// Subjects=13
28	4	62
16	0	-38

// Hennion S, 2016: Subgroup of Mesial Temporal Lobe Epilepsy, Right MTLE
// Subjects=12
10	-64	18
34	-8	-34
8	54	40
-14	-64	-30
-8	30	-14
0	36	-18
-14	48	-14
-64	-42	34
-62	-50	34

// Hennion S, 2016: Healthy Controls
// Subjects=25
10	-64	18
34	-8	-34
8	54	40
-14	-64	-30
28	4	62
16	0	-38
-8	30	-14
0	36	-18
-14	48	-14
-64	-42	34
-62	-50	34
58	-50	12
28	-40	-16
36	-84	4
-44	-70	20
-40	-48	-14
30	-92	-4
-46	-60	-10
-32	-76	22
42	-78	14

// Oyegbile T O, 2018: All Participants: 2-back > 0-back
// Oyegbile T O, 2018: Healthy Controls (HC) > Temporal Lobe Epilepsy (TLE): 
// 2-back > 0-back
// Oyegbile T O, 2018: All Participants: Negative Correlation between 2-back > 
// 0-back and N-back Accuracy
// Oyegbile T O, 2018: All Participants: Negative Correlation between 2-back > 
// 0-back and N-back Speed
// Oyegbile T O, 2018: All Participants: Negative Correlation between 2-back > 
// 0-back and D-KEFS Interference Inhibition Accuracy
// Oyegbile T O, 2018: All Participants: Negative Correlation between 2-back > 
// 0-back and D-KEFS Interference Inhibition Speed
// Oyegbile T O, 2018: All Participants: Negative Correlation between 2-back > 
// 0-back and Speeded Dexterity
// Subjects=15
-39	-40	50
-30	5	62
-54	14	32
-45	-61	-10
-30	8	56
-30	8	56
-36	-37	44
36	11	50
-30	8	56
-36	-37	44
-30	8	56
36	11	50
-54	14	32
-42	-61	-7
-12	-88	-7
3	-79	11
-27	-64	56
-51	14	32
21	11	65
-24	-67	41
-51	14	32
21	11	65
-45	-64	-7
-24	-67	41
-51	14	32
21	11	65
-42	-64	-4

// Armbruster D J N, 2016: Negative correlation with error costs in task 
// switching
// Armbruster D J N, 2016: Negative correlation with error costs in distractor 
// inhibition
// Armbruster D J N, 2016: Positive correlation with reaction time in 
// distractor inhibition
// Armbruster D J N, 2016: Positive correlation with intra-individual 
// coefficient of variation (ICV) in ongoing
// Armbruster D J N, 2016: Negative correlation with ICV in task switching
// Subjects=76
-34	6	40
-36	32	34
2	40	16
-2	62	2
-2	10	46
6	-38	46
44	-22	24
34	26	12
2	-96	0
-16	-28	2
6	32	-10
0	60	8
56	28	10
2	-50	44
-52	-62	36
62	-50	28
14	-86	42
-42	12	40
-34	8	40
6	22	30
48	-14	32
52	-14	0
56	-58	14
42	-78	-12
-12	-2	22
-2	-18	16
36	-14	40
-52	-10	14
2	-2	50
48	-6	4
-42	-16	10
-63	-30	28

// Berron D, 2015: Flanker, Incongruent > Congruent
// Berron D, 2015: Garner, Filtering > Baseline
// Berron D, 2015: Interaction, Filtering (incongruent > congruent) > Baseline 
// (incongruent > congruent)
// Berron D, 2015: Flanker, Incongruent > Congruent, first experimental run
// Berron D, 2015: Garner, Filtering > Baseline, first experimental run
// Berron D, 2015: Interaction, Filtering (incongruent > congruent) > Baseline 
// (incongruent > congruent), first experimental run
// Berron D, 2015: Flanker, Incongruent > Congruent, second experimental run
// Berron D, 2015: Interaction, Filtering (incongruent > congruent) > Baseline 
// (incongruent > congruent), second experimental run
// Subjects=24
-4	32	54
50	18	27
0	-48	43
2	-42	48
4	2	1
-4	8	-2
6	20	-5
0	-44	-2
12	-34	-5
-4	-22	9
44	-50	-2
48	-60	-2
64	-50	-7
-30	-58	54
-34	-50	54
-30	-60	-5
-34	-72	-2
48	0	-15
-18	-14	-15
-14	-24	-13
-24	-58	-15
28	-44	-23
16	-40	-23
30	-44	-31
-32	-48	-26
4	-38	35
-2	-24	35
-4	26	-2
2	34	-2
2	36	9
-22	-78	46
-34	-70	32
22	6	46
22	-6	54
24	-16	48
16	-18	56
26	-38	51
26	-56	51
18	-54	46
42	52	-10
28	16	-13
-10	32	38
-8	40	35
34	-66	43
32	-66	51
40	-50	38
32	-60	-15
-28	-78	-15
-12	-76	-15
-14	-84	-15
2	-42	43
18	-78	46
34	-34	-7
-28	-38	-10
28	-50	-10
-58	-28	-1
-66	-30	3
16	18	-2

// Campanella S, 2017: Correct Inhibitions during Neutral Context, All 
// Participants
// Campanella S, 2017: Correct Inhibitions during Alcohol-related Context, All 
// Participants
// Campanella S, 2017: Correct Inhibitions during Non-alcohol Context, All 
// Participants
// Campanella S, 2017: Correct Inhibitions during all Contexts, All 
// Participants
// Campanella S, 2017: Failed Inhibitions during all Contexts, All 
// Participants
// Campanella S, 2017: Failed Inhibitions during all Contexts, Light > Heavy 
// drinkers
// Campanella S, 2017: Failed Inhibitions during all Contexts, Heavy > Light 
// drinkers
// Subjects=17
48	60	42
50	50	-4
-46	56	40
62	26	-2
-44	52	-12
-50	36	-18
-50	66	44
-66	26	-14
-16	56	34
-40	46	-14
-4	46	44
-50	68	42
50	66	44
36	44	-16
-66	22	-18
-50	68	38
-44	52	-12
4	34	26
48	26	-10
-44	18	-14
58	-42	50
-58	-60	32
50	22	-14
-48	18	-16
8	30	30
18	-36	-20
-26	-92	22
-14	4	-14
-26	-6	26

// Aasen I, 2018: High load > control cue
// Aasen I, 2018: High load > control association
// Aasen I, 2018: High load > low load association
// Aasen I, 2018: Low load > control cue
// Aasen I, 2018: Low load > high load cue
// Aasen I, 2018: Low load > control association
// Aasen I, 2018: Control > low load cue
// Aasen I, 2018: Control > high load association
// Aasen I, 2018: Control > low load association
// Subjects=17
26	-70	30
-8	1	-3
-18	-58	26
-30	-66	34
28	22	2
4	30	42
40	60	-32
0	-20	30
44	-70	34
-34	-50	40
-34	-86	-2
20	-36	-48
38	20	24
2	14	54
-30	96	2
32	-54	38
36	-42	-26
52	18	28
30	-52	32
-40	22	20
0	14	48
-36	52	40
20	36	-48
-58	-54	18
62	-18	10
52	-64	28
6	62	12
0	58	4
-40	-14	-4
60	-36	42
0	-24	44
-62	-40	4
-40	-12	-4
40	-16	-4
0	58	6
-4	-22	46

// Daamen M, 2015: Very Preterm and Very Low Birth Weight (VP/VLBW) Group
// Subjects=73
16	-62	22
37	-76	26
16	-72	44
-6	-90	18
-17	-94	11
12	-58	51
34	-47	-25
19	-44	-10
19	-69	-21
23	-29	-21
23	-69	-43
16	-69	-39
16	-62	-32
16	-62	22
19	-44	-14
23	-29	-21
30	-47	-25
55	18	11
62	0	26
59	-51	8
55	-44	44
59	-40	26
-35	-51	44

// Daamen M, 2015: Control Group
// Subjects=73
16	-62	22
37	-76	26
16	-72	44
-6	-90	18
-17	-94	11
12	-58	51
34	-47	-25
19	-44	-10
19	-69	-21
23	-29	-21
23	-69	-43
16	-69	-39
16	-62	-32
16	-62	22
19	-44	-14
23	-29	-21
30	-47	-25

// Duggirala S X, 2016: 2-back words > 0-back words
// Duggirala S X, 2016: 2-back objects > 0-back objects
// Duggirala S X, 2016: 2-back faces > 0-back faces
// Duggirala S X, 2016: 2-back faces and 2-back words > 0-back faces and 
// 0-back words
// Subjects=50
32	24	2
-30	-58	-34
-42	-70	-20
-46	-48	-28
-36	-50	44
-36	-44	38
-36	-44	38
-44	2	28
-48	22	26
-38	20	26
-30	24	-2
-44	16	4
-54	12	2
-10	-76	-32
-8	12	48
-26	4	50
8	16	46
8	22	40
38	48	12
32	24	0
46	16	4
-30	-56	-34
-42	-50	-26
-34	-72	-26
-34	-50	42
-44	-48	46
-30	-72	24
-32	20	4
-12	-74	-32
-42	2	30
-46	20	30
-44	30	36
-44	6	30
-26	-64	-32
-10	-76	-32
-14	-68	-32
-42	-48	54
-36	-48	38
-52	-36	46
32	26	2
42	20	8
-30	28	2
-2	-60	-30
10	22	38
-30	-82	20
-40	-78	-18
-40	-66	-14
-26	-64	-32
-36	-48	38
-50	-40	42
-34	-62	38
-44	6	30
32	26	2
-30	28	2

// Geiger L S, 2018: Novel > Practice
// Geiger L S, 2018: Practice > Novel
// Geiger L S, 2018: Novel (encoding > retrieval) > Practiced (encoding > 
// retrieval)
// Geiger L S, 2018: Practice (encoding > retrieval) > Novel (encoding > 
// retrieval)
// Subjects=74
33	23	6
18	14	6
6	8	60
-36	23	3
9	20	36
-18	8	6
-3	11	54
-6	17	42
-42	-7	48
48	-1	45
6	-4	3
-6	-7	3
-45	32	18
27	-64	45
45	-40	48
36	-85	12
45	-61	-15
45	-61	-15
-24	-64	54
-27	-76	24
-42	-40	42
-48	-61	-15
-30	-64	-12
39	41	27
-39	-58	-24
36	-52	-27
-6	-58	27
-51	-70	39
54	-67	36
21	14	6
33	23	6
6	5	63
48	-1	45
-18	8	3
9	20	36
-36	23	3
-6	17	39
-3	5	63
-54	8	18
48	11	18
-51	-1	36
9	-7	0
-6	-10	0
36	-85	12
45	-64	-6
45	-37	48
39	-61	-12
-36	-88	3
-21	-64	54
-30	-64	-12
27	-61	51
-45	-73	-6
-39	-40	45
-48	-70	42
-6	-58	24
54	-64	36

// Kodama K, 2015: 3-back > 2-back
// Subjects=33
-10	-76	-4
-12	-72	-4

// Li X, 2019: Schizophrenia Patients (SCZ)
// Subjects=20
0	24	45
-30	3	63
-27	12	60
36	-42	39
45	-48	54
27	-57	39
33	27	3
-30	60	18
-45	48	6
-33	-48	39
-45	-48	54
-27	-66	42
42	39	30
39	54	18
42	6	27
33	6	63
27	6	51
-30	27	0
-3	-39	-33
36	-6	-27
39	15	-27
33	-15	-21
48	15	36
18	-54	69
30	-45	69
57	-36	51

// Li X, 2019: Healthy Controls (HC)
// Subjects=24
-30	24	3
51	15	36
33	24	3
-33	-45	42
-45	-39	42
-39	-54	57
30	-60	-30
12	-72	-27
-9	-75	-27
36	-6	-27
39	15	-27
33	-15	-21
48	15	36
18	-54	69
30	-45	69
57	-36	51

// Liu S, 2018: Higher capacity group
// Subjects=16
34	-56	62
-18	-68	44
-28	-72	36
2	22	48
-30	-8	70
56	-58	-8
-52	16	26
24	2	56
-32	-74	-28
0	22	48
-6	50	16
36	-52	60
-18	-64	62
10	4	46
4	56	0
2	-32	34

// Liu S, 2018: Lower capacity group
// Subjects=15
-18	-64	62
-14	-54	-4
32	-68	40
48	-32	58
20	-60	64
-8	-56	52
-20	0	54
-32	-80	32
20	-10	72
-56	14	32
-24	-66	-24
-2	4	58
-12	-6	16
44	36	30
8	-74	-26
38	-60	-28
52	-48	10

// Liu S, 2018: Higher capacity group (alternate criteria)
// Subjects=17
22	-62	68
-28	-58	64
10	6	46
-6	48	16
-22	56	28
66	-32	32
-8	-24	38

// Liu S, 2018: Lower capacity group (alternate criteria)
// Subjects=11
52	-48	10

// Nayyeri M D, 2019: Main effect of 'Pressure'
// Nayyeri M D, 2019: Main effect of 'n-back'
// Nayyeri M D, 2019: 2-back > 0-back
// Nayyeri M D, 2019: 0-back > 2-back
// Nayyeri M D, 2019: Pressure > No Pressure
// Subjects=24
52	-20	23
54	-16	48
-4	60	14
-40	-44	44
-62	-12	-20
-2	-50	28
32	4	60
40	-44	44
-50	-64	26
62	-6	-18
30	-82	-34
32	22	0
-28	24	0
38	-66	-28
-8	-74	-24
56	-64	30
66	-30	30
-32	-82	-34
-34	-66	-28
-20	-96	22
-64	-48	-4
-40	-44	44
32	4	60
32	22	0
-28	24	0
38	-66	-28
-8	-74	14
-34	-66	28
-4	60	14
-2	-50	28
-50	-64	30
62	-6	-18
30	-82	-34
56	-64	30
66	-30	30
28	-92	20
-32	-82	-34
-20	-96	22
-64	-48	-4
44	-12	60
52	-20	23
54	-16	48

// Omata K, 2018: voluntary stop > forced stop
// Omata K, 2018: voluntary start > forced start
// Omata K, 2018: forced stop > voluntary stop
// Omata K, 2018: forced start > voluntary start
// Omata K, 2018: voluntary stop > fixation
// Omata K, 2018: forced stop > fixation
// Omata K, 2018: Conjunction analysis: voluntary > forced
// Omata K, 2018: Conjunction analysis: voluntary and forced stop > fixation
// Subjects=26
26	12	58
42	40	22
54	-40	46
-30	-62	-30
-32	58	14
-8	-90	2
56	8	18
-34	12	2
32	-60	-26
-46	-48	50
20	12	6
-8	2	66
46	12	6
-16	4	10
-40	-60	-32
-38	52	22
56	-36	44
-50	-38	22
40	-56	-16
-44	-70	-12
-24	-70	44
-10	6	58
-44	4	34
-50	-8	48
48	-64	14
-8	2	62
-50	-76	8
54	0	40
-18	0	4
-24	48	28
14	-16	38
22	48	26
64	6	18
20	8	2
-12	10	32
34	-52	54
2	10	44
8	2	70
42	8	-2
56	-38	52
-42	6	0
38	10	6
38	-54	-18
62	-42	18
-36	20	6
8	14	44
-40	-56	-16
-14	0	68
-8	2	66
20	12	62
-2	18	46
56	-36	44
54	12	20
28	56	22
-34	12	2
-18	10	4
-34	58	16
-34	-60	-34
-6	-90	8
20	12	6
-46	-44	50
-54	12	10
8	2	70
2	8	46
42	12	-2
54	16	12
-42	10	0
58	-30	48

// Peterburs J, 2019: Significant activations for high>low load during 
// maintenance
// Peterburs J, 2019: Significant deactivations for high>low load during 
// maintenance
// Subjects=20
26.44	-76.8	-62.43
26.99	-70.52	-18.24
-.25	12.35	65.91
-46.21	29.72	24.64
-54.48	-.34	47.92
-24.48	-61.2	15.33
40	-37.32	-8.3
47.25	-29.35	53.54
-20.8	-87.86	-40.36
31.16	-82.59	-32.8
-22.43	-99.22	-1.11
-30.69	32.69	55.45
-39.22	-78.11	41.91
-50.69	-17.45	2.49
29.47	-103.09	0.63
53.81	-57.19	53.94
12.55	-41.35	41.87
61.62	-13.01	-2.11

// Peterburs J, 2016: Significant activations for high > low load during 
// encoding
// Peterburs J, 2016: Significant deactivations for high > low load during 
// encoding
// Peterburs J, 2016: Significant activations for the eye regressor during 
// encoding
// Peterburs J, 2016: Significant deactivations for the eye regressor during 
// encoding
// Subjects=15
-65.54	-37.32	20.39
38.29	-84.28	17.67
21.7	-62.05	-7.78
56.41	-57.6	3.51
-23.46	-40.89	14.43
-16.53	-3.97	-27.44
-37.12	-85.11	35.84
-41.38	-21.15	54.24
33.56	-65.41	-9.89
34.45	-56.63	60.94
62.05	3.28	34.37
48.99	13.46	29.11
38.48	9.12	52.13
5.38	-33.39	-10.34
-24.77	-74.33	-10.26
-7.15	24.52	35.69
-19.85	-89.51	33.74
-3.2	-35.13	-5.54
50.56	-85.06	-37.37
62.38	-53.32	48.93
29.39	-44.62	6.05
59.44	23.97	3.24
40.84	-79.13	49.61
70.92	-40.94	43.08
-37.06	-19.01	53.96
-26.87	-45.44	0.37
-.72	46.02	35.7
-44.23	4.26	4.71
-37.24	-55.33	32.9
-9.26	-10.15	32.43
-52.71	-16.42	13.62

// Philip N S, 2016: Healthy Controls
// Subjects=13
-46.38	67.73	-33.75
38.93	24.77	63.67
-26.7	87.79	31.25
3.43	61.59	47.6
67.24	22.63	-7.85
38.43	88.81	24.84
-.81	-44.6	9.72
-65.13	10	5.88
57.97	42.63	45.22
-55.77	63.47	-5.4
-1.54	37.91	-51.84
3.66	0.26	52.74
35.44	74.47	46.15
-32.96	-19.41	7.98
35.74	14.97	61.18
-36.17	70.62	43.96
38.1	58.98	-30.64
32.25	-18.77	10.52
9.74	11.22	14.95
-.66	-56.26	24.08
51.22	78.6	15.52
-45.88	-23.78	-6.01
-45.85	73.22	37.16
57.69	69.38	19.56
12.9	86.51	38.71

// Philip N S, 2016: Early Life Stress (ELS) Group
// Subjects=13
42.1	34.3	62.83
-7.76	99.17	-2.26
3.35	54.22	34.84
-46.02	84.62	19.47
-65.13	10	5.88
57.97	42.63	45.22
-55.77	63.47	-5.4
-42.3	-26.42	42.13
-36.14	66.56	46.53
3.54	-57.01	14.05
-49.1	36.5	16.85
3.23	52.94	18.22
51.4	-32.71	-6.38
-45.88	-23.78	-6.01
-45.85	73.22	37.16
57.69	69.38	19.56
12.9	86.51	38.71

// Shi Y, 2018: Instruction (reversal > nonreversal)
// Shi Y, 2018: Task Switch > Task Repetition
// Shi Y, 2018: Reversal (late - early) > Nonreversal (late - early)
// Shi Y, 2018: Conjunction (reversal (late-early), nonreversal (late-early)
// Subjects=32
-42	44	16
-42	32	34
-42	14	22
45	11	22
-27	23	-20
-39	-10	61
27	-4	55
12	26	31
-48	-37	43
42	-43	34
9	-64	52
-18	5	-11
18	17	-8
-33	20	7
36	14	-5
-12	-16	4
6	-19	7
-15	-76	10
-24	-88	-17
3	-97	-2
-36	47	22
-45	32	31
-48	8	34
42	26	28
-27	-4	58
36	-4	55
-6	20	46
-36	-52	46
36	-58	37
-3	70	52
-18	-4	-5
15	2	1
-30	20	1
33	20	7
-12	-16	10
18	-13	10
-9	-79	7
-21	-94	-11
0	-91	4
-30	-61	-32
33	-67	-32
15	-19	67
-24	-34	58
-6	-19	55
33	8	4
-36	-16	13
48	-19	19
-3	53	-2
-39	11	-23

// Siemann J, 2016: Incongruent > Congruent, all cue types
// Siemann J, 2016: Incongruent > Congruent (valid cues)
// Siemann J, 2016: All Congruent > Fixation
// Siemann J, 2016: All Incongruent > Fixation
// Siemann J, 2016: All Congruent & Incongruent > Fixation
// Subjects=20
-23.98	-53.1	55.99
-26.45	-2.89	42.09
-23.92	-54.82	60.64
25.82	-57.62	62.31
55.14	-38.22	-7.35
-46.31	-73.89	-4.33
-18.72	62.56	-16.06
-41.8	-48.4	15.48
-15.26	-66.69	59.42
-24.28	1.58	43.86
-62.36	11.48	25.6
-59.89	-14.71	43.83
-50.45	-20.05	20.67
-35.5	-18.05	6.77
-39.63	-65.82	12.69
-32.61	-4.88	67.05
-33.45	17.26	5.48
67.21	13.55	17.58
53.69	-26.34	50.89
63.08	-29.87	24.19
31.5	-46.09	1.68
-62.35	9.35	25.81
-59.87	-14.5	46.05
-34.8	-5.1	64.87
-31.29	17.27	5.44
-32.72	-53.86	48.36
-23.95	-41.95	60.48
-4.96	16.02	36.5
33.66	-46.08	1.64
67.25	13.86	20.91
51.51	-24.33	49.61
65.22	-30.07	21.93
-42.01	-.74	8.53
-31.09	-49.08	7.52
-35.92	-44.12	-30.98
-2.61	5.36	48.72
24.85	-62.66	-14.5
25.06	-38.15	6.61
25.19	-41.57	15.91
37.55	-41.63	-31.36
44.27	3.95	-3.49

// Soylu F, 2016: two-digit > one-digit
// Soylu F, 2016: one-digit > two-digit
// Soylu F, 2016: Main effect of tapping
// Soylu F, 2016: Interaction between tapping and addition difficulty
// Subjects=13
-40	6	30
-2	18	46
30	-54	50
-28	-56	54
-4	40	34
-44	-66	40
-42	-12	0
-56	-42	28
60	-12	24
6	54	36
-32	-24	58
18	-60	6
48	-60	34
48	-60	34
-42	-68	40
-36	-22	54
-28	-56	54
8	54	42
-4	-40	34
38	-34	14

// Uehara S, 2019: Switch > Repeated
// Uehara S, 2019: Flip analysis for Switch > Repeated
// Subjects=32
-30	-48	50
-18	-72	50
-42	-44	48
-54	-34	40
-52	-40	56
-48	4	28
-42	-8	38
-56	4	38
-50	6	14
-24	-6	54
-44	-42	54
-32	-40	58
-32	-52	44

// Walitt B, 2016: Healthy Controls
// Subjects=13
0	16	54
-36	-56	40
44	36	32
-42	54	8
-30	22	4
32	22	8
-24	6	6
32	-2	32
32	22	8
-22	8	14
34	-2	30
-22	6	14

// Walitt B, 2016: Fibromyalgia patients
// Subjects=16
44	-46	40
28	14	54
-30	22	-8
-36	-54	-34
32	22	8
66	-30	30
48	-80	8
-42	-40	-6
30	-34	-16
-36	-74	16
-22	6	14

// Ward N, 2019: Dual Task Only > Baseline
// Ward N, 2019: Switch Only > Baseline
// Ward N, 2019: Switch/Dual > Switch Only
// Ward N, 2019: Switch/Dual > Dual-Task Only
// Ward N, 2019: Switch/Dual > Baseline
// Ward N, 2019: (Dual-Task Only > Baseline) > (Switch Only > Baseline)
// Subjects=30
54	-40	54
38	58	6
-32	-50	44
-24	-6	52
36	-60	56
-2	6	64
-44	-28	46
-26	-8	50
50	-26	62
-36	-48	44
-40	10	30
42	-50	46
32	4	62
-4	12	54
32	-82	4

// Yin S, 2018: Task Switching > Repetition
// Subjects=26
-30	42	18
-51	9	6
-6	18	45
-27	-6	57
-51	-3	39
-60	-45	24
-39	-39	45
-15	-63	51
-18	-75	6
48	15	0
21	-3	63
66	-36	30
33	-36	45
18	-57	57
9	-75	12

// Zhang H, 2018: Go trials comparison (all go < go bias < no-go bias)
// Zhang H, 2018: No-go trials comparison (no-go bias < go bias)
// Zhang H, 2018: Positive correlation b/w reaction time & fMRI activation for 
// go trials (no-go bias, go bias, all go)
// Zhang H, 2018: Negative correlation b/w reaction time & fMRI activation for 
// go trials (no-go bias, go bias, all go)
// Zhang H, 2018: Negative correlation b/w commission error rate & fMRI 
// activation for no-go trials (go & no-go bias)
// Zhang H, 2018: All Go > Baseline
// Zhang H, 2018: Go > Baseline (Bias Conditions)
// Zhang H, 2018: No-Go > Baseline (Bias Conditions)
// Zhang H, 2018: Positive correlation b/w reaction time & fMRI activation for 
// All Go < Go Bias < No-Go Bias
// Zhang H, 2018: Negative correlation b/w reaction time & fMRI activation for 
// All Go < Go Bias < No-Go Bias
// Zhang H, 2018: Negative correlation b/w error rate and Go bias > No-go bias
// Subjects=20
44	48	6
-42	44	2
52	30	4
44	28	36
36	26	-4
-36	24	-6
10	22	62
40	16	-4
-38	8	-8
32	8	-40
-32	6	-42
28	0	-42
-32	-2	-42
46	-26	-4
66	-28	-6
-2	22	34
8	-36	46
-6	-44	18
48	-24	-24
-54	-36	46
64	-40	38
-6	-38	46
8	-74	46
22	60	30
-6	36	20
4	34	26
-4	44	28
10	28	64
30	22	-14
44	20	-2
42	18	-6
52	16	4
-32	20	-16
-46	18	-4
-40	18	-6
-52	16	-2
-56	-36	-10
-58	-50	36
40	28	-6
-36	22	-12
34	22	-6
-18	-6	-8
20	-6	-6
4	-16	-22
-34	-82	-12
-4	-82	-14
-8	-102	-2
22	-4	62
24	-6	50
66	-16	22
60	-22	28
58	-28	26
8	-48	54
20	-48	68
18	-64	58
-22	-82	42
6	-62	4
-8	-72	0
-46	-82	0
34	-82	0
22	-72	30
30	-90	30
24	-4	62
6	-6	44
8	-12	46
26	-22	64
30	-32	62
4	-52	-14
-10	-40	-18
-48	38	8
-52	14	4
52	14	4
-66	-24	8
60	-32	12
30	-44	-16
20	-62	-20
-42	-66	-10
40	-76	-10
-34	-80	-18
-42	42	8
42	42	8
-52	14	4
52	14	4
-66	-24	8
60	-32	12
30	-44	-16
-44	-84	0
40	-76	-10
-34	-80	-18
-52	36	18
52	36	18
-40	32	22
40	32	22
-52	32	20
52	32	20
38	-54	-16
40	-78	-10
-42	-86	0
20	54	32
-4	30	42
-46	32	22
-10	-6	66
-6	-8	64
-24	-14	66
-30	-38	58
-30	-42	66
8	-50	-8
-8	-62	-2
10	-64	0
-64	-18	16
-60	-18	14
-68	-24	6
-64	-24	10

// Kumfor F, 2019: Positive films > Baseline, All Participants
// Kumfor F, 2019: Neutral films > Baseline, All Participants
// Kumfor F, 2019: Negative films > Baseline, All Participants
// Kumfor F, 2019: Positive, Neutral, and Negative films > Baseline, All 
// Participants
// Kumfor F, 2019: Positive Correlation between facial EMG response and 
// Positive films > Baseline, All Participants
// Kumfor F, 2019: Positive Correlation between facial EMG response and 
// Neutral films > Baseline, All Participants
// Kumfor F, 2019: Positive Correlation between facial EMG response and 
// Negative films > Baseline, All Participants
// Kumfor F, 2019: Positive Correlation between skin conductance levels and 
// Positive films > Neutral films, All Participants
// Kumfor F, 2019: Positive Correlation between skin conductance levels and 
// Negative films > Neutral films, All Participants
// Subjects=14
38	-16	8
-30	-28	-12
-22	14	48
36	-10	4
-22	-32	-32
-70	-12	14
-54	2	-24
-38	32	42
-28	-14	-48
-12	12	-18
38	-16	8
-30	-28	-12
-22	14	48
-53	13	-18
-52	14	-24
-18	4	26
-20	-12	22
-18	0	-12
24	26	48

// Clark C M, 2017: Working Memory Traning Group (WMTG)
// Subjects=25
-16	-62	60
14	-78	-32
8	38	58
34	24	-28
22	-58	48
-44	18	22
-10	-52	24
-4	40	20
16	-56	50
-36	36	6
8	-50	68
-40	46	-20
-24	56	-12
10	52	6
18	30	56
42	-6	-8
-38	2	-24
14	-44	32
36	-2	-6
-2	-30	26
-44	22	-22
-36	36	6
-46	-22	54

// Clark C M, 2017: Processing Speed Training Group (PSTG)
// Subjects=24
46	-54	-18
26	24	48
46	10	32
38	-78	34
60	-52	36
-54	-64	32
-24	-56	-12
10	52	6
18	30	56
42	-6	-8
-38	2	-24
14	-44	32
36	-2	-6
-2	-30	26
-44	22	-22
-36	36	6
-46	-22	54

// Baumann A, 2018: Patients with Parkinson's Disease (PD)
// Subjects=11
-4	-10	38
6	0	60
0	-4	66
52	0	2
28	-2	4
54	-10	18
-44	-32	18
-44	-8	22
-58	4	12
-40	22	18
-28	22	10
52	-22	-8
52	-28	6
56	-2	46
-48	22	2
-40	18	0
-54	6	-10
12	-8	64
-2	-14	68
-10	0	68
62	-8	6
52	-14	26
-62	8	16
-52	34	14
-56	14	10
36	-76	-12
8	-86	4
14	-82	-8
-28	-10	-18
-34	-42	-22
-36	-70	-10
60	2	18
48	14	-8
56	18	8
52	26	0
-62	-36	0
-56	-40	10
-50	-52	-2
-8	-2	62
30	-12	36
-54	12	10
-40	18	18
-42	24	12
34	-40	-24
-58	-40	22
36	-76	-10
28	2	40
38	-6	28
30	6	20
-26	-44	46
-24	-62	34
-18	-52	34
30	-46	42
44	-36	34

// Baumann A, 2018: Healthy Controls (HC)
// Subjects=11
-4	-10	38
6	0	60
0	-4	66
52	0	2
28	-2	4
54	-10	18
-44	-32	18
-44	-8	22
-58	4	12
-40	22	18
-28	22	10
52	-22	-8
52	-28	6
56	-2	46
-48	22	2
-40	18	0
-54	6	-10
12	-8	64
-2	-14	68
-10	0	68
24	-78	-14
-36	-86	-8
38	-66	-20
-44	14	20
-46	4	44
-54	2	16
-28	-46	44
-46	-40	36
-48	-44	18
30	-50	52
34	-56	34
28	-70	46
-8	14	50
8	18	46
0	-6	62
62	8	14
46	10	22
-38	-86	-6
-38	-66	-12
34	-78	-18
-44	4	44
-2	10	46
0	-2	62
32	-2	58
28	-4	44
50	10	46
-58	-32	4
-20	6	8
-50	10	14
30	-50	48
34	-58	40
28	-72	44
-26	-46	44
-20	-68	50

// Brabenec L, 2019: BOLD response to Reading > Baseline
// Subjects=16
-57	-22	-5
42	-25	7
9	5	67
-9	-19	-2
21	-61	7
15	-61	-20

// Bomyea J, 2019: Interference control activation during stimulus encoding
// Bomyea J, 2019: Interference control activation during stimulus recall
// Bomyea J, 2019: PTSD - SI > PTSD + SI during stimulus recall
// Bomyea J, 2019: Inference coding during encoding and recall, PCL and BDI-II 
// covariates
// Bomyea J, 2019: Healthy Controls > Patients, Encoding
// Bomyea J, 2019: Healthy Controls > PTSD patients, Recall
// Subjects=9
-7	16	45
-11	10	5
-29	39	28
14	-95	8
35	-70	-31
-13	-67	6
-31	-15	56
-25	-1	-4
-39	-34	48
20	-57	51
-28	-57	57
28	-3	34
-48	-44	-14
28	-3	34
30	0	32
-48	-44	-14
-47	-44	-16
-42	-77	8
20	19	56
1	-61	2

// Jiang J, 2016: Conscious: Incongruent > Congruent
// Jiang J, 2016: Unconscious: Incongruent > Congruent
// Jiang J, 2016: Congruent > Fixation
// Jiang J, 2016: Unconscious > Fixation
// Subjects=24
8	18	48
-45	-36	42
33	21	6
45	9	33
-27	42	27
36	-63	45
-42	-57	-12
45	33	30
21	-63	24
-24	-96	-9
9	-54	48
-15	-63	24
-9	-3	51
3	18	48
45	-54	-18
33	18	6
-27	-9	60
-36	15	6
36	45	15
-51	-60	-15
36	-87	-9
-36	48	18
48	9	33
15	-57	9
21	-63	24
9	-54	48
12	-78	51
9	-39	45
-3	-63	63
-9	-54	48
-9	-81	48
18	-54	12
18	-63	66
-3	-75	36
-24	-96	-9
-15	-63	24
-18	-72	6
-21	-54	0
-9	-3	51
0	0	48
9	3	48
39	-87	-6
27	-81	-6
33	-84	3
60	-30	42
60	-30	42
57	-21	54
48	39	9
45	-54	-18
45	-66	-6
33	-66	27
27	-63	42
60	12	33
45	3	33
-60	-42	21
-63	-24	18
-51	-42	24
-66	-48	9
-69	-21	9
24	0	57
24	0	57
27	-12	72
12	6	69
36	0	60
3	18	24
-30	-69	27
57	-39	21
57	0	-3
57	9	0
57	9	-9
60	15	9
-33	-57	-18
-39	-66	-9
36	-42	45
-39	-24	63

// Mattheiss S R, 2018: Words > Nonwords
// Mattheiss S R, 2018: Nonwords > Words
// Subjects=20
-38.41	2.59	3.96
-49.72	-22.52	51.92
15	9.25	2.79
50.4	14.18	22.04
-2.85	13.54	46.13
-4.28	-19.9	-14.62
30.79	52.99	-11.1
28.97	-25.01	-1.19
-46.91	35.97	23.56
41.64	-46.28	-29.66
-2.06	-77.21	-26.56
-30.72	-90.82	-7.25
26.02	-93.77	4.61
-32.04	-46.13	-21.02
-34.32	-12.47	-26.05
33.72	-60.69	46.36
-9.26	-53.48	19.48
-46.47	-78.14	34.24
2.16	37.53	11.72
3.06	70.94	3.33
5.28	9.22	-10.48
13.33	-93.61	21.47
67.18	-3.32	-26.86
38.19	24.8	-32.24
-25.37	26.81	40.81
-18.02	60.69	37.89
-25.61	-29.46	-12.46
42.85	-11.9	2.01
28.81	-16.78	-18.6
28.03	25.73	35.83
42.11	-18.34	42.71
-58.85	-2.33	-16.58

// Vachon-Presseau E, 2016: chronic back pain (CBP)
// Subjects=14
-36	-2	-6
44	-22	-2
-20	-10	-14
-50	42	-10
-2	54	4
6	-14	40
-18	-50	0
2	36	-4
50	48	-2
18	14	0
-62	-46	6
-54	-30	16
6	-74	28
-34	-88	22
34	18	12
-50	2	18
54	-32	22
20	2	24
-50	22	30
36	-84	28
-60	-46	30
-38	-16	40
66	-32	28
-44	-38	34
52	-56	42
-18	-86	36
6	18	64
-46	-10	48
-34	-30	-18
10	-96	4
52	10	-14
-50	-62	-10
-4	-86	-8
-14	-54	-10
46	0	-30
-36	-26	-14
-38	-76	-10
42	-68	-10
46	-68	-6
-36	-32	16
-22	-84	16
14	-94	18
16	-72	38
52	-10	42
-48	-14	44
14	10	42
4	-4	52
-2	-74	46
-8	-36	60
18	22	52
40	-40	58
14	14	60
34	-28	66
6	-54	64
-18	-6	68
16	-14	74
-22	-24	74
-48	0	-16
48	-4	-20
-26	-22	-20
-22	-42	-6
24	-44	-4
0	54	0
-44	-84	0
50	-72	12
2	36	-2
-26	-62	4
-30	-92	12
26	64	12
16	-92	28
36	-82	28
22	-80	34
6	-46	34
4	-36	40
-28	36	42
26	36	44
54	-56	42
2	44	48
16	-74	48
58	-32	50
26	-44	54
-6	-58	54
-2	-46	60
10	-54	62
-14	-54	68

// Vachon-Presseau E, 2016: Healthy controls (HC)
// Subjects=16
-28	-16	46
-46	-10	48
40	-12	-20
-16	-86	-12
36	-72	-8
-18	-70	38
-14	-52	52
24	32	50
14	14	62
-18	6	66
46	0	-30
-36	-26	-14
-38	-76	-10
42	-68	-10
46	-68	-6
-36	-32	16
-22	-84	16
14	-94	18
16	-72	38
52	-10	42
-48	-14	44
14	10	42
4	-4	52
-2	-74	46
-8	-36	60
18	22	52
40	-40	58
14	14	60
34	-28	66
6	-54	64
-18	-6	68
16	-14	74
-22	-24	74
-48	0	-16
48	-4	-20
-26	-22	-20
-22	-42	-6
24	-44	-4
0	54	0
-44	-84	0
50	-72	12
2	36	-2
-26	-62	4
-30	-92	12
26	64	12
16	-92	28
36	-82	28
22	-80	34
6	-46	34
4	-36	40
-28	36	42
26	36	44
54	-56	42
2	44	48
16	-74	48
58	-32	50
26	-44	54
-6	-58	54
-2	-46	60
10	-54	62
-14	-54	68

// Errante A, 2019: Cerebral Palsy
// Subjects=10
-36	-44	48
32	-54	52
26	-4	50
26	-4	6
18	-2	-2
28	-56	51
-28	-60	42
34	2	52
28	-12	11

// Errante A, 2019: Healthy Controls
// Subjects=12
-26	-62	64
22	-60	56
-42	-42	46
30	-44	44
28	-2	50
60	-36	30
54	12	-2
-32	-60	-20
30	-58	-20

// Mickleborough M J S, 2016: Healthy Controls > Migraine: Voluntary Attention 
// > Rest
// Mickleborough M J S, 2016: Migraine > Healthy Controls: Voluntary Attention 
// > Rest
// Mickleborough M J S, 2016: Healthy Controls > Migraine: Reflexive Attention 
// > Rest
// Mickleborough M J S, 2016: Migraine > Healthy Controls: Reflexive Attention 
// > Rest
// Subjects=16
48.47	-55.08	21.18
-5.05	-77.2	1.35
-61.77	-55.34	0.17
-13.34	-94.4	27.42
55.98	-64.64	20.78
-7.26	-87.85	-12.23

// Sgandurra G, 2018: Cerebral Palsy
// Subjects=12
-45.68	-67.84	2.15
-49.98	-35.12	12.83
-45.46	-38.07	43.14
-36.84	-42.79	50.13
-15.39	-64.87	51.73
-35.86	-6.32	53.75
-41.37	8.4	38.08
-52.21	17.71	21.81
-23.13	-88.52	8.08
51.53	-63.2	-1.59
57.92	-32.62	8.04
52.81	-33.51	38.28
41.21	-47.35	52.96
25.2	-60.4	50.89
38.95	-3.58	54.89
47.33	11.13	37.95
44.94	27.21	12.09
49.08	35.72	-2.05
24.98	-86.91	10.74

// Sgandurra G, 2018: Healthy Controls
// Subjects=12
48.35	-62.97	1.77
54.76	-39.87	10.91
62.33	-28.93	27.75
36.92	-42.01	53.68
26.3	-62.33	53.27
35.76	-8.98	54.26
47.3	6.47	32.76
47.13	21.22	17.03
44.82	26.01	-3.42
27.07	-86.27	5.09
-45.69	-66.79	2.06
-53.17	-40.51	12.21
-58.39	-29.4	32.52
-32.53	-41.28	55.53
-24.99	-65.9	53.04
-33.69	-11.51	55.27
-48.87	1.49	32.05
-40.57	42.98	17.33
-34.26	25.45	-3.58
-22.08	-86.48	6.78
-41.1	-29.44	57.98
46.52	-25.66	57.77
-52.06	-24.67	24.25
59.04	-17.75	21.28
-59.52	-.34	36.79
-2.71	-21.27	50.16
22.42	-56.09	-30.85
42.24	-26.91	55.69
-41.11	-20.81	59.49
54.79	-23.06	21.77
-56.28	-28.5	30.19
46.35	-4.4	43.72
2.65	-13.4	55.02
-12.75	-65.3	-22.98

// Sgandurra G, 2018: Subgroup of Cerebral Palsy, Contralateral Hemisphere
// Subjects=7
-36.85	-23.07	57.4
-52.02	-27.59	27.84
-58.51	0.12	28.94
-45.76	-9.37	15.09
39	-25.07	52.23
54.81	-17.35	26.87
52.62	7.3	29.29
36.58	-22.54	16.36

// Sgandurra G, 2018: Subgroup of Cerebral Palsy, Ipsilateral Hemisphere
// Subjects=5
41.13	-25.15	51.1
55.88	-21.74	24.99
16.05	-55.7	-25.23
-42.27	-18.42	49.26
-52.03	-27.68	26.73
-56.37	-1.98	29.09
-47.94	-11.93	9.75
-13.85	-55.71	-22.66

// Bugden S, 2019: (NA) Nonsymbolic Addition > NA Control
// Bugden S, 2019: Symbolic Addition (SA) > SA Control
// Bugden S, 2019: Conjunction between SA > SA Control and NA > NA Control
// Bugden S, 2019: (SA > SA Control) - (NA > NA Control)
// Bugden S, 2019: (NA > NA Control) - (SA > SA Control)
// Subjects=24
57.19	-31.31	52.55
-39.03	-41.12	44.44
60	-54.06	-8.03
-51.09	-61.96	-3.86
26.26	-64.96	46.8
52.53	7.5	18.12
49.24	38.49	20.02
44.34	-37.1	47.6
-37.97	-41.2	43.32
-25.07	-70.01	41.12
33.67	-70	35.99
54.63	-51.1	-10.45
-52.21	-60.28	-9.56
28.22	3.58	52.18
-26.27	2.2	52.92
20.38	7.51	7.34
-16.93	6.03	19.04
-25.67	20.47	0.09
-2.83	14.86	49.36
-43.63	2.7	19.63
44.37	-36.85	50.93
-39.03	-41.12	44.44
54.63	-52.15	-10.36
-52.18	-61.08	-6.15
21.99	-65.96	48.05
15.13	-2.58	14.93
-11.66	0.89	7.14
1.47	7.48	49.93
18.64	8.27	58.59
-24.02	0.07	66.46
-48.98	2.58	18.58
-5.07	-58.71	6.49
-8.04	-84.86	26.56
2.11	-59.64	-33.66
1.47	7.48	49.93
-14.55	-100.18	7.85
-38.2	-76.6	-1.67
31.05	-40.92	-14.38
-26.55	-77.56	-15.1
-52.89	-57.4	41.5

// Eiler W J A, 2017: Main Effect of Sucrose > Water
// Subjects=37
-36	-6	6
-36	4	-12
-30	16	4
38	-4	10
38	6	-12
38	18	-2
22	32	-18
-60	-18	26
60	-12	28
60	6	28
-24	36	-16
40	42	8
48	48	8
20	-2	-12
-62	-54	34
-60	-52	44
-42	42	10
12	8	-2
-12	8	-2
-22	-6	-12

// Hauser T U, 2016: Novel > Repeated
// Hauser T U, 2016: Repeated > Novel
// Hauser T U, 2016: Active > Sham: Novel > Repeated
// Subjects=20
-45	-39	52
-26	-63	30
-26	-66	63
42	-37	43
20	-67	63
29	-63	32
35	-48	49
53	6	25
-44	3	25
6	20	51
33	2	66
-26	2	46
-53	2	45
-51	-60	31
59	-61	27
-9	30	54
-6	54	25
68	-39	39
-5	82	33
14	-49	33
-18	47	39
56	39	7

// Otto T, 2018: 3 back > 1 back
// Otto T, 2018: [Post-helicopter training (3-back > 1-back) > Pre-training 
// (3-back > 1-back)]
// Subjects=16
33.71	-66.32	42.37
55.85	13.12	35.45
33.08	26.02	-2.17
30.36	4.74	53.18
13.93	10.3	2.71
-4.96	13.79	49.48
10.88	-17.75	11.79
-8.42	-8.61	7.9
-14.9	3.79	3.59
-30.52	-1.97	54.44
-43.29	-44.31	44.75
-34.26	22.19	-4.42
-50.01	24.92	32.33
-46.76	5.65	30.57
-8.42	34.17	24.39
-17.66	1.79	60.67
-24.43	7.93	16.74
-34.22	32.48	4.75
-36.89	-8.1	58.37

// Salavert J, 2018: ADHD, 1-back > baseline
// Salavert J, 2018: Controls, 1-back > baseline
// Salavert J, 2018: ADHD, 1 back < baseline ADHD
// Salavert J, 2018: Controls, 1 back < baseline
// Salavert J, 2018: ADHD, 2 back > baseline
// Salavert J, 2018: Controls, 2 back > baseline
// Salavert J, 2018: ADHD, 2 back < baseline
// Salavert J, 2018: Controls, 2 back < baseline
// Subjects=15
-4	6	54
36	2	64
-42	-70	0
40	-46	42
-46	2	32
-42	-72	-2
48	18	44
4	-46	40
-8	70	14
-40	-82	30
56	-10	-12
-68	-14	-16
2	-52	30
-2	56	-2
-44	4	26
-44	4	28
-4	-54	14
-50	-68	22
0	46	-8

// Thothathiri M, 2017: Sentence Generation > Word Generation
// Subjects=14
-18	-78	46
-16	-82	50
20	-84	42
10	10	50
8	14	36
6	8	48
-46	0	44
-44	10	26
-54	-2	42
40	-6	52
28	-6	56
54	6	40

// Eddy C M, 2016: All Participants, False Belief > False Photo
// Eddy C M, 2016: Controls > Patients, False Belief > False Photo
// Eddy C M, 2016: Controls > Patients, False Belief and False Photo > Rest
// Eddy C M, 2016: All Participants, False Photo > False Belief
// Subjects=25
8	-52	34
52	-54	18
-48	-60	18
-50	4	-32
58	-6	-20
-2	62	-12
-38	22	40
-20	40	30
0	-18	34
-36	56	-14
0	-18	34
44	-48	16
34	4	-26
6	-40	36
-12	-104	8
-20	18	54
-30	12	-28
44	4	-24
-58	8	6
20	-60	-16
64	-6	14
56	-44	42
4	26	18
-40	-42	46
2	-4	28
-4	2	52
-44	2	42
-40	40	20
28	-6	46
44	26	42
-26	16	62
-22	-72	10
-44	-42	-26
12	-72	42
-18	-84	50
-48	-28	22
-46	-68	28
-54	-56	-8
-14	-70	34
-56	-64	-8
30	-36	-20
58	-52	-12
-34	-36	-20
50	40	8
-48	6	20
64	-8	2
-50	36	10
-28	-80	32
62	-26	42
-46	-48	54
-40	-16	0
-60	-2	10

// Filippi I, 2019: Family History of Alcohol Use Disorder (FH+)
// Subjects=37
6	-1	53
6	-7	47
-6	-4	44
0	38	8
0	29	2
-24	-40	-13
24	-55	-13
21	-52	-10
-9	-67	-4
-9	-58	-10
30	-31	-13
24	-34	-10
-24	-49	2

// Filippi I, 2019: No Family History of Alcohol Use Disorder (FH-)
// Subjects=36
6	-1	53
6	-7	47
-6	-4	44
0	38	8
0	29	2

// Hardee J E, 2017: Family History of Alcoholism
// Subjects=36
-44	26	-2
-30	16	-18
-16	-54	28
-2	-48	24
-8	50	14
-6	56	20
-2	48	34
48	24	-8
32	20	-16
46	20	-16
-50	-30	-6
-56	-16	-12
-8	58	24
-12	46	36
-4	52	36
26	-94	-6
16	-50	-22
30	-46	-28
-20	-96	-8
-40	-76	-18
-38	-62	-14
-44	28	-4
-38	-20	52
-26	-30	-4
-6	12	52
-8	26	62
-6	2	68
26	-28	-2
30	-40	4
26	-96	-6
14	-50	-22
44	-70	-26
-22	-98	-10
-40	-78	-20
-40	-66	-16
-38	-20	52
-26	-20	72
-4	12	52
-10	50	38
-12	38	52
-42	28	0
-46	22	18
-52	16	-6
32	-38	4
28	-28	-2
20	18	16
6	2	-8
10	10	-6
16	0	-8
2	-36	-24
26	-94	-6
14	-50	-22
4	-64	18
-20	-98	-10
-42	-78	-18
-44	-58	-16
-38	-20	52
-38	-24	68
-48	-20	60
-4	12	52
-4	12	66
-4	30	62
-12	-20	4
-28	-28	-4
-28	-6	-4
-6	-22	-14
-16	-12	-16
26	-26	-4
32	-38	2
16	16	-2
20	18	18
20	18	8

// Martz M E, 2018: No-Go (correct inhibition) > Baseline, p<0.05
// Martz M E, 2018: No-Go (correct inhibition) > Baseline, p<0.00005
// Martz M E, 2018: Reward Anticipation > Neutral, p<0.05
// Martz M E, 2018: Reward Anticipation > Neutral, p<0.00005
// Subjects=57
-52	-8	42
54	-8	38
58	-50	42
60	-32	-18
6	8	50
40	44	26
48	46	-10
-4	-4	56
-38	-16	52
14	-44	-24
-10	4	2
8	10	0

// Peraza J, 2015: No Family History Alcoholism (FHN) > Family History of 
// Alcholism (FHP): Fearful > Neutral
// Subjects=14
-3.48	-42.39	79.82

// Takeuchi H, 2018: Positive correlation between 0-back > Fixation and 
// Raven's Advanced Progressive Matrices (RAPM) score
// Takeuchi H, 2018: Negative correlation between 0-back > Fixation and RAPM 
// score
// Takeuchi H, 2018: Positive correlation between 2-back > Fixation and RAPM 
// score
// Takeuchi H, 2018: Negative correlation between 2-back > Fixation and RAPM 
// score
// Takeuchi H, 2018: Positive correlation between 2-back > 0-back and RAPM 
// score
// Takeuchi H, 2018: Positive correlation between 0-back > Fixation and Digit 
// Span Score
// Takeuchi H, 2018: Positive correlation between 2-back > 0-back and Digit 
// Span Score
// Subjects=1235
24	69	9
36	-36	45
27	-12	57
6	-72	30
9	9	69
12	42	54
36	-39	48
18	-6	12
6	6	69
6	30	51
24	-15	-21
-30	-30	75
51	-12	15
-18	-3	-24

// Aarts E, 2018: Gilles de la Tourette syndrome
// Subjects=11
-60	-20	-8
-11	47	46
-23	-90	-14
58	-4	-20
65	-17	-2
32	57	7
56	33	16
6	-46	-8
47	11	37
-54	9	7
-38	-2	1
6	53	-5
10	46	-2
-16	51	43
-23	22	58
6	62	31
6	46	31
-5	0	67
8	7	52
-36	7	7
58	11	10
28	4	13
32	-55	-26
60	-24	28
23	-59	-23
-5	-4	64

// Aarts E, 2018: Healthy Controls
// Subjects=19
-54	11	7
-38	9	1
28	-2	61
34	22	10
54	15	10
47	20	1
-25	-6	7
-13	-2	14
65	-24	31
43	-35	46
-38	-44	55
8	0	70
-8	0	61
-32	-6	55
30	51	37
6	53	-5
10	46	-2
-16	51	43
-23	22	58
6	62	31
6	46	31
-5	0	67
8	7	52
-36	7	7
58	11	10
28	4	13
32	-55	-26
60	-24	28
-16	-46	-2
8	-61	19
14	-55	7
3	13	-5
3	22	-8
8	40	-8
-5	64	-8

// Klabunde M, 2015: All Participants: Symmetry > Trained
// Klabunde M, 2015: Fragile X Syndrome > Healthy Controls: 
// Transitivity/Equivalence > Fixation
// Subjects=8
-46.24	-30.34	27.67
-42.01	-28.06	29.71
-44.18	-15.68	25.54
40.53	-62.11	30.44
-17.69	-2.18	69.97
-17.63	-20.24	67.87
-17.52	-56.43	62.58
-1.75	-26.28	70.41

// McCloskey M S, 2016: Intermittent Explosive Disorder
// Subjects=20
-18	-24	-20
24	-10	18
6	-38	-24
-26	6	46
-36	4	75
16	-28	10
22	-18	27
-50	-2	19

// McCloskey M S, 2016: Healthy Controls
// Subjects=20
-18	-24	-20
24	-10	18
6	-38	-24
-30	-58	-26
30	-62	-26
-14	-56	-50
-28	-46	-50
12	-42	24
0	-84	44
24	-10	18
-8	-74	-6
16	24	20
36	12	28

// McKechanie A G, 2019: Fragile X Syndrome (FXS) > Fragile X Syndrome with 
// Autism (FXS+): Fearful > Fixation
// McKechanie A G, 2019: All Participants: Positive Correlation between ADOS 
// Calibrated Severity Score and Faces > Fixation
// Subjects=7
-64	-30	22
-24	-42	-34

// Moon H I, 2016: All Participants: Swallow > Rest
// Moon H I, 2016: Healthy Elderly > Healthy Young: Swallow > Rest
// Subjects=15
-3	41	-19
-48	38	-7
-51	5	-28
-51	-49	53
33	-13	2
60	-46	41
63	-49	-4
-51	35	14
-24	26	-13
-12	5	11
-42	-58	-40
9	5	35
-15	-100	5
-33	38	-7
-57	-55	5
18	62	14
-21	-82	-7
-18	-91	-4
-9	-85	29

// Carreiras M, 2015: All Phrases> Baseline
// Carreiras M, 2015: Number Mismatch > Number Match
// Carreiras M, 2015: Number Match > Number Mismatch
// Carreiras M, 2015: Match, Determiner-Noun > Mismatch, Determiner-Noun
// Carreiras M, 2015: Mismatch, Determiner-Noun > Match, Determiner-Noun
// Carreiras M, 2015: Interaction between Word Type and Agreement Pattern
// Subjects=32
26	-70	32
27	-91	8
16	-66	10
35	-59	-13
42	-73	-6
54	-38	14
46	-34	44
28	-55	51
32	20	4
32	14	-2
17	7	-1
19	-27	1
44	8	28
28	-4	52
40	-4	58
-14	-72	6
-42	-76	36
-20	-76	29
-35	-80	-4
-18	-62	-4
-35	-64	-12
-21	-29	-3
-56	-6	-10
-28	14	-2
-10	-18	5
-53	-45	13
-58	-4	-8
-54	12	-18
-10	-78	26
-23	-59	50
-6	10	48
-56	-18	24
-40	-5	49
-40	30	10
-48	7	17
-38	-4	14
32	26	-2
28	20	4
-36	-42	42
-28	24	0
-50	10	26
-42	20	-4
-40	14	28
-46	-2	48
-6	4	62
32	-92	-10
58	-12	-22
44	12	-30
46	-72	36
2	-36	40
8	-52	38
6	28	-12
2	56	-4
-26	-96	-4
-34	-90	-12
0	-52	36
-60	-8	-16
-60	-20	-24
-22	-18	-26
-44	-66	48
-24	38	46
-24	30	54
-4	46	-18
-6	36	-12
-4	50	8
14	-52	36
-58	-6	-14
-48	6	30
-46	0	24
-8	-72	30
-56	-6	-10

// Hartung F, 2017: Normals
// Subjects=52
18	-30	58
26	-32	56
8	-30	56
-20	-28	54
-22	-26	62
-18	-36	54
-44	-74	-4
18	-86	-16
-40	-6	-22
-34	-12	-22

// Hartung F, 2017: Subgroup of Normals, Observers
// Subjects=14
16	60	10
18	58	2
-10	-96	0
-16	-92	8
-18	-86	-2
26	-86	8
16	-92	-2
36	-80	-12
38	34	22
54	26	30
48	28	22
-54	-18	48
-58	-36	16
-56	-24	20
-34	-60	-50
52	-40	10
50	-32	2
64	-38	14
44	2	-26
56	-6	-22
62	-14	-18
38	42	-12
46	46	-12
24	40	-12
20	2	22
22	-8	22
28	-12	32
16	-72	-12
18	-28	64
-4	-26	70
-24	-20	64
4	-38	50
-6	-32	48
44	-6	6
48	2	10
58	0	14
18	-40	6
14	-22	6
24	-44	14
50	-52	-6
54	-58	-12
52	-42	-8
18	-18	70
32	-10	66
28	-50	64
-12	56	4
8	58	0
6	62	8
24	-44	2
20	-48	-6
16	-42	6
38	24	54
34	28	48
20	26	58
-4	30	2
-12	34	-4
-14	58	4
18	-16	70
18	6	70
26	-8	66
14	60	10
8	58	0
-14	-10	70
-22	-12	66
-12	-18	74
-6	-72	42
-10	-72	34

// Hartung F, 2017: Subgroup of Normals, Enactors
// Subjects=15
16	60	10
18	58	2
-10	-96	0
-16	-92	8
-18	-86	-2
26	-86	8
16	-92	-2
36	-80	-12
38	34	22
54	26	30
48	28	22
-54	-18	48
-58	-36	16
-56	-24	20
-34	-60	-50
52	-40	10
50	-32	2
64	-38	14
44	2	-26
56	-6	-22
62	-14	-18
38	42	-12
46	46	-12
24	40	-12
20	2	22
22	-8	22
28	-12	32
16	-72	-12
18	-28	64
-4	-26	70
-24	-20	64
4	-38	50
-6	-32	48
44	-6	6
48	2	10
58	0	14
18	-40	6
14	-22	6
24	-44	14
50	-52	-6
54	-58	-12
52	-42	-8
30	-46	0
28	-42	8
14	-40	-4
2	-22	70
-16	-46	68
-12	-20	74
-16	32	46
-2	36	52
6	36	50
-40	32	34
-36	36	26
-32	24	30
-14	-94	12
-2	-96	12
-18	-98	20
62	-6	-20
58	2	-20
46	18	8
56	28	2
58	20	10
36	-14	68
40	-18	54
44	-8	58
-32	-56	-14
-28	-50	-10
24	-56	66
30	-48	70
36	-52	62
30	-38	-18
32	-40	-26
32	-28	-18
-28	-14	62
22	-82	42
14	-86	42
34	-76	44
14	-24	22
12	-28	14
14	-22	4
-26	-80	42
30	-90	10
24	-96	16
2	24	12
-54	-24	18
-60	-16	16
-14	-98	8
-10	-96	24
-16	-100	16
38	-86	-10
56	-50	4
18	-74	-14
0	-20	72
-8	-24	70
16	-40	54
20	-32	56
10	-42	60
-24	-88	-14
-10	-88	-12
18	2	28
26	-22	34
34	-28	40
-30	-34	62
12	-20	54
-2	-20	52

// Hartung F, 2017: Subgroup of Normals, Hypersimulators
// Subjects=12
30	-46	0
28	-42	8
14	-40	-4
2	-22	70
-16	-46	68
-12	-20	74
-16	32	46
-2	36	52
6	36	50
-40	32	34
-36	36	26
-32	24	30
-14	-94	12
-2	-96	12
-18	-98	20
62	-6	-20
58	2	-20
46	18	8
56	28	2
58	20	10
36	-14	68
40	-18	54
44	-8	58
-32	-56	-14
-28	-50	-10
24	-56	66
30	-48	70
36	-52	62
30	-38	-18
32	-40	-26
32	-28	-18
-28	-14	62
22	-82	42
14	-86	42
34	-76	44
14	-24	22
12	-28	14
14	-22	4
-26	-80	42
18	-18	70
32	-10	66
28	-50	64
-12	56	4
8	58	0
6	62	8
24	-44	2
20	-48	-6
16	-42	6
38	24	54
34	28	48
20	26	58
-4	30	2
-12	34	-4
30	-90	10
24	-96	16
2	24	12
-54	-24	18
-60	-16	16
-14	-98	8
-10	-96	24
-16	-100	16
38	-86	-10
56	-50	4
18	-74	-14
0	-20	72
-8	-24	70
16	-40	54
20	-32	56
10	-42	60
-24	-88	-14
-10	-88	-12
18	2	28
26	-22	34
34	-28	40
-30	-34	62
12	-20	54
-2	-20	52
-14	58	4
18	-16	70
18	6	70
26	-8	66
14	60	10
8	58	0
-14	-10	70
-22	-12	66
-12	-18	74
-6	-72	42
-10	-72	34

// Hubers F, 2016: Social Norm Violation > Neutral
// Hubers F, 2016: Grammatical Norm Violation > Truly Grammatical
// Hubers F, 2016: Truly Ungrammatical > Truly Grammatical
// Hubers F, 2016: (Social Norm Violation > Neutral)> (Grammatical Norm > 
// Truly Grammatical)
// Hubers F, 2016: Grammatical Norm Violation > Grammatical (incl. Truly 
// Ungrammatical > Truly Grammatical)
// Hubers F, 2016: Grammatical Norm Violation >Truly Ungrammatical (incl. 
// Truly Grammatical > Truly Ungrammatical)
// Hubers F, 2016: Social Norm Violation > Semantic Violation  (incl. Neutral  
// > Semantic Violation)
// Hubers F, 2016: Disgust > Neutral Face
// Hubers F, 2016: Contempt > Neutral Face
// Subjects=30
-10	48	40
-8	48	26
-8	58	24
-52	14	-4
-50	10	6
-46	24	-2
8	16	66
-6	18	48
-8	12	56
44	26	0
50	20	-8
40	16	-2
-52	14	-4
-52	12	4
-52	10	12
54	16	14
52	24	26
48	14	20
-2	10	58
-8	18	46
10	10	62
-34	-56	44
-28	-62	46
-42	-42	36
32	-62	44
-56	-32	0
50	-32	0
-52	8	-36
-48	-18	-10
-54	-2	-30
-10	50	36
-16	46	40
-12	40	44
-52	14	-4
-50	10	6
-46	24	-2
8	16	66
-6	18	48
-8	12	56
44	26	0
50	20	-8
40	16	-2
-4	64	24
0	52	48
-4	44	52
-46	-68	28
-46	-80	32
-8	48	16
-12	60	8
-12	42	8
-6	-50	30
4	-52	26
-60	-18	-18
-62	-26	-14
10	-22	44
0	-30	44
-8	-30	42
-10	54	42
-20	42	44
-24	32	42
64	-8	-16
58	-2	-18
46	6	-40
-50	-56	26
-56	-64	28
-46	-64	28
50	-34	4
50	-16	-8
52	-26	-2
-24	-104	2
50	-34	4
50	-16	-8
52	-26	-2
-24	-104	2

// Moser J S, 2017: I > Own Name
// Subjects=50
2	53	22

// Pi?ango M M, 2016: Condition A, Event 1 > Condition D, Event 1
// Pi?ango M M, 2016: Condition B, Event 1 > Condition D, Event 1
// Pi?ango M M, 2016: Condition A, Event 1 > Condition D, Event 1 VS Condition 
// A, Event 2 > Condition D, Event 2
// Pi?ango M M, 2016: Condition B, Event 2 > Condition C, Event 2
// Pi?ango M M, 2016: Condition A, Event 2 > Condition D, Event 2
// Pi?ango M M, 2016: Condition B, Event 2 > Condition D, Event 2
// Pi?ango M M, 2016: Condition B, Event 2 > Condition C, Event 2 VS Condition 
// B, Event 2 > Condition D, Event 2
// Pi?ango M M, 2016: Condition B, Event 2 > Condition C, Event 2 VS Condition 
// B, Event 1 > Condition C, Event 1
// Pi?ango M M, 2016: Condition B, Event 2 > Condition C, Event 2 VS Condition 
// A, Event 2 > Condition D, Event 2
// Subjects=15
-54	18	-3
-9	-66	45
-6	15	45
-51	30	-6
0	-63	36
24	-69	-33
-39	-18	57
15	-87	-6
18	21	6
-24	-9	57
-18	-69	-9
-30	21	0
-12	-87	-3
-33	-18	60
15	-87	-6
-39	-27	57
15	-87	-6
18	21	12
-51	-18	51
18	-84	-12

// Pliatsikas C, 2017: Extraction across a verb phrase (EVP) + Extraction 
// across a noun phrase (ENP) > Non-extraction with embedded verb phrase (NVP) 
// + Non-extraction with embedded noun phrase (NNP)
// Subjects=23
-48	-44	6
-60	-48	12
-56	-34	0
-58	-30	2
-60	-26	2
-60	-34	2
-20	-62	-10
-6	-66	-2
-26	-76	-4
-28	-72	-12
-26	-64	-12
-38	-72	-14
-10	-84	6
6	-68	14
-10	-74	10
10	-60	2
10	-64	2
14	-68	18

// Shibata H, 2018: Sentence > Picture
// Shibata H, 2018: Picture > Sentence
// Shibata H, 2018: First Perspective (1 PP) > Second Perspective (2 PP)
// Subjects=12
12	-76	5
-15	-94	-7
-9	-82	-1
-51	2	47
-42	11	29
-57	-37	2
51	-64	-4
36	-82	14
45	-49	-16
-51	-67	-1
54	-22	41
-63	-25	41
-21	-13	50
-15	32	-1

// Yang X, 2018: Two back > Zero back
// Yang X, 2018: Two back < Zero back
// Yang X, 2018: Positive Correlation between Discourse > Fixation and Context 
// Length
// Subjects=24
-45	-42	42
-48	3	36
-6	6	63
-30	0	63
24	6	60
42	-45	42
-12	-51	21
-9	39	6
15	-99	12
6	-9	39
36	-15	18
30	-33	-12
-30	-30	-12
36	-72	-12
-57	0	24
54	3	-27
-15	-96	0
-33	-18	18
45	-30	21
45	-18	45
-45	-72	30
36	36	15
36	-60	54
0	30	33
-30	-57	39
12	3	-3
3	-27	27
-24	9	12
-54	9	-6

// van der Burght  C L, 2019: ProsOnly1 > BL_ProsOnly
// van der Burght  C L, 2019: GramOnly > BL_GramOnly
// van der Burght  C L, 2019: ProsOnly1 > BL_ProsOnly, Lateralisation Analysis
// van der Burght  C L, 2019: BL ProsNoChoice > ProsOnly2, Lateralisation 
// Analysis
// Subjects=26
-45	29	-4
-57	-16	2
-51	11	8
-54	29	5
30	-19	56
54	-4	8
-6	23	50
-51	-34	2
9	23	50
6	-55	41
48	44	8
51	20	8
-39	-16	50
57	-37	8

// Chen N, 2015: Migraine with cutaneous allodynia (MWCA)
// Subjects=15
-6	-66	-15
9	-66	-15
-30	-18	-6
-21	-33	-33
-18	-15	-18
24	-3	-15
42	-57	18
57	-33	42
3	-33	-30

// Chen N, 2015: Migraine without cutaneous allodynia (MWoCA)
// Subjects=19
-9	-39	-27
18	-60	-24
-18	-18	-6
-9	45	24
-21	-27	6
57	-33	42
3	-33	-30

// Chen N, 2015: Controls
// Subjects=20
-6	-66	-15
9	-66	-15
-30	-18	-6
-21	-33	-33
-18	-15	-18
24	-3	-15
42	-57	18
-9	-39	-27
18	-60	-24
-18	-18	-6
-9	45	24
-21	-27	6

// Conforto A B, 2017: All Participants: Finger tapping at 1 Hz > Rest
// Conforto A B, 2017: All Participants: Finger tapping at 2 Hz > Rest
// Subjects=10
-14	-92	-6
52	-12	-8
-14	-24	58
42	-72	-8
-1	-90	24

// Cremers H, 2016: All Participants: Faces > Fixation
// Cremers H, 2016: Healthy Controls (HC) > Intermittent Explosive Disorder 
// (IED): Faces > Fixation
// Cremers H, 2016: Escitalopram > Placebo: Faces > Fixation
// Cremers H, 2016: Group x Drug Interaction: Faces > Fixation
// Subjects=14
40	-46	-28
-22	-32	-8
-52	30	10
32	-10	-22
24	-30	-6
56	32	10
-18	-6	-16
6	58	18
-10	26	62
-2	-60	-42
34	-10	-40
-4	54	30
44	-64	32
-28	-64	46
-44	46	10
10	-82	-44
10	-52	-38
-26	56	-20
-22	-82	52
-48	-48	18
-60	24	14
-4	-82	54
12	0	16
-34	22	-24
-46	-60	18
38	-40	-50

// Zhu C, 2017: All Participants: 0-Back > Baseline
// Zhu C, 2017: All Participants: 1-Back > Baseline
// Zhu C, 2017: All Participants: 2-Back > Baseline
// Subjects=18
10.23	-21.13	64.5
0.21	47.14	39.93
51.48	14.27	23.14
-38.95	-44.66	53.65
-41.25	-25.53	39.81
3.48	-5.94	27.62
-28.76	23.85	16.57
1	4.8	-12.29
22.63	-38.63	2.26
-.79	-5.96	27.67
1	4.8	-12.29
29.11	24.77	37.01
-28.41	18.65	59.38
16.26	40.89	40.27
-22.06	21.34	52.39
-12.57	40.98	43.94
-28.64	14.05	27.42
39.01	-43.65	45.98
-28.46	-42.25	28.8
3.71	-40.95	42.82
-.57	-40.97	42.87
6.33	6.86	-13.64
-19.1	26.54	22.92
-28.74	-33.11	-4.31
48.05	-33.13	-25.26
-58.77	-57.46	-27.57
22.6	10.58	19.32
32.56	-14.45	52.53
-28.41	18.65	59.38
13.16	34.33	52.01
-12.52	38.15	48.64
45.26	-27.72	31.19
-47.53	-34.05	53.98
2.58	-38.29	35.92
0.44	-38.31	35.94
2.3	10.46	19.56
0.16	10.45	19.59
25.83	-38.61	2.22
-6.23	-35.54	3.45
-38.37	-29.99	-4.46
42.24	-66.44	40.05
-2.7	-67.31	32.83

// Luo Y, 2016: Healthy Controls (HC) > Persistent Somatoform Pain Disorder 
// (PSPD), Negative pictures without pinprick pain > Rest
// Luo Y, 2016: PSPD > HC, Negative pictures without pinprick pain > Rest
// Luo Y, 2016: HC > PSPD, Positive pictures without pinprick pain > Rest
// Luo Y, 2016: PSPD > HC, Positive pictures without pinprick pain > Rest
// Luo Y, 2016: HC > PSPD, Neutral pictures with pinprick pain > Rest
// Luo Y, 2016: PSPD > HC, Positive pictures with pinprick pain > Rest
// Luo Y, 2016: PSPD > HC, Negative pictures with pinprick pain > Rest
// Luo Y, 2016: HC > PSPD, Neutral pictures with pinprick pain > Neutral 
// pictures without pinprick pain
// Luo Y, 2016: PSPD > HC, Neutral pictures with pinprick pain > Neutral 
// pictures without pinprick pain
// Luo Y, 2016: HC > PSPD, Positive pictures with pinprick pain > Positive 
// Pictures without pinprick pain
// Luo Y, 2016: PSPD > HC, Negative pictures with pinprick pain > Negative 
// pictures without pinprick pain
// Subjects=10
-45	-9	42
-48	-6	51
-60	-48	12
-30	-57	54
-27	-78	-12
-54	12	6
63	-9	36
63	-3	30
-9	42	-6
-48	-66	15
12	45	-6
0	51	-6
48	-21	0
48	-48	15
-30	-54	51
6	-66	48
9	-60	42
-15	-48	69
-33	24	3
-42	3	6
48	-6	-6
57	2	-6
54	18	0
42	6	-15
-9	-24	42
-42	-18	18
-48	-18	6
-48	0	-9
-27	-81	-12
-21	-75	-3
6	-12	39
27	-18	-12
42	0	6
42	0	15
-6	-72	-39
-30	-72	-39
-33	30	-12
27	-66	-39
24	15	-9
39	24	45
42	18	33
9	-3	21
-9	-72	-36
-24	-57	-36
-45	-63	15
-45	-57	-30
-45	-42	-9
-15	-6	27
-24	-12	27
33	-45	-36
48	-63	24
24	-36	24
51	15	48
3	-9	-9
48	-51	12
48	-48	21
-21	6	42
-24	-87	39
-12	-78	45
-21	42	3
-24	45	12
45	45	21
39	48	30
60	-42	42
12	-39	45
0	30	15
-21	42	3
-24	45	12
-15	-51	72
-27	-45	72
-27	-81	-12
-36	-69	-12
-3	63	24
36	-81	-12
51	39	24
-18	-48	-39
-21	-33	-36
-36	54	21
-30	54	30
-33	60	12
-24	-72	-39
-27	-63	-39
-12	-60	-36
-6	21	66
-60	-45	30
-60	-51	18
-66	-39	24
-57	21	24
-42	27	3
39	6	27
36	12	15
30	-45	-39
48	9	54
30	-87	24
48	-57	-27
0	-69	-42
9	21	66
30	-63	42

// Sandstr?m A, 2019: Rheumatoid Arthritis
// Subjects=31
58	-38	34
34	10	6
14	-18	52
34	-26	58
60	-38	34
30	28	4
16	-16	52
-12	-8	42
32	-14	36
14	-98	-2
22	-78	0
16	-20	52
-18	-80	-2
52	-16	20
20	-80	2
-26	12	-16
36	-22	46
6	-8	50
-58	0	2
40	-18	16
14	-16	0
-20	-52	-26
-10	-18	0
6	-38	20
-6	-30	-16
40	-18	40
-28	-42	18
-46	-22	16
38	-18	46
-16	-54	-20
42	-16	16
6	-8	50
56	4	4
-60	0	2
8	-8	58
-44	-18	12
54	6	6
8	-22	0
-18	-58	-22
-16	-82	0
-14	-68	2
12	-22	34

// Sandstr?m A, 2019: Healthy Controls
// Subjects=23
58	-38	34
34	10	6
14	-18	52
34	-26	58
60	-38	34
30	28	4
16	-16	52
36	-22	46
6	-8	50
-58	0	2
40	-18	16
14	-16	0
-20	-52	-26
-10	-18	0
6	-38	20
-6	-30	-16
40	-18	40
-28	-42	18
32	-16	60
-56	0	4
34	-1	10
36	4	6
60	-38	38
12	-16	0
-22	-54	-28
34	28	4
42	-22	34
-56	2	4
44	34	-2
-60	-32	26
8	-32	-18
-24	-58	-26
-16	-10	38
-8	4	32
-42	-28	-6
-36	-20	12
-12	-68	28
-18	66	-54

// Wilcox S L, 2016: Migraine > Controls, Neutral
// Wilcox S L, 2016: Migraine > Controls, Negative
// Subjects=23
4	-74	-10
-4	-66	0
8	-86	2
14	-76	-6
24	-70	0
-2	-68	4
-12	-60	50
0	-88	32
-4	-14	6
-2	-64	2
-14	-60	46
10	-52	4
2	50	-22
12	34	-14
-14	42	-24
-12	46	-14
8	56	-4
4	54	-10
22	38	40
22	30	38
16	40	40
38	2	40
26	10	68
40	6	40
-30	22	54
-30	18	56
-52	12	44
-48	14	40
-42	4	56
-26	32	36

// Zapparoli L, 2016: Gilles de la Tourette syndrome (GTS)
// Subjects=24
-38	-18	62
-30	-12	62
-58	4	32
-36	-26	54
-44	-30	46
-54	-22	30
-2	-2	54
-26	-52	62
-54	-22	22
-48	-64	6
-18	-50	-26
-4	-56	-14
-22	0	10
-14	-22	8
-12	-20	4
54	-22	20
34	-12	60
40	-20	56
34	-36	48
30	-46	62
60	-16	24
60	-28	22
18	-52	-24
14	-18	4
26	4	58
20	8	58
-30	-4	50
-34	40	26
-38	40	14
-42	38	14
-50	8	6
-52	8	38
-10	2	58
-6	4	54
-18	-66	56
-42	-38	40
-38	-52	54
-34	-56	56
-56	-36	34
-32	18	0
-40	12	-2
26	4	58
20	8	58
56	12	8
52	8	18
50	6	40
32	-2	50
50	6	30
46	2	44
18	-68	60
36	-48	48
44	-36	42
48	-34	44
-32	28	40
-34	30	34
-32	34	36
-38	34	16
28	-4	64
22	-12	58
34	32	30
34	42	28
38	32	38
32	8	54
32	10	46
-10	42	44
-6	46	22
18	42	46
20	26	32
10	54	30
2	50	32
14	50	28
12	34	52
-26	44	34
-24	36	44
16	26	30
14	16	38
30	30	36
24	50	30
40	16	-10
52	-52	30
58	-54	30
58	-46	14
60	-50	20
46	-44	12
46	-38	10
44	16	-18
40	-32	2
0	56	26
-16	-18	70
-12	-10	62
14	-8	74
2	-8	64
16	-2	68
-18	-6	62
-20	-12	58
-26	-16	62
-32	-14	66
-12	-8	64
-6	-10	64
28	-2	58
28	12	58
34	2	62
12	-8	66
4	-10	62
30	-62	60
18	-70	52
-52	22	-34
62	-10	24
-52	8	-2
-4	2	66

// Zapparoli L, 2016: Healthy Controls
// Subjects=24
-38	-18	62
-30	-12	62
-58	4	32
-36	-26	54
-44	-30	46
-54	-22	30
-2	-2	54
-26	-52	62
-54	-22	22
-48	-64	6
-18	-50	-26
-4	-56	-14
-22	0	10
-14	-22	8
-12	-20	4
54	-22	20
34	-12	60
40	-20	56
34	-36	48
30	-46	62
60	-16	24
60	-28	22
18	-52	-24
14	-18	4
26	4	58
20	8	58
-30	-4	50
-34	40	26
-38	40	14
-42	38	14
-50	8	6
-52	8	38
-10	2	58
-6	4	54
-18	-66	56
-42	-38	40
-38	-52	54
-34	-56	56
-56	-36	34
-32	18	0
-40	12	-2
26	4	58
20	8	58
56	12	8
52	8	18
50	6	40
32	-2	50
50	6	30
46	2	44
18	-68	60
36	-48	48
44	-36	42
48	-34	44
-32	28	40
-34	30	34
-32	34	36
-38	34	16
28	-4	64
22	-12	58
34	32	30
34	42	28
38	32	38
32	8	54
32	10	46
-10	42	44
-6	46	22
18	42	46
20	26	32
10	54	30
2	50	32
14	50	28
12	34	52
-26	44	34
-24	36	44
16	26	30
14	16	38
30	30	36
24	50	30
40	16	-10
52	-52	30
58	-54	30
58	-46	14
60	-50	20
46	-44	12
46	-38	10
44	16	-18
40	-32	2
0	56	26

// Dlabac-de Lange J J, 2015: Planning > Fixation, After active rTMS > After 
// sham rTMS
// Dlabac-de Lange J J, 2015: Planning > Counting, After sham rTMS > After 
// active rTMS
// Subjects=11
56	8	42
6	4	56
-4	-54	14

// Buse J, 2018: All Participants: Disharmonic > Harmonic
// Buse J, 2018: Group x Condition Interaction
// Subjects=17
4.04	-46.94	51.54
57.41	-10.07	6.64
31.43	-56.49	-6.26
25.23	46.32	37.47
-39.57	11.23	33.08
51.23	-45.01	23.65
-29.09	-59.04	-7.21
9.84	11.45	9.8
-63.52	-38.36	9.26
-24.56	41.06	29.87
1.19	28.85	12.71
-26.26	18.23	61.29
16.77	-13.69	39.06
-14	-50.48	-8.32
-16.22	-26.88	-8.37
-31.33	-24.6	-6.1
53.5	1.75	41.39
27.03	-43.95	-9.66
48.53	5.67	-8.22

// Eddy C M, 2017: Tourette Syndrome
// Subjects=25
22	-72	-2
-58	4	36
-52	-44	50
-24	-22	46
28	-52	-22
-38	28	-8
-12	-52	20
26	-4	-8
54	-46	22
4	0	58
-26	-60	6
-62	10	0
-36	-44	64
-30	-18	40
16	-82	42
22	-72	-4
10	-74	8
32	-54	-24
6	-60	26
8	58	16
-30	-72	48
-50	22	16
-20	-92	34
66	-44	22
-64	-62	8
56	16	24
-32	-82	16
18	-82	0
60	-24	14
-44	-6	46

// Eddy C M, 2017: Healthy Controls
// Subjects=25
22	-72	-2
-58	4	36
-52	-44	50
-24	-22	46
28	-52	-22
-38	28	-8
-12	-52	20
26	-4	-8
54	-46	22
4	0	58
-26	-60	6
-62	10	0
-36	-44	64
-30	-18	40
16	-82	42
22	-72	-4
10	-74	8
32	-54	-24
6	-60	26
8	58	16
-30	-72	48
-50	22	16
-20	-92	34
66	-44	22
-64	-62	8
56	16	24
-32	-82	16
18	-82	0
60	-24	14
-44	-6	46
26	-68	-12
56	18	26
22	-28	0
-20	-30	-2
-40	10	26
-4	14	48
-16	8	8
-50	-36	2
14	4	12
-12	-14	10
12	-12	8
-14	8	26
0	-16	-22
18	-10	20
-16	-8	-10
0	14	72
-8	-32	-24
26	-70	-14
20	-30	2
-4	20	44
34	20	2
0	-46	8
-28	26	0
36	10	28
32	0	58
-28	0	58
-46	10	34
-4	6	28
4	-34	-26
-38	20	26
4	-64	60
0	-46	8

// Huang J S, 2016: Group x Pain Anticipation
// Huang J S, 2016: Group x Pain Experience
// Subjects=10
-6.23	36.99	33.05
-3.05	-11.58	10.32
-36.5	20.01	-18.71
36.23	19.98	-11.74
38.24	-0.03	-36.84
34.97	9.21	-40.93
-12.79	-63.44	-26.48
-29.86	-8.36	-.79
43.28	-37.02	48.72
10.08	-61.06	29.93
41.72	35.82	13.64
2.2	-44.44	-15.98
-23.09	-63.88	23.86
-18.39	54.64	-12.9

// Kim T, 2016: Female and Male pictures > Neutral pictures
// Kim T, 2016: Female pictures > Male pictures
// Kim T, 2016: Male pictures > Female pictures
// Subjects=11
-58	10	24
48	-56	-14
-32	-46	44
-44	-36	46
64	-18	32
64	-17	33
46	-59	-11
46	12	34
48	-54	-18
30	-52	46
-32	-45	41
-56	-26	42
-48	-34	49
46	-60	-14
5	58	20
0	26	40
-8	23	26
-1	26	37
6	0	-12
46	10	36
-52	10	30
48	-66	-4
47	-53	-18
30	-53	42
-12	-62	62
26	-76	47
38	-87	10
16	-74	-44
5	-78	-31

// Marshall C R, 2019: All Participants: Facial emotions > Fixation
// Marshall C R, 2019: All Participants: Facial emotions > Mosaic
// Marshall C R, 2019: All Participants: Positive > Negative emotions
// Marshall C R, 2019: All Participants: Negative > Positive emotions
// Subjects=9
15	-94	14
-12	91	2
51	-70	2
57	-34	2
63	-58	14
54	-67	-4
60	-55	11
-3	-88	23
6	-82	38
24	-88	2
15	-91	-4
21	-82	-7

// Belyk M, 2018: Phonation > Rest
// Belyk M, 2018: Low pitch > Rest
// Belyk M, 2018: Comfortable pitch > Rest
// Belyk M, 2018: Middle pitch > Rest
// Belyk M, 2018: High pitch > Rest
// Subjects=12
-43	-18	46
48	-13	42
6	-2	63
2	7	62
2	-3	70
-3	-3	61
-43	-18	44
6	2	64
-4	-3	61
18	2	64
-42	-19	47
48	-14	41
6	-2	64
-47	-17	43
47	-15	40
40	-16	35
-7	-4	61
2	-3	70
40	-15	35
-42	-18	46
52	-13	48
47	-14	41
-5	-2	61
3	6	63
26	-73	25

// Kryshtopava M, 2017: Comfortable phonation > Rest
// Kryshtopava M, 2017: High-pitched phonation > Rest
// Kryshtopava M, 2017: Prolonged exhalation > Rest
// Kryshtopava M, 2017: Comfortable Phonation > Prolonged exhalation
// Kryshtopava M, 2017: High-pitched phonation > Prolonged exhalation
// Subjects=15
45.23	-4.92	37.09
-44.52	-13.03	36.57
24.9	28.77	47.88
-22.11	28.49	48.44
-28.49	23.33	51.18
-50.38	48.53	-6.44
28.24	-40.17	36.89
7.85	-54.35	20.47
-1.75	-54.24	22.8
40.91	-77.9	2
62.13	-16.81	5.55
-55.3	-34.98	15.11
44.22	-69.19	17.96
-41.22	-76.85	22.92
14.09	-8.84	16.59
3.26	-87.38	-34.69
-28.83	-59.31	-26.64
49.5	-3.83	36.95
-46.64	-13.93	38.9
9.9	40.31	47.08
-7.2	40.21	47.29
-54.68	48.33	-8.61
4.06	57.06	-11.13
7.85	-54.35	20.47
-1.73	-51.87	25.95
42.96	-75.57	-9.38
-47.59	-76.46	28.54
57.81	-13.93	2.01
-58.52	-34.03	13.96
14.09	-8.84	16.59
3.33	-85.47	-23.7
-29.9	-60.37	-26.54
-3.15	-28.01	-9.49
5.4	-27.96	-9.59
46.26	-6.4	31.62
50.31	5.58	7.15
-43.43	-13.91	38.86
42.98	-73.11	-5.12
-43.18	-52	55.43
15.05	-5.64	2.92
12.86	-36.97	-16.73
-19.22	-36.28	-18.65
57.87	-21.07	5.96
-49	-24	5.2
34.49	-33.04	18.38
55.72	-20.11	4.79
-51.16	-23.12	2.92
36.63	-33.03	18.36
-4.21	-29.07	-9.39

// Kleber B, 2017: Singers
// Subjects=11
-36	-30	12
42	-27	12
51	-39	36
57	-45	48
-48	-48	36
-60	-51	36
39	-51	36
-30	-63	39
54	15	3
-12	3	72
0	21	51
-15	9	63
9	15	57
48	9	-9
33	27	3
42	-66	-27
39	-75	-30

// Kleber B, 2017: Non-singers
// Subjects=11
-33	-30	15
36	-24	9
45	-18	6
66	-24	21
57	-27	21
-63	-42	24
-45	-39	42
-57	15	-3
-12	-6	72
-36	-18	36
-27	-36	60
-39	-9	45
-36	-12	42
-48	0	48
-6	6	30
-36	-6	9
-15	-66	-48
-30	-54	-21
12	-60	-15
12	-15	6
-9	-12	9
24	-27	9
-12	-27	-3
24	3	12

// Berlingeri M, 2016: Main Effect: Painful > Neutral, p<0.001
// Berlingeri M, 2016: Main Effect: Painful > Neutral, p<0.05
// Berlingeri M, 2016: Painful > Neutral (stimulus phase), p<0.05
// Berlingeri M, 2016: Painful > Neutral (stimulus phase/significant in-group 
// effect), p<0.001
// Berlingeri M, 2016: Painful > Neutral (response phase), p<0.001
// Berlingeri M, 2016: Painful > Neutral (response phase), p<0.05
// Berlingeri M, 2016: Painful > Neutral (response phase/significant out-group 
// effect)
// Berlingeri M, 2016: Main Effect: Stimulus > Response, p<0.001
// Berlingeri M, 2016: Main Effect: Stimulus > Response, p<0.05
// Subjects=25
-36	58	6
-44	46	2
-2	-44	36
-2	-64	22
-6	-58	12
48	-56	10
-4	24	40
-48	0	28
-34	24	-8
-30	22	6
-54	-26	34
-42	-36	38
40	42	18
44	30	26
50	10	30
50	14	16
0	-38	50
62	-22	38
64	-20	34
42	-44	52
50	-32	48
-58	-24	24
-56	-24	30
64	-18	34
-58	-24	24
-56	-24	30
64	-18	34
-52	22	28
-50	10	12
-50	-42	46
-40	-54	46
-34	6	50
-4	26	40
-34	52	12
-44	50	2
-38	20	-8
6	22	50
2	36	44
46	42	10
48	30	24
48	18	16
44	-48	46
-50	0	24
-34	6	50
-34	52	12
-44	50	2
36	16	50
48	30	24
48	18	16
-46	6	28
-20	30	44
-28	-80	12
-44	-72	4
-24	-70	-10
-40	-18	46
-6	-16	46
0	-78	20

// Bestelmeyer P E G, 2015: Normals
// Subjects=40
54	-19	1
63	-16	1
-60	-16	4
-24	8	-20
33	-1	-20
60	-19	16
0	23	22

// Brown T I, 2017: Normals
// Subjects=19
-44	-60	56
-20	20	60
-44	-52	-12
-28	-16	-12
-28	16	4
-8	16	52
-52	16	28
40	-44	-16
28	-12	-16

// Cao Y, 2015: Painful > Non-painful
// Cao Y, 2015: Chinese > Caucasian
// Subjects=30
-32	22	-12
40	32	-2
-2	22	56
-42	-26	56
0	58	28
16	42	14

// Chen P A, 2015: Main effect of Group: In-group > Out-group
// Subjects=22
48	-72	-3
-12	-84	-30
36	-66	-30
12	6	0
-18	-3	6
-42	-72	-3

// Smucny J, 2018: Target > Nontarget cues: Controls > Psychiatric patients 
// (BPD and SZ)
// Smucny J, 2018: Target > Nontarget cues: Controls > BPD > SZ
// Subjects=24
-40	22	48
-44	30	40
-48	36	28
22	10	52
38	10	52
26	24	56
50	-46	48
52	-50	38
48	-62	46
-46	-52	40
-32	-48	52
6	36	50
8	20	48
14	18	42
-40	22	46
42	20	42
26	12	50
42	28	44
48	-50	52

// Firat R B, 2017: Middle-class Whites > Blacks
// Subjects=13
12.8	-27.62	-19.74

// Fourie M M, 2017: Normals
// Subjects=38
1.64	5.85	70.14
-5.17	28.11	28.21
52.31	32.74	0.39
-43.82	22.65	2.34
55.69	14.75	15.24
49.57	-2.01	46.83
-49.91	2.97	37.52
-37.33	0.48	4.13
55.83	-62.92	1.68
-46.75	-73.31	0.39
42.78	-45.51	-19.7
17.12	6.89	-.38
-8.51	10.17	2.98
17.33	-7.43	20.89
-11.6	-1.77	14.06
-5.21	-28.39	-.51
1.64	5.85	70.14
-4.91	20.9	58.92
39.47	32.41	-2.78
46.32	4.06	43.01
-40.24	3.54	44.05
-4.74	-79.49	40.57
-1.75	-15.77	38.54
-17.55	-76.14	43.78
49.29	-14.86	4.42
-56.53	-15.75	2.36
48.87	13.78	-38.13
-50.44	7.35	-29.75
-47.17	17.91	-17.3
55.59	-19.28	-12.01
-56.61	-23.13	-10.4
-21.43	-7.31	-15.48
10.81	1.28	10.2
-8.5	13.6	6.04
20.48	-27.72	5.83
-21.24	-28.49	-.32
-5.28	-25.73	-7.42
-49.85	-59.1	19.3
7.91	20.98	58.76
8.08	-79.42	40.42
4.66	-15.73	38.46
52.73	-58.48	18.07
1.61	-63.59	39.16
1.27	-47.39	1.01
-11.97	66.91	-6.2
1.61	-63.59	39.16
1.27	-47.39	1.01
7.91	-48.29	30
-40.57	16.58	6.16
52.76	-45.02	26.98
20.78	8.37	59.67
-59.84	-23.4	-13.69
-23.91	-69.06	53.3
10.82	4.71	13.26
-1.83	-89.16	-2.15
-4.92	-48.37	30.16
-8.42	4.6	13.49
4.58	-89.12	-2.22

// Hein G, 2016: Subgroup of Normals, Control Group
// Subjects=18
-30	17	-4
-30	26	-13
-33	11	-13
36	-13	-1
-12	-22	11
-21	29	35
39	47	20
45	-25	44
-27	17	-13
-30	26	-13
-33	14	-1
42	8	-1
42	-16	20
42	-40	56
-33	14	32
48	44	8
51	-43	32
-39	-22	2
-21	-10	-10
-51	-54	11
54	-46	11
-27	-70	29
21	-73	17

// Hein G, 2016: Subgroup of Normals, Experimental Group
// Subjects=20
-39	26	-7
-27	17	-13
-42	-49	32
54	-40	50
-51	11	-4
-45	-34	-1
30	-76	17
-33	17	-4
-27	17	-13
-30	26	-13
-33	14	-1
42	8	-1
42	-16	20
42	-40	56
-33	14	32
48	44	8
51	-43	32
-39	-22	2
-21	-10	-10
-51	-54	11
54	-46	11
-27	-70	29
21	-73	17

// Izuma K, 2019: South Korea > Japan
// Subjects=70
12	-97	-2
-18	-106	-5

// Jiang X, 2018: Confident > Doubtful
// Jiang X, 2018: Doubtful > Neutral
// Jiang X, 2018: In-group > Out-group (Regional + Foreign)
// Jiang X, 2018: Out-group (Regional + Foreign) > In-group
// Jiang X, 2018: Out-group/Regional (Confident>Neutral) > In-group 
// (Confident>Neutral)
// Jiang X, 2018: Out-group/Regional (Confident>Doubtful) > In-group 
// (Confident>Doubtful)
// Jiang X, 2018: Out-group/Foreign (Confident>Neutral) > In-group 
// (Confident>Neutral)
// Jiang X, 2018: Out-group/Foreign (Confident>Doubtful) > In-group 
// (Confident>Doubtful)
// Jiang X, 2018: Out-group/Foreign (Doubtful>Neutral) > In-group 
// (Doubtful>Neutral)
// Jiang X, 2018: In-group (Confidence>Neutral) > Out-group/Regional 
// (Confident>Neutral)
// Subjects=25
-32	-38	16
24	-34	-12
46	-24	0
-64	-26	2
-14	62	20
-34	-76	12
40	-62	14
0	-22	52
50	-18	0
-50	-22	2
18	-4	26
12	18	48
-6	-86	26
29	-45	-12
38	-54	58
64	-42	6
-16	-48	-48
-8	38	34

// Kim K, 2015: Ingroup > Outgroup
// Subjects=24
-8	42	-22
-22	-60	6
26	-62	0
32	-80	26
6	-82	2
-42	44	-16
44	-28	56

// Krosch A R, 2019: Black > White
// Krosch A R, 2019: White > Black
// Krosch A R, 2019: Control > Scarce
// Krosch A R, 2019: Scarcity x Race
// Subjects=30
-15	-54	9
33	30	42
-39	27	42
36	-57	-3
18	12	0
-15	-21	-21
42	9	9
-20	-36	-36
-9	69	69
3	18	18

// Lau T, 2017: Out-group/In-group > (Identical In-group, Different In-group): 
// Repetition Suppression
// Lau T, 2017: (Identical In-group and Different In-group) > 
// Out-group/In-group: Repetition Enhancement
// Subjects=22
40	-58	48
-40	-54	54
48	34	38
-44	30	28
64	-28	-12
-58	-40	-12
-42	-30	66
36	-18	66
40	-38	24
48	2	10

// Li T, 2016: White > Black
// Li T, 2016: Negative > Positive
// Li T, 2016: White Negative > White Positive
// Li T, 2016: Black Negative > Black Positive
// Li T, 2016: White Positive > Black Positive
// Li T, 2016: White Positive and Black Negative > White Negative and Black 
// Positive
// Subjects=44
-24	-57	-24
24	-54	-15
36	-69	-27
-9	-90	0
-54	-39	0
-57	-39	0
-12	-96	0
-3	45	30
-42	18	-18
-9	-93	12
27	-48	-24
-30	-45	-27
18	-63	24
27	-78	27
33	-30	72
39	-63	-6
-3	0	33
18	-66	24

// Lin L C, 2018: Ingroup > Outgroup
// Subjects=45
-34	20	-16
-20	2	-20
-28	20	-20
-8	10	-6
-54	2	-24
50	42	-6
48	42	26
28	20	-18
-4	60	-18
-2	60	32
6	54	0
-10	48	12
6	-30	6
66	-28	-8
64	-32	-10
12	-44	-44
-6	-38	-54

// Liu Y, 2015: [(Disgusted Out-group > Neutral Out-group) > (Disgusted 
// In-group > Neutral In-group)]
// Liu Y, 2015: Disgust > Neutral
// Liu Y, 2015: Out-group > In-group
// Subjects=26
30	0	-18
45	21	-6
-15	33	-18
51	24	-6
39	9	-3
-33	15	0
48	3	51
-33	12	57
54	39	3
57	-39	51
44	-46	-20
-42	-57	-18
51	-54	0
-51	-57	3
45	-77	-6
-36	-84	-6
-12	-78	-45
-27	-6	-12
27	-84	-12
-32	-74	-18
51	-54	0
-51	-72	12
27	-96	-9
-15	-96	-9
18	-96	0
-15	-96	-3
18	-12	0
-3	-21	0
-63	-21	33
51	-3	45
-12	-30	-45
-9	-42	-54

// Luo S, 2015: Subgroup of Normals, G/G Individuals
// Subjects=30
-4	24	42
-36	20	-12
32	24	-14
-56	-22	24
64	-22	24
52	6	40
36	-54	60
-40	-54	-20
34	-62	-26
2	18	60
-58	12	16
60	8	18
58	10	40
-56	-26	28
56	-22	26
28	-56	56
52	-62	-10
-32	-94	0
0	36	42

// Luo S, 2015: Subgroup of Normals, A/A Individuals
// Subjects=30
4	10	36
-40	12	-8
40	32	-10
-38	-2	-6
40	-2	8
-56	-22	22
60	-20	32
-46	-52	-16
-38	-84	20
-8	18	34
-32	20	6
36	30	-2
-40	-2	14
38	-4	-8
62	12	10
-62	-22	28
60	-22	32
30	-52	60
-4	12	-8

// Marsh L E, 2016: Imitative compatibility (Incompatible > Compatible), 
// p<0.001
// Marsh L E, 2016: Imitative compatibility (Incompatible > Compatible), 
// p=0.002
// Marsh L E, 2016: Imitative compatibility (Incompatible > Compatible), 
// p=0.02
// Marsh L E, 2016: Imitative compatibility (Incompatible > Compatible), 
// p=0.014
// Marsh L E, 2016: Spatial compatibility (Incompatible > Compatible)
// Marsh L E, 2016: Gaze x Spatial compatibility
// Marsh L E, 2016: Group x Gaze x Spatial compatibility
// Marsh L E, 2016: General compatibility (Incompatible > Compatible), p<0.001
// Marsh L E, 2016: General compatibility (Incompatible > Compatible), p=0.041
// Marsh L E, 2016: Group x Gaze x General compatibility
// Subjects=24
62	6	16
62	6	34
52	8	24
60	-26	42
50	-18	46
-50	-28	26
-44	-32	22
-42	-40	32
10	12	48
18	4	48
10	20	40
-14	-58	68
-56	-26	46
-38	-38	56
56	-26	42
20	-56	68
60	-32	38
22	-4	66
24	-10	58
-16	-6	54
38	-10	64
40	-24	54
25	-15	55
30	56	24
56	-26	48
64	-28	40
52	-26	38
30	0	48
22	-4	66
56	12	6
-54	-32	30
-54	-24	20
-60	4	26
36	50	30
40	60	2
40	58	16
28	62	12

// Mattan B D, 2018: White > Black
// Mattan B D, 2018: Black > White
// Mattan B D, 2018: low-status Black - high-status Black > low-status White - 
// high-status White
// Subjects=60
-42	-39	75
36	-99	-3
6	60	9
33	-51	9

// McCutcheon R, 2018: Subgroup of Normals, Black Ethnicity
// Subjects=17
33	-58	-26

// Molapour T, 2015: Acquisition: Conditioned Stimulus (CS+) > Unconditioned 
// Stimulus (CS )
// Molapour T, 2015: Acquisition: CS- > CS+
// Molapour T, 2015: Acquisition: Black > White
// Molapour T, 2015: Acquisition: White > Black
// Molapour T, 2015: Acquisition: [(White CS+ > White CS-) > (Black CS+ - 
// Black CS-)]
// Molapour T, 2015: Extinction: CS+ > CS-
// Molapour T, 2015: Extinction: CS- > CS+
// Molapour T, 2015: Extinction: Black > White
// Molapour T, 2015: Extinction: White > Black
// Molapour T, 2015: Extinction: [(Black CS+ > Black CS-) > (White CS+ > White 
// CS-)]
// Molapour T, 2015: Acquisition: CS+ > CS- (Linear change over time)
// Molapour T, 2015: Acquisition: CS- > CS+ (Linear change over time)
// Molapour T, 2015: Acquisition: Black > White (Linear change over time)
// Molapour T, 2015: Acquisition: White > Black (Linear change over time)
// Molapour T, 2015: Acquisition: [(White CS+ > White CS-) > (Black CS+ - 
// Black CS-)] (Linear change over time)
// Molapour T, 2015: Extinction: CS+ > CS- (Linear change over time)
// Molapour T, 2015: Extinction: CS- > CS+ (Linear change over time)
// Molapour T, 2015: Extinction: Black > White (Linear change over time)
// Molapour T, 2015: Acquisition: (Black CS+ > Black CS-) and (White CS+ > 
// White CS-)
// Subjects=20
42	-13	40
46	-15	33
9	6	40
28	8	34
50	-54	-23
44	-57	-9
39	-64	-12
-56	-27	0
-48	-49	12
-50	-19	-8
32	-87	25
14	-76	34
10	-76	52
30	-52	48
32	-51	39
68	-24	-5
69	-37	-5
-16	-66	-3
-4	-72	-11
-32	-67	-2
27	-15	-8
34	-12	-14
-26	-64	24
-21	-66	36
-30	-12	-11
-27	-84	-9
18	-58	-8
-24	11	13
-15	-7	67
57	18	33
28	0	-33
-40	24	43
-50	-30	16
12	-49	1
-28	-48	37
-12	-70	9
-36	-55	33
-33	-49	54
-38	-33	52
24	6	-15
9	-70	13
-24	-42	9
-27	-22	-6
18	-27	-20
42	-46	28
60	-1	-17
-14	-40	34
22	-24	55
-30	18	-6
33	-37	4
42	9	6
62	-40	-12
40	-60	56
-39	-70	40
-42	-55	34
33	14	51
-42	6	33
69	-30	10
-30	12	49
-39	12	54
-38	6	60
-18	33	48
-6	-54	18
54	-37	31
-16	3	48
-62	-33	42
-66	-39	31
-18	0	63
34	-3	60
-18	-54	49
-51	-43	55
-46	-49	58
51	2	28
34	-49	63
-4	-15	19
-20	-21	1
-27	12	-17
14	-22	21
64	-48	34
51	-46	33
-42	15	10
40	44	12
21	-42	3
33	12	-2
-58	3	33
-20	17	63
-6	30	58
-30	-4	58
-4	-10	67
32	-51	3
-24	-52	69
16	3	66
10	-82	-24
-36	-13	66
-21	-18	60
44	3	58
36	-16	49
62	-6	36
58	6	39
-57	-9	28
-58	-1	40
-58	-16	46
-21	-81	48
28	-79	43
58	-30	6
-51	-18	13
34	-40	51
9	-21	28
12	-55	21
-40	-30	9
12	-39	36
63	-18	-2
26	30	36
-30	-28	16
-27	18	18
-14	-1	24
10	-81	-26
-6	-70	-9
-14	-60	-29
-50	-48	12
18	-70	1
16	-42	58
-22	-6	-27
45	-22	16
9	-9	45
-42	-13	6
-34	-7	6
-58	15	10
22	-3	-3
60	15	10
-66	-46	13
-33	53	19
-64	-3	27
62	3	28
-20	-67	42
-22	-64	31
-20	-76	51
-42	-43	-9
-30	-40	-3
-51	-51	-9
22	-67	42
26	-67	52
27	-57	60
18	-13	-18
22	-33	6
-36	-13	-20
46	-12	-8
-27	35	-9
45	-6	-14
58	-4	-20
36	-4	-18
52	-39	-17
33	-63	-11
32	-52	-5
27	-48	-12
14	-4	-20
22	28	-12
-36	-51	-12
-28	-58	-2
-30	-58	-11
-22	-42	-12
-16	36	54
45	-3	30
-34	-82	-17
-33	-85	7
-38	-82	19
-32	76	12
-9	42	-12
-45	5	-39
-52	0	-38
-38	17	-23
48	-54	0
-34	35	-17
-22	-75	24
24	-42	49
52	3	-32
30	-75	6
15	-15	46
-52	-66	-5
33	-37	-24
39	24	-21
-15	38	34
-33	-67	16
45	-13	31
-46	-1	40
45	24	9
6	3	40
44	11	28
-9	9	0
-60	8	-2
24	51	16
24	33	-15
50	-52	-23
6	44	-12
-18	50	18
-9	3	33
-6	-24	48
2	-4	67
-10	-34	52
10	12	1
-30	36	31
45	20	16
60	3	7
58	2	19
40	28	-5
52	-67	-2

// Moradi Z, 2017: Rival > In-group
// Subjects=20
-36	14	31
-42	32	4
-51	20	10
-33	-61	-14
-42	-40	64
-21	-76	46

// Rauchbauer B, 2015: Incongruent > Congruent
// Rauchbauer B, 2015: Happy (Incongruent > Congruent)
// Rauchbauer B, 2015: Angry (Incongruent > Congruent)
// Rauchbauer B, 2015: Out-group (Incongruent > Congruent)
// Rauchbauer B, 2015: In-group (Incongruent > Congruent)
// Subjects=41
-32	-46	44
12	-64	52
58	-40	32
40	18	-6
26	-10	54
-30	-8	-62
-34	14	-10
-56	-64	2
2	8	46
-12	2	68
28	34	24
4	-48	-12
-24	-58	-20
6	28	26
30	-52	68
64	-46	38
22	-8	56
-8	-6	68
4	-52	-8
-38	-74	-7
-34	-42	40
32	24	4
22	-8	56
2	8	46
-52	2	10
-28	22	12
-48	-58	-2
4	-64	-14

// Richins M T, 2019: Painful > Neutral
// Richins M T, 2019: Exeter > Cardiff + Sussex > Cardiff
// Richins M T, 2019: [(Exeter Pain > Exeter Neutral + Cardiff Neutral > 
// Cardiff Pain) + (Sussex Pain > Sussex Neutral + Cardiff Neutral > Cardiff 
// Pain)]
// Richins M T, 2019: Other-focussed > Self-focused
// Subjects=69
48	-74	2
0	56	26
-44	-56	-18
-52	18	-12
43	24	-2
-2	-62	32
60	-10	-14
-40	-68	36
2	10	40
-14	-26	18
-20	20	-16
0	-50	20
-40	12	52
30	-54	34
20	-60	-30
-38	48	2
0	-8	12
-44	48	-4
-38	24	-32
22	62	18
56	-10	-20
58	-50	16
-36	-74	-32
42	-62	-34
66	-50	-2
-4	8	68
-30	54	-12
-56	16	24
36	18	-10
-10	66	-6
-54	-54	16
-32	46	26
-52	-14	-10
20	60	-16
-56	-72	6
-46	0	-10
0	-50	2
-10	-20	20
36	-32	10
48	-42	52
2	28	20
0	16	46
-30	-2	44
-32	20	-8
46	-64	-8
-68	-30	-8
0	40	36
-52	-72	2
-54	16	28
58	20	22
48	-28	-4
50	38	-12
50	-64	-6
50	-68	16
-38	-30	14
-42	-48	-20
-10	-88	-24
40	-48	54
-52	-38	26
66	-18	26
-4	-12	16
-50	-22	32
0	-54	48
-62	-10	0
34	58	0
48	-42	-20
50	-22	34
26	68	4
-40	6	-12
0	48	0
-44	-44	50
-36	-24	-24
-4	8	66
-26	16	56
-32	-98	-8
28	-10	-18
0	-2	-16
46	12	-16
-30	-40	-24
0	56	-12
62	-40	-4
-58	-30	-14
-8	-44	38
-22	-88	-12
-38	-84	12
-18	0	6
44	-30	28
-40	-78	-30
-26	36	34
58	-48	30
42	-72	0
8	-42	28
-64	-2	24
-12	26	0
-54	-32	46
16	44	16
0	34	12
-2	56	26
2	-66	32
-46	26	36
48	-60	26
-54	-68	28
54	12	-32
-62	-16	-14
-8	6	10
60	-12	-12
-32	62	2
58	26	6
10	-56	-38
-38	-68	-30
-28	24	-20
-4	-16	6
-38	-12	-14
-48	8	38
-4	0	50
64	8	16
4	-24	-26
-2	-34	60
32	-42	38
-34	-44	42

// Ruckmann J, 2015: Pain > Neutral
// Ruckmann J, 2015: Ingroup > Outgroup
// Ruckmann J, 2015: Main effect of gender
// Ruckmann J, 2015: Pain x Condition Interaction
// Ruckmann J, 2015: Pain x Gender Interaction
// Subjects=15
-54	6	20
-58	-22	28
64	-22	38
58	12	14
-4	26	36
-44	44	10
-12	-92	-22
-10	-82	2
26	-68	-28
12	-90	22
-18	6	2
16	-86	-4
-14	-100	20
46	-60	16
38	10	28
-36	-56	56
36	-86	6
-30	-92	12
28	-78	42
-4	-84	12
-28	-74	46
60	8	38
-2	-96	-4
12	-88	-2
-24	-26	0
14	-6	-2
2	-66	-36
16	-78	-36
22	-20	-6
-32	-28	6
6	-46	76
20	-2	32

// Telzer E H, 2015: Donations > Pure Reward
// Telzer E H, 2015: In-group Donations > Outgroup Donations
// Telzer E H, 2015: In-group Donations > Pure Reward
// Telzer E H, 2015: Out-group Donations > Pure Reward
// Telzer E H, 2015: Group Identity (Out-group > In-group)
// Telzer E H, 2015: Chinese > American
// Subjects=13
6	17	5
45	-43	46
-40	-46	46
9	23	37
-32	58	1
-24	41	28
33	17	10
33	53	28
30	5	1
-30	5	-2
-27	26	7
-42	-22	40
2	-81	16
18	20	-8
12	22	-2
-33	56	19
33	44	34
3	17	46
45	-22	61
-12	-55	49
12	-97	7
28	-1	-14
-38	8	-2
-6	5	58
-33	53	22
30	53	25
-42	-22	37
-27	-34	49
42	-10	40
-18	-28	58
8	-85	20
-48	-67	31
-15	41	46
15	41	49
9	41	13
57	-19	-26
45	50	-5
-39	53	-12
-48	-58	21
50	-67	37
60	-52	25
63	-28	-5
-12	-70	40

// Wang C, 2015: Painful > Non-painful
// Wang C, 2015: Priming x Race interaction
// Subjects=30
9	2	67
-3	8	70
0	-1	34
-57	5	1
-42	-4	13
60	11	7
57	11	22
51	-55	-11
57	-22	34
36	-52	-23
-33	-61	-26
-3	26	52
-50	17	31
51	-52	31

// Watson R, 2017: Shape Categorisation: Black bodies > White bodies
// Watson R, 2017: Shape Categorisation: White angry bodies > Black angry 
// bodies
// Watson R, 2017: Shape Categorisation: Black happy bodies > White happy 
// bodies
// Watson R, 2017: Emotion Categorisation: Black bodies > White bodies
// Watson R, 2017: Emotion Categorisation: White bodies > Black bodies
// Watson R, 2017: Emotion Categorisation: Black happy bodies > White happy 
// bodies
// Watson R, 2017: Emotion + Shape Categorisation: Black bodies > White bodies
// Watson R, 2017: Emotion + Shape Categorisation: White angry bodies > Black 
// angry bodies
// Watson R, 2017: Emotion + Shape Categorisation: Black happy bodies > White 
// happy bodies
// Subjects=21
15.19	-30.5	11.7
47.31	3.3	33.03
-23.17	-64.74	12.78
-22.87	-79.26	45.22
-1.79	12.32	43.99
-16.86	39.72	41.86
-31.59	-85.42	21.3
-53.21	-64	-2.55
44.97	-47.18	-14.01
-53.13	-49.94	14.11
55.66	-20.71	-2.97
49.41	-65.16	0.83
-51.01	-45.7	13.73
-59.63	-39.92	6.66
62.36	-46.28	23.63
11.31	-72.54	46.49
2.72	-64.3	43.67
-7.94	-68.42	46.37
-14.48	-69.83	28.72
-22.97	-71.49	35.65
23.97	-82.98	20.46
17.81	-62.84	61.22
30.52	-59.56	47.42
-44.41	-26.17	45.48
-37.93	-40.77	48.86
-44.28	-42.41	55.76
-1.67	-15	48.51
-3.71	-33.7	54.56
-24.99	-35.09	66.07
-42.52	-70.45	-4.36
36.67	-81.98	4.62
-31.72	-86.8	3.58
-35.94	-84.02	12.31
36.56	-76.5	-6.99
-31.46	-84.05	39.03
19.36	-49.11	-9.09
-19.12	-49.51	-10.85
-1.78	3.69	42.48
-1.75	-31.18	32.02
36.33	26.56	4.44
0.45	11.25	57.44
-1.83	22.89	43.1
27.7	-11.67	-21.25
49.36	13.37	25.47
-38.26	10.73	26.7
34.18	26.37	2.25
-38.49	21.54	1.26
4.67	12.87	50.56
-48.98	-62.2	-7.21
-61.63	-25.36	29.99
47.11	-47.17	-14.04
53.75	-11.81	29.76
38.72	5.02	28.52
53.52	3.4	6.18
-33.95	11.1	31.08
-24.98	-32.8	68.11
-55.01	-29.78	54.82
-50.86	-28.84	39.08
19.96	-64.94	61.37
-21.41	-73.07	-40.07
-33.59	-66.46	46.5
6.8	15	50.36
30.45	-.92	62.57
-44.65	-76.98	-6.02
-31.61	-79.08	20.77
36.84	-80.27	26.78
-38.07	-84.03	12.34
-33.61	-84.24	36.84
-14.64	-78.06	4.88
-42.19	-62.63	41.82
-34.16	-41.65	-18.03
-42.73	-55.08	-25.72
-44.84	-48.23	-19.58
32.04	26.36	2.28
-36.36	19.26	-.8
-4.47	-30.67	-43.82

// Wu C, 2018: SAME-DM2 > COM-DM2
// Wu C, 2018: DIFF-DM2 > COM-DM2
// Wu C, 2018: COM-DM2 > SAME-DM2
// Wu C, 2018: COM-DM2 > DIFF-DM2
// Wu C, 2018: SAME-DM2 > DIFF-DM2
// Wu C, 2018: Humanoid-DM2 > non-humanoid-DM2 [(SAME-DM2 > COM-DM2)  
// (DIFF-DM2 > COM-DM2)]
// Wu C, 2018: Non-humanoid-DM2 > humanoid-DM2 [(COM-DM2 > SAME-DM2)  (COM-DM2 
// > DIFF-DM2)]
// Wu C, 2018: Reciprocate > Defect
// Wu C, 2018: Defect > Reciprocate
// Wu C, 2018: SAME-DM2 defects > SAME-DM2 reciprocates
// Wu C, 2018: DIFF-DM2 reciprocates > DIFF-DM2 defects
// Subjects=54
42	16	58
-40	18	54
16	50	40
-4	62	32
-54	-66	30
2	-50	28
56	-68	10
-46	-78	2
0	52	-14
-30	18	-14
38	-50	-20
-40	18	56
46	20	50
20	44	42
2	-50	28
-46	-62	28
58	-64	18
-50	-10	-20
54	-2	-24
-36	-88	22
-26	-44	-14
-34	-88	24
30	-46	-10
-30	-44	-10
-26	-62	-16
-2	12	12
6	18	10
42	16	58
20	46	50
-46	-64	30
56	-66	28
6	-54	28
30	-46	-10
-36	-88	22
-26	-44	-16
-24	-94	-10
-4	4	64
6	14	60
-36	4	48
48	-24	-6
2	18	58
-4	10	52
46	-42	2
0	12	12
-2	20	12

// Kryshtopava M, 2019: Comfortable phonation > Rest
// Kryshtopava M, 2019: High-pitched phonation > Rest
// Kryshtopava M, 2019: Prolonged exhalation > Rest
// Kryshtopava M, 2019: Phonation > Rest
// Subjects=4
45.24	-10.29	36.42
57.09	-6.02	49.31
-42.42	-13.44	31
32.49	22.18	58.38
-26.31	29.23	58.46
28.18	-44.11	27.19
40.91	-77.9	2
-38.16	-78.37	2.94
62.15	-26.42	5.24
-59.67	-27.15	6.7
38.49	-62.25	-29.4
-36.32	-62.7	-28.5
-4.51	-27.75	-47.41
50.63	-3.23	44.69
-51.97	-4.01	43.7
29.05	48.37	39.5
-26.51	48.04	40.16
11.99	45.27	42.18
-9.39	45.14	42.44
-4	2.82	31.43
40.91	-77.9	2
48.92	25.29	-26.82
30.75	6.44	-35.07
-31.21	-.28	-33.8
-46.2	20.15	-29.76
-65.1	-13.86	0.07
3.32	-6.51	6.48
3.15	-47.83	-32.43
-1.12	-47.85	-32.38
0.95	-27.67	-32.98
46.26	-6.4	31.62
50.31	5.58	7.15
-43.43	-13.91	38.86
42.98	-73.11	-5.12
-43.18	-52	55.43
15.05	-5.64	2.92
12.86	-36.97	-16.73
-19.22	-36.28	-18.65
46.23	-3.39	29.14
57.12	-16.59	50.2
-43.53	-3.93	30.22
-54.01	-17.26	51.53
58.93	-23.35	3.9
-55.25	-42.13	19.06

// Boccia M, 2015: Visuo-spatial Imagination (Imagery) > Baseline
// Subjects=15
-45	-64	37
-15	-97	-2
9	-82	7
3	-76	28
-21	-37	-17
24	-37	-17
27	-34	-2
-51	5	28
48	-4	16
-39	-43	49
42	-40	49
54	-58	-14
-3	-76	4
30	-4	52
-24	-4	49
30	-64	34
-30	-40	-14
30	-31	-14
39	-22	61
-3	-79	46
-18	-61	16
15	-55	10
-24	-67	55
27	-61	61

// Fulford J, 2018: Low-Vividness Group > High-Vividness Group, Imagery > 
// Imagery Control
// Fulford J, 2018: High-Vividness Group > Low-Vividness Group, Imagery > 
// Imagery Control
// Fulford J, 2018: Positive Correlation between BOLD signal and vividness of 
// individual images, All Participants
// Fulford J, 2018: Negative correlation between BOLD signal and vividness of 
// individual images, All Participants
// Fulford J, 2018: Low-Vividness Group > High-Vividness Group, Perception > 
// Perception Control
// Subjects=14
-48.03	-38.9	37.06
-18.71	60.43	-15.85
-37.56	37.41	25.97
-13.56	11.94	39.29
-28.84	-81.19	8.42
-39.52	-49.68	24.54
-35.32	-5.75	23.48
-55.86	5.02	25
-9.26	-10.15	32.43
-52.16	-45.11	51.19
-17.81	-11.68	39.45
-20.13	-15.06	26.38
-37.31	-65.73	24.97
-3.25	59.68	9.73
-37.31	-65.73	24.97
-3.25	59.68	9.73
50.77	-17.82	-7.05
49.82	-11.37	4.65
38.06	49.68	26.83
42.33	44.93	21.62
21.04	-87.32	20.5
25.48	-87.54	29.41
20.57	13.1	3.85
53.19	7.12	18.46
23.32	-55.77	36.39
11.96	33.04	10.99
34.01	-61.02	25.53
3.32	43.96	13.42
-4.71	33.19	59.44
-28.79	-34.86	21.77
-43.69	-77.04	30.67
-36.28	-55.2	22.78
-46.01	-55.23	22.95
-.38	-50.97	43.05
4.15	-43.98	60.21
7.83	-48.74	9.07
-39.9	-75.55	-11
-9.29	-55.21	21.21
-17.83	-52.28	30.03
-9.23	-45.97	28.13
28.13	-42.68	-7.57
22.57	-35.12	-18.3
42.41	-44.16	10.27
46.92	-52.57	23.35
60.55	55.96	12.38
29.28	-78.29	-9.66
27.33	-54.84	11.58
-17.79	-47.61	34.05
58.84	-54.45	25.57
63.59	-5.74	-16.31
53	26.49	7.58
-9.25	-76.79	19.98
10.16	-73.74	17.1
-7.59	34.37	3.35
-52.82	-11.73	6.44
-50.45	-37.58	16.8
38.1	-90.09	1.44
28.36	-94.58	-.19
30.06	-48.35	57.96
52.91	31.29	1.5
55.31	-19.44	9.84
55.22	-14.64	3.77
48.64	-18.69	-4.69
-43.95	7.5	27.92
55.31	2.45	14.4
-29.04	-42.26	0.09
-26.1	-55.03	58.45
-24.1	-52.87	47
46.8	-65.52	11.18
-54.81	-55.34	10.79
56.28	-68.41	-8.86

// de Wit S J, 2015: Obsessive Compulsive Disorder (OCD) Patients
// Subjects=39
18	17	4
-18	2	7
-15	14	7
-51	-34	-8
-57	-9	-8
-57	8	10
39	14	7
-45	-82	10
9	-40	-11
18	-10	4
-24	-31	4
-21	-10	4
-39	2	58
-45	5	-35
18	-43	64
45	-67	43
51	-25	34
-21	-46	-2
51	2	13
48	-76	16
15	-37	-20
-15	-34	-23
12	-91	31
3	-85	37
-9	2	34
-12	-7	37
57	-19	4
-48	2	7

// de Wit S J, 2015: Healthy Controls
// Subjects=38
-48	-10	52
-51	5	22
45	11	10
-21	20	46
30	-37	-5
33	-79	-2
-30	-88	-8
45	-34	34
-33	-61	-32
-39	-49	-26
-36	-52	-14
51	-37	43
54	-1	19

// Berteletti I, 2015: Positive Correlation between Number Line estimation 
// error and Subtraction Small > Large
// Subjects=39
-56	-56	2
4	-66	58
-20	-16	-6
-38	-40	46
16	14	-2
56	-54	6

// Luculano T, 2015: Mathematical Learning Disabilities (MLD)
// Subjects=15
-14	26	60
-30	50	6
-30	30	0
40	12	-12
12	56	6
-20	44	36
20	26	58
-58	-36	46
-34	-58	60
6	-76	46
24	-80	-14
-30	-32	-24
-36	-62	-34
36	-68	-32
6	12	-12
-30	16	-8
-28	-20	-20
-52	20	30
-8	12	58
32	2	66
36	2	-6
-30	28	0
36	-64	54
-26	-50	46
18	-74	-16
-22	-68	-20
-36	-60	-30
36	-64	-28
44	28	14
-42	-8	32
40	12	-12
-8	14	58
-54	10	8
-20	50	8
46	30	30
-36	-4	-2
2	30	58
-30	-56	64
-30	-32	-24
-36	-62	-34
36	-70	-30
-28	-18	-20
-30	-16	-8
-22	52	10
44	30	32
-48	6	44
-4	12	58
-50	22	-10
34	-60	50
-20	-70	46
48	-52	-24
-10	-68	6
-50	-44	-8

// Luculano T, 2015: Typically Developing (TD)
// Subjects=15
-14	26	60
-30	50	6
-30	30	0
40	12	-12
12	56	6
-20	44	36
20	26	58
-58	-36	46
-34	-58	60
6	-76	46
24	-80	-14
-30	-32	-24
-36	-62	-34
36	-68	-32
6	12	-12
-30	16	-8
-28	-20	-20
-36	2	28
30	-54	38
-36	-84	-4
44	28	14
-42	-8	32
40	12	-12
-8	14	58
-54	10	8
-20	50	8
46	30	30
-36	-4	-2
2	30	58
-30	-56	64
-30	-32	-24
-36	-62	-34
36	-70	-30
-28	-18	-20
-30	-16	-8

// Matejko A, 2019: Adults
// Subjects=26
41.36	38.03	25.27
36.26	20.76	2.11
-6.32	-75.21	-5.85
34.29	58.86	29.5
1.83	-14.09	12.38
-0.08	14.98	47.63
-40.06	17.31	26.97
-33.06	-12.37	39.07
57.59	-39.93	23.13
34.61	-85.74	0.81
35.43	-63.14	-13.87
10.48	-74.1	37.71
-21.81	-96.07	2
-53.73	15.1	25.35
32.4	-57.59	-28.71
29.88	-67.86	29.76
-.69	-84.66	1.42
-.95	-26.18	-29.86
-19.31	-63.05	42.31
-12.43	-3.05	12
-38.75	25.14	19.6
-2.73	-86.57	2.2
-25.39	-57.08	39.54
-42.24	32.64	27.45
-14.58	-98.16	1.92
-41.94	37.07	24.97
55.16	-13.73	2.13
40.9	-35	40.93
31.54	24.74	0.77
26.88	1.94	42.32
-3.51	19.76	43.52
1.2	35.51	-9.08
2.41	-73.13	-25.3
-7.73	-83.55	3.59
-31.62	-46.72	41.65
-32.33	-63.62	-27.82
-30.82	1.26	43.74
-49.62	-26.59	20.43
-42.11	39.16	16.29

// Matejko A, 2019: Children
// Subjects=42
56.09	-39.7	-10.42
33.88	-53.16	48.27
36.89	26.31	26.45
-3.08	-76.32	-8.71
0.65	21.1	43.5
-32.67	-51.74	47.95
-39.17	17.99	24.27
-37.33	55.04	0.05
-6.85	-77.76	-8.02
28.02	-65.3	54.15
16.62	-60.45	6.06
-24.62	-62.3	51.06
-41.16	-34.91	48.71
-43.59	12.54	35.04
6.23	-72.45	31.05
33.53	21.26	2.04
5	18.57	43.38
-32.21	-70.89	-17.34
-33.51	19.63	4.83
29.26	-57.25	48.02
32.97	22.74	0.54
-4.27	-89.9	1.67
-.44	45.06	-4.28
1.95	20.17	43.35
-8.4	58.76	25.69
-24.14	-62.31	50.35
24.17	-68.25	54.53
-.98	-91.6	4.51
-23.52	-61.47	51.97
-41.94	37.07	24.97
57.67	-18.16	7.03
38.73	-40.93	45.25
4.2	7.31	-7.24
0.79	57.16	9.85
-11.13	-38.93	44.06
-25.44	1.66	-14.55
-40.48	-43.25	45.44
-44.5	-40.19	20.95
-57.29	-3.54	9.53

// Polspoel B, 2019: Large Problem Size > Small Problem Size (corrected)
// Polspoel B, 2019: Small Problem Size > Large Problem Size (uncorrected)
// Polspoel B, 2019: Large Problem Size > Small Problem Size (uncorrected)
// Polspoel B, 2019: Low Interference > High Interference (uncorrected)
// Polspoel B, 2019: High Interference > Low Interference (uncorrected)
// Subjects=20
42	-60	-18
-34	-78	-18
18	-96	4
22	-86	-20
-6	-84	48
-28	0	56
46	-82	-6
20	36	-6
-18	42	-4
42	-60	-18
-36	-78	-18
-6	-84	48
-28	0	56
-28	-66	56
24	-64	48
64	-54	-8
-38	0	20
58	-64	38
8	-22	26
-6	14	56

// Polspoel B, 2017: Retrieval > Procedural
// Polspoel B, 2017: Procedural > Retrieval
// Polspoel B, 2017: Multiplication > Subtraction
// Polspoel B, 2017: Hard retrieval > Easy procedural
// Polspoel B, 2017: Easy procedural > Hard retrieval
// Subjects=20
-6	-50	-4
-52	-4	-32
-54	-58	36
70	-48	8
66	-44	42
-12	16	50
-44	-46	52
32	-62	54
-50	6	38
24	-90	-6
-22	-96	4
52	10	26
-34	20	4
36	20	8
32	6	66
-50	46	10
18	-96	4
-22	-96	2
64	-40	38
-6	34	0
-56	-22	-8
-48	-4	-30
4	56	2
54	-56	38
-20	4	60
-48	4	34
-48	-40	50
28	-56	50
24	-4	48
-52	46	12
-50	32	40
-34	18	4
52	10	26
-28	-94	6
-22	-90	-12
20	-98	10
58	30	30
22	-88	-6

// Huang J, 2016: Schizophrenia patients
// Subjects=23
3	12	3
23	-43	16
-2	-73	52
12	-36	33
-12	0	70

// Huang J, 2016: Healthy controls
// Subjects=23
3	12	3
23	-43	16
-2	-73	52
12	-36	33
-12	0	70
24	-96	-6
8	15	1
-2	15	4
-35	42	33
-5	18	7
8	18	6
26	-96	-8
-27	-97	18
29	-42	13

// Tiksz A, 2019: Effect of effort: Schizophrenia (SZ) > Healthy Controls 
// (HC)
// Tiksz A, 2019: Effect of success: SZ > HC
// Tiksz A, 2019: Effect of reward: SZ > HC
// Subjects=23
-11.64	50.53	29.75
39.81	-79.39	-3.44
20.79	-90.4	21.12
-24.44	4.5	13.68
-37.07	-89.11	1.6
-50.08	1.17	14.25
-65.99	-24.04	19.9
26.75	10.38	2.56
10.93	15.77	32.4
-8.24	6.39	36.75
-7.93	-6.9	71.32
-24.5	13.76	9.56
-31.13	8.24	-20.01
-30.8	31.38	31.57
-43.39	-38.74	34.25

// Yang X, 2016: Healthy controls
// Subjects=25
0	-60	-4
-21	-18	32
-24	-3	48
-45	-36	40
-18	-6	52
9	-36	4
3	3	40
24	-30	16
-45	-33	12
9	15	8
9	15	8
3	-18	16
27	-87	-20
0	-12	12
-30	36	28
-36	-78	-20
-30	0	48
-3	9	48
12	18	0
30	-54	40
-9	15	0
-3	-87	-4
-57	15	20
-36	0	44
-9	15	0
12	18	0
9	3	12
-3	9	48
-6	57	0
-45	-30	12
-18	-33	52
24	-30	16
18	-81	-36
-33	-78	-40
-18	27	0
18	-45	48
0	-15	16
54	-15	8
9	15	4
-12	-90	-16
-21	-75	-24
24	-30	20
-36	-66	28
-18	-33	52
42	-18	12
45	-51	20
-39	-33	16
24	-81	-36
-63	-39	16
-6	-48	36

// Yang X, 2016: Depressive patients
// Subjects=25
0	-60	-4
-21	-18	32
-24	-3	48
-45	-36	40
-18	-6	52
9	-36	4
3	3	40
24	-30	16
-45	-33	12
9	15	8
9	15	8
3	-18	16
0	-63	-40
-33	-24	48
-27	-93	-12
-30	-72	-16
-54	21	12
-39	-3	44
6	54	-8
15	-84	-40
-30	-72	-12
-42	24	28
6	54	-8

